СПИСЪК С ЦИТИРАНИЯ НА НАУЧНИТЕ ТРУДОВЕ НА ПРОФ. Д-Р ЛЮДМИЛА БОЯНОВА ГЕОРГИЕВА, ДМ, ДМН,

професор в Катедра по медицинска микробиология, Медицински факултет на Медицински университет – София ЗА ЦЕЛИЯ ПЕРИОД

(КАНДИДАТЪТ УЧАСТВА В КОНКУРСА С ВСИЧКИ НАУЧНИ ТРУДОВЕ)

Брой на цитиранията	Общо	В посл. 5 г.
Общо брой цитирания	**2767**	**1118**
в международни и чуждестранни списания	**2166**	914
в български списания	**49**	9
в чуждестранни монографии/книги	**175**	66
в български монографии/книги	**9**	5
в чуждестранни дисертации	**341**	118
в български дисертации	**27**	6
Общо цитирания в международни и чуждестранни трудове	**2682**	**1098**
Общо цитирания в български трудове	**85**	**20**

Цитиранията са подредени по азбучен ред на първия автор на цитирянето, първо на латиница, след тях на кирилица.

-В СПИСАНИЯ В ЧУЖБИНА:

ЦИТИРАНА: 1А: Megraud F, Trimoulet P, Lamouliatte H, **Boyanova L**. Bactericidal effect of amoxicillin on *Helicobacter pylori* in an vitro model using epithelial cells. Antimicrob Agents Chemother. 1991; **35**(5): 869 -872. **Цитирана от:**

1) Alarcon T, Domingo D, Sanchez I, Derojas FD, Lopez-Brea M. In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of *Helicobacter pylori*. Eur J Clin Microbiol Infect Dis. 1996; **15**(12): 937-940.
2) Amiji MM. Tetracycline-containing chitosan microspheres for local treatment of *Helicobacter pylori* infection. Cellulose. 2007; **14**(1):3-14.
3) Arulnathan E, Lakshminarasimmaiah BN, Naik HJ. Gastric Microenvironment Enables Persistence of *Helicobacter pylori*: a physician's combat towards eradication and directions for the future. Journal of Young Investigators, 2018;**35**(6).
4) Badhan AC, Mashru RC, Shah PP, Thakkar AR, Dobaria NB. Development and evaluation of sustained release gastroretentive minimatrices for effective treatment of *H. pylori* Infection. AAPS PharmSciTech. 2009; **10**(2): 459-467.
5) Beil W, Kilian P. EPs® 7630, an extract from *Pelargonium sidoides* roots inhibits adherence of *Helicobacter pylori* to gastric epithelial cells Phytomedicine. 2007; **14**(Suppl 1): 5-8.
6) Berry V, Woodnutt G. Is bactericidal activity of amoxicillin against *Helicobacter pylori* concentration dependent? (autor's replay) Antimicrob Agents Chemother. 1996; **40**(5): 1327-1328.
7) Cardaci G, Lambert JR, King RG, Onishi N, Midolo P. Reduced amoxicillin uptake into human gastric mucosa when gastric juice pH is high. Antimicrob Agents Chemother. 1995; **39**(9): 2084-2087.
8) Corthesy-Theulaz I, Porta N, Pringault E, Racine L, Bogdanova A, Kraehenbuhl JP, Blum AL, Michetti P. Adhesion of *Helicobacter pylori* to polarized T-84 human intestinal cell monolayers is pH dependent. Infect Immun. 1996; **64**(9): 3827-3832.
9) Coudron P, Stratton C.. Utilization of time - kill kinetic methodologies for assessing the bactericidal activities of ampicillin and bismuth, alone and in combination, against *Helicobacter pylori* in stationary and logarithmic growth phases. Antimicrob Agents Chemother. 1995; **39**(1): 66 - 69.
10) Dacoll C, Sánchez-Delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for *Helicobacter pylori* eradication achieves high cure rates in Uruguay. Gastroenterologia y hepatologia. 2017; **40**(7):447-454.
11) de Souza MPC, de Camargo BA F, Spósito L, Fortunato GC, Carvalho GC, Marena GD, ... & Chorilli M. Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of *Helicobacter pylori* infections. Crit Rev Microbiol. 2021; 1-26.
12) Drago L, Mombelli B, Ciardo G, De Vecchi E, Gismondo MR. Effects of three different fish oil formulations on *Helicobacter pylori* growth and viability: In vitro study. J Chemother. 1999; **11**(3): 207-210.
13) Du RJ, Ho B. Surface localized Heat Shock Protein 20 (HslV) of *Helicobacter pylori.* Helicobacter 2003; **8**(4) , 257-267.
14) Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of *Helicobacter pylori* infection. J Antimicrob Chemother. 1997; **39**(1): 5-12.
15) Ghosh P, Sarkar A, Ganguly M, Raghwan, Alam J, De R, Mukhopadhyay AK. *Helicobacter pylori* strains harboring babA2 from Indian sub population are associated with increased virulence in ex vivo study. Gut Pathog. 2016;**8**:1. doi: 10.1186/s13099-015-0083-z. eCollection 2016.

16) Gismondo MR, Drago L, Lombardi A, Fassina MC, Mombelli B. Interference on *Helicobacter pylori* growth and adhesion by omeprazole and other drugs. J Chemother. 1998; **10**(3): 225-230.
17) Glupczynski Y. In vitro susceptibility testing of *Helicobacter pylori* to antimicrobial agents: basis for treatment or microbiologists' obsession? Zbl Bact. 1993; **280**: 227-238.
18) Graham DY. Antibiotic resistance in *Helicobacter pylori*-implications for therapy. Gastroenterology. 1998; **115**(5): 1272-1277.
19) Graham DY, Opekun AP, Klein PD. Clarithromycin for the eradication of *Helicobacter pylori*. J Clin Gastroenterol. 1993; **16**: 292-294.
20) Harris AG, Hazell SL, Netting AG. Use of digoxigenin-labeled ampicillin in the identification of penicillin binding proteins in *Helicobacter pylori*. J Antimicrob Chemother. 2000; **45**(5): 591-598.
21) Heinrich M, Leimkugel J. Medicinal plants in the German and European pharmacopoeia. Zeitschrift fur Phytotherapie. 1999; **20**(5): 264-267.
22) Hussein Salim R, Karim Hassan A, Qasim Al-tamemi N, M Saeed A, AL-Obaidi Z, M Almusawi J, & H Alaayedi M. Effect of Hydroxy Propyl Methyl Cellulose (HPMC) on Amoxicillin Floating Tablet. Kerbala journal of pharmaceutical sciences. 2017; **8**(13): 311-319.
23) Ikemoto A, Teratani N, Ikeda F, Yokota Y. Adhesion of *Haemophilus influenzae* to HEp-2 cells and the bactericidal effect of cefixime on the adherent bacteria. Japanese J Chemother. 1996; **44**(9): 731-735.
24) Irie Y, Tateda K, Matsumoto T, Miyazaki S, Yamagushi K. Antibiotic MICs and short time killing against *Helicobacter pylori* - therapeutic potential of kanamycin. J Antimicrob Chemother. 1997; **40**(2): 235-240.
25) Jan HM, Chen YC, Yang TC, Ong LL, Chang CC, Muthusamy S, ... & Lin CH. (2020). Cholesteryl α-D-glucoside 6-acyltransferase enhances the adhesion of *Helicobacter pylori* to gastric epithelium. Communications biology. 2020; **3**(1), 1-13.
26) Kane-Dumbre S, Momin M, Ravikumar P, Khatri R. Drug delivery strategies for *Helicobacter pylori* infection management: An overview. Indian Drugs. 2019; **56**(10): 7-21.
27) Krakowka S, Eaton KA, Leunk RD. Antimicrobial therapies for *Helicobacter pylori* infection in gnotobiotic piglets. Antimicrob Agents Chemother. 1998; **42**(7): 1549-1554.
28) Kwack WG, Lim YJ, Lim CY, Graham DY. High dose ilaprazole/amoxicillin as first-line regimen for *Helicobacter pylori* infection in Korea. Gastroenterol Res Pract. 2016; **2016**: Article ID 1648047. doi:10.1155/2016/1648047
29) Larsen AL, Ragnhildstveit E, Moayeri B, Eliassen L, Melby KK. Resistance rates of metronidazole and other antibacterials in *Helicobacter pylori* from previously untreated patients in Norway. APMIS. 2013;**121**(4):353-358.
30) Leung WK, Graham DY. Clarithromycin for *Helicobacter pylori* infection. Expert Opin Pharmacother. 2000; **1**(3):507-514.
31) Li ZX, Ma JL, Guo Y, Liu WD, Li M, Zhang LF, Zhang Y, Zhou T, Zhang JY, Gao HE, Guo XY, Ye DM, Li WQ, You WC, Pan KF. Suppression of *Helicobacter pylori* infection by daily cranberry intake: A double-blind, randomized, placebo-controlled trial. J Gastroenterol Hepatol. 2021;**36**(4):927-935.
32) Lozniewski A, Duprez A, Renauld C, Muhale F, Conroy MC, Weber M, Lefau A, Jehl F. Gastric penetration of amoxicillin in a human *Helicobacter pylori* infected xenograft model. Antimicrob Agents Chemother. 1999; **43**(8): 1909-1913.
33) Lozniewski A, Weber M, De Korwin JD, Conroy MC, Franck P, Floquet J, Le Faou A, Burdin JC. Use of cryomicrotomy to study gastric diffusion of amoxicillin in guinea pigs. Antimicrob Agents Chemother. 1995; **39**(3): 766–768.
34) Monteiro L. Principe du traitement de l'infection par *Helicobacter pylori* et rôle du biologiste dans sa surveillance. Revue Francaise des Laboratoires. 1999 (**316**): 55-62.
35) Narkar M, Sher P, Pawar A. Stomach-specific controlled release gellan beads of acid-soluble drug prepared by ionotropic gelation method. AAPS PharmSciTech. 2010; **11**(1): 267-277.
36) Obonyo M, Zhang L, Thamphiwatana S, Pornpattananangkul D, Fu V, Zhang L. Antibacterial activities of liposomal linolenic acids against antibiotic-resistant *Helicobacter pylori*. Mol Pharm. 2012;**9**(9):2677-85.
37) Oricha BS, Umar H. The pharmacokinetics of amoxicillin in healthy adult Nigerians. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2010; **1**(3): 799-807.
38) Pavicic MJA, Namavar M, Verboom T, van Winkelhoff AJ, de Graaf J. *In vitro* susceptibility of *Helicobacter pylori* to several antimicrobial combinations. Antimicrob Agents Chemother. 1993; **37**: 1184 -1186.
39) Puig I, Baylina M, Sanchez-Delgado J, Lopez-Gongora S, Suarez D, Garcia-Iglesias P, Munoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor,amoxicillin and metronidazole for *Helicobacter pylori* first-line treatment. J Antimicrob Chemother. 2016;**71**(10):2740-53..
40) Quintero Díaz M, Behar Hasday R, García Lima CE, Pupo Olivero D, Hernández Domínguez M, Díaz Elías J, Pérez Suárez F. Use of viscous gel Aloe® in treatment of patients presenting duodenal ulcer and positive *Helicobacter pylori* | [Aloe gel viscoso® en el tratamiento de pacientes con úlcera duodenal y *Helicobacter pylori* positivo]. Revista Cubana de Plantas Medicinales. 2009; **14**(4).
41) Rohdewald P, Beil W. In vitro inhibition of *Helicobacter pylori* growth and adherence to gastric mucosal cells by Pycnogenol®. Phytother Res. 2008; **22**(5):685-688.
42) Sánchez-Delgado J, García-Iglesias P, Castro-Fernández M, Bory F, Barenys M, Bujanda L, Lisozain J, Calvo MM, Torra S, Gisbert JP, Calvet X. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high *Helicobacter pylori* eradication rates. Aliment Pharmacol Ther. 2012;**36**(2):190-6.
43) Shah S, Qaqish R, Patel V, Amiji M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for *Helicobacter pylori* infection. J Pharm Pharmacol. 1999; **51**(6): 667-672.
44) Sherwood PV, Wibawa JIremove tab formattingD, Atherton JC, Jordan N, Jenkins D, Barrett DA, Shaw PN, Spiller RC. Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats. Gut. 2002; **51**(4): 490-495.
45) Shmuely H, Yahav J, Samra Z, Chodick G, Koren R, Niv Y, Ofek I. Effect of cranberry juice on eradication of *Helicobacter pylori* in patients treated with antibiotics and a proton pump inhibitor. Mol Nutr Food Res. 2007; **51**(6):746-751.

46) Simala-Grant JL, Lam E, Keelan M, Taylor DE. Characterization of the DNA adenine 5′-GATC-3′ methylase HpyIIIM from *Helicobacter pylori*. Curr Microbiol. 2004; **49**(1): 47-54.
47) Simon PM. Pharmaceutical oligosaccharides. Drug Discovery Today. 1996; **1**(12):522-528.
48) Sjostrom JE, Larsson H. Factors affecting growth and antibiotic susceptibility of *Helicobacter pylori* - effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. J Med Microbiol. 1996; **44**(6):425-433.
49) Smaill F. Antibiotic susceptibility and resistance testing: An overview. Can J Gastroenterol. 2000; **14**(10): 871-875.
50) Thombre NA, Gide PS. Floating-bioadhesive gastroretentive *Caesalpinia pulcherrima*-based beads of amoxicillin trihydrate for *Helicobacter pylori* eradication. Drug Deliv. 2016;**23**(2):405-419.
51) von Rosenvinge EC, Graeme AO, Macfarlane S, Macfarlane GT, Shirtliff ME. Microbial biofilms and gastrointestinal diseases. Pathog Dis. 2013;**67**(1): 25-38.
52) White RL. What in vitro models of infection can and cannot do. Pharmacotherapy. 2001; **21**(11, Part 2): 292S-301S.
53) Williamson R, Pipkin GA, Wood JR. New options in *Helicobacter pylori* eradication- efficacy, resistance and synergy. Scand J Gastroenterol. 1998; **33**(S225): 36-40.
54) Yamamoto Y, Hakki A, Friedman H, Okubo S, Shimamura T, Hoffman PS, Rossignol JF. Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti- *Helicobacter pylori* agent with anti-vacuolating toxin activity. Chemotherapy. 1999; **45**(4): 303-312.
55) Yang JC, Lu CW, Lin CJ. Treatment of *Helicobacter pylori* infection:current status and future concepts. World J Gastroenterol. 2014;**20**(18):5283-93.

ЦИТИРАНА: 2А: Megraud F, **Boyanova L**, Lamouliatte H. Activity of lansoprazole against *Helicobacter pylori*. Lancet. 1991; **337**: 1486. **Цитирана от:**

56) Alassi MT, Cole RA, Karttunen TJ, Ezimaity HE, Genta RM, Graham DY. Treatment of *Helicobacter pylori* infection with omeprazole - amoxicillin combination therapy versus ranitidine - sodium bicarbonate - amoxicillin. Am J Gastroenterol. 1995; **90**(9): 1411-1414.
57) Alassi MT, Genta RM, Graham DY. Omeprazole-tetracycline combinations are inadequate as therapy for *Helicobacter pylori* infection. Aliment Pharmacol Ther. 1994; **8**(2): 259-262.
58) Arens MJ, Dent J. Acid pump blockers what are their current therapeutic-roles? Bailliere Clin. Gastroenterol. 1993;**7**(1): 95-129.
59) Axon ATR. The potential value of lansoprazole in *Helicobacter pylori* eradication. J Clin Gastroenterol. 1995; **20**(suppl 1): S43-S47.
60) Aydin A, Onder GF, Akarca US, Tekin F, Tunçyürek M, Musoğlu A. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on *Helicobacter pylori* eradication in clarithromycin resistant and- sensitive cases. Turk J Gastroenterol. 2005; **16**(4):203-206.
61) Barraddel LB, Faulds D, Mc Tavish D. Lanoprazole. A rewiew of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992; **44**(2): 255-250.
62) Bateson MC. Gastroenterology. 1. Gatroduodenal disease and *Helicobacter pylori* Postgrad Med J. 1994; **70** (826): 561-567.
63) Bazzoli F, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G, Berretti D, Deluca L. Efficacy of lansoprazole in eradicating *Helicobacter pylori* - a meta-analysis. Helicobacter. 1998; **3**(3): 195-201.
64) Bell GD, Powell KU, Burridge SM, Spencer G, Bolton G, Purser K, Brooks S, Prosser S, Harrison G, Gant PW, et al. Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant *Helicobacter pylori*. Aliment Pharmacol Ther. 1992; **6**(6):751-758.
65) Bell NJ, Hunt RH. Progress with proton pump inhibition. Yale J Biol & Medicine. 1992; **65**(6): 649-657.
66) Berlin RG. Current clinical management of peptic ulcer disease. Yale J Biol & Medicine. 1992; **65** (6): 689-692.
67) Berstad AE, Hatlebakk JG, Maartmannmoe H, Berstad A, Brandtzaeg P. *Helicobacter pylori* gastritis and epithelial cell proliferation in patients with reflux esophagitis after treatment with lansoprazole. Gut. 1997; **41**(6):740-747.
68) Bhasin DK, Sharma BG, Ray P, Pathak CM, Singh K. Comparison of 7 days and 14 days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of *Helicobacter pylori*- a report from India. Helicobacter. 2000; **5**: 84-87.
69) Blecker U, Gold BD. Treatment of *Helicobacter pylori* infection - a review. Pediatr Infect Dis J. 1997; **16**(4): 391-399.
70) Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. American Journal of Health-system pharmacy. 1996; **53**(12):1401-1415.
71) Buckley MJM, Xia HX, Hyde DM, Keane CT, O'Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Digest Dis Sci. 1997; **42**(10):2111-2115.
72) Burette A, Glupczynski Y. *Helicobacter pylori* - the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease. Infection. 1995; **23**(suppl 1): S44- S52.
73) Cahill RJ, Xia H, Kilgallen C, Beattie S, Hamilton H, O' Morain C. Effect of eradication of *Helicobacter pylori* infection on gastric epithelial cell proliferation. Digest Dis Science. 1995;**40**(8): 1627-1631.
74) Cammarota G, Tursi A, Papa A, Montalto M, Veneto G, Cuoco L, Fedeli G, Gasbarrini G. *Helicobacter pylori* eradication using one-week low-dose lansoprazole plus amoxicillin and either clarithromycin or azithromycin. Aliment Pharmacol Ther. 1996; **10**(6): 997-1000.
75) Couruzzi G, Adami M, Bertaccini G. Gastric antisecretory activity of lansoprazole in different experimental models - comparison with omeprazole. Gen Pharmacol. 1995; **26**(5): 1027-1032.
76) Dattilo M, Figura N. *Helicobacter pylori* infection, chronic gastritis, and proton pump inhibitors. J Clin Gastroenterol. 1998; **27**(S1): S163-S169.
77) DeBoer WA, Vanetten RJXM, Schade RWB, Ouwehand ME, Schneeberger PM, Tytgat GNJ. 4 day lansoprazole quadruple therapy - a highly effective cure for *Helicobacter pylori* infection. Am J Gastroenterol. 1996; **91**(9): 1778-1782.

78) Deboer WA, Vanetten RJXM, Schade RWB, Ouwehand ME, Schneeberger PM, Vanunnik AJM, Tytgat GNJ. One-day intensified-lansoprazole-quadruple therapy for cure of *Helicobacter pylori* infection. Aliment Pharmacol Ther. 1997; **11**(1):109-112.
79) Figura N, Crabtree JE, Dattilo M. *In vitro* activity of lansoprazole against *Helicobacter pylori* . J Antimicrob Chemother. 1997; **39**(5): 585-590.
80) Freston JW. Future prospects for proton pump inhibitors. Aliment Pharmacol Ther. 1993; **7**(suppl 1): 68-75.
81) Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists - their efficacy with antibiotics in *Helicobacter pylori* eradication. Aliment Pharmacol Ther. 2003,**18**(8):757-766.
82) Gisbert JP. Lansoprazole: An overview of its role in *Helicobacter pylori* eradication therapy [Lansoprazol: Revision de su papel en el tratamiento erradicador de *Helicobacter pylori*] Rev Esp Enferm Dig. 1999; **91**(2):133-143.
83) Gisbert JP. Potent gastric acid inhibition in *Helicobacter pylori* eradication. Drugs. 2005; **65** Suppl 1:83-96.
84) Graham DY, Genta R, Evans DG, Reddy R, Clarridge E, Olson DA, Edmonds AL, Siepman N. *Helicobacter pylori* does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol. 1996; **91**(10): 2120-2124.
85) Graham DY, Go MF, Evans Jr DJ. Review article: urease, gastric ammonium/ammonia, and *Helicobacter pylori* — the past, the present, and recommendations for future research. Aliment Pharmacol Ther. 1992; **6**(6): 659-669.
86) Graham DY, Hammoud F, El-Zimaity HM, Kim JG, Osato MS, El-Serag HB. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for *Helicobacter pylori* eradication. Aliment Pharmacol Ther. 2003; **17**(10):1229-1236.
87) Graham DY, Lew GM, Ramirez FC, Genta RM, Klein PD, Malaty HM. Short report: a non -metronidazole triple therapy for eradication of *Helicobacter pylori* infection-tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther. 1993;**7**:111-113.
88) Graham DY, Ramirez FC, Lew GM, Klein PD, Malaty HM, Genta RM. Omeprazole as an adjuvant to antimicrobial therapy for eradication of *Helicobacter pylori* infection. Current Ther Res. (Clinical and experimental). 1994; **55**(3): 213-219.
89) Graham KS, Malaty H, Elzimaity HMT, Genta RM, Cole RA, Alassi MT, Yousfi MM, Neil GA, Graham DY. Variability with omeprazole, amoxicilin combinations for treatment of *Helicobacter pylori* infection. Am J Gastroenterol. 1995; **90**(9):1415-1418.
90) Gupta VK, Dhar A, Srinivasan S, Rattan A, Sharma MP. Eradication of *Helicobacter pylori* in a developing country-comparison of lansoprazole versus omeprazole with norfloxacin, in a dual- therapy study. Am J Gastroenterol. 1997; **92**(7): 1140-1142.
91) Harris AW, Gummett PA, Logan RPH, Ashworth HM, Baron JH, Misiewicz JJ.. Eradication of *Helicobacter pylori* with lansoprazole and clarithromycin. Aliment Pharmacol Ther. 1995; **9**(2): 201-204.
92) Hatlebakk JG, Nesje LB, Hausken T, Bang CJ, Berstad A. Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Scand J Gastroenterol. 1995; **30**(11):1053-1057.
93) Kashimura H, Suzuki K, Hassan M, Ikezava K, Sawahata T, Watanabe T, Nakahara A, Mutoh H, Tanaka N. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxicillin and clarithromycin increases the cure rate of *Helicobacter pylori* infection. Aliment Pharmacol Ther. 1999; **13**(4): 483-487.
94) Katoh M, Asaka M, Kudoh M, Kagaya H, Katagiri M, Takeda H. Clinical efficacy of lansoprazole in eradication of *Helicobacter pylori.* J Clin Gastroenterol. 1995; **20**(suppl. 2): S112-S114.
95) Kayser S, Flury R, Zbinden R, Fried M, Wirth HP. Comparative effect of lansoprazole/amoxicillin and omeprazole/amoxicillin for eradication of *Helicobacter pylori* in duodenal ulcer patients. Schweiz Med Wschr. 1997; **127**(17): 722-727.
96) Korman MG, Bolin TD, Nicholson FB, Engelman JL. Lansoprazole quadruple therapy is effective in curing *Helicobacter pylori* infection. Helicobacter. 1998; **3**(3): 202-205.
97) Korman MG, Tytgat GNJ. *Helicobacter pylori* and peptic ulcer. Scand J Gastroenterol. 1995; **30** (suppl 210): 92-96.
98) Kuipers EJ, Lee A, Klinkenbergknol EC, Meuwissen SMG. The development of atrophic gastritis - *Helicobacter pylori* and the effect of acid suppresive therapy. Alim Pharm Therap. 1995; **9**(4): 331-340.
99) Labenz J. Current role of acid suppressants in *Helicobacter pylori* eradication therapy. Best Pract Res Clin Gastroenterol. 2001;**15**(3):413-431
100) Lanza F, Goff J, Scowcroft C, Jennings D, Greskirose P. Double - blind comparison of lansoprazole, ranitidine and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol. 1994; **89**(8):1191-1200.
101) Lanza F, Goff J, Silvers D, Winters J, Jhala N, Jennings D, Greskirose P. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole-a double blind placebo-controlled study. Dig Dis Sci. 1997; **42**(12): 2529-2536.
102) Lim AG, Walker C, Chambers S, Gould SR. *Helicobacter pylori* eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxicillin. Aliment Pharmacol Ther. 1997; **11**(3): 537-540.
103) Logan RPH. The chemotherapeutic effect of H+/K+ inhibitors on *Helicobacter pylori* infection. Pharmacol Therapeut. 1996; **69**(1): 79-83.
104) Louw JA., Marks IN.. The management of peptic ulcer desease in the 1990s. South African Medical Journal. 1995; **85**(6): 514–517.
105) Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract—evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020; **51**(5): 505-526.
106) Malaty H, Elzimaity HMT, Genta RM, Cole RA, Graham DY. High-dose proton pump inhibitor plus amoxicillin for the treatment or retreatment of *Helicobacter pylori* infection. Aliment Pharmacol Ther. 1996; **10**(6):1001-1004.
107) Matsukawa, Y., Kurosaka, H., Kato, K., Hayashi, I., Minekawa, K., Arakawa, Y., Sawada, S. Lansoprazole increases serum IgG and IgM in *H. pylori*-infected patients. Int J Immunopathol Pharmacol. 2007; **20**(1):173-179.
108) Mehmet S, Ozdal E, Kamil O, Beşir K, Huseyin D, Nihat A, Cigdem EY, Nusret E. Eradication of *Helicobacter pylori* in follicular and nonfollicular gastritis. Hepato-Gastroenterology. 2009; **56**(91-92): 930-934.
109) Mirshahi F, Fowler G, Patel A, Shaw G. Omeprazole may exert both a bacteriostatic and a bactericidal effect on the growth of *Helicobacter pylori* (NCTC-11637) in vitro by inhibiting bacterial urease activity. J. Clin. Pathol. 1988; **51**(3): 220-224.

110) Misiewicz JJ. *Helicobacter pylori*: past, present and future. Scand J Gastroenterol. 1992; **194** (suppl): 25-29.
111) Nakamura M, Matsui H, Serizawa H, Tsuchimoto K. Lansoprazole novel effector sites revealed by autoradiography: Relation to *Helicobacter pylori*, colon, esophagus and others. J Clin Biochem Nutr. 2007; **41** (3):154-159.
112) Nakao M, Tada M, Tsuchimori K, Uekata M. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against *Helicobacter pylori*. Eur J Clin Microbiol Infect Dis. 1995; **14**(5): 391-399.
113) Nakata H, Itoh H, Nishioka S. Efficacy of lansoprazole and amoxicillin in eradicating *Helicobacter pylori* - evaluation using 13C UBT and monoclonal *Helicobacter pylori* antibody testing. J Clin Gastroenterol. 1995, **20**(suppl 2): S118-S120.
114) Özden A, Seven G, Bektaş M. Effectiveness of different treatment regimens in *Helicobacter pylori* eradication: Ten-year experience of a single institution. Turk J Gastroenterol. 2010; **21**(3): 218-223.
115) Patel SK, Pratap CB, Jain AK, Gulati AK, Nath G. Diagnosis of *Helicobacter pylori*: what should be the gold standard? World J Gastroenterol. 2014;**20**(36):12847-59.
116) Pilotto A, Franceschi M, Leandro G, Bozzola L, Fortunato A, Rassu M, Meli S, Soffiati G, Scagnelli M, Dimario F, Valerio G. Efficacy of 7-day lansoprazole based triple therapy for *Helicobacter pylori* infection in elderly patients. J Gastroen Hepatol. 1999; **14**(5): 468-475.
117) Richardson P, Hawkey CJ, Stack WA. Proton-pump inhibitors-pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998; **56**(3): 307-335.
118) Sherman P, Shames B, Loo V, Maltow A, Drumm B, Penner J. Omeprazole therapy for *Helicobacter pylori* infection. Scand J Gastroenterol., 1992; **27**: 1018-1022.
119) Spencer CM, Faulds D. Lansoprasole-a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994; **48**(3): 404-430.
120) Spinzi GC, Bierti L, Bortoli A, Colombo E, Fertitta AM, Lanzi GL, Venturelli R, Minoli G. Comparison of omeprazole and lansoprazole in short-term triple therapy for *Helicobacter pylori* infection. Aliment Pharmacol Ther. 1998; **12**(5): 433-438.
121) Suzuki H, Hibi T. Novel effects other than antisecretory action and off-label use of proton pump inhibitors. Expert Opin Pharmacother. 2005; **6**(1):59-67
122) Trevisani L, Sartori S, Galvani F, Ruina M, Caselli M, Verdianelli G, Abbasciano V. Evaluation of a new ultra short triple therapy for *Helicobacter pylori* disease. Aliment Pharmacol Ther. 1998; **12**(12): 1269-1272.
123) Tsutsui N, Taneike I, Ohara T, Goshi S, Kojio S, Iwakura N, Matsumaru H, Wakisaka-Saito N, Zhang H-M, Yamamoto T. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of *Helicobacter pylori*. Antimicrob Agents Chemother. 2000; **44**:3069-3073.
124) Tytgat GNJ. Antimicrobial therapy for *Helicobacter pylori* infection. Helicobacter. 1997; **2**(S1): S81-S88.
125) Tytgat GNJ. Treatments that impact favorably upon the eradication of *Helicobacter pylori* and ulcer recurrence. Alim Pharm Therap. 1994; **8**(4): 359-368.
126) Verdu EF, Fraser R, Armstrong D, Blum AL. Effects of omeprazole and lansoprazole on 24 hour interagastric pH in *Helicobacter pylori*- positive volunteers. Scand J Gastroenterol. 1994; **29**(12): 1065-1069.
127) Vesper BJ, Jawdi A, Altman KW, Haines III GK, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009; **10**(1): 84-89.
128) Wagner S, Gebel M, Manns M. Treatment of *Helicobacter pylori* infection: the present state (Review) Z Gastroenterol. 1993; **31**: 459-463.
129) Zimmermann AE, Katona BG. Lansoprazole-a comprehensive review. Pharmacotherapy. 1997; **17**(2): 308-326.

ЦИТИРАНА: 20B: Pehlivanov N, **Boyanova L**, Petrov S. Failure of eradication of *Helicobacter pylori* using triple therapy and its resistance *in vitro*. Cs. Gastroenterol. Vyz. 1993; **47** (2): 113. **Цитирана от:**

130) Matysiak - Budnic T., Megraud F. *Helicobacter pylori* in eastern european countries. What is the current status? Gut. 1994; **35** (12):1683 - 1686.

ЦИТИРАНА: 4A: Boyanova L, Andreev N, Bouchard S, Megraud F. *Helicobacter pylori* seroprevalence in Bulgaria. Med. Microbiol. Lett. 1994; **3**: 107-113. **Цитирана от:**

131) Azevedo NF, Guimarães N, Figueiredo C, Keevil CW, Vieira MJ. A new model for the transmission of *Helicobacter pylori*: Role of environmental reservoirs as gene pools to increase strain diversity. Crit Rev Microbiol. 2007; **33**(3): 157-169.

ЦИТИРАНА: 5A: Petrov S., Pehlivanov N, **Boyanova L**, Mitova R, Dragnev I. Advantages of applications of a yellow filter and simple half - Gram staining for detection of *Helicobacter pylori* infection in gastric biopsy specimens. Modern Pathology. 1995; **8**(3): 339-340. **Цитирана от:**

132) Flejou JF, Sipponen P. Pathology. Curr Opin In Gastroenterol., 1996; **12**(suppl 1): 28-32.

ЦИТИРАНА: 6A: **Boyanova L**, Stancheva I, Todorov D, Kumanova R, Petrov S, Vladimirov B, Pehlivanov N, Mitova R, Chakarski I, Churchev I. Comparison of three urease tests for detection of *Helicobacter pylori* in gastric biopsy specimens. Eur J Gastroenterol Hepatol. 1996; **8**(9): 911-914**. Цитирана от:**

133) Bazzoli F, Zagari RM, Pozzato P, Fossi S, Ricciardiello L, De Luca L, Nicolini G, Berretti D, Maltoni S, Gorini B, Martuzzi C, Fuccio L, Roda E. *Helicobacter pylori:* Optimum diagnosis and test of cure. J Chemother. 1999; **11**(6): 601-605.
134) Helaly GF, El-Afandy NM, Hassan AA, Dowidar NL, Sharaf SM. Diagnostic Value of Housekeeping [glmM] gene expression in antral biopsies in comparison to rapid urease test and histological detection of *Helicobacter pylori* infection. Egyptian Journal of Medical Microbiology, 2009; **18** (4):119-130.
135) Leyva LM, Pascual MG-C. *Helicobacter pylori* en la patología gastroduodenal: una puesta al día. Gastroenterologia. 2008-2011. http://www.sld.cu/sitios/gastroenterologia/temas.php?idv=18247
136) López-Brea M, Alarcón T, Mégraud F. Diagnosis of *Helicobacter pylori* infection. Curr Opin In Gastroenterol. 1997; **13**(Suppl 1):13-19.
137) Marshall BJ, Winsdor H, Ho G, Chairman S, Mendis A. Diagnosis of *Helicobacter pylori*. Baillieres Clin Infect Dis. 1997; **4**(3): 367-393.

138) Megraud F, Lehours P. *Helicobacter pylori* detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007; **20**(2): 280-322.
139) Talebi Bezmin Abadi A. Diagnosis of *Helicobacter pylori* using invasive and noninvasive approaches. J Pathog. **2018**;2018.
140) Tanih NF, Clarke AM, Mkwetshana N, Green E, Ndip LM, Ndip RN. *Helicobacter pylori* infection in Africa: Pathology and microbiological diagnosis. African Journal of Biotechnology. 2008; **7**(25):4653-4662.
141) Westblom TU, Bhatt BD. Diagnosis of *Helicobacter pylori* infection. Curr. Top. Microbiol. Immunol. 1999; **241**: 215-235.

ЦИТИРАНА: 7A: Boyanova L, Koumanova R, Jelev Chr, Petrov S. *Helicobacters* in Bulgarian children. J R Soc Med. 1997; **90** (10): 588-589. **Цитирана от:**

142) Hasan ÜM, Ünsal G, Tezel A, Soylu AR. *Helicobacter pylori* infection and benign gastroduodenal diseases, data from the Trakya region. Balkan Med J. 2010; **2010**(5).
143) Ignat A, Burlea M, Lupu VV, Ciubară A, Florea I, Păduraru G. Infecţia cu *Helicobacter pylori* la copil – date de actualitate. Revista Românå De Boli infecºioase. 2015; **XVIII**(2-3). http://rjid.com.ro/articles/2015.2-3/Infectio_Nr-2-3_2015_Art-4.pdf
144) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016;**43**(4):514-33.
145) Ümit H, Ünsal G, Tezel A, Soylu AR. *Helicobacter pylori* infection and benign gastroduodenal diseases, data from the Trakya Region. Trakya Univ Tip Fak Derg (Balkan Med J) 2010; **27**(4): 400-403.

ЦИТИРАНА: 10A: Boyanova L, Neshev G. Inhibitory effect of rose oil products on *Helicobacter pylori* growth in vitro: preliminary report. J. Med. Microbiol. 1999; **48**: 705-706. **Цитирана от:**

146) Abduelrahman AA, Yusoff MM, Nour AH. Antibacterial Activity of the Essential Oils of Sudanese accessions of basil (*Ocimum basilicum* L.). Journal of Applied Sciences. 2009; **9**(23):4161-4167.
147) Alam P, Gupta J, Firdouse S, Arshia Firdouse Juveriya Afshan. HPTLC method for qualitative and quantitative estimation of eugenol from Ocimum sanctum Linn in polyherbal formulation. Pharmacie Globale (IJCP) 2012; **3** (10):1-3.
148) Annalakshmi T, Fathima KM, Innocent BX, Sivagurunathan A. Evaluation of immunostimulatory potential of *Phyllanthus amarus* in labeo rohita infected with *Aeromonas hydrophila*: haematological assessment. International Journal of Research in Ayurveda & Pharmacy. 2013 Jan 1;4(1). http://www.ijrap.net/admin/php/uploads/956_pdf.pdf
149) Becker PM. Physiological Achilles' heels of enteropathogenic bacteria in livestock. Curr Issues Intest Microbiol. 2005; **6**(2):31-54.
150) Bhadoriyal SS, Mandoriya N. Immunomodulatory effect of *Tricosanthes dioica* Roxb. Asian Pacific Journal of Tropical Biomedicine. 2012; **2**(2):S985-S987.
151) Bhattamisra SK, Yan VL, Lee CK, Kuean CH, Candasamy M, Liew YK, Sahu PS. Protective activity of geraniol against acetic acid and *Helicobacter pylori*-induced gastric ulcers in rats. J Tradit Complement Med. 2018; **9**(3): 206-214.
152) Bhattamisra, S.K., Kuean, C.H., Chieh, L.B., (...), Candasamy, M., Sahu, P.S. Antibacterial activity of geraniol in combination with standard antibiotics against *Staphylococcus aureus*, *Escherichia coli* and *Helicobacter pylori*. Natural Product Communications 2018; **13**(7): 791-793.
153) Caroline Jeba R, Vaidyanathan R, Rameshkumar G. Efficacy of *Ocimum basilicum* for immunomodulatory activity in Wistar albino rat. International Journal of Pharmacy and Pharmaceutical Sciences. 2011; **3**(4): 199-203.
154) Choudhury S, Sinha MP. Effects of *Psidium guajava* aqueous extract on testosterone and serum lipid profile of albino rats. Middle-East J Sci Res. 2014; **21**(10): 1893-1897. http://www.idosi.org/mejsr/mejsr21(10)14/30.pdf
155) Dizdar OS, Eminler AT, Ayyildiz T, Kahyaoğlu Z, Dolar E. Gastric xanthalesmas: Report of five cases and review of the literature. Journal of Experimental and Clinical Medicine. 2015; **32**(2): http://dergi.omu.edu.tr/omujecm/article/view/5000016019/0
156) Franklin L, Pimentel J, inventors; Franklin Lanny Udell, Pimentel Julio L., assignee. Prevention and treatment of digestive tract infections. United States patent application US 10/045,352. 2002.
157) Gomez-Flores R, Calderon CL, Scheibel LW, Tamez-Guerra P, Rodriguez-Padilla C, Tamez-Guerra R, Weber RJ. Immunoenhancing properties of Plantago major leaf extract. Phytother Res. 2000; **14**(8): 617-622.
158) Gomez-Flores R, Verástegui-Rodríguez L, Quintanilla-Licea R, Tamez-Guerra P, Tamez-Guerra R, C. Rodríguez-Padilla C. In vitro rat lymphocyte proliferation induced by *Ocinum basilicum*, *Persea americana*, *Plantago virginica*, and *Rosa* spp. extracts. Journal of Medicinal Plants Research 2008; **2**(1): 5-10.
159) Grandics P. Cancer: A single disease with a multitude of manifestions?. J Carcinog 2003;**2**:9.
160) Gülçin I, Elmastaş M, Aboul-Enein HY. Determination of antioxidant and radical scavenging activity of basil (*Ocimum basilicum L.* Family *Lamiaceae*) assayed by different methodologies. Phytother Res. 2007; **21**(4): 354-361.
161) Haristoy X., Angioi-Duprez K., Duprez A., Lozniewski A. Efficacy of sulforaphane in eradicating *Helicobacter pylori* in human gastric xenografts implanted in nude mice. Antimicrob Agents Chemother. 2003; **47**(12): 3982-3984.
162) Hierro I, Valero A, Perez P, Gonzalez P, Cabo MM, Montilla MP, Navarro MC. Action of different monoterpenic compounds against Anisakis simplex s.l. L3 larvae. Phytomedicine. 2004; **11**(1): 77-82.
163) Jeba RC, Vaidyanathan R, Rameshkumar G. Immunomodulatory activity of aqueous extract of *Ocimum sanctum* in rat. International Journal on Pharmaceutical and Biomedical Research (IJPBR). 2011; **2**(1): 33-38.
164) Kalpoutzakis E, Aligiannis N, Mentis A, Mitaku S, Charvala C. Composition of the essential oil of two *Nepeta* species and in vitro evaluation of their activity against *Helicobacter pylori*. Planta Med. 2001; **67**(9): 880-883.
165) Kara A, Algur Öf, Köseoğlu Mş. Bazı Şifalı Bitkilerin *Helicobacter pylori* üzerindeki Antimikrobiyal Aktiviteleri. Cumhuriyet Science Journal. 2016;**37**(2):129-140.
166) Kullu AR, Tabassum W, Sinha MP. Effects of *Psidium guajava* aqueous extracts on haematological profile and serum lipid variables of albino rats. The Bioscan. 2013; **8**(2):743-746, 2013 (Supplement on Medicinal plants).
167) Lee BB, Choi J-S, Moon HE, Ha Y-M, Kim MS, Cho KK et al . Inhibition of growth and urease of *Helicobacter pylori* by Korean edible seaweed extracts. Bot. sci 2013; **91**(4): 515-522. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2007-42982013000400010&lng=es.

168) Moulaei H, Namakin K, Namaei MH, Azarkar Z. The effect of red rose extract on *Helicobacter pylori* eradication: A randomized controlled clinical trial. International Journal of Pediatrics. 2019; **7**(12): 10473-10480.
169) Nanganuru HY. Effect of concentration of leaves extract on the α- amylase, α-glucosidase activity and microorganism growth. International Journal of Engineering Sciences & Research Technology 2013; **2**(2): 312-315.
170) Nour, AH, Elhussein, SA, Osman, NA, Ahmed, NE, Abduelrahman, AA, Yusoff, MM, Nour, AH. Antibacterial activity of the essential oils of Sudanese accessions of basil (*Ocimum basilicum L.*). Journal of Applied Sciences. 2009; **9**(23): 4161-4167.
171) Opalchenova G, Obreshkova D. Comparative studies on the activity of basil-an essential oil from *Ocimum basilicum* L.- against multidrug resistant clinical isolates of the genera *Staphylococcus*, *Enterococcus* and *Pseudomonas* by using different test methods. J Microbiol Methods. 2003; **54**(1): 105-110.
172) Reyes S, Tamez G, Christina Rodriguez P, Patricia Tamez G, Weber RJ, Ricardo Gomez F, Calderon CL. Activacion de macrophagos y linfocitos in vitro por extrctos metanolicos de hojas de plantago major. Ciencia Uanl. 2001; **IV**(3):304-313.
173) Silva D, Denham E, Faleiro L, Miguel G, Cavaleiro C, Salgueiro L. Antimicrobial activity of the essential oils of *Dittrichia viscosa* subsp. *viscosa* on *Helicobacter pylori.* Acta Hort. (ISHS) 2005; (No. 680): 147-151.
174) Tamez Guerra RS, Rodríguez Padilla C, Tamez Guerra P, Weber RJ, Gómez Flores RA, Calderón CL. Activación de macrófagos y linfocitos in vitro por extractos metanólicos de hojas de *Plantago major*. Ciencia UANL. 2001;**4**(3):304-313.

ЦИТИРАНА: 11А: Petrov S, Churtchev J, Mitova R, **Boyanova L**, Tarassov M. Xanthoma of the stomach-some morphometrical peculiarities and scanning electron microscopy. Hepato- Gastroenterology. 1999; **46**: 1220-1222. **Цитирана от:**

175) Akın M, Ersoy İH, Şenol A, Aksakal G. (2014). Xanthelasmas of the upper gastrointestinal tract: their significance and association with dyslipidemi. Cytokine,.2014; **74:** 78.
176) Basyigit S, Kefeli A, Asilturk Z, Sapmaz F, Aktas B. Gastric Xanthoma: A Review of the Literature. Shiraz E-Medical Journal. 2015; **16**(7): e29569.
177) Bhattacharya S, Banerjee D, Bauri AK, Chattopadhyay S, Bandyopadhyay SK. Dyslipidemia and *H pylori* in gastric xanthomatosis World J Gastroenterol. 2007; **13**(34): 4598-4601.
178) Detlefsen S, Fagerberg CR, Ousager LB, Lindebjerg J, Marcussen N, Nathan T, Sørensen FB. Histiocytic disorders of the gastrointestinal tract. Human pathology. 2013; **44**(5), 683-696.
179) Dizdar OS, Eminler AT, Ayyildiz T, Kahyaoglu Z, Dolar E. Gastric xanthalesmas: Report of five cases and review of the literature. Journal of Experimental and Clinical Medicine (Turkey). 2015; **32**(2): 91-95.
180) Gencosmanoglu R, Sen-Oran E, Kurtkaya-Yapicier O, Tozun N. Xanthelasmas of the upper gastrointestinal tract. J Gastroenterol. 2004; **39**(3): 215-219.
181) Gencosmanoglu R. Duodenal xanthelasmas. J Gastroenterol. 2005; **40**(6): 658-659.
182) Gómez MA, Otero W, Buitrago M. Gastric xanthoma is associated with malignant ad premalignant lesions. Rev Col Gastroenterol. 2015; **30**(2):150-154.
183) Halabi I, Yaseen M, Vesoulis Z. Multiple gastric xanthomas in a 3-year-old patient. Gastroenterol Hepatol (NY). 2010; **6**(3):181-183.
184) Kamisawa T, Egawa N, Tsuruta K, Okamoto A. Gallbladder carcinoma associated with pancreaticobiliary maljunction presenting as severe acute pancreatitis. J Gastroenterol. 2005; **40**(6): 659-660.
185) Koike T, Kanke K, Ishikawa J, Morita K, Sasai T, Suzuki Y, Watanabe H, Hiraishi H. A case of early gastric cancer which look like xanthoma during follow-up monitoring. Dokkyo Journal of Medical Sciences 2007; **34**(1): 63-68.
186) Nostrant TT. Multiple gastric xanthomas in a 3-year-old patient. Gastroenterology & Hepatology. 2010; **6**(3): 183-184.
187) Oviedo J, Swan N, Farraye FA. Gastric xanthomas. Am J Gastroenterol. 2001; **96**(11): 3216-3218.
188) Pérez RP, Torres PR, Peláez RP, Prieto VH. Xantelasma gástrico y *Helicobacter pylori*. Reporte de un caso y revisión de la literatura.Medisur, 2013; **11**(1): 80-86.
189) Sekikawa A, Fukui H, Maruo T, Tsumura T, Kanesaka T, Okabe Y, Osaki Y. Gastric xanthelasma may be a warning sign for the presence of early gastric cancer. J Gastroenterol Hepatol. 2014; **29**(5): 951-956.
190) Uğuz A, Doran F, Gümürdülü D, Karaoğlan A, Öksüz M. Xanthoma on the basis of chronic gastritis: A case report. Annals of Medical Sciences. 2002; **11**(2-4): 49-51.
191) Xiao D, Tong X, Yuan X, Wu Y, Chen P. Gastric xanthelasma may be a warning sign of intestinal metaplasia: A cross-sectional study. Oncology Reports. 2020; **44**(3): 1275-1281.
192) Xiong Q, Wang Z, He L, Zhang Y. Relationship Between Gastric Xanthelasma and Atrophic Gastritis: A Single center retrospective study. Chinese Journal of Gastroenterology. 2017; **22**(9):529-533.
193) Yi SY. Dyslipidemia and *H pylori* in gastric xanthomatosis. World J Gastroenterol. 2007; **13**(34): 4598-4601.

ЦИТИРАНА: 12А: Boyanova L, Spassova Z, Krastev Z, Petrov S, Stancheva I, Docheva J, Mitov I, Koumanova R. Characteristics and trends in macrolide resistance among *Helicobacter pylori* strains isolated in Bulgaria over four years. Diagn Microbiol Infect Dis. 1999; **34** (4): 309 -313. **Цитирана от:**

194) Canton R, de Argila CM, de Rafael L, Baquero F. Antimicrobial resistance in *Helicobacter pylori* Rev Med Microbiol. 2001; **12**:47-61.
195) Di Mario F, Cavallaro LG, Scarpignato C. 'Rescue' therapies for the management of *Helicobacter pylori* infection. Dig Dis. 2006; **24**(1-2): 113-130.
196) García Díaz E, Romero Gómez M, Vargas J, Guil A, Bernal S, Castro M. Prevalence and clinical significance of antibiotic resistance in *Helicobacter pylori*. Rev Esp Enferm Dig 2000; **92**(10): 651-660.
197) Gold BD. *Helicobacter pylori* infection in children. Curr Probl Pediatr., 2001, **31**(8): 247-266.
198) Lü L, Mei Z-C. The mechanism and detection of *Helicobacter pylori* resistance to macrolides. Chinese Journal of Antibiotics 2007; **32**(1).
199) Masuda H, Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Characteristics and trends of clarithromycin-resistant *Helicobacter pylori* isolates in Japan over a decade. Pathobiology. 2004; **71**(3): 159-163.
200) Megraud F. *H pylori* antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; **53**(9): 1374-1384.

201) Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of *Helicobacter pylori* to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001; **161**(9): 1217-1220.
202) Osato MS, Reddy SG, Piergies AA, Bochenek WJ, Testa RT, Graham DY. Comparative efficacy of new investigational agents against *Helicobacter pylori*. Aliment Pharmacol Ther. 2001; **15**(4):487-492.
203) Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. *Helicobacter pylori* antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther. 2001; **15**(9):1473-1438.
204) Rhomberg PR, Biedenbach DJ, Jones RN. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, *Campylobacter jejuni*, *Helicobacter pylori* and *Legionella* spp. Diagn Microbiol Infect Dis. 2001; **40**(1-2): 45-49.
205) Taneike I, Goshi S, Tamura Y, Wakisaka-Saito N, Matsumori N, Yanase A, Shimizu T, Yamashiro Y, Toyoda S, Yamamoto T. Emergence of clarithromycin-resistant *Helicobacter pylori* (CRHP) with a high prevalence in children compared with their parents. Helicobacter. 2002; **7**(5):297-305.
206) Taneike I, Nami A, O'Connor A, Fitzgerald N, Murphy P, Qasim A, O'Connor H, O'Morain C. Analysis of drug resistance and virulence-factor genotype of Irish *Helicobacter pylori* strains: is there any relationship between resistance to metronidazole and *cagA* status? Aliment Pharmacol Ther. 2009; **30**(7): 784-790.
207) Toracchio S, Marzio L. Primary and secondary antibiotic resistance of *Helicobacter pylori* strains isolated in central Italy during the years 1998-2002. Dig Liver Dis. 2003; **35**(8): 541-545.
208) Touati E, Correia M, Machado JC, Michel V, inventors; Machado Jose Carlos, Michel Valerie, assignee. Docosahexanoic acid as inhibitor of *H. pylori*. United States patent application US 12/558,344. 2009 Sep 11.
209) Walter R. Miscellaneous antibacterial drugs. Side Effects of Drugs Annual. 2001;**24**:283-313.
210) Williamson JS. *Helicobacter pylori*: Current chemotherapy and new targets for drug design. Curr Pharm Des. 2001; **7**(5):355-392
211) Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of *Helicobacter pylori* in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol. 2002; **51**(8):705-709.
212) Zanetti MV. Epidemiologia delle resistenze di *Helicobacter pylori* alle sostanze antibatteriche piú utilizzate nella terapia di eradicazione (Ospedale di Merano 1998–2002). Microbiologia Medica. 2003;**18**(3): 227-233.
213) Абдулхаков РА, С. Р. Абдулхаков СР. Резистентность *Helicobacter pylori* к препаратам, используемым в схемах эрадикационной терапии и распространенность резистентных штаммов. Практическая медицина. 2006; **4**(18):7-10. (на стр. №8)

ЦИТИРАНА: 13A: Boyanova L. Comparative evaluation of two methods for testing metronidazole susceptibility of *Helicobacter pylori* in routine practice. Diagn Microbiol Infect Dis. 1999; **35** (1): 33 - 36. **Цитирана от:**

214) Falsafi T, Mobasheri F, Nariman F, Najafi M. Susceptibilities to different antibiotics of *Helicobacter pylori* strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol. 2004; **42**(1): 387-389.
215) Kataria R, Khatkar A. In-silico design, synthesis, ADMET studies and biological evaluation of novel derivatives of Chlorogenic acid against Urease protein and *H. pylori* bacterium. BMC Chemistry. 2019; **13**(3):41.
216) Khashei R, Shojaei H, Adibi P, Shavakhi A, Aslani MM, Naser AD. Genetic diversity and drug resistance of *Helicobacter pylori* strains in Isfahan, Iran. Iranian Journal of Basic Medical Sciences. 2008; **11**(3): 174-182.
217) Kulsantiwong P, Chomvarin C, Mairiang P, Sangchan A, Chanlertrith K, Chaicumpar K, ... & Kularbkaew C. PCR-RFLP and antimicrobial susceptibility profiles of *Helicobacter pylori* isolated from antrum and corpus of dyspeptic patients in Thailand. Southeast Asian Journal of Tropical Medicine & Public Health. 2012;**43**(4), 933-942.
218) Megraud F, Lehours P. *Helicobacter pylori* detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007; **20**: 280-322.
219) Nakajima S, Inoue H, Inoue T, Maruoka Y. Multiple-antibiotic-resistant *Helicobacter pylori* infection eradicated with atailor-made quadruple therapy. J Gastroenterol Hepatol. 2012;**27** Suppl 3:108-111.
220) Naser D. Genetic diversity and drug resistance of *Helicobacter pylori* strains in Isfahan, Iran. Iran J Basic Med Sci. 2008; 11:174-182.
221) Osato MS. Antimicrobial susceptibility testing for *Helicobacter pylori*: Sensitivity test results and their clinical relevance. Curr Pharm Des. 2000; **6**(15): 1545-1555.
222) Perna, Figura, Gatta, Ricci, Bernabucci, Vaira. Accuracy of E-test for metronidazole susceptibility in *H. pylori*. Am J Gastroenterol. 2004; **99**(12): 2500-2500.
223) Wang YC, Huang TL. Anti-*Helicobacter pylori* activity of *Plumbago zeylanica* L. FEMS Immunol Med Mic. 2005; **43**(3): 407-412.
224) Wang YC, Huang TL. Screening of anti-*Helicobacter pylori* herbs deriving from Taiwanese folk medicinal plants. FEMS Immunol Med Mic. 2005; **43**(2): 295-300.
225) Wang YC. Medicinal plant activity on *Helicobacter pylori* related diseases. World J Gastroenterol. 2014; **20**(30), 10368.

ЦИТИРАНА: 14A: Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in *Helicobacter pylori* in Sofia, Bulgaria. J. Med. Microbiol. 2000; **49**: 415–418. **Цитирана от:**

226) Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in *Helicobacter pylori* strains isolated from the northern population of Iran. J Microbiol. 2011;**49**(6):987-993.
227) Alarcón-Millán J, Fernández-Tilapa G, Cortés-Malagón EM, Castañón-Sánchez CA, de Sampedro-Reyes J, Carmen IC, Betancourt-Linares R,Román-Román A. Clarithromycin resistance and prevalence of *Helicobacter pylori* virulent genotypes in patients from Southern Mexico with chronic gastritis. Infect Genet Evol. 2016; **44**:190-198.
228) Claros PM, Bilbao RP, Damiani ME, Gonzales DE, Estensoro CM, Alvarez AMT. Actividad anti-*Helicobacter pylori* de *Plantago majo*r, *Clinopodium bolivianum*, *Calendula officinalis* y *Viper angustifolium* por el método de difusión de disco. Biofarbo. 2007; **15**(1): 37-42.

229) Dailidiene D, Bertoli MT, Miciuleviciene J, Mukhopadhyay AK, Dailide G, Pascasio MA, Kupcinskas L, Berg DE. Emergence of tetracycline resistance in *Helicobacter pylori*: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother. 2002; **46**(12): 3940-3946.
230) Dial EJ, Lichtenberger LM. Effect of lactoferrin on *Helicobacter felis* induced gastritis. Biochem Cell Biol, 2002; **80**: 113-117.
231) Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminathan B, Taylor T, Hoekstra M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmid S, Parsonnet J, Triadafilopoulos G, Perez-Perez GI, Vakil N, Ernst P, Czinn S, Dunne D, Gold BD. Antimicrobial resistance incidence and risk factors among *Helicobacter pylori*–infected persons, United States. Emerg Infect Dis. 2004; **10**(6): 1088-1094.
232) Eng NF, Ybazeta G, Chapman K, Fraleigh NL, Letto R, Altman E, Diaz-Mitoma F. Antimicrobial susceptibility of Canadian isolates of *Helicobacter pylori* in Northeastern Ontario. Can J Infect Dis Med Microbiol. 2015; **26**(3):137-144.
233) Ezzat AHH, Ali MH, El-Seidi EA, Wali IE, Sedky NAER, Naguib SMM. Genotypic characterization of *Helicobacter pylori* isolates among Egyptian patients with upper gastrointestinal diseases. The Chinese-German Journal of Clinical Oncology. 2012; **11**(1):15-23.
234) Falsafi T, Mobasheri F, Nariman F, Najafi M. Susceptibilities to Different Antibiotics of *Helicobacter pylori* Strains Isolated from Patients at the Pediatric Medical Center of Tehran, Iran. J Clin Microbiol. 2004; **42** (1): 387-389.
235) Fujimura S, Kato S, Iinuma K, Watanabe A. In vitro activity of fluoroquinolone and the *gyrA* gene mutation in *Helicobacter pylori* strains isolated from children. J Med Microbiol. 2004; **53**(10): 1019-1022.
236) Gao XZ, Qiao XL, Song WC, Wang XF, Liu F. Standard triple, bismuth pectin quadruple and sequential therapies for *Helicobacter pylori* eradication. World J Gastroenterol. 2010; **16**(34): 4357–4362.
237) Gerrits MM, Berning M, Van Vliet AHM, Kuipers EJ, Kusters JG. Effects of 16S rRNA gene mutations on tetracycline resistance in *Helicobacter pylori*. Antimicrob Agents Chemother. 2003; **47**(9): 2984-2986.
238) Gerrits MM, de Zoete MR, Arents NLA, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in *Helicobacter pylori*. Antimicrob Agents Chemother. 2002; **46**(9): 2996-3000.
239) Ghotaslou R, Milani M, Akhi MT; Hejazi MS, Nahaei MR, Hasani A, Sharifi Y. Relationship between drug resistance and cagA gene in *Helicobacter pylori*. Jundishapur Journal of Microbiology. 2013; **6**(10): e8480
240) Gonzalez CC, Garcia CA, Daroch MF, Kawaguchi PF, Solar RH, Rivera FN, Vega CE. Susceptibilidad in vitro de cepas de *Helicobacter pylori*: aislamiento de cepas resistentes a claritromicina. Rev méd Chile. 2001; **129**(6):643-646.
241) Gościniak G, Iwańczak B, Przondo-Mordarska A, Grabińska J, Iwánczak F. Susceptibility of *H. pylori* strains to selected chemotherapeutics. [Ocena wraiżliwości szczepów *Helicobacter pylori* na wybrane chemioterapeutyki] Pediatria Polska 2001; **76**(12): 873-877.
242) Gosciniak G, Iwanczak B, Przondo-Mordarska A, Grabinska J, Iwanczak F. High level of resistance to metronidazole and clarithromycin in *Helicobacter pylori* isolated from paediatric patients in Poland (1997-2001). Folia Microbiologica. 2004; **49**(2): 133-136.
243) Hiyama T, Tanaka S, Masuda H, Shima H, Kose K, Tuncel H, Ito M, Kitadai Y, Sumii M, Uemura N, Yoshihara M, Shimamoto F, Haruma K, Chayama K. Prevalence of *Helicobacter pylori* resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and *rdxA* gene analyses in Hiroshima, Japan. J Gastroenterol Hepatol. 2003; **18**(10): 1202-1207.
244) Huang, L-P, Zhuang, M-L, Gu, C-P. Antimicrobial resistance of 36 strains of *Helicobacter pylori* in adolescents. Chinese Journal of Contemporary Pediatrics. 2009; **11**(3): 210-212.
245) Kese D, Gubina, M, Kogoj R, Strasek K, Tepes B. Detection of point mutations in the *gyrA* gene of *Helicobacter pylori* isolates in Slovenia. Hepato-Gastroenterology. 2009; **56**(91-92): 925-929.
246) Khashei R, Shojaei H, Adibi P, Shavakhi A, Aslani MM, Naser AD. Genetic diversity and drug resistance of *Helicobacter pylori* strains in Isfahan, Iran. Iranian Journal of Basic Medical Sciences. 2008; **11**(3): 174-182.
247) Khedmat H, Amini M, Jafari AM, Afshar FN, Soltanpoor MJ, Fallahian F, Izadi M, Hosseini MS. In vitro susceptibility testing of *Helicobacter pylori* to metronidazole, amoxicillin, tetracycline and ciprofloxacin in Iran. Research Journal of Microbiology 2007; **2**(12): 947-953.
248) Kimber I, Cumberbatch M, Dearman RJ, Headon DR, Bhushan M, Griffiths CE. Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. Biochemistry and cell biology. 2002; **80**(1):103-107.
249) Kulsantiwong, P.,Chomvarin, C.,Mairiang, P., (...),Namwat, W.,Kularbkaew, C. Pcr-rflp and antimicrobial susceptibility profiles of *Helicobacter pylori* isolated from antrum and corpus of dyspeptic patients in Thailand. Southeast Asian J Trop Med Public Health. 2012; 43 (4): 933-942.
250) Kulsuntiwong P, Chomvarin C, Chaicumpar K, Namwat W, Kaewkes W, Mairiang P, Sangchan A. Antimicrobial susceptibility of *Helicobacter pylori* isolated from gastric biopsies in dyspeptic patients. Southeast Asian J Trop Med Public Health. 2008; **39**(6): 1102-1109.
251) Kwon DH., Kim JJ., Lee M., Yamaoka Y., Kato M., Osato MS., El-Zaatari FAK., Graham DY. Isolation and characterization of tetracycline-resistant clinical isolates of *Helicobacter pylori.* Antimicrob Agents Chemother. 2000; **44**(11): 3203-3205.
252) Leodolter A, Mégraud F. Diagnosis of *Helicobacter pylori* infection. Curr Opin Gastroenterol. 2001; **17**(Suppl. 1): S19-S23.
253) Lin G-Y. Progress in research into the molecular mechanism of drug resistance of *Helicobacter pylori*. World Chinese Journal of Digestology 2007; **15**(25): 2698-2703.
254) Manyi-Loh, CE, Clarke, AM, Mkwetshana, NF, Ndip, RN. Treatment of *Helicobacter pylori* infections: Mitigating factors and prospective natural remedies. African Journal of Biotechnology. 2010; **9**(14): 2032-2042.
255) Milani M, Ghotaslou R, Akhi MT, Nahaei MR, Hasani A, Somi MH, Rafeey M, Sharifi Y. The status of antimicrobial resistance of *Helicobacter pylori* in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother. 2012;**18**(6):848-852.

256) Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, Mitani T, Morita Y, Tamura T, Kinoshita S, Okano Y, Kumagai S, Kasuga M. Primary levofloxacin resistance and gyrA/B mutations among *Helicobacter pylori* in Japan. Helicobacter. 2006; **11**(4): 243-249.
257) Nishizawa T, Suzuki H, Hibi T. Quinolone-based third-line therapy for *Helicobacter pylori* eradication. J Clin Biochem Nutr. 2009; **44**(2):119-124.
258) Nelson, F., Ybazeta, G., Chapman, K., (...), Altman, E., Diaz-Mitoma, F. Antimicrobial susceptibility of Canadian isolates of *Helicobacter pylori* in Northeastern Ontario Canadian Journal of Infectious Diseases and Medical Microbiology. 2015; 26(3): 137-144.
259) Ozbey G, Bahcecioglu IH, Acik MN. Resistance rates to various antimicrobial agents of *Helicobacter pylori* isolates in Eastern Turkey. Inter J Mol Clin Microbiol. 2012; **2**:148-152.
260) Safaralizadeh R, Siavoshi F, Malekzadeh R, Akbari MR, Derakhshan MH, Sohrabi MR, Massarrat S. Antimicrobial effectiveness of furazolidone against metronidazole-resistant strains of *Helicobacter pylori.* East Mediterr Health J. 2006; **12**(3-4):286-293.
261) Segura-Cabrera A, Guo X, Rojo-Domínguez A, Rodríguez-Pérez MA. Integrative computational protocol for the discovery of inhibitors of the *Helicobacter pylori* nickel response regulator (NikR). J Mol Model. 2011; **17** (12): 3075-3084.
262) Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of *Helicobacter pylori* resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. Int J Antimicrob Agents. 2002; **19**(2):155-158.
263) Siavoshi F, Safari F, Doratotaj D, Khatami GR, Fallahi GH, Mirnaseri MM. Antimicrobial resistance of *Helicobacter pylori* isolates from Iranian adults and children. Arch Iran Med. 2006; **9**(4):308-314.
264) Suzuki H, Nishizawa T, Hibi T. *Helicobacter pylori* eradication therapy. Future Microbiol. 2010; **5**(4): 639-648.
265) Suzuki RB, Almeida CM, Sperança MA. Absence of *Helicobacter pylori* high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol. 2012; **12**:49.
266) Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of *Helicobacter pylori* in Mazandaran, North of Iran. Helicobacter. 2010; **15**(6): 505-509.
267) Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in *gyrA* but not in *gyrB* are associated with low- and high-level fluoroquinolone resistance in *Helicobacter pylori*. Antimicrob Agents Chemother. 2003; **47**(12): 3942-3944.
268) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016;**43**(4):514-33.
269) Ubani UA, Timothy CO, Ihesiulor GC. Assessment of *Helicobacter pylori* in glaucoma disease in abia state of Nigeria. International Educational Applied Scientific Research Journal. 2017;**2**(3): 2456-5040.
270) Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of *Helicobacter pylori* in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol. 2002; **51**(8): 705-709.
271) Yakoob J, Fan X, Hu G, Liu L, Zhang Z. Antibiotic susceptibility of *Helicobacter pylori* in the Chinese population. J Gastroenterol Hepatol 2001; **16**: 981–985.
272) Yu C, Li L, Chen W, Jiao Y, Yang N, Yang E, Zhang J, Chen L, Li Y. Levofloxacin susceptibility testing for *Helicobacter pylori* in China: comparison of E-test and disk diffusion method. Helicobacter. 2011; **16**(2):119-123. https://www.researchgate.net/profile/Jianzhong_Zhang2/publication/50849552_Levofloxacin_Susceptibility_Testing_for_Helicobacter_pylori_in_China_Comparison_of_E-Test_and_Disk_Diffusion_Method/links/00b7d52a02189ea0e9000000.pdf
273) Zhen-Hua Z, De-Qiang H, Yong X, Lin-Lin L, Nong-Hua L. Characterization of 23S rRNA gene mutation in primary and secondary clarithromycin-resistant *Helicobacter pylori* strains from East China. Turk J Gastroenterol 2013; **24** (1):5-9.
274) Zou J, Li X-X, Yang Z-X, Zhang L. In vitro activities of levofloxacin against *Helicobacter pylori.* Chinese Journal of Antibiotics 2003; **28**(5): 292-294.
275) Сичинава ИВ, Горелов АВ. Аллергический фактор в генезе хронических заболеваний желудка и двенадцатиперстной кишки у детей. Доктор. Ру. 2011(5):52-56.
276) Сичинава ИВ. Клинико-морфологические аспекты хронических гастродуоденитов у детей. Вопросы детской диетологии. 2010;**8**(1):31-40.

ЦИТИРАНА: 15A: Boyanova L, Petrov D, Osmanliev D, Mitov I, Usunova I, Minchev Tz, Goranov E, Plochev M, Dimitrov J. Anaerobic bacteriology in 75 cases of thoracic empyema in Sofia, Bulgaria. Anaerobe, 2000; **6**: 81-85. **Цитирана от:**

277) Demirci M, Gemicioglu B, Saribas S, (...), Kocazeybek BS, Bahar-Tokman H. A retrospective analysis of anaerobic bacteria isolated in 236 cases of pleural empyema and their prevalence of antimicrobial resistance in Turkey. Clinical Laboratory. 2018; **64**(7-8):1269-1277.
278) Gamboa-Coronado MM, Rodríguez-Cavallini E, Rojas-Contreras G, Sánchez-Porras R, Gutiérrez-Espeleta G. Flora bacteriana oral y su perfil de sensibilidad a antibióticos en monos de Costa Rica (*Alouatta palliata* y *Atelles geoffroyi*). Neotrop Primates. 2004; **12**: 24-30.
279) Porcel JM, Vбzquez P, Vives M, Noguйs A, Falguera M, Manonelles A. Pleural Space Infections: Microbiologic and fluid characteristics In 84 patients: The Internet Journal of Pulmonary Medicine. 2003; **3**(1). http://ispub.com/IJPM/3/1/7201
280) Považan A, Vukelić A, Kurucin T, Hadnadjev M, Považan D. The most common isolates from pleural infections. Acta Microbiol Immunol Hung. 2012; **59**(3) doi 10.1556/AMicr.59.2012.3.8
281) Rodrнguez-Rodrнguez CE, Rodrнguez-Cavallini E, del Mar Gamboa-Coronado M, Jimйnez-Cuadra S, Sбnchez-Porras R, Gutiйrrez-Espeletai GA. Flora bacteriana de la cavidad oral del Mono TitH (Saimiri Oerstedii) y su perfil de sensibilidad a antibiyticos. Neotrop Primates. 2007; **14**(3):103-112.

ЦИТИРАНА: 16A: Boyanova L, Osmanliev D, Petrov D, Mitov I, I. Usunova, Petrov S, Minchev Tz. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study. Clin. Microbiol. Infect. 2000; **6**: 622-624. **Цитирана от:**

282) Bhagat N, Nagori S, Zarbin M. Post-traumatic infectious endophthalmitis. Surv Ophthalmol. 2011; **56**(3): 214-251.
283) Shenoy PA, Lobo S, Shetty S, Vishwanath S, Chawla K. Antimicrobial susceptibility profile of clinical isolates of *Peptostreptococcus anaerobius*. Journal of Pure and Applied Microbiology. 2018;**12**(3):1239-46.

ЦИТИРАНА: 17A: Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarcheken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M. The status of antimicrobial resistance of *Helicobacter pylori* in eastern Europe. Clin Microbiol Infect. 2002; **8**(7): 388-396**. Цитирана от:**

284) Albrecht P, Kotowska M, Banasiuk M, Gawrońska A, Sienkiewicz E, Łazowska-Przeorek I, Banaszkiewicz A, Karolewska-Bochenek K, Dziekiewicz M, Radzikowski A. Sequential therapy for *H. pylori* in children–own experience. Postępy Nauk Medycznych. 2011; **12**: 990-994.
285) Albrecht P, Łazowska I. Choroba wrzodowa oraz zakażenie *Helicobacter pylori* u dzieci. Przegląd Gastroenterologiczny 2007; **2**(1): 56–64.
286) Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, Dogantzis P, Vlachou E, Kalantzis C, Tsibouris P, Alexandrakis G. Concomitant versus sequential therapy for the treatment of *Helicobacter pylori* infection: a Greek randomized prospective study. Scand J Gastroenterol. 2016;**51**(2):145-151.
287) Aydemir S, Boyacioglu S, Gur G, Demirbilek M, Can FK, Korkmaz M, Yilmaz U. *Helicobacter pylori* infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. World J Gastroenterol. 2005; **11**(6): 842-845.
288) Aydin A, Onder G, Akarca U, Tekin F, Tuncyurek M, Ilter T. Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases. Eur J Intern Med. 2007; **18**(6): 496-500.
289) Bağci S, Dağalp K. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of *Helicobacter pylori*. Turk J Gastroenterol. 2004; **15**(4): 219-224.
290) Bağlan HP, Özden A. *Helicobacter pylori*'nin Antibiyotiklere Direnci. Guncel Gastroenteroloji. 2003; 7/3: 220-225.
291) Bago P, Vcev A, Tomic M, Rožankovic M, Marušić M, Bago J. High eradication rate of *H. pylori* with moxifloxacin-based treatment: a randomized controlled trial. Wiener klinische Wochenschrift 2007; **119**(11-12):372-378.
292) Bak-Romanyszyn L, Planeta-Maleka I. [Therapeutic failures in *Helicobacter pylori* eradication]. Ped. Wsp. Gastroent. Hep. 2004; **6**(4): 387-391.
293) Biernat MM, Poniewierka E, Błaszczuk J, Czapla L, Kempiński R, Ksiądzyna D, Grabińska J, Bińkowska A, Megraud F, Gościaniak G. Antimicrobial susceptibility of *Helicobacter pylori* isolates from Lower Silesia, Poland. Arch Med Sci. 2014;**10**(3):505-509.
294) Birol Цzer, Ender Serin, Arif Coşar, Fazilet Kayaselзuk, Gьrden Gьr, Uğur Yilmaz, Sedat Boyacioğlu. The comparison of lansoprazole, clarithromycin and amoxicillin with ranitidine bismuth citrate, lansoprazole, clarithromycin and amoxicillin for *Helicobacter pylori* eradication therapy. Akademik Gastroenteroloji Dergisi, 2004; **3**(3): 125-128.
295) Biswas S,Bhowmick D, Ghosh C.. Identification of CagA harboring *Helicobacter pylori* from buccal swab collected from tobacco addicted women subjects. Int J Pharm Bio Sci 2013; **4**(2):165-175.
296) Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in *Helicobacter pylori* strains from patients living in Belgium. Helicobacter 2006; **11** (5), 441–445.
297) Çağdaş, U., Otağ, F., Tezcan, S., Sezgin, O., Aslan, G., & Emekdaş, G. Mide biyopsi örneklerinden *Helicobacter pylori*'nm tanimlanmasi ve antimikrobiyal direncinin araştirilmasi [Detection of *Helicobacter pylori* and antimicrobial resistance in gastric biopsy specimens] Mikrobiyoloji Bulteni 2012; **46** (3): 398-409
298) Calhan T, Kahraman R, Sahin A, Senates E, Doganay HL, Kanat E, Ozdil K, Sokmen HM. Efficacy of two levofloxacin-containing second-line therapies for *Helicobacter pylori*: A Pilot Study. Helicobacter. 2013;**18**(5):378-383.
299) Chaudhary P, Gupta V, Sachdev A. Pattern of antibiotic resistance in *Helicobacter pylori*. Journal of Gastrointestinal Infections. 2016; **6**(1):16-21.
300) Cheng H, Hu F-L, Li J. Influence of resistance of *Helicobacter pylori* to antibiotics on the *Helicobacter pylori* eradication regimens. National Medical Journal of China 2006; **86**(38): 2679-2682
301) Chomvarin C, Kulsantiwong P, Chantarasuk Y, Chantrakooptungool S, Kanjanahareutai S. Comparison of media and antibiotic supplements for isolation of *Helicobacter pylori* from gastric biopsies. Southeast Asian J Trop Med Public Health. 2006; **37**(6):1163-1169.
302) Crispino P, Iacopini F, Pica R, Consolazio A, Bella A, Cassieri C, Nardi F, Paoluzi P. Beta-lactamase inhibition with clavulanic acid supplementing standard amoxicillin-based triple therapy does not increase *Helicobacter pylori* eradication rate. Dig Liver Dis. 2005; **37**(11):826-831.
303) Crone J, Gold BD. *Helicobacter pylori* infection in pediatrics. Helicobacter. 2004; **9**(Suppl 1): 49-56.
304) De Korwin J-D. *Helicobacter pylori infection* and antimicrobial agents resistance | [Infection à *Helicobacter pylori* et résistance aux antibiotiques]. Revue de Medecine Interne 2004; **25**(1):54-64.
305) Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminathan B, Taylor T, Hoekstra M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmid S, Parsonnet J, Triadafilopoulos G, Perez-Perez GI, Vakil N, Ernst P, Czinn S, Dunne D, Gold BD. Antimicrobial resistance incidence and risk factors among *Helicobacter pylori*–infected persons, United States. Emerg Infect Dis. 2004; **10**(6):1088-1094.
306) Fan, H., Wu, X., Yu, F., Bai, Y., Long, B. Oral Immunization with recombinant *Lactobacillus acidophilus* expressing the adhesin Hp0410 of *Helicobacter pylori* induces mucosal and systemic immune responses Clinical and Vaccine Immunology 2014;**21**(2):126-32.
307) Federico A, Gerarda Gravina A, Miranda A, Loguercio C, Romano M. Eradication of *Helicobacter pylori* infection: Which regimen first? World J Gastroenterol. 2014; **20**(3): 665-672.
308) Foroumadi A, Safavi M, Emami S, Siavoshi F, Najjari S, Safari F, Shafiee A. Structure-activity relationship study of a series of N-substituted piperazinyl-fluoroquinolones as Anti-*Helicobacter pylori* agents. Med Chem. 2008; **4**(5): 498-502.
309) Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of *Helicobacter pylori* antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010;**15**(5): 460-466.

310) Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W, Droździk M. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate *of Helicobacter pylori* infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol. 2010; **66**(7): 681-687.
311) Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line *H. pylori* eradication: a randomized trial. J Clin Gastroenterol. 2013;**47**(3):228-232.
312) Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line *Helicobacter pylori* eradication regimen in Greece. Helicobacter. 2012 Feb;17(1):49-53.
313) Georgopoulos SD, Papastergiou V, Karatapanis S. *Helicobacter pylori* Eradication therapies in the era of increasing antibiotic resistance: a paradigm shift to improved efficacy. Gastroenterol Res Pract. 2012;**2012**:757926.
314) Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of *Helicobacter pylori*. Expert Opin Pharmacother. 2013;**14(**2):211-223.
315) Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E, Spiliadi C, Sotiropoulou M, Petraki K, Zografos K, Laoudi F, Sgouras D, Mentis A, Kasapidis P, Michopoulos S. Randomized clinical trial comparing ten day concomitant and sequential therapies for *Helicobacter pylori* eradication in a high clarithromycin resistance area. Eur J Intern Med. 2016; **32**:84-90.
316) Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of *Helicobacter pylori* in a high clarithromycin resistance area. Helicobacter. Helicobacter. 2013;**18**(6):459-467.
317) Ghasemi A, Mohammad N, Mautner J, Karsabet MT, Ardjmand A, Moniri R. Immunization with recombinant FliD confers protection against *Helicobacter pylori* infection in mice. Molecular immunology. 2018;**94**:176-82.
318) Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for *Helicobacter pylori* has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther, 2011; **34**(11-12):1255-1268.
319) Guliter S, Keles H, Ozkurt ZN, Cengiz DU, Kolukisa E. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of *Helicobacter pylori?* Turk J Gastroenterol 2005; **16**(1):29-33.
320) Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of *Helicobacter pylori* with triple 7-14 days and quadruple therapy in Turkey. World J Gastroenterol. 2004; **10**(5): 668-671.
321) Guo L, Li X, Tang F, He Y, Xing Y, Deng X, Xi T. Immunological features and the ability of inhibitory effects on enzymatic activity of an epitope vaccine composed of cholera toxin B subunit and B cell epitope from *Helicobacter pylori* urease A subunit. Appl Microbiol Biotechnol. 2012;**93**(5):1937-1945.
322) Harmanci UD, Sivri B. Peptik Ülser Tedavisi. Dahili Tıp Bilimleri Dergisi 2005; **12**(1):14-20.
323) Hojsak I, Kos T, Dumančić J, Mišak Z, Jadrešin O, Jaklin Kekez A, Lukić Grlić A, Kolaček S. Antibiotic resistance of *Helicobacter pylori* in pediatric patients - 10 years' experience. Eur J Pediatr. 2012;**171**(9):1325-1330.
324) Hongying F, Xianbo W, Fang Y, Yang B, Beiguo L. Oral immunization with recombinant *Lactobacillus acidophilus* expressing the adhesin hp0410 of *Helicobacter pylori* induces mucosal and systemic immune responses. Clin Vaccine Immunol. 2014; **21**(2):126-132.
325) Hu CT, Wu CC, Lin CY, Cheng CC, Su SC, Tseng YH, Lin NT. Resistance rate to antibiotics of *Helicobacter pylori* isolates in eastern Taiwan. J Gastroenterol Hepatol 2007; **22**(5), 720–723.
326) Hung K-H, Sheu B-S, Chang W-L, Wu H-M, Liu C-C, Wu J-J. Prevalence of primary fluoroquinolone resistance among clinical isolates of *Helicobacter pylori* at a University Hospital in Southern Taiwan. Helicobacter. 2009; **14** (1):61-65.
327) Iwańczak F, Gościniak G, Iwańczak B, Grabińska J. 10-Years evaluation of the prevalence of *Helicobacter pylori* infection and assessment of resistance to metronidazole and clarithromycin in children. Gastroenterologia Polska 2004; **11**(2):141-146.
328) Jacobson LM, Redd JT, Schneider E, Lu X, Chern SW, Oberste MS, Erdman DD, Fischer GE, Armstrong GL, Kodani M, Montoya J, Magri JM, Cheek JE. Outbreak of lower respiratory tract illness associated with human enterovirus 68 among American Indian children. Pediatr Infect Dis J. 2012;**31**(3):309-312.
329) Janssen MJR, Hendrikse L, de Boer SY, Bosboom R, de Boer WA, Laheij RJF, Jansen JBMJ. *Helicobacter pylori* antibiotic resistance in a Dutch region: trends over time. Neth J Med. 2006; **64** (6): 191-195.
330) Janssen MJR, Schneeberger PM, De Boer WA, Laheij RJF, Jansen JBMJ. Low prevalence of metronidazole- and clarithromycin-resistant *Helicobacter pylori* in the 's-Hertogenbosch region, 1998-2003 [Lage prevalentie van metronidazol- en claritromycineresistente *Helicobacter pylori* in de regio 's-Hertogenbosch, 1998-2003]. Nederlands Tijdschrift voor Geneeskunde 2005; **149**(39):2175-2177.
331) Jeng, YW, Kim JJ, Reddy R, Wang WM, Graham DY, Kwon DH. Tetracycline-resistant clinical *Helicobacter pylori* isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother. 2005; **49**(2):578-583.
332) Jeverica S, Tepeš B, Ihan A, Skvarč M. Primary resistance of *Helicobacter pylori.* Zdrav Vestn 2010; **79**:25-30.
333) Jung MK Lee JK Heo J, Kang EJ, Lee YR. The effect of concomittent therarpy and quadruple therapy for patients who had 23S ribosomal ribonucleic acid mutated *Helicobacter pylori* in Daegu and Kyoungpook Area. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2014; **14**(4):249-254.
334) Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of *Helicobacter pylori* with triple therapy: An epidemiologic analysis of trends in Turkey over 10 years. Clinical Therapeutics. 2006; **28**(11): 1960-1966.
335) Kadayifci A. What is the best first choice treatment option for *Helicobacter pylori*? Turk J Gastroenterol. 2007; **18**(1):1-4.
336) Karabiber H, Selimoglu MA, Otlu B, Yildirim O, Ozer A. Virulence factors and antibiotic resistance in children with *Helicobacter pylori* gastritis. J Pediatr Gastroenterol Nutr. 2014; **58**(5):608-612.

337) Karatapanis S,Georgopoulos SD,Papastergiou V, (...), Fragkou P, Mentis A. 7, 10 and 14-days rabeprazole-based standard triple therapies for *H. pylori* eradication: Are they still effective? a randomized trial. Acta Gastro-Enterologica Belgica 2011; **74**(3):407-412.
338) Karczewska E, Wojtas I, Budak A. Prevalence of *Helicobacter pylori* primary resistance to antimicrobial agents in Poland and around the world [Występowanie pierwotnej oporności *Helicobacter pylori* na leki przeciwbakteryjne w polsce i na świecie]. Postepy Mikrobiologii. 2009; **48** (1):31-41.
339) Karczewska E, Wojtas-Bonior I, Sito E, Zwoliñska-Wcisło M, Budak A. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to *Helicobacter pylori* in southern Poland. Pharmacological Reports. 2011; **63**:799-807.
340) Kawai T, Kawakami K, Kataoka M, Itoi T, Takei K, Moriyasu F, Takagi Y, Aoki T, Serizawa H, Rimbard E, Noguchi N, Sasatsu M. A study of the relationship between *Helicobacter pylori* microbial susceptibility, ^{13}C-urea breath test values. Hepato-Gastroenterology 2008; **55**(82-83):786-790.
341) Kawai T, Kawakami K, Kudo T, Takei K, Moriyasu F, Takagi Y, Aoki T, Koyanagi Y, Serizawa H, Rinbara E, Noguchi M, Sasatsu M. Resistance to antimicrobial agents in eradication of *Helicobacter pylori* infection. Annals of Cancer Research and Therapy. 2003; **11**(1-2):129-142.
342) Keshavarz AA, Izadi B, Rezaei M, Shahkarami A. A comparative study of eradication of *H. pylori* infection in dyspepsy. Journal of Kermanshah University of Medical Sciences (J Kermanshah Univ Med Sci). 2009;**13**(1). http://journals.kums.ac.ir/ojs/index.php/jkums/article/view/371
343) Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for *Helicobacter pylori* isolated from Korean patients. Int J Antimicrob Agents. 2006; **28**(1):6-13.
344) Kim T, Song HJ, Shin SY, Kim JH, Na SY, Boo SJ, Choi EK, Cho YK, Kim HU, Song BC. Clarithromycin-resistant *Helicobacter pylori* associated with 23S rRNA Point Mutations in Jeju Island. Korean J Gastroenterol. 2013;**61**(5):252-258.
345) Kim IK, Lee JS, Mun JK, Choi MS, Ha JH, Jeong MY, Seo JH, Cheung DY, Kim JI. Primary amyloidosis with involvement of stomach, duodenum and colon. The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 2014; **14**(4):279-282.
346) Kulsuntiwong P, Chomvarin C, Chaicumpar K, Namwat W, Kaewkes W, Mairiang P, Sangchan A. Antimicrobial susceptibility of *Helicobacter pylori* isolated from gastric biopsies in dyspeptic patients. Southeast Asian J Trop Med Public Health. 2008; **39**(6):1102-1109.
347) Kumala W, Rani A. Patterns of *Helicobacter pylori* isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. Southeast Asian J Trop Med Public Health. 2006; **37**(5):970-974.
348) Kupcinskas J, Leja M. Management of *Helicobacter pylori*-related diseases in the Baltic States. Dig Dis. 2014; **32**(3): 295-301.
349) Kupčinskas L, Malfertheiner P. *Helicobacter pylori* infection, premalignant gastric lesions and gastric cancer in the Baltic States: a review. Acta medica Lituanica. 2011; **18**(3): 107-112.
350) Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M. Effect of CYP2C19*17 gene variant on *Helicobacter pylori* eradication in peptic ulcer patients. Eur J Clin Pharmacol. 2006; **62**(10): 877-880.
351) Li Y, Wang X-Y, Shen S-R. Efficacy of 4 kinds of triple strategy for *Helicobacter pylori* eradication. Journal of Central South University (Medical Sciences). 2008; **33**(12): 1129-1131.
352) Lin LC, Chattopadhyay S, Lin JC, Hu CM. Advances and opportunities in nanoparticle-and nanomaterial-based vaccines against bacterial infections. Advanced healthcare materials. 2018; **7**(13):1701395.
353) Liu KY, Shi Y, Luo P, Yu S, Chen L, Zhao Z, Mao XH, Guo G, Wu C, Zou QM. Therapeutic efficacy of oral immunization with attenuated *Salmonella typhimurium* expressing *Helicobacter pylori* CagA, VacA and UreB fusion proteins in mice model. Vaccine. 2011; **29**(38): 6679-6685.
354) Liu W, Tan Z, Xue J, Luo W, Song H, Lv X, Zheng T, Xi T, Xing Y. Therapeutic efficacy of oral immunization with a non-genetically modified *Lactococcus lactis*-based vaccine CUE-GEM induces local immunity against *Helicobacter pylori* infection. Appl Microbiol Biotechnol. 2016; **100**(14):6219-6229.
355) Lochmannova J, Kolбř M, Lochmann O. Problematika rezistencproblematika rezistence *Helicobacter pylori* k antimikrobnнm lйčivům/Resistance of *Helicobacter pylori* to antibiotics. Klin Farmakol Farm 2004; **18**:142-143.
356) Lopes AI, Oleastro M, Palha A, Fernandes A, Monteiro L. Antibiotic-resistant *Helicobacter pylori* strains in Portuguese children. Pediatr Infect Dis J. 2005; **24**(5): 404-409.
357) Maçin S, Demir H, Özen H, Yüce A, Akyön Y. Determination of *Helicobacter pylori* antibiotic resistance patterns in pediatric gastroenterology patients: the Hacettepe experience. Turk J Pediatr. 2015; **57**(3):254-257.
358) Maçin S, Alp A, Şener B, Sökmensüer C, Orhan D, Özen H, Kav T, Akyön Y. Comparison of culture, Real-time-PCR, ELISA, and histopathological examination methods for identification of *Helicobacter pylori*. Istanbul Medical Journal. 2018;**19**(2).
359) Maciorkowska E, Kaczmarski M, Kowalczuk J, Kondej-Muszyńska K, Roszko I, Cieśla J, Zielińska A, Musaibili S. Resistance to antibiotics used in *Helicobacter pylori* infection in children | [Oporność na antybiotyki stosowane w zakażeniu *Helicobacter pylori* u dzieci]. Polski Merkuriusz Lekarski 2004; **16**(96):543-546.
360) Majlesi A, Sayedin Khorasani M, Khalilian AR, Aslani MM, Jaefari M, Alikhani MY. Antibiotic susceptibility of *Helicobacter pylori* clinical isolates in Hamadan, West of Iran. Int J Enterpathog. 2013; **01**(01): 8-11.
361) Maldonado H. Zinc-Carnosine: An exciting approach to gastric mucosal health and dyspeptic symptom relief. Applied Nutritional Science Reports. 2003; **789**, 8/03.
362) Martirosian G, Jozwiak J, Radosz-Komoniewska H. Vacuolization of target cells: response to microbial toxins. World Journal of Microbiology & Biotechnology. 2005; **21**(5):781-785.
363) Megraud F. *H pylori* antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; **53**(9): 1374-1384.

364) Miciulevičienė J, Čalkauskas H, Jonaitis L, Kiudelis G, Tamošiūnas V, Praškevičius A, Kupčinskas L, Duglas Berg D. *Helicobacter pylori* genotypes in Lithuanian patients with chronic gastritis and duodenal ulcer. Medicina (Kaunas) 2008; **44**(6): 449-454.
365) Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of *Helicobacter pylori* infection. Expert Opin Investig Drugs. 2006; **15**(9):995-1016.
366) Najar Peerayeh S, Atoofi J, Hoseinkhani S, Farshchian M. Cloning and expression of *Helicobacter pylori hpaA* gene. Yakhteh. 2009; **11**(3):273-276.
367) Nishizawa T, Suzuki H, Kurabayashi K, Masaoka T, Muraoka H, Mori M, Iwasaki E, Kobayashi I, Hibi T. Gatifloxacin resistance and mutations in *gyrA* after unsuccessful *Helicobacter pylori* eradication in Japan. Antimicrob Agents Chemother. 2006; **50**(4):1538-1540.
368) Noophun P, Mahachai V, Thong-ngam D, Vilaichone R, Tumwasorn S, Kullavanijaya P. *Helicobacter pylori* eradication rate in clarithromycin-resistant strains by pantoprazole -amoxicillin - clarithromycin regimen. Thai J Gastroenterol 2004; **5**(2): 93-97.
369) Nyström J, Svennerholm A-M. Oral immunization with HpaA affords therapeutic protective immunity against *H. pylori* that is reflected by specific mucosal immune responses. Vaccine 2007; **25**(4): 2591-2598.
370) Onder G, Aydin A, Akarca U, Tekin F, Ozutemiz O, Ilter T. High *Helicobacter pylori* resistance rate to clarithromycin in Turkey. J Clin Gastroenterol. 2007; **41**(8):747-750.
371) Peerayeh SN, Atoofi J, Hoseinkhani S, Farshchian, M. Cloning and expression of *Helicobacter pylori HpaA* gene. Yakhteh Medical Journal. 2009; **11**(3): 273-276.
372) Peerayeh SN, Farshchian M, Sadeghizadeh M, Atoofi J. Cloning and expression of *Helicobacter pylori* UreB122(a segment of the B-subunit of urease gene). Iran J Clin Infect Dis 2011; **6** 4):161-164.
373) Prechtl J, Deutschmann A, Savic T, Jahnel J, Bogiatzis A, Muntean W, Hauer AC, Hoffmann KM. Monitoring of antibiotic resistance rates of *Helicobacter pylori* in Austrian children, 2002-2009. Pediatr Infect Dis J. 2012; **31**(3):312-314.
374) Radosz-Komoniewska H, Bek T, Jozwiak J, Martirosian G. Pathogenicity of *Helicobacter pylori* infection. Clin Microbiol Infec. 2005; **11**(8):602-610.
375) Raghavan S, Nyström J, Fredriksson M, Holmgren J, Harandi AM. Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of *Helicobacter pylori* infection. Infect Immun. 2003; **71**(12):7014-7022.
376) Rasheed F, Khan A, Farooqui A, Ahmad T, Manzoor H, Akhtar SS. Emerging antimicrobial resistance in *Helicobacter pylori* strains isolated from gastric disease patients in Karachi, Pakistan. Pak J Sci. 2011; **54**(2):59-63.
377) Raymond J, Kalach N. *Helicobacter pylori (H. pylori)* infection in childhood: What is new in 2003? [Diagnostic de l'infection à *Helicobacter pylori* chez l'enfant: Quoi de neuf en 2003?] Journal de Pediatrie et de Puericulture 2003; **16**(8): 423-428.
378) Regnath T, Raecke O, Enninger A, Ignatius R. Increasing metronidazole and rifampicin resistance of *Helicobacter pylori* isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter. 2017; **22**(1). doi: 10.1111/hel.12327
379) Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative *H. pylori* eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009; **104**(1): 21-25.
380) Sezgin O, Aslan G, Altintaş E, Tezcan S, Serin MS, Emekdaş G. Detection of point mutations on 23S rRNA of *Helicobacter pylori* and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey. Turk J Gastroenterol. 2008; **19**(3):163-167.
381) Sivri B, Simsek K, Hulagu S, Kadayifci A, Tozun N, Akarsu M, Uraz S, Savas MC, Koruk M, Bozbas A.. The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in *H. pylori* eradication and duodenal ulcer healing. Curr Med Res Opin. 2004; **20**(8): 1301-1307.
382) Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Ohashi K, Hishida A, Ishizaki T. Treatment strategy to eradicate *Helicobacter pylori* infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother. 2007; **8**(16): 2701-2717.
383) Sung H, Chung H-J, Kim M-N, Lee GH. Clinical usefulness of antimicrobial susceptibility test for *Helicobacter pylori.* Korean J Lab Med. 2006; **26**(3): 179-184.
384) Sung H, Kang J-O, Lee MA, Lee J, HK Lee, M-K Lee M-K, Lim J-H, Kim M-N, Helicobacter Study Group. Clarithromycin and amoxicillin susceptibility testing of *Helicobacter pylori* by disk diffusion method. Korean J Clin Microbiol. 2009; **12** (1):30-36.
385) Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of *Helicobacter pylori* in Mazandaran, North of Iran. Helicobacter. 2010;**15**(6):505-509.
386) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016; **43**(4):514-533.
387) Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, Rao UA, Rajasambandam P, Ramathilagam B, Bhasin D, Sharma MP, Naik SR, Habibullah CM. Geographical difference in antimicrobial resistance pattern of *Helicobacter pylori* clinical isolates from Indian patients: Multicentric study. J Gastroen Hepatol. 2003; **18**(12): 1373-1378.
388) Tüzün Y, Bayan K, Yilmaz S, Dursun M, Ozekinci T. The prevalence of primary and secondary *Helicobacter pylori* resistance to clarithromycin and probable contributing cofactors: Data from Southeastern Anatolia. Hepato-Gastroenterology 2008; **55**(81): 289-293
389) Uygun A, Kadayifci A, Yesilova Z, Ates Y, Safali M, Ilgan S, Bagci S, Dagalp K. Poor efficacy of ranitidine bismuth citrate-based triple therapies for *Helicobacter pylori* eradication. Indian J Gastroenterol 2007; **26**:174-177.
390) Uygun A, Kadayifçi A, Yeşilova Z, Savaş Mc, Ateş Y, Karslioğlu Y, Ciğerim M, de Korwin JD. *Helicobacter pylori* infection and antimicrobial agents resistance. Rev Med Interne. 2004; **25**(1): 54-64.

391) Uygun A, Tüzün A, Yeşilova Z, Aslan M, Ateş Y, Polat Z, Erdil A, Bağci S, Günhan Ö, Gülşen M, Dağalp K. Comparison of the 7 and 14 days lansoprazole, amoxicillin, and clarithromycin protocol in the eradication of *Helicobacter pylori*. Akademik Gastroenteroloji Dergisi. 2005; **4**(3): 172-175.
392) Uygun A, Kadayifçi A, Yeşilova Z, Savaş MC, Ateş Y, Karslioğlu Y, Ciğerim M, (...), Dağalp K. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of *Helicobacter pylori*. Turk J Gastroenterol. 2004; **15**(4): 219-224.
393) Veres G, Pehlivanoglu E. *Helicobacter pylori* infection in pediatrics. Helicobacter. 2007; **12**(s1): 38-44.
394) Watanabe K, Tanaka A, Imase K, Tokunaga K, Sugano H, Kai A, Ishida H, Itoh T, Takahashi S. Amoxicillin resistance in *Helicobacter pylori*: studies from Tokyo, Japan from 1985 to 2003. Helicobacter. 2005; **10**(1): 4-11.
395) Watanabe K. Evaluation of gatifloxacin-based triple therapy for refractory *H. pylori.* Japanese Journal of Gastroenterology 2005; **102**(5): 619-620
396) Wenzhen Y, Kehu Y, Bin M, Yumin L, Quanlin G, Donghai W, Lijuan Y. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of *Helicobacter pylori* infection: a meta-analysis of randomized controlled trials. Intern Med. 2009;**48**(24):2069-2076.
397) Wewer V, Kalach N. *Helicobacter pylori* infection in pediatrics. Helicobacter. 2003; **8**(suppl 1): 61-67.
398) Wu JY, Kim JJ, Reddy R, Wang WM, Graham DY, Kwon DH. Tetracycline-resistant clinical *Helicobacter pylori* isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother. 2005; **49**(2): 578-583.
399) Xiong LJ, Tong Y, Wang Z, Mao M. Detection of clarithromycin-resistant *Helicobacter pylori* by stool PCR in children: a comprehensivereview of literature. Helicobacter. 2013;**18**(2):89-101.
400) Yuan W, Yang K, Ma B, Li Y, Guan Q, Wang D, Yang L. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of *Helicobacter pylori* infection: A meta-analysis of randomized controlled trials. Internal Medicine. 2009; **48**(24): 2069-2076.
401) Yuk YS, Kim GY. Rates of clarithromycin resistance in *Helicobacter pylori* sampled from healthy subjects in Cheonan, Korea. Australasian Medical Journal (Online). 2019;**12**(1):15-20.
402) Zawadska-Gralec A, Wroblewska M, Szaflarska-Poptawska A, Mierzwa G, Parzecka M, Bala G, Slusarska-Kopala J, Szerwionka-Szaflarska M. The drug sensitivity of *Helicobacter pylori* strains- our own observations. Pediatria Wspolczesna. Gastroenterologia, Hepatologia I Zywienie Dziecka. 2008, **10**(1): 29-31.
403) Zevit N, Levy I, Shmuely H, Samra Z, Yahav J. Antibiotic resistance of *Helicobacter pylori* in Israeli children. Scandinavian Journal of Gastroenterology. 2010; **45**(5): 550-555.
404) Zhao W, Wu W, Xu X. Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against *H. pylori* infection in BALB/c mice. Vaccine. 2007; **25**(44):7664-7673.
405) Zhu X-F, Duan Z-Y, Niu W-W, Wang W-W, Fan H-Y, Huo X-H. The effect of JinghuaWeikang capsule and PPI trilogy on the treatment of *Helicobacter pylori* infection in 80 cases. Chinese Journal of New Drugs 2012; **21**(20): 2417-2419.
406) Андреева И.В. Потенциальние возможности применения пробиотиков в клинической практике. Клин микробиол антимикроб химиотер. 2006; **8**(2):151-172.
407) Вдовиченко ВІ, Демидова АЛ. Динаміка резистентності штамів *Helicobacter pylori* до антибіотиків та ефективність лікування виразкової хвороби дванадцятипалої кишки. Сучасна гастроентерологія, 2006; **30**: 55-59.
408) Дехнич НН, Костякова ЕА, Пунин АА, Алимов АВ, Иванчик НВ, Козлов РС. Антибиотикорезистентность *H. pylori*: результаты микробиологического регионального исследования. РЖГГК он-лайн – www.gastro-j.ru, No. 10, September 2011, 2: 37-42.
409) Каганов БС, Исаков ВА, Эрдес СИ. Лечение заболеваний, ассоциированных с *H. pylori*-инфекцией. Вопросы диетологии. 2014;**4**(4):35-50.
410) Каримов, М. М., Саатов, З. З., Спиридонова, А. Ю., & Ахматходжаев, А. М. Применение альфа нормикса в комплексе эрадикационной терапии у больных язвенной болезнью двенадцатиперстной кишки. Функционьльная гастроэнтерология. http://www.gastroscan.ru/literature/authors/4273
411) Рачина СА. Клиническая фармакология и практическое использование кларитромицина. Consilium medicum. 2006; 8(3). http://www.consilium-medicum.com/article/9905
412) Рудакова АВ. Еще раз об эрадикации *Helicobacter pylori* (взгляд с позиций доказательной медицины). ФАРМиндекс-Практик. 2005; 9: 38-43.

ЦИТИРАНА: 18A: Boyanova L, Koumanova R, Gergova G, Popova M, Mitov I, Kovacheva Y, Derejian S, Katsarov N, Nikolov R, Krastev Z. Prevalence of resistant *Helicobacter pylori* isolates in Bulgarian children. J Med Microbiol. 2002; **51**:786-790.

Цитирана от:

413) Asfaw T. Prevalence and emergence of drug resistance in *Helicobacter pylori*. Int. Res. J. Microbiol. 2018; **7**(2):056-066.
414) Chaudhary P, Gupta V, Sachdev A. Pattern of antibiotic resistance in *Helicobacter pylori*. Journal of Gastrointestinal Infections. 2016; **6**(1):16-21.
415) Cheng H, Hu F-L, Li J. Influence of resistance of *Helicobacter pylori* to antibiotics on the *Helicobacter pylori* eradication regimens. National Medical Journal of China 2006; **86**(38): 2679-2682.
416) Chisholm, SA, Owen, RJ. From Nobel to no cure: A case for monitoring antibiotic resistance in the gastric pathogen *Helicobacter pylori*. Expert Rev Anti Infect Ther. 2006; **4**(3): 349-351.
417) Farshad S, Alborzi A, Japoni A, Ranjbar R, Hosseini Asl K, Badiee P, Amin Shahidi M, Hosseini M. Antimicrobial susceptibility of *Helicobacter pylori* strains isolated from patients in Shiraz, Southern Iran. World J Gastroenterol. 2010; **16**(45): 5746-5751.
418) Fathi MS, EL-Folly RF, Hassan RA, El-Arab ME. Genotypic and phenotypic patterns of antimicrobial susceptibility of *Helicobacter pylori* strains among Egyptian patients. Egyptian Journal of Medical Human Genetics. 2013;**14**(3): 235-246.

419) Ghorbani Ranjbary A, Asmarian S, Marhamatizadeh M. Identification of the prevalence of resistance to clarithromycin in *Helicobacter pylori* isolated from gastric biopsy via PCR method. Journal of Babol University of Medical Sciences. 2015; **17**(5): 37-43.
420) Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, Miranda MDB, Mendonca S, Pedrazzoli J. Analysis of antimicrobial susceptibility and virulence factors in *Helicobacter pylori* clinical isolates. BMC Gastroenterol. 2003; **3**(1): 20.
421) Goudarzi M, Seyedjavadi SS, Fazeli M, (...), Navidinia M, Goudarzi H. Identification of a novel cassette array in integron-bearing *Helicobacter pylori* strains isolated from Iranian patients. Asian Pacific Journal of Cancer Prevention.2016; **17**(7): 3309-3315.
422) Green KA, Gregorchuk BS, Reimer SL, Cartwright NH, Beniac DR, Hiebert SL, ... & Bay DC. Phenotypic and multi-omics characterization of *Escherichia coli* K-12 adapted to quaternary ammonium compounds identifies lipid A and cell envelope alterations regulated by mar-sox-rob and stress inducible pathways. 2020;bioRxiv.
423) Hiyama T, Tanaka S, Masuda H, Shima H, Kose K, Tuncel H, Ito M, Kitadai Y, Sumii M, Uemura N, Yoshihara M, Shimamoto F, Haruma K, Chayama K. Prevalence of *Helicobacter pylori* resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan. J Gastroenterol Hepatol. 2003; **18**(10): 1202-1207.
424) Iacopini F, Crispino P, Paoluzi OA, Consolazio A, Pica R, Rivera M, Palladini D, Nardi F, Paoluzi P. One-week once daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for *Helicobacter pylori* eradication. Dig Liver Dis. 2005; **37**(8): 571-576.
425) Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for *Helicobacter pylori* strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother. 2004; **48**(12): 4843-4847.
426) Kim JM, Kim JS, Jung HC, Oh YK, Kim N, Song IS. Inhibition of *Helicobacter pylori*-induced nuclear factor-kappa B activation and interleukin-8 gene expression by ecabet sodium in gastric epithelial cells. Helicobacter. 2003; **8**(5): 542-553.
427) Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K et al. Changing Antimicrobial susceptibility epidemiology of *Helicobacter pylori* strains in Japan between 2002 and 2005. J Clin Microbiol. 2007; **45**(12): 4006-4010.
428) Maciorkowska E, Kaczmarski M, Kowalczuk J, Kondej-Muszyńska K, Roszko I, Cieśla J, Zielińska A, Musaibili S. Resistance to antibiotics used in *Helicobacter pylori* infection in children [Oporność na antybiotyki stosowane w zakażeniu *Helicobacter pylori* u dzieci] Polski Merkuriusz Lekarski 2004; **16**(96): 543-546.
429) Marmo MCR, Neto UF. Úlcera péptica gastroduodenal. The Electronic Journal of Pediatric Gastroenterology, Nutrition and Liver Diseases. 2005; 1 Available at: http://www.e-gastroped.com.br/mar05/ulcerapeptica.htm
430) Megraud F. *H pylori* antibiotic resistance: prevalence, importance, and advances in testing. Gut, 2004; **53**(9): 1374-1384.
431) Minakari M, Davarpanah Jazi AH, Shavakhi A, Moghareabed N, Fatahi F. A randomized controlled trial: Efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with *Helicobacter pylori* infection. Helicobacter. 2010; **15**(2): 154-159.
432) Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High *Helicobacter pylori* resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;**56**(6):645-648.
433) Pandya HB, Agravat HH, Patel JS, Sodagar N. (2014). Emerging antimicrobial resistance pattern of *Helicobacter pylori* in central Gujarat. Indian journal of medical microbiology. 2014; **32**(4): 408.
434) Power MH, Zamora OR, González BLR. The resistance to antibiotics in *Helicobacter pylori* [La resistencia a antibióticos en *Helicobacter pylori*]. Revista Cubana de Medicina 2008; **47**(4).
435) Rossi A, Conti C, Colombo G, Castrati L, Scarpignato C, Barata P, Sandri G, Caramella C, Bettini R, Buttini F, Colombo P. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. Drug Dev Ind Pharm. 2016;**42**(2):332-339.
436) Seck A, Mbengue M, Gassama-Sow A, Diouf L, Ka MM, Boye CS. Antibiotic susceptibility of *Helicobacter pylori* isolates in Dakar, Senegal. J Infect Dev Ctries. 2009; **3**(2):137-140.
437) Shokrzadeh L, Alebouyeh M, Mirzaei T, Farzi N, Zali MR. Prevalence of multiple drug-resistant *Helicobacter pylori* Strains among patients with different gastric disorders in Iran. Microbial Drug Resist. 2015, **21**(1): 105-110.
438) Shokrzadeh L, Jafari F, Dabiri H, Baghaei K, Zojaji H, Alizadeh AH, Aslani MM, Zali MR. Antibiotic susceptibility profile of *Helicobacter pylori* isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol. 2011;**17**: 261-264.
439) Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, Rao UA, Rajasambandam P, Ramathilagam B, Bhasin D, Sharma MP, Naik SR, Habibullah CM. Geographical difference in antimicrobial resistance pattern of *Helicobacter pylori* clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatorose oill. 2003; **18**(12): 1373-1378.
440) Асланова Х.Р. Частота встречаемости *H. pylori* в различных социальных группах населения. SAĞLAMLIQ. 2019; № 2:67-70.

ЦИТИРАНА: 19A: Boyanova L, Derejian S, Koumanova R, Katsarov N, Gergova G, Mitov I, Nikolov R, Krastev Z. Inhibition of *Helicobacter pylori* growth *in vitro* by Bulgarian propolis: preliminary report. J. Med. Microbiol. 2003; **52**: 417-419. **Цитирана от:**

441) Abdulbasit A, Ibrahim Oladayo M, Roehan Olamide F, (...),Ridwan Babatunde I,Wasiu Gbolahan B. Effect of Nigerian propolis on glycemia, lipid profile, and oxidative stress markers in alloxan-induced diabetic rats. Pharmacologyonline 2013; 2: 149-158.
442) Adetutu, Adewale, Olorunnisola, O. Sinbad and Oyewo, E. Bukoye. Phytochemical composition, antioxidant properties and antibacterial activities of five west-african green leafy vegetables. SENRA Academic Publishers, British Columbia. 2013; **7**(2): 2357-2362. http://www.cjpas.net/Jun-13.pdf#page=56
443) Bello OO, Osho A. Antimicrobial effects of spices on spoilage organisms of Moin-Moin. Advances in Bioresearch, 2012; **3** (2): 60–65.
444) Bone K. *Helicobacter*: a hidden factor in cardiovascular, digestive, autoimmune, and skin disorders. Townsend Letter: The Examiner of Alternative Medicine. 2006 (271-272):48-51.

445) Campana R, Patrone V, Franzini IT, Diamantini G, Vittoria E, Baffone W. Antimicrobial activity of two propolis samples against human *Campylobacter jejuni*. J Med Food. 2009; **12**(5):1050-1056.
446) de Mendonça MA, Ribeiro AR, Lima AKD, Bezerra GB, Pinheiro MS, de Albuquerque-Júnior RL, ... & Cardoso JC. Red propolis and its dyslipidemic regulator formononetin: evaluation of antioxidant activity and gastroprotective effects in rat model of gastric ulcer. Nutrients. 2020; **12**(10), 2951.
447) Dos Santos CR. Otimização do processo de extração de própolis através da verificação da atividade antimicrobiana. Rev Bras Farmacogn. 2003; **13**(suppl10): 71-74 .
448) Fahey JW, Stephenson KK, Wallace AJ. Dietary amelioration of *Helicobacter* infection. Nutr Res. 2015; **35**(6):461-473.
449) Guzmán EL, Guzmán ODL, Luis AC, Pacheco JMS, , Guillén AJP, Hernández AAV. Interaction between propoleum extracts and ciprofloxacin and levofloxacin for the in vitro inhibition of methicillin-resistant *Staphylococcus aureus* isolates . African Journal of Microbiology Research. 2014; **8**(10): 1089-1097.
450) Holcová S, Hladicová M. Effect and local tolerability of a shampoo containing the propolis special extract GH 2002 in dermatitis seborrhoica with distinct dandruff formation | [Wirkung und lokale verträglichkeit eines Shampoo mit dem Propolis Spezialextrakt GH 2002 bei Dermatitis seborrhoica mit ausgeprägter Kopfschuppenbildung] Kosmetische Medizin 2007; **28**(2): 76-80.
451) Holcová S, Hladicová M. Efficacy and tolerance of a hypoallergenic propolis special extract GH 2002 in the galenic form of a shower gel/shampoo on patients with acne vulgaris-A open dermatologic study [Wirksamkeit und Verträglichkeit eines hypoallergenen Propolis Spezial Extraktes GH 2002 in der galenischen Form eines Duschgels /Shampoo bei Patienten mit Acne vulgaris-Eine offene dermatologische Studie]. Kosmetische Medizin 2008; **29**(3): 142-147.
452) Holcová S, Hladiková M. Efficacy and tolerability of propolis special extract GH 2002 as a lip balm against herpes labialis: a randomized, double-blind three-arm dose finding study. Health. 2011; **3(**1): 49-55.
453) Holcova S, Schmidt M. Showering gel and shampoo with a special concentrate from propolis for the treatment of seborrhoic eczema, psoriasis and atopic eczema - An observational study. Haut 2005; **16**(7): 311-315.
454) Holcová, S., Hladiková, M. Inhibierung der entwicklung von lippenbläschen durch frühzeitige anwendung eines pflegenden lippenbalsams mit dem wirkstoff propolis spezialextrakt GH 2002 im vergleich mit aciclovircreme 5% | [Inhibition of the development of cold sores through early use of a nurishing lip balm containing the active constituent propolis special extract GH 2002 in comparison with aciclovir cream 5 %] Kosmetische Medizin 2012; **33** (3): 100-104.
455) Hubicka U, Krzek J, Kaleta J, Niedźwiedź A. Evaluation of densitometric TLC for quantitative analysis of selected phenolic acids for standardization of propolis concentrates. Journal of Planar Chromatography - Modern TLC 2006; **19**(112): 449-453.
456) Kamiji MM, de Oliveira RB. Non-antibiotic therapies for *Helicobacter pylori* infection. Eur J Gastroenterol Hepatol. 2005; **17**(9): 973-981.
457) Krasteva A, Panov V, Krasteva A, Kisselova A. Oral cavity and systemic diseases – *Helicobacter pylori* and dentistry. Biotechnol. & Biotechnol. Eq. 2011, **25**(3), 2447-2541.
458) Krzek JAN, Kaleta J, Hubicka U, Niedznwiedz A. Reversed-phase high-performance liquid chromatography determination of selected phenolic acids in propolis concentrates in terms of standardization for drug manufacturing purposes J AOAC Int. 2006; **89**(2): 352-358.
459) Lotfy M. Biological activity of bee propolis in health and disease. Asian Pac J Cancer Prev. 2006; **7**: 22-31.
460) Lozano-Guzmán E, López-Guzmán OD, Bocanegra-Salazar M, (...), de la Cruz Flores LB, Cervantes Flores M. Propolis and oregano (*Lippia graveolens Kunth* s.l.) sinergyc interation against *Staphylococcus aureus* | [Interacción sinérgica de propóleo (Propolis) y orégano (*Lippia graveolens Kunth* s.l.) contra *Staphylococcus aureus*] Revista Mexicana de Ciencias Farmaceuticas. 2013; **44** (4), pp. 73-78.
461) Macêdo JS, Mendonça FS, da Silva KR, de Barros ME, Evêncio-Neto J. Incidence and pathological aspects of infection by *Helicobacter* spp. in cats from the city of Recife, Pernambuco, Brazil. Arquivos do Instituto Biológico. 2012; **79**(4):519-524.
462) Martini S, D'Addario C, Colacevich A, Focardi S, Borghini F, Santucci A, Figura N, Rossi C. Antimicrobial activity against *Helicobacter pylori* strains and antioxidant properties of blackberry leaves *(Rubus ulmifolius)* and isolated compounds. Int J Antimicrob Agents. 2009; **34**(1):50-59.
463) Mavri A, Abramovič H, Polak T, Bertoncelj J, Jamnik P, Smole Možina S, Jeršek B. Chemical properties and antioxidant and antimicrobial activities of slovenian propolis. Chem Biodivers. 2012; **9**(8):1545-58.
464) McCue P, Lin YT, Labbe RG, Shetty K. Sprouting and solid-state bioprocessing by *Rhizopus oligosporus* increase the in vitro antibacterial activity of aqueous soybean extracts against *Helicobacter pylori.* Food Biotechnol. 2004; **18**(2): 229-249.
465) McLoughlin R, Racz I, Buckley M, O'Connor HJ, O'Morain C. Therapy of *Helicobacter pylori*. Helicobacter. 2004; **9**(Suppl 1): 42-48.
466) Medina J, Peraza S, Casanova R, Akiko S, Silva O, Castro D, Otero W, Fierro W. Cáncer gástrico en una zona con alto potencial para la cultura apícola y su aplicación en la prevención de las lesiones gástricas premalignas y malignas. GEN. 2013; **67**(3):170-174.
467) Melek AT, El-Sharkawy MR, Khaery EM. Neopterin as a biomarker in liver fibrosis of Schistosoma mansoni. Med. J. Cairo Univ. 2011; **79**(1):199-209.
468) Moreno-Cruz FJ, Cervantes-Flores M, Lopez-Guzman OD, Vertiz-Hernandez AA, Ceniceros-Medina RE, Lozano-Guzman E. Synergistic interaction of extracts of garlic (*Allium sativum*) and propolis against methicillin-resistant *Staphylococcus aureus*. African Journal of Microbiology Research. 2014; **8**(52):3986-3991.
469) Motib AS. The effect of vinegar solution on the bacteria that cause impetigo. Diyala journal of pure science. 2012; **8**(2): 60-67. http://www.iasj.net/iasj?func=fulltext&aId=31027
470) Murali MR, Naveen SV, Son CG, Raghavendran HRB. Current knowledge on alleviating *Helicobacter pylori* infections through the use of some commonly known natural products: bench to bedside. Integrative Medicine Research. 2014; **3**(3):111-118.

471) Nakhaei M, Khaje-Karamoddin M, Ramezani M. Inhibition of *Helicobacter pylori* growth in vitro by Saffron (*Crocus Sativus L*). Iranian Journal of Basic Medical Sciences. 2008; **11**(2): 91-96.
472) Nostro A, Cellini L, Di Bartolomeo S, Di Campli E, Grande R, Cannatelli MA, Marzio L, Alonzo V. Antibacterial effect of plant extracts against *Helicobacter pylori*. Phytother Res. 2005; **19**(3): 198-202.
473) Nzeako BC, Al-Namaani F. The antibacterial activity of honey on *Helicobacter pylori*. Sultan Qaboos Univ Med J. 2006; **6**(2): 71-76.
474) Ojeda-Contreras A-J, Hernández-Martínez J, Domínguez Z, Mercado-Ruiz J-N, Troncoso-Rojas R, Sánchez-Estrada A, Tiznado-Hernández M-E. Utilization of caffeic acid phenethyl ester to control alternaria alternata rot in tomato (*Lycopersicon esculentum Mill*.) Fruit Journal of Phytopathology 2007; **156**(3): 164–173.
475) Okokon JE, Nwafor PA. Antimicrobial activity of root extract and crude fractions of *Croton zambesicus.* Pakistan Journal of Pharmaceutical Sciences. 2010; **23**(1): 114-118.
476) Osho A, Otuechere CA, Adeosun CB, Oluwagbemi T, Atolani O. Phytochemical, sub-acute toxicity, andantibacterial evaluation of *Cordia sebestenaleaf* extracts. J Basic Clin Physiol Pharmacol. 2016; **27**(2):163-170.
477) Peraza S, Medina J, Casanova R, Akiko S, Silva O, Castro D, Otero W, Fierro W. Cáncer gástrico en una zona con alto potencial para la cultura apícola y su aplicación en la prevención de las lesiones gástricas premalignas y malignas. Revista GEN. 2016;**67**(3):170-174.
478) Pobiega K, Gniewosz M, Kraśniewska K. Antimicrobial and antiviral properties of different types of propolis. Zeszyty Problemowe Postępów Nauk Rolniczych. 2017;589.
479) Rosendale DI, Maddox IS, Miles MC, Rodier M, Skinner M, Sutherland J. High-throughput microbial bioassays to screen potential New Zealand functional food ingredients intended to manage the growth of probiotic and pathogenic gut bacteria. International Journal of Food Science and Technology. 2008; **43**(12): 2257-2267.
480) Salman, M. A., Zben, N. K., Mohammed, L. S., & Auribi, M. A. Study of the antioxidant activity and inhibition effect of propolis extract on some microorganisms. Annals of the Romanian Society for Cell Biology. 2021; 8542-8551.
481) Samet N, Laurent C, Susarla SM, Samet-Rubinsteen N. The effect of bee propolis on recurrent aphthous stomatitis: a pilot study. Clin Oral Investig. 2007;**11**(2):143-147.
482) Shapla UM, Raihan MJ, Islam MA, Alam F, Solayman M, Gan SH, Hossen MS, Khalil MI. Propolis: The future therapy against *Helicobacter pylori*-mediated gastrointestinal diseases. 2018;**16**(2):81-99.
483) Stojanovska AA, Popovska M, Muratovska I, Mitic K, Stefanovska E, Nikolovska VR. The rapeutic effect of proaftol in treatment of recurrent aphthous stomatitis. Prilozi. 2014;**35**(3):195-202.
484) Teke GN, Kuiate J-R, Kueté V, Teponno RB, Tapondjou LA, Tane P, Giacinti G, Vilarem G. Bio-guided isolation of potential antimicrobial and antioxidant agents from the stem bark of *Trilepisium madagascariense*. South African Journal of Botany. 2011; **77**(2): 319-327.
485) Teke GN, Kuiate JR, Ngouateu OB, Gatsing D. Antidiarrhoeal and antimicrobial activities of *Emilia coccinea (Sims) G*. Don extracts. Journal of Ethnopharmacology 2007; **112**(2): 278-283.
486) Vega AE, Silva HJ, Cortiñas TI. Evaluation of a serum-free transport medium supplemented with cyanobacterial extract, for the optimal survival of *Helicobacter pylori* from biopsy samples and strains European Journal of Clinical Microbiology and Infectious Diseases. 2012; **31**(2): 135-139.
487) Villanueva M, González M, Fernández H, Wilson M, Manquián N, Otth C, Otth L. Actividad antibacteriana in vitro de propóleos chilenos sobre *Helicobacter pylori*. Revista chilena de infectología, 2015; **32**(5): 530-535.
488) Weseler A, Geiss HK, Saller R, Reichling J. A novel colorimetric broth microdilution method to determine the minimum inhibitory concentration (MIC) of antibiotics and essential oils against *Helicobacter pylori*. Pharmazie. 2005; **60**(7): 498-502.
489) Хлгатян СВ, Бержец ВМ, Хлгатян ЕВ. Прополис: состав, биологические свойства и аллергенная активность. Успехи современной биологии, 2008; **128**(1): 77-88.

ЦИТИРАНА: 20A: Boyanova L, Koumanova R, Lazarova E, Jelev C. *Helicobacter pylori* and *Helicobacter heilmannii* in children. A Bulgarian study. Diagn Microbiol Infect Dis. 2003; **46**: 249-252. **Цитирана от:**

490) Al-Hamoudi WK, Alpert L, Szilagyi A. Acute symptomatic gastritis due to *Helicobacter heilmannii.* Helicobacter. 2006; **11**(5): 446-450.
491) Al-Shamahy HA. Seroprevalence of *Helicobacter pylori* among children in Sana'a, Yemen. Ann Saudi Med. 2005; **25**(4): 299-303.
492) Baele M, Pasmans F, Flahou B, Chiers K, Ducatelle R, Haesebrouck F. Non-*Helicobacter pylori* helicobacters detected in the stomach of humans comprise several naturally occurring *Helicobacter* species in animals. FEMS Immunol Med Mic. 2009; **55**(3), pp. 306-313.
493) Bani-Hani KE., Shatnawi NJ., El Qaderi S., Khader YS., Bani-Hani BK. Prevalence and risk factors of *Helicobacter pylori* infection in healthy schoolchildren. Chin J Dig Dis. 2006; **7**(1): 55-60.
494) Best LM, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, Yaghoobi M, Gurusamy KS. Non-invasive diagnostic tests for *Helicobacter pylori* infection. Cochrane Database of Systematic Reviews. 2018(3).
495) De la Rosa HI, Mendez JCV, Barreto RMG. Infeccion por *Helicobacter pylori* en adultos sintomaticos. Archivo Medico de Camaguey 2005; **9**(2):1025-0255.
496) De Rodríguez, B.J., Taborda, D.A., Ortiz, L.C. Association of gastric ulcer and *Helicobacter* spp. in pigs in Antioquia, Colombia [Asociación de úlcera gástrica y *Helicobacter* spp en cerdos en Antioquia, Colombia]. Revista Colombiana de Ciencias Pecuarias. 2009; **22**(1): 54-60.
497) Gasbarrini A, Carloni E, Gasbarrini G, Chisholm SA. *Helicobacter pylori* and extragastric diseases -other Helicobacters. Helicobacter. 2004; **9**(Suppl 1): 57-66.
498) Gasbarrini A, Carloni E, Gasbarrini G, Menard A. *Helicobacter pylori* and extragastric diseases -- other helicobacters. Helicobacter. 2003; **8**(Suppl 1): 68-76.

499) Goji S, Tamura Y, Sasaki M, Nakamura M, Matsui H, Murayama SY, Ebi M, Ogasawara N, Funaki Y, Kasugai K. *Helicobacter suis*-infected nodular gastritis and a review of diagnostic sensitivity for *Helicobacter heilmannii*-like organisms. Case Rep Gastroenterol. 2015; **9**(2):179-187.
500) Gościniak G, Skała J, Kublak K, Iwanłczak B, Biernat M, Grabińska J. The role of environmental *Helicobacter heilmannii* infection in etiopathogenesis of gastric diseases Gastroenterologia Polska 2006; **13**(4): 320-323.
501) Guarner, Lázaro, Gascón, Royo, Eximan, Herrero. Map of Digestive Disorders & Diseases (MDD). 2008: http://www.worldgastroenterology.org/UserFiles/file/wdhd-2008-map-of-digestive-disorders.pdf
502) Guendulain C, Sibilla ML. *Helicobacter* gástricos en perros y gatos y su significancia en la salud humana. Ab Intus. 2018 **17**;1(2):93-100.
503) Haesebrouck F, Pasmans F, Flahou B, Chiers K, Baele M, Meyns T, Decostere A, Ducatelle R. Gastric helicobacters in domestic animals and nonhuman primates and their significance for human health. Clin Microbiol Rev. 2009; **22**(2):202-223.
504) Hernández C, Serrano CA, Villagrán A, Torres J, Venegas A, Harris PR. *Helicobacter pylori vacA* virulence factor in uncultured *Helicobacter heilmannii* sensu lato from an infected child. JMM Case Rep, 2016. 3. doi: 10.1099/jmmcr.0.005026.
505) Iwanczak B, Biernat M, Iwanczak F, Grabinska J, Matusiewicz K, Gosciniak G. The clinical aspects of *Helicobacter heilmannii* infection in children with dyspeptic symptoms. J Physiol Pharmacol. 2012; **63**(2):133-136.
506) Kanani, B., Khosrowshahi, A., Khaledabad, M. A., & Pourahmad, R. Probiotic yogurt formulated with Nettle (Urtica Dioica) extract, a compound with dual functionalities: *Bifidobacterium* growth promoter and *Helicobacter Pylori* growth inhibitor. Biomed J Sci & Tech Res, 2018; 10 (1).
507) Kato S, Ozawa K, Sekine H, Ohyauchi M, Shimosegawa T, Minoura T, Iinuma K. *Helicobacter heilmannii* infection in a child after successful eradication of *Helicobacter pylori*: case report and review of literature. J Gastroenterol. 2005; **40**(1): 94-97.
508) Kubota-Aizawa, S., Matsubara, Y., Kanemoto, H., Mimuro, H., Uchida, K., Chambers, J., ... & Tsujimoto, H. Transmission of *Helicobacter pylori* between a human and two dogs: A case report. 2021; Helicobacter, e12798.
509) Lee NM, Yun SW, Chae SA, Yoo BH, Cha SJ, Kwak BK. Perforated duodenal ulcer presenting with massive hematochezia in a 30-month-old child. World J Gastroenterol. 2009; **15**(38): 4853-4855.
510) Liu J, He L, Haesebrouck F, Gong Y, Flahou B, Cao Q, Zhang J. Prevalence of coinfection with gastric non-*Helicobacter pylori Helicobacter* (NHPH) Species in *Helicobacter pylori*-infected patients suffering from gastric disease in Beijing, China. Helicobacter. 2015;**20**(4):284-290.
511) Matos R, De Witte C, Smet A, Berlamont H, De Bruyckere S, Amorim I, ... & Haesebrouck F. Antimicrobial susceptibility pattern of *Helicobacter heilmannii* and *Helicobacter ailurogastricus* isolates. Microorganisms. 2020; **8**(6), 957.
512) Matos R, Amorim I, Magalhaes A, (...), Gartner F, Reis CA. Adhesion of *Helicobacter* species to the human gastric mucosa: A deep look into glycans role. Frontiers in Pharmacology. 2021;**12**: art. no. 667584..
513) Matsui H, Takahashi T, Murayama SY, Uchiyama I, Yamaguchi K, Shigenobu S, Matsumoto T, Kawakubo M, Horiuchi K, Ota H, Osaki T, Kamiya S, Smet A, Flahou B, Ducatelle R, Haesebrouck F, Takahashi S, Nakamura S, Nakamura M. Development of New PCR primers by comparative genomics for the detection of *Helicobacter suis* in gastric biopsy specimens. Helicobacter. 2014; **19**(4):260-271.
514) Moghaddam MN. In vitro Inhibition of *Helicobacter pylori* by some spices and medicinal plants used in Iran. Global Journal of Pharmacology. 2011; **5**(3):176-180.
515) Moghaddam MN, Karamoddin M-AK, Ramezani M. In vitro anti-bacterial activity of sweet basil fraction against *Helicobacter pylori.* Journal of Biological Sciences. 2009; **9**(3): 276-279
516) Moghaddam MN, Moghaddam MN. Metronidazole resistance of *Helicobacter pylori* clinical isolates in a hospital in Iran and protein pattern of two strains showing differences in susceptibility. J Biol Sci. 2008; **8**(2): 466-469.
517) Nakhaei M, Khaje-Karamoddin M, Ramezani M. Inhibition of *Helicobacter pylori* growth in vitro by Saffron (*Crocus Sativus L*). Iranian Journal of Basic Medical Sciences. 2008; **11**(2): 91-96.
518) Nakhaei MM, Malekzadeh F, Khaje-Karamoddin M, Ramezani M. In vitro anti-*Helicobacter pylori* effects of sweet basil (*Ocimum basilicum* L.) and purple basil (*Ocimum basilicum* var. *purpurascens*) Pak J Biol Sci. 2006; **9**(15): 2887-2891.
519) Okiyama Y, Matsuzawa K, Hidaka E, Sano K, Akamatsu T, Ota H. *Helicobacter heilmannii* infection: Clinical, endoscopic and histopathological features in Japanese patients. Pathol Int. 2005; **55**(7): 398-404.
520) Orel R, Mlinaric V, Stepec S, Luzar B, Brencic E, Cerar A. Acute phlegmonous gastritis associated with *Helicobacter heilmannii* infection in a child. Dig Dis Sci. 2006; **51**(12): 2322-2325.
521) Stalke P, Abu Al-Soud W, Bielawski KP, Bakowska A, Trocha H, Stepinski J, Wadstrom T. Detection of *Helicobacter* species in liver and stomach tissues of patients with chronic liver diseases using polymerase chain reaction-denaturing gradient gel electrophoresis and immunohistochemistry. Scand J Gastroenterol. 2005; **40**(9): 1032-1041.
522) Sykora J, Siala K; Varvarovska J; Pazdiora P; Pomahacova R; Huml M. Epidemiology of *Helicobacter pylori* infection in asymptomatic children: a prospective population-based study from the Czech Republic. Application of a monoclonal-based antigen-in-stool enzyme immunoassay. Helicobacter. 2009; **14**(4): 286-297.
523) Yari F, Abiri R, Soleymani-Dorjagh M, Gholipour A, Alvandi A. Evaluation of the egg yolk enriched columbia agar for isolation of *Helicobacter pylori* from gastric biopsy specimens. Journal of Shahrekord University of Medical Sciences. 2015; **16**(6):67-74.
524) Цуканов ВВ, Сокольских ТВ, Манчук ВТ, Бармаков АЕ, Куперштейн ЕЮ, Поливанова ТВ. Клинико морфологическая характеристика заболеваний гастродуоденальной зоны в семьях детей, проживающих в сельской местности. Педиатрия.. 2008; **87**(6):37-41.

ЦИТИРАНА: 21A: Boyanova L. Influence of transport conditions and media on *Helicobacter pylori* isolation. J. Med. Microbiol. 2003; **52**(Pt 12): 1129-1130. **Цитирана от:**

525) Asma S, Boga C, Ozdogu H, Serin E. The association of pagophagia with *Helicobacter pylori* infection in patients with iron-deficiency anemia. International Journal of Hematology. 2009; **90**(1): 28-32.

526) Babić T, Miljković-Selimović B, Kocić B, Nagorni A, Ristić L. Successful isolation of *Helicobacter pylori* after prolonged incubation: A case report of prolonged incubation for *H. pylori*. Archives of Biological Sciences. 2012; **64**(4): 1297-1299.
527) ElMorsy I, Lotfy H, ElDegla H, Bahgat M. Rapid versus conventional diagnosis of clarithromycin resistant *Helicobacter pylori* among high risk patients with gastritis in specialized medical hospital (SMH), Mansoura, Egypt. The Egyptian Journal of Medical Microbiology. 2012; **38**(1231), 1-9.
528) Farshad S, Japoni A, Shahidi MA, Hosseini M, Alborzi A. An improvement in isolation and preservation of clinical strains of *Helicobacter pylori.* Trop Gastroenterol. 2011; **32**(1): 36-40.
529) Hosseini Doust R, Mohabati Mobarez A, Amini M, Haghi Tumetri F, Inhibitory effects of probiotics on *H. pylori* by co-culture method. Scientific Journal of Kurdistan University of Medical Sciences, 2008; **13**(3): 62-69.
530) Sarma A, Hazarika BB, Patgiri SJ, Saikia L, Begum S, Hussain MD. Isolation of *Helicobacter pylori* from gastric biopsy specimens and evaluation of common contaminants associated with *H. pylori* cultures. Int J Res Prof. 2016;**2**(2):161-164.
531) Savari M, Abdollahi H, Zahedi MJ, Darvish Moghadam S, Bakhsh Abasi Hayat M. Antibiotic-resistance patterns of *Helicobacter pylori* isolates obtained from patients in Kerman-2009. Journal of Kerman University of Medical Sciences 2011; **18**(1): 73-82.
532) Savari M, Abdollahi H, Zahedi MJ, Darvish Moghadam S. Antibiotic-resistance patterns of *Helicobacter pylori* isolates obtained from patients in Kerman-2009. Journal of Kerman University of Medical Sciences. 2015.
533) Vega AE, Silva HJ, Cortiñas TI. Evaluation of a serum-free transport medium supplemented with cyanobacterial extract, for the optimal survival of *Helicobacter pylori* from biopsy samples and strains. Eur J Clin Microbiol Infect Dis. 2012;**31**(2):135-139.
534) Yin Y, He LH, Zhang JZ. Successful isolation of *Helicobacter pylori* after prolonged incubation from a patient with failed eradication therapy. World J Gastroenterol 2009; **15**(12): 1528-1529.

ЦИТИРАНА: 22A: Boyanova L, Katsarov N, Gergova G, Nikolov R, Deredjian S, Spassova Z, Mitov I, Krastev Z. *Helicobacter pylori* infectión in elderly Bulgarian patients. J. Med. Microbiol. 2003; **52**(Pt 12): 1131-1133. **Цитирана от:**

535) Avila Vargas JC, Lias RV, Medina AC, Guzmán AMZ, Guerrero VG, Martinez CM. Uso de pruebas invasivas para la detección de *Helicobacter pylori* en una poblacion de adultos mayores. Endoscpoia 2009 (1): 37-47.
536) Giles H, Hajek C, Stoitsova T, Choi CW. Intergenerational communication satisfaction and age boundaries in Bulgaria and the United States. J Cross Cult Gerontol. 2010; **25**(2):133-147.

ЦИТИРАНА: 23A: Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev Z. *Campylobacter* infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease and other chronic intestinal diseases. Diagn Microbiol Infect Dis. 2004; **49**(1): 71-74. **Цитирана от:**

537) Abd El Tawab, A. A., Ammar, A. M., Ahmed, H. A., & Hefny, A. A. Macrolides and Fluoroquinolones Resistance Mechanisms in *Campylobacter*s and their Incidence in Egypt; a Review Article. Zagazig Veterinary Journal, 2017; 45(Supplementary 1), 1-19.
538) Arora Z, Mukewar S, Wu X, Shen B. Risk factors and clinical implication of superimposed *Campylobacter jejuni* infection in patients with underlying ulcerative colitis. Gastroenterol Rep (Oxf). 2016;**4**(4):287-292.
539) Ašanin R, Mišić D, Krnjaić D. Značaj monitoringa rezistencije bakterija na antimikrobna sredstva. Tehnologija mesa. 2005; **46**(1-2):75-79.
540) Bièche C, de Lamballerie M, Chevret D, Federighi M, Tresse O. Dynamic proteome changes in *Campylobacter jejuni* 81-176 after high pressure shock and subsequent recovery. J Proteomics. 2012; **75**(4):1144-1156.
541) Cabré E, Domènech E. Impact of environmental and dietary factors on the course of inflammatory bowel disease. World J Gastroenterol. 2012; **18**(29):3814-22.
542) Cagliero C, Cloix L, Cloeckaert A, Payot S. High genetic variation in the multidrug transporter *cmeB* gene in *Campylobacter jejuni* and *Campylobacter coli*. J Antimicrob Chemother. 2006; **58**(1): 168-172.
543) Cagliero C, Mouline C, Payot S, Cloeckaert A. Involvement of the CmeABC efflux pump in the macrolide resistance of *Campylobacter coli*. J Antimicrob Chemother. 2005; **56**(5): 948-950.
544) Cagliero C, Mouline C, Cloeckaert A, Payot S. Synergy between efflux pump CmeABC and modifications in ribosomal proteins L4 and L22 in conferring macrolide resistance in *Campylobacter jejuni* and *Campylobacter coli*. Antimicrob Agents Chemother. 2006; **50**(11): 3893-3896.
545) Campana R, Federici S, Ciandrini E, Baffone W. Antagonistic activity of *Lactobacillus acidophilus* ATCC 4356 on the growth and adhesion/invasion characteristics of human *Campylobacter jejuni*.Curr Microbiol. 2012;**64**(4):371-8.
546) Casey E, Fitzgerald E, Lucey B. Towards understanding clinical *campylobacter* infection and its transmission: time for a different approach?. British Journal of Biomedical Science. 2017;**74**(2):53-64.
547) Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of *Helicobacter* and *Campylobacter* species in IBD: a systematic review and meta-analysis. Gut. 2017; **66**(2):235-249.
548) Daskalov H,Maramski A. Prevalence and factors aff ecting the presence of *Campylobacter* spp. in broiler carcasses in Bulgaria. Turkish Journal of Veterinary and Animal Sciences 2012; **36** (5): 539-545.
549) Fu Y, Almansour A, Bansal M, Alenezi T, Alrubaye B, Wang H, Sun X. Microbiota attenuates chicken transmission-exacerbated *campylobacter*iosis in Il10−/− mice. Scientific reports. 2020; **10**(1): 1-10.
550) Gellynck X, Messens W, Halet D, Gruspeerdt K, Hartnett E, Viaene J. Economics of reducing *Campylobacter* at different levels within the Belgian poultry meat chain Journal of Food Protection 2008; **71**(3): 479-485.
551) Gibreel A, Taylor DE. Macrolide resistance in *Campylobacter jejuni* and *Campylobacter coli*. J Antimicrob Chemother. 2006; **58**(2): 243-255.
552) Gradel KO, Nielsen HL, Schønheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after *Salmonella* or *Campylobacter* gastroenteritis. Gastroenterology. 2009; **137**(2):495-501.
553) Grover M, Camilleri M, Smith K, Linden DR, Farrugia G. On the fiftieth anniversary. Postinfectious irritable bowel syndrome: mechanisms related to pathogens. Neurogastroenterol Motil. 2014; **26**(2):156-167.

554) Guérin A, Sulaeman S, Coquet L, Ménard A, Barloy-Hubler F, Dé E, Tresse O. Membrane proteocomplexome of *Campylobacter* jejuni using 2-D blue native/SDS-PAGE combined to bioinformatics analysis. Frontiers in microbiology. 2020; 11.
555) Heimesaat M M, Genger C, Biesemeier N, Klove S, Weschka D, Mousavi S, Bereswill S. Inflammatory immune responses and gut microbiota changes following *Campylobacter* coli infection of IL-10-/-mice with chronic colitis. Pathogens. 2020; **9**(7), 560.
556) Jin D, Zhang H, Sun J. Manipulation of microbiome, a promising therapy for inflammatory bowel diseases. J Clin Cell Immunol 2014; **5**: 234.
557) Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global Epidemiology of *Campylobacter* infection. Clin Microbiol Rev. 2015;**28**(3):687-720.
558) Kaakoush NO, Mitchell HM. *Campylobacter concisus* - A new player in intestinal disease. Front Cell Infect Microbiol. 2012;**2**:4.
559) Kovach Z, Kaakoush NO, Lamb S, Zhang L, Raftery MJ, Mitchell H. Immunoreactive proteins of *Campylobacter* concisus, an emergent intestinal pathogen. FEMS Immunology and Medical Microbiology. 2011; **63**(3): 387-396.
560) Lee J. Increased short-and long-term risk of inflammatory bowel disease after *Salmonella* or *Campylobacter* gastroenteritis. Korean J Gastroenterol. 2009; **54**(4):261-263.
561) Lobatón T, Domènech E. Bacterial intestinal superinfections in Inflammatory Bowel Diseases beyond *Clostridum difficile*. Inflammatory Bowel Diseases. 2016; **22** (7):1755-1762.
562) Louwen R, Hays JP. Is there an unrecognised role for *Campylobacter* infections in (chronic) inflammatory diseases? World J Clin Infect Dis. 2013; **3**(4): 58-69.
563) Lynch OA, Cagney C, McDowell DA, Duffy G. A method for the growth and recovery of 17 species of *Campylobacter* and its subsequent application to inoculated beef. J Microbiol Methods. 2010; **83**(1): 1-7.
564) McGill K, Cowley D, Moran L, Scates P, O'Leary A, Madden RH, Carroll C, McNamara E, Moore JE, Fanning S, Collins JD, Whyte P. Antibiotic resistance of retail food and human *Campylobacter* isolates on the island of Ireland from 2001-2002. Epidemiol. Infect. 2006; **134**(6):1282-1291.
565) Mikuličová, M., & Steinhauserová, I. The susceptibility of *Campylobacter* jejuni strains to selected antimicrobial agents. Folia veterinaria. 2005; **49**(1), 36-39.
566) Navarro-Llavat M, Domènech E, Bernal I, Sánchez-Delgado J, Manterola JM, Garcia-Planella E, Mañosa M, Cabré E, Gassull MA. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion. 2009; **80**(1):25-29.
567) Palyada, K., Sun, Y.-Q., Flint, A., Butcher, J., Naikare, H., Stintzi, A. Characterization of the oxidative stress stimulon and PerR regulon of *Campylobacter jejuni.* BMC Genomics. 2009; **10**(art. no. 1471): 481.
568) Pavlova M, Velev V, Dobreva E, Asseva G, Mangarov A, Tomova I, Kantardjiev T. Advantages of Eva Green real-time mPCR compared to culture methods for differentiating *C. jejuni/coli* directly from feces. Merit Research Journal of Medicine and Medical Sciences. 2017; **5**(5):259-262.
569) Pavlova M, Velev V, Dobreva E, Asseva G, Ivanov IN, Tomova I, Kantardjiev T. Advantages of eva green real-time mpcr with culture and immunochromato-graphic methods for differentiating C. *jejuni/coli* directly from feces. Acta Medica Mediterranea. 2018;**34**(4):1027-1030.
570) Pavlova, M., Alexandrova, E., Donkov, G., Mitova-Mineva, Y., Kantardjiev, T., & Velev, V. *Campylobacter* infections among Bulgarian children: molecular characterization and antimicrobial susceptibility. Biotechnol Biotechnol Equip. 2020; **34**(1): 1038-1042.
571) Pryjma M, Apel D, Huynh S, Parker CT, Gaynor EC. FdhTU-modulated formate dehydrogenase expression and electron donor availability enhance recovery of *Campylobacter jejuni* following host cell infection. J Bacteriol. 2012;**194**(15):3803-3813.
572) Rodríguez N, Real BD, Cruz Ortiz M, Sarabia LA, Herrero A. Usefulness of parallel factor analysis to handle the matrix effect in the fluorescence determination of tetracycline in whey milk. Anal Chim Acta. 2009; **632**(1): 42-51.
573) Rodriguez-Avial I, Rodriguez-Avial C, Olga Lopez O, Culebras E, Picazo JJ. In vitro activity of tigecycline (GAR-936) and other antimicrobials against tetracycline- and ciprofloxacin-resistant *Campylobacter* clinical isolates. Int J Antimicrob Agents. 2006; **27**(4): 303-306.
574) Shariati A, Fallah F, Pormohammad A, Taghipour A, Safari H, chirani AS, Sabour S, Alizadeh-Sani M, Azimi T. The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. Journal of cellular physiology. 2019; **234**(6), 8550-8569.
575) Sulaeman S, Hernould M, Schaumann A, Coquet L, Bolla JM, Dé E, Tresse O. Enhanced Adhesion of *Campylobacter jejuni* to Abiotic Surfaces Is Mediated by Membrane Proteins in Oxygen-Enriched Conditions. PLoS One. 2012;**7**(9):e46402.
576) Sun X, inventor; University of Arkansas, assignee. Bile acid compositions and methods of use. United States patent application US 16/009,398. 2018 Dec 20.
577) Tambur Z, Arnautović Mira, Doder R, Ristić Anđelka. Investigation of sensitivity to ampicillin of *Campylobacter jejuni* et *coli* isolated from animals and humans. Veterinaria. 2008; **57**(1-2): 27-43.
578) Tambur Z, Miljkovic-Selimovic B, Doder R, Kulisic Z. Susceptibility of *Campylobacter jejuni* and *Campylobacter coli* isolated from animals and humans to tetracycline. African Journal of Microbiology Research. 2010; **4**(12): 1246-1250.
579) Tambur Z, Miljković-Selimović B, Radaković S, Kulišić Z, Marković M. Frequency of antimicrobial resistance in thermophilic *Campylobacter* strains from humans, poultry and pigs/Učestalost antimikrobne rezistencije termofilnih C*ampylobacter* sojeva poreklom od ljudi, živine i svinja Vojnosanitetski pregled. 2013; **70** (2): 200-206.
580) Tambur, Z., Miljković-Selimović, B., Bokonjić, D. [Determination of sensitivity to antibiotics of *Campilobacter jejuni* and *Campilobacter coli* isolated from human feces]. Vojnosanitetski Pregled. 2009; **66**(1): 49-52.

581) Tambur, Z., Miljkovic-Selimovic, B., Bokonjic, D., Kulisic, Z. Susceptibility of *Campylobacter jejuni* and *Campylobacter coli* isolated from animals and humans to ciprofloxacin. Polish Journal of Veterinary Sciences. 2009; **12**(2): 269-273.
582) Velev V, Pavlova M, Mangarov A, Ivanov I, Kantardjiev T. Establishment of *Campylobacter* infection with immunochromatographic test. Merit Research Journal of Medicine and Medical Sciences. 2017; **5**(11):597-599.
583) Viaene J, Gellynck X., Messens, W. The economics of reducing *Campylobacter* in the Belgian poultry meat chain. Biotechnology in Animal Husbandry. 2007; **23**(5-6): 155–167.
584) Wine E, Chan VL, Sherman PM. *Campylobacter jejuni* mediated disruption of polarized epithelial monolayers is cell-type specific, time dependent, and correlates with bacterial invasion. Pediatr Res. 2008; **64**(6): 599-604.
585) Zeitouni S, Guyard-Nicodème M, Kempf I. Comparison of adhesion, invasion, motility, and toxin production of *Campylobacter* strains and their resistant mutants. Microb Drug Resist. 2013;**19**(2):130-137.

ЦИТИРАНА: 24A: Boyanova L, Gergova G, Koumanova R, Jelev C, Lazarova E, Mitov I, Kovacheva Y. Risk factors for primary *Helicobacter pylori* resistance in Bulgarian children. J. Med. Microbiol.; 2004; **53** (Pt 9): 911-914. **Цитирана от:**

586) Lawson AJ, Elviss NC, Owen RJ. Real-time PCR detection and frequency of 16S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in *Helicobacter pylori* from England and Wales. J Antimicrob Chemother. 2005; **56**(2): 282-286.
587) Xuan S-H, Zhou Y-G, Wang H-M. Advance in *Helicobacter pylori* resistance to clarithromycin. World Chinese Journal of Digestology. 2008; **16**(27): 3060-3064.
588) Njume C, Afolayan AJ, Ndip RN. An overview of antimicrobial resistance and the future of medicinal plants in the treatment of *Helicobacter pylori* infections. African Journal of Pharmacy and Pharmacology. 2009; **3**(13): 685-699.
589) Vécsei, A., Kipet, A., Innerhofer, A., Graf, U., Binder, C., Gizci, H., Hammer, K., Bruckdorfer, A., Huber, W.-D., Hirschl, A. M., Makristathis, A. Time trends of *Helicobacter pylori* resistance to antibiotics in children living in Vienna, Austria. Helicobacter. 2010; **15**: 214–220.
590) Orr, S.T., Blazer, D.G., Orr, C.A. Maternal prenatal depressive symptoms, nicotine addiction, and smoking-related knowledge, attitudes, beliefs, and behaviors. Maternal and Child Health Journal. 2012; **16** (5): 973-978.

ЦИТИРАНА: 25A: Boyanova L, Djambazov V, Gergova G, Iotov D, Petrov D, Osmanliev D, Minchev Z, Mitov I. Anaerobic microbiology in 198 cases of pleural empyema. A Bulgarian study. Anaerobe. 2004; **10**(5): 261-267. **Цитирана от:**

591) Abdalla, A. A., Ali, R., Oberoi, M., & Berger, P. Recurrent lymphocytic pleural effusion as a complication of ventriculopleural shunt meningitis caused by *Cutibacterium acnes*. Cureus. 2021; 13(2).
592) Alauzet C, Marchandin H, Lozniewski A. New insights into *Prevotella* diversity and medical microbiology. Future Microbiol. 2010; **5**(11):1695-1718.
593) Al-Jebouri MM, Al-Hadeethy HM.. Antibiotics resistance among anaerobic pathogens causing human periodontitis. World journal of pharmacy and pharmaceutical sciences. 2014; **3**(6):1720-1733
594) Alves J, Peres S, Gonçalves E, Mansinho K. Anaerobic bacteria with clinical relevance: Morphologic and taxonomic classification, distribution among human microbiota and microbiologic diagnosis. Acta Médica Portuguesa. 2017;**30**(5):409-417.
595) Barrera-López, L., Macía-Rodríguez, C., Ferreiro-Fernández, L., & Díaz-Peromingo, J. A. *Fusobacterium nucleatum* Empyema: An Atypical Presentation. European journal of case reports in internal medicine. 2020; 7(7).
596) Bartlett Infectious Diseases Review: December 31, 2004. Medscape today. Available online at: http://www.medscape.com/viewarticle/496021_4
597) Bartlett JG. Anaerobic bacterial infection of the lung. Anaerobe. 2012; **18**(2):235-239.
598) Bartlett JG. How important are anaerobic bacteria in aspiration pneumonia: when should they be treated and what is optimal therapy. Infect Dis Clin North Am. 2013;**27**(1):149-55. doi: 10.1016/j.idc.2012.11.016
599) Bedawi EO, Hassan M, Rahman NM. Recent developments in the management of pleural infection: a comprehensive review. The clinical respiratory journal. 2018;**12**(8):2309-20.
600) Bedawi EO, Hassan M, McCracken D, Rahman NM. Pleural infection: a closer look at the etiopathogenesis, microbiology and role of antibiotics. Expert review of respiratory medicine. 2019 Apr 4(just-accepted).
601) Cargill TN, Hassan M, Corcoran JP, Harriss E, Asciak R, Mercer RM, McCracken DJ, Bedawi EO, Rahman NM. A systematic review of comorbidities and outcomes of adult patients with pleural infection. Eur Respir J. 2019; **54**(3): 1900541.
602) Chaini E, Chainis ND, Ioannidis A, Magana M, Nikolaou C, Papaparaskevas J, Liakata MV, Katopodis P, Papastavrou L, Tegos GP, Chatzipanagiotou S. Pneumonia and pleural empyema due to a mixed *Lactobacillus* spp. infection as a possible early esophageal carcinoma signature. Front Med (Lausanne). 2016; **3**: 42. doi: 10.3389/fmed.2016.00042
603) Cobo F, Borrego J, Rodríguez-Granger J, Sampedro A, Navarro-Marí JM. A rare case of pleural infection due to *Propionibacterium acnes (Cutibacterium acnes)*. Revista Española de Quimioterapia. 2018;**31**(2):173.
604) Corcoran JP, Wrightson JM, Belcher E, DeCamp MM, Feller-Kopman D, Rahman NM. Pleural infection: past, present, and future directions. Lancet Respir Med. 2015; **3**(7):563-577.
605) Demirci M, Gemicioglu B, Saribas S, (...), Kocazeybek BS, Bahar-Tokman H. A retrospective nalysis of anaerobic bacteria isolated in 236 cases of pleural empyema and their prevalance of antimicrobial resistance in Turkey. Clinical Laboratory. 2018; **64**(7-8): 1269-1277.
606) Denes E, Barraud O. *Fusobacterium nucleatum* infections: clinical spectrum and bacteriological features of 78 cases. Infection. 2016; **44**(4):475-481.
607) Diego RR, Carlos QG, Evelyn RC. Antimicrobial resistance of clinical isolates of anaerobic bacteria from a regional hospital in Costa Rica. Revista médica de la Universidad de Costa Rica. 2010; **4**(1): 79-83.
608) Esquibel A, Dababneh AS, Palraj BR. *Lactobacillus gasseri* causing bilateral empyema. Case reports in infectious diseases. 2017;**2017**.
609) Girdhar A, Shujaat A, Bajwa A. Management of infectious processes of the pleural space: a review. Pulm Med. 2012; **2012**:816502.

610) Gobis K, Foks H, Kędzia A, Wierzbowska M, Zwolska Z. Synthesis and antibacterial activity of novel pyridine and pyrazine derivatives obtained from amidoximes. Journal of Heterocyclic Chemistry. 2009; **46**(6), 1271-1279.
611) Gobis K, Foks H, Kędzia A, Wierzchowska M, Kwapisz E, Zwolska Z, Augustynowicz-Kopeć E. Studies on pyrazine derivatives. XLVII. Synthesis and antibacterial activity of novel pyrazine derivatives with amidoxime moiety. Acta Poloniae Pharmaceutica- Drug Research 2006; **63**(1): 39-45.
612) Gobis K, Foks H, Zuralska A, Kedzia A. Studies on pyrazine derivatives. XLIX. Synthesis and antibacterial activity of 6-methoxypyrazine-2-carboxylic acid hydrazide derivatives. Heterocycles 2006; **68**(12): 2615-2626.
613) Granov, Đ., Bekić, D., Đulić, E. J., & Dedeić-Ljubović, A. Prevalence and susceptibility pattern of anaerobic bacteria isolated from wound swabs in Clinical Centre University of Sarajevo. Acta Medica Saliniana. 2019; 49.
614) Hagihara M, Kato H, Shibata Y, Sakanashi D, Asai N, Suematsu H, ... & Mikamo H. In vivo pharmacodynamics of lascufloxacin and levofloxacin against *Streptococcus pneumoniae* and *Prevotella intermedia* in a pneumonia mixed-infection mouse model. Anaerobe. 2021; **69**, 102346.
615) Hassan M, Cargill T, Harriss E, Asciak R, Mercer RM, Bedawi EO, ... & Rahman NM. The microbiology of pleural infection in adults: a systematic review. European Respiratory Journal. 2019; **54**(3).
616) Hassan M, Corcoran JP, Daneshvar C. Factors associated with variations in the rate of referrals and microbiology of pleural infection. Expert Review of Respiratory Medicine. 2020; **14**(11), 1165-1171.
617) Jwa H, Lee J, Seong GM, Kim C. Iatrogenic pleural empyema caused by *Propionibacterium acnes*. Allergy, Asthma & Respiratory Disease. 2019;**7**(1):61-4.
618) Kawanami T, Fukuda K, Yatera K, Kido M, Mukae H, Taniguchi H. A higher significance of anaerobes: the clone library analysis of bacterial pleurisy. Chest. 2011; **139**(3):600-608.
619) Kaynaklı ABNOT, Yağmur UDG. Anaerop Haber Mayıs 2015 sayısının konu başlığı: Yurt içi/yurt dışı anaerop yayınlar. Anaerop_Haber_Mayis_2015.pdf
620) Kierzkowska M,Majewska A,Sawicka-Grzelak A,Młynarczyk G. Beztlenowe ziarenkowce gram-dodatnie (GPAC) - Diagnostyka i znaczenie kliniczne | [Gram-positive anaerobic cocci (GPAC) - Diagnostic and clinical significance] Postepy Mikrobiologii 2014; **53**(1): 35-42.
621) Kim SC. Complicated pleural effusion. Diagnosis and treatment of complicated pleural effusion. The Korean Journal of Medicine. 2011; **81**(2):143-149.
622) Liu Y, Zhang X, Liu Y, Jin X, Fan C, Ye H, Ou M, Lv L, Wu G, Zhou Y. Bi-functionalization of a calcium phosphate-coated titanium surface with slow-release simvastatin and metronidazole to provide antibacterial activities and pro-osteodifferentiation capabilities. PLoS One. 2014; **9**(5):e97741.
623) Mikasa K, Aoki N, Aoki Y, Abe S, Iwata S, Ouchi K, Kasahara K, Kadota J, Kishida N, Kobayashi O, Sakata H, Seki M, Tsukada H, Tokue Y, Nakamura-Uchiyama F, Higa F, Maeda K, Yanagihara K, Yoshida K. JAID/JSC Guidelines for the treatment of respiratory infectious diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to clinical management of infectious disease/Guideline-preparing Committee Respiratory Infectious Disease WG. J Infect Chemother. 2016;**22**(7S):S1-S65.
624) Mitsuhashi S, Kryukov K, Nakagawa S, Takeuchi JS, Shiraishi Y, Asano K, Imanishi T. A portable system for rapid bacterial composition analysis using a nanopore-based sequencer and laptop computer. Sci Rep. 2017;**7**(1):5657.
625) Murphy EC, Frick IM. Gram-positive anaerobic cocci—commensals and opportunistic pathogens. FEMS Microbiol Rev. 2013; **37**(4):520-553.
626) Nagaoka K, Yanagihara K, Harada Y, Yamada K, Migiyama Y, Morinaga Y, Izumikawa K, Kohno S. Quantitative detection of periodontopathic bacteria in lower respiratory tract specimens by real-time PCR. Journal of Infection and Chemotherapy. 2017;**23**(2):69-73.
627) Nagaoka K, Yanagihara K, Morinaga Y, Kohno S. Detection of *Fusobacterium nucleatum* in two cases of empyema and lung abscess using paromomycin-vancomycin supplemented Brucella HK agar. Anaerobe. 2017; **43**:99-101.
628) Riordan T. Human infection with *Fusobacterium necrophorum* (Necrobacillosis), with a focus on Lemierre's syndrome. Clin Microbiol Rev. 2007; **20**(4):622-659.
629) Rivera Ruiz D, Quesada Gómez C, Rodríguez Cavallini E. Antimicrobial resistance of clinical isolates of anaerobic bacteria from a regional hospital in Costa Rica. Revista Médica de la Universidad de Costa Rica 2009; **4**(1).
630) Rosenthal ME, Rojtman AD, Frank E. *Finegoldia magna* (formerly *Peptostreptococcus magnus*): an overlooked etiology for toxic shock syndrome? Med Hypotheses. 2012; **79**(2):138-140.
631) Ruiz, D. R., Gómez, C. Q., & Cavallini, E. R. Antimicrobial resistance of clinical isolates of anaerobic bacteria from a regional hospital in Costa Rica. Revista Médica de la Universidad de Costa Rica. 2010; **4**(1), 79-84.
632) Senol G, Coskun M, Gunduz, A, Bicmen C, Tibet G. Anaerobes in nosocomial and community acquired pleural infections. Indian Journal of Medical Microbiology. 2013; **31**(4):392-394.
633) Shiraishi, Y., Kryukov, K., Tomomatsu, K., Sakamaki, F., Inoue, S., Nakagawa, S., ... & Asano, K. Diagnosis of pleural empyema/parapneumonic effusion by next-generation sequencing. Infectious Diseases. 2021; **53**(6), 450-459.
634) Strange, C., Ramirez, J. A., & Bond, S. Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults. Up to date. 2020; https://www.uptodate.com/contents/epidemiology-clinical-presentation-and-diagnostic-evaluation-of-parapneumonic-effusion-and-empyema-in-adults
635) Towe, C. W., Srinivasan, S., Ho, V. P., Bachmann, K., Worrell, S. G., Perry, Y., ... & Linden, P. A. Antibiotic resistance is associated with morbidity and mortality after decortication for empyema. The Annals of Thoracic Surgery. 2021; **111**(1), 206-213.
636) Yağmur G, Demirel H, Şahin MF, Akçay A, Koç S. Anaerop bakterilerin neden olduğu toplum kaynaklı plevrapulmoner enfeksiyona bağlı gelişen ölümcül sepsis vakası. [A case of community-acquired pleuropulmonary infection and fatal septicemia caused by anaerobic bacteria] Turk Hij Den Biyol Derg, 2014; **71**(4):201-206.

637) Zhou H, Shen Y, Shen Q, Zhou J. Thoracic empyema caused by *Prevotella* spp. diagnosed using 16S rDNA sequence analysis. Clin Respir J. 2015; **9**(1):121–124.
638) Hyeyoung Jwa, Jaechun Lee, Gil Myeong Seong, Changhwan Kim. [Iatrogenic pleural empyema caused by *Propionibacterium acnes.]* Allergy, Asthma & Respiratory Disease, 2019; **7**(1), 61-64.

ЦИТИРАНА: 26A: Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains *in vitro* by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; **54** (Pt 5):481-483. **Цитирана от:**

639) Abd-El-Rhman AM. Antagonism of *Aeromonas hydrophila* by propolis and its effect on the performance of *Nile tilapia*, *Oreochromis niloticu*s. Fish Shellfish Immunol. 2009; **27**(3):454-459.
640) Abd Elkodous M, El-Sayyad GS, Youssry SM, Nada HG, Gobara M, Elsayed MA, ... Matsuda A. Carbon-dot-loaded Co x Ni 1− x Fe 2 O 4; x= 0.9/SiO 2/TiO 2 nanocomposite with enhanced photocatalytic and antimicrobial potential: An engineered nanocomposite for wastewater treatment. Scientific Reports. 2020; **10**(1):11534-11534.
641) Adefuye AO, Samie A, Ndip RN. In-vitro evaluation of the antimicrobial activity of extracts of bridelia micrantha on selected bacterial pathogens. Journal of Medicinal Plant Research. 2011; **5** (20):. 5116-5122.
642) Ajjai S, Nair P, Grace JL, Vennila R. Anti-microbial effectiveness of lemon grass oil (cymbopogan citrate) against aerobic and anaerobic organisms. International Journal of Current Pharmaceutical Research. 2021; 21-23.
643) Akkaoui S, Johansson A, Yagoubi M, Haubek D, Rida S, Claesson R, Ennibi O. Chemical composition, antimicrobial activity, in vitro cytotoxicity and leukotoxin neutralization of essential oil from origanum vulgare against *Aggregatibacter actinomycetemcomitans*. Pathogens. 2020, 9.3: 192.
644) Alasmary FA, Awaad AS, Alqahtani SM, El-Meligy RM, Abdullah DA, Alqasoumi S I. Evaluation of the chemical constituents and potential biological activities of *Cunninghamella blakesleeana*. Saudi Pharmaceutical Journal, 2020; 28(10): 1197-1202.
645) Aleixo MLM, Galbiati C, Lemos LMS. Produtos naturais anti - *Helicobacter pylori*: revisão. Revista Ibero-Americana de Ciências Ambientais. 2018;9(1). http://www.sustenere.co/index.php/rica/article/view/CBPC2179-6858.2018.001.0005/1049
646) Alfarrayeh I, Fekete C, Gazdag Z, Papp G. Propolis ethanolic extract has double-face in vitro effect on the planktonic growth and biofilm formation of some commercial probiotics. Saudi Journal of Biological Sciences, 2021; **28**(1), 1033-1039.
647) Amara AA. Methods other than experimental animals for screening antitumor compounds. American Journal of Cancer Science. 2013; **2**(1):1-27.
648) Astani A, Zimmermann S, Hassan E, Reichling J, Sensch KH, Schnitzler P. Antimicrobial activity of propolis special extract GH 2002 against multidrug-resistant clinical isolates. Pharmazie. 2013;**68**(8):695-701.
649) Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for *Helicobacter pylori* infection. World J Gastroenterol. 2014;**20**(6):1450-1469.
650) Aydin S, Kinalioğlu K. Antimicrobial Activity of the Lichen Extracts of *Pseudevernia furfuracea* (L.) Zopf var. *furfuracea* and *Parmelina tiliaceae* (Hoffm.). Karadeniz Fen Bilimleri Dergisi / The Black Sea Journal of Sciences. 2010; **1**(2): 30-38.
651) Aytar M, Oryaşin E, Başbülbül G, Bozdoğan B. Agar well difüzyon yönteminde standardizasyon çalişmasi. Bartın Üniversitesi Uluslararası Fen Bilimleri Dergisi. 2019; **2**(2), 138-145.
652) Azam MA, Dharanya L, Mehta CC, Sachdeva S. Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system. Acta Pharm. 2013; **63**: 19–30.
653) Azimi G, Hakakian A, Ghanadian M, Joumaa A, Alamian S. Bioassay-directed isolation of quaternary benzylisoquinolines from *Berberis integerrima* with bactericidal activity against *Brucella abortus*. Research in Pharmaceutical Sciences. 2018;**13**(2):149.
654) Babiker EE, Al-Juhaimi FY, Alqah HA, Adisa AR, Adiamo OQ, Ahmed IAM., ... Ozcan MM. The effect of *Acacia nilotica* seed extract on the physicochemical, microbiological and oxidative stability of chicken patties. Journal of food science and technology. 2019; 56.8: 3910-3920.
655) Bankova V, Atanassov A, Denev R, Shishinjova M. Bulgarian bee products and their health promoting potential. Biotechnol Biotechnol Equip. 2012, **26**(4): 3086-3088.
656) Barbarić M, Mišković K, Bojić M, Lončar MB, Smolčić-Bubalo A, Debeljak Z, Medić-Šarić M. Chemical composition of the ethanolic propolis extracts and its effect on HeLa cells. J Ethnopharmacol. 2011;**135**(3):772-8.
657) Baumann LS. Less-known botanical cosmeceuticals. Dermatol Ther 2007; **20**(5):330–342.
658) Bektas H, Albay C, Sökmen BB, Aydın S, Menteşe E, Aydın G, Şen D. Synthesis, Antioxidant, and Antibacterial Activities of Some New 2-(3-fluorobenzyl)-1H-benzimidazole Derivatives. Journal of Heterocyclic Chemistry. 2018;**55**(10):2400-7.
659) Bergamaschi, A., Magrini, A., Pietroiusti, A. Recent advances in the treatment of *Helicobacter pylori* infection recent patents on anti-infective. Drug Discovery 2007; **2**(3): 197-205.
660) Bertrams J, Kunz N, Müller M, Kammerer D, Stintzing FC. Phenolic compounds as marker compounds for botanical origin determination of German propolis samples based on TLC and TLC-MS. Journal of Applied Botany and Food Quality. 2013; **86**. DOI: 10.5073/JABFQ.2013.086.020
661) Bhadauria, M. Combined treatment of HEDTA and propolis prevents aluminum induced toxicity in rats. Food and Chemical Toxicology. 2012; **50**(7): 2487-2495.
662) Bonvehí, J.S., Gutiérrez, A.L. The antimicrobial effects of propolis collected in different regions in the Basque Country (Northern Spain). World Journal of Microbiology and Biotechnology. 2012; **28**(4): 1351-1358.
663) Bouzahouane H, Ayari A, Guehria I, Riah O. The propolis: antimicrobial activity and chemical composition analysis. Journal of Microbiology, Biotechnology and Food Sciences, 2021, https://doi.org/10.15414/jmbfs.3211.
664) Boztepe C, Tosun E, Bilenler T, Sislioglu K. Synthesis and characterization of acrylamide-based copolymeric hydrogel–silver composites: Antimicrobial activities and inhibition kinetics against *E. coli*. International Journal of Polymeric Materials and Polymeric Biomaterials. 2017;**66**(18):934-942.

665) Brahmi F, Haddad S, Bouamara K, Yalaoui-Guellal D, Prost-Camus E, de Barros JPP, Lizard G. Comparison of chemical composition and biological activities of Algerian seed oils of *Pistacia lentiscus* L., *Opuntia ficus indica* (L.) mill. and *Argania spinosa* L. Skeels. Industrial Crops and Products. 2020; **151**:112456.
666) Campana, R., Patrone, V., Franzini, I.T.M., Diamantini, G., Vittoria, E., Baffone, W. Antimicrobial activity of two propolis samples against human *Campylobacter jejuni*. Journal of Medicinal Food. 2009, **12** (5): 1050-1056.
667) Cardinault, N.,Cayeux, M.-O.,Percie Du Sert, P. La propolis : origine, composition et propriétés | [Propolis: Origin, composition and properties] Phytotherapie 2012; **10** (5): 298-304.
668) Chakotiya AS, Chawla R, Thakur P, Tanwar A, Narula A, Grover SS, Goel R, Arora R, Sharma RK. In vitro bactericidal activity of promising nutraceuticals for targeting multidrug resistant *Pseudomonas aeruginosa*. Nutrition. 2016; **32**(7-8):890-897.
669) Chandra JS, Parvathi V, Sunandamma Y. Growth, characterization, NLO and biological activities of Fe (III) ions doped Mn (II) L-Histidine hydrochloride monohydrate crystals. Materials Today: Proceedings. 2018;**5**(13):26380-8.
670) Chauhan HP, Carpenter J, Joshi S. Synthetic aspects, spectral, thermal studies andantimicrobial screening on bis(N,N-dimethyldithiocarbamato-S,S')antimony(III)complexes with oxo or thio donor ligands. Spectrochim Acta A Mol Biomol Spectrosc. 2014;**130**:230-237.
671) Chauhan HPS, Joshi S, Bakshi A, Carpenter J. Structural investigation on toluene-3, 4-dithiolatoantimony (III) alkyldithiocarbonate complexes: thermal, powder XRD and biological studies. ***New J. Chem.***, 2015,**39**, 2279-2288. doi**:** 10.1039/C4NJ02094D
672) Chauhan HPS, Joshi S, Carpenter J. Mixed bismuth(III) complexes with sulfur donor ligands. Journal of Thermal Analysis and Calorimetry. 2016; **124**(1):117-130.
673) Chauhan HPS, Carpenter J, Joshi S. Mixed bis (morpholine-4-dithiocarbamato-S, S′) antimony (III) complexes: synthesis, characterization and biological studies. Applied Organometallic Chemistry, 2014; **28**(8):605-613.
674) Chowdhury FT, Sarker M, Islam MS, Nur HP, Islam MR, Khan H. Bioresearch Communications. Journal Homepage: www. bioresearchcommunications. com. 2018 Jan;4(01).
675) Chukeatirote E, Jenjai N. Antimicrobial activity of wood vinegar from *Dimocarpus longan*. EnvironmentAsia. 2018;**11**(3).
676) Deb A, Saikia R, Chowdhury D. Nano-Bioconjugate Film from Aloe vera to detect hazardous chemicals used in cosmetics. ACS omega, 2019; **4**(23): 20394-20401.
677) DeNaan DN. Natural product (*Abutilon hirtum* extracts) in treating environment-related infections (Salmonellosis and Typhoid fever). GSC Biological and Pharmaceutical Sciences, 2020;13(2), 128-135.
678) Di Mario F, Cavallaro LG, Scarpignato C. 'Rescue' therapies for the management of *Helicobacter pylori* infection. Dig Dis. 2006; **24**(1-2): 113-130.
679) El-Refai AA, Sharaf AM, Azzaz NAE., El-Dengawy MM. (2020). Antioxidants and antibacterial activities of bioactive compounds of clove (*Syzygium aromaticum*) and thyme (*Tymus vulgaris*) extracts. Journal of Food and Dairy Sciences. 2020; **11**(9), 265-269.
680) Feroze N, Arshad B, Younas M, Afridi MI, Saqib S, Ayaz A. Fungal mediated synthesis of silver nanoparticles and evaluation of antibacterial activity. Microscopy Research and Technique. 2020; **83**(1): 72-80.
681) Fokt H, Pereira A, Ferreira AM, Cunha A, Aguiar C. How do bees prevent hive infections? The antimicrobial properties of propolis. Current Research, Technology and Education Topics in Applied Microbiology and Microbial Biotechnology. 2010;1:481-493.
682) Gao, Z., Yin, J., Xie, X., Lin, C., Long, H., & Qi, X. Intracellular Signaling Mechanisms Pharmacological Action of *Jasminum amplexicaule* Buch.-Ham.(Oleaceae) on Gastrointestinal Secretion. Iranian Journal of Pharmaceutical Research. 2014; **13** (3): 959-965
683) Ghedira K, Goetz, Le Jeune R. Practical Materia Medica: Propolis [Matière médicale pratique: Propolis]. Phytothérapie. 2009 ; **7**(2): 100-105.
684) Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate *Helicobacter pylori*: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; **8**(4):6530-6543.
685) Gönen F, Tekinerdoğan G. Synthesis of Specific ZnF Based Nanoparticles (ZnFe2O4): Antimicrobial Properties, Surface Characteristics, and Adsorption Activity for AB 29 Textile Dye. Journal of Nanotechnology. 2020: Article ID 3139701.
686) Governa P, Biagi M. *Copaifera langsdorffii* Desf.: in vitro investigation on anti-*Helicobacter pylori* and anti-inflammatory activities of oleoresin and fruit methanolic extract. Plant Biosystems-An International Journal Dealing with all Aspects of Plant Biology. 2020, 154.1: 117-124.
687) Guzeldag G, Kadioglu L, Mercimek A, Matyar F. Peliminary examination of herbal extracts on the inhibition of *Helicobacter pylori.* African Journal of Traditional, Complementary and Alternative Medicines. 2014; **11**(1):93-96.
688) Guna V, Ilangovan M, Adithya K, Srinivas CV, Yogesh S, Nagananda GS, ... Reddy N. Carbohydrate polymers. 2019, **218**: 243-249.
689) Hamayeli H, Shoshtari AN, Hassanshahian M, Hesni MA. Journal of Coastal Life Medicine. Journal of Coastal Life Medicine. 2016;**4**(8):612-615.
690) Hamayeli H, Hassanshahian M, Hesni MA. The antibacterial and antibiofilm activity of sea anemone (*Stichodactyla haddoni*) against antibiotic-resistant bacteria and characterization of bioactive metabolites. International Aquatic Research. 2019; **11**(1): 85-97.
691) Hammad K, Elsayed N, Elkashef H. (2021). Development of a whey protein concentrate/apple pomace extract edible coating for shelf life extension of fresh-cut apple. International Food Research Journal. 2021; 28(2): 377-385.
692) Hannan A, Batool A, Qamar MU, Khalid F. Propolis as an antibacterial agent against clinical isolates of MDR-*Acinetobacter baumannii*. J Ayub Med Coll Abbottabad. 2015; **27**(1):216-219.
693) Hasali NH, Zamri AI, Lani MN, Mubarak A. Antibiotic susceptibility, antibacterial activity and probiotic characterisation of isolated *Lactobacillus brevis* strains from *Heterotrigona itama* honey. Malaysian Applied Biology. 2018; **47**(6):105-112.

694) Hosseini M, Jamshidi A, Raeisi M, Azizzadeh M. The Antibacterial and antioxidant effects of clove (*Syzygium aromaticum*) and lemon verbena (*Aloysia citriodora*) essential oils. Journal of Human, Environment and Health Promotion. 2019; **5**(2), 86-93.
695) Ilahi I, Khuda F, Sahibzada MUK, Alghamdi S, Ullah R, Dablool AS, ... & Khalil AAK. Synthesis of silver nanoparticles using root extract of Duchesnea indica and assessment of its biological activities. Arabian Journal of Chemistry, 2021; **14**(5): 103110.
696) Islam NUI, Jalil K, Shahid M, Muhammad N, Rauf A. *Pistacia integerrima* gall extract mediated green synthesis of gold nanoparticles and their biological activities. Arabian Journal of Chemistry. 2015: http://www.sciencedirect.com/science/article/pii/S1878535215000489
697) Islam NUI; Ahsan F, Khan I; Shah MR; Shahid M; Khan MA. Green synthesis and biological activities of gold nanoparticles functionalized with *Citrus reticulata, Citrus aurantium, Citrus sinensis* and *Citrus grandis.* Journal of the Chemical Society of Pakistan. 2015; **37**(4):721-773.
698) Islam NU, Jalil K, Shahid M, Rauf A, Muhammad N, Khan A, ... Khan MA. Green synthesis and biological activities of gold nanoparticles functionalized with Salix alba. Arabian Journal of Chemistry. 2019; 12.8: 2914-2925.
699) Islam NU, Jalil K, Shahid M, Muhammad N, Rauf A. *Pistacia integerrima* gall extract mediated green synthesis of gold nanoparticles and their biological activities. Arabian Journal of Chemistry. 2019; **12**(8): 2310-2319.
700) Jafari B, Ebadi A, Aghdam BM, Hassanzade Z. Antibacterial Activitiesof Lemon Grass Methanol Extract and Essence on Pathogenic Bacteria. American-Eurasian J Agric & Environ Sci. 2012; **12**(8):1042-1046.
701) Jagatheswaran P, Krishnaveni M. Antimicrobial substance produced by *Aeromonas* KC954626 and its effect on meat isolates. Journal of Pharmacy Research. 2013; **6**(5):538-542.
702) Jain R, Jain SC. Studies on antimicrobial and antioxidant potentials of triterpenoidal saponins from *Mimosa Hamata* Willd. International Journal of Pharmaceutical and Phytopharmacological Research. 2017;**4**(6):337-339.
703) Jain R, Saxena U, Rathore K, Jain SC. Bioactivities of polyphenolics from the roots of *Bauhinia racemosa*. Arch Pharm Res. 2008; **31**(12):1525-1529.
704) Jain SC, Pancholi B, Jain R. Rapid in vitro multiplication and biological potentialities of Sericostoma pauciflorum stocks ex Wight. Journal of Medicinal Plants Research. 2014; **8**(1):45-51.
705) Jain SC, Pancholi B, Jain R. *Aizoaceae* plants as potential antimicrobial agents. Romanian Biotechnological Letters. 2012; **17**(5):7577-7581.
706) Jain SC, Pancholi B, Jain R. *Peltophorum pterocarpum* (DC.) Baker ex. K. Heyne Flowers: Antimicrobial and antioxidant efficacies. Research Journal of Medicinal Plant. 2011; **5** (3), 274-280.
707) Jain SC, Pancholi B, Singh R, Jain R. Antibacterial and antifungal potential of some Arid Zone plants. Indian J Pharm Sci. 2010; **72**(4): 510-513.
708) Jain SC, Pancholi B, Jain R. In-vitro callus propagation and secondary metabolite quantification in *Sericostoma pauciforum*. Iranian Journal of Pharmaceutical Research. 2012; **11** (4): 1103-1109.
709) Jain, S.C., Pancholi, B., Jain, R. In vivo and in vitro phytochemical, microbial and antioxidant evaluation of sericostoma pauciflorum stocks ex wight callus. International Journal of Pharmacy and Pharmaceutical Sciences. 2012; **4** (1): 332-336.
710) Jain SC, Pancholi B, Jain R. Studies on antimicrobial and antioxidant potentials of *Pergularia daemia* (Forsk.) Chiov. Asian Journal of Chemistry. 2012; **24** (8):3513-3516.
711) Jayakumar R, Ramya C, Kumar PS, Snima KS, Lakshmanan VK, Nair SV. In vitro anti-cancerous and anti-microbial activity of propolis nanoparticles. J. Nanopharm. Drug Deliv. 2013;**1**:150-156.
712) Junjian R, Xinhong L, Ruixiang Z, Lili Z, Gang L. Purification, characterization of a novel lactobacillin LA1 produced by *Lactobacillus rhamnosus* ZRX01. Research Journal of Biotechnology. 2017; **12**(11): 46-53
713) Kakanejadifard A, Khojasteh V, Zabardasti A, Azarbani F. New azo-schiff base ligand capped silver and cadmium sulfide nanoparticles preparation, characterization, antibacterial and antifungal activities. Organic Chemistry Research. 2018; **4**(2):210-26.
714) Kalia P, Kumar NR, Harjai K. Studies on the therapeutic effect of propolis along with standard antibacterial drug in *Salmonella enterica* serovar Typhimurium infected BALB/c mice. BMC complementary and alternative medicine. 2016;**16**(1):485.
715) Kalia P, Kumar NR, Harjai K. Preventive effect of honey bee propolis on *Salmonella enterica* serovar *Typhimurium* infected BALB/c mice: A Hematological Study. Research Journal of Pharmacy and Technology. 2020; **13**(7): 3389-3393.
716) Kalidoss R, Ayyappadasan G, Gnanamangai BM, Ponmurugan P. Antibacterial activity of lichen *Parmotrema* spp. International Journal of Pharmaceutical and Biological Science Archive. 2020; **8**(2).
717) Karadağ A, Aydın A, Dede S, Tekin Ş, Yanar Y, Çadırcı BH, Soylu MS, Andaç Ö. Five novel dicyanidoaurate(I)-based complexes exhibiting significant biological activities: synthesis, characterization and three crystal structures. New J. Chem. 2015; **39:** 8136-8152.
718) Karadağ A, Korkmaz N, Aydın A, Tekin Ş, Yanar Y, Yerli Y, Korkmaz ŞA. In vitro biological properties and predicted DNA–BSA interaction of three new dicyanidoargentate (i)-based complexes: synthesis and characterization. New Journal of Chemistry. 2018; **42**(6):4679-92.
719) Kaur H, Amini MH , Prabhakar PK, Singh A, Suttee A. Phytochemical screening and antimicrobial activity of *Caesalpinia sappan* L. leaves. International Journal of Pharmacognosy and Phytochemical Research 2016; **8**(6):1040-1045.
720) Kaya EG, Özbilge H, Albayrak S. Kayseri Propolisinin Etanolik Ekstraktının Antimikrobiyal Aktivitesi. [Antimicrobial activity of the ethanolic extract of Kayseri propolis[. Selçuk Tıp Derg. 2012; **28**(4):209-212.
721) Khalil WF, El-Sayyad GS, El Rouby WM, Sadek MA, Farghali AA, El-Batal AI. Graphene oxide-based nanocomposites (GO-chitosan and GO-EDTA) for outstanding antimicrobial potential against some *Candida* species and pathogenic bacteria. International Journal of Biological Macromolecules. 2020; **164**: 1370-1383.

722) Khan H, Badshah A, Said M, Murtaza G, Sirajuddin M, Ahmad J, Butlere IS. Synthesis, structural characterization and biological screening of heteroleptic palladium(II) complexes. Inorganica Chimica Acta. 2016; **447**:176–182.
723) Korkmaz N, Aydın A, Karadağ A, Yanar Y, Maaşoğlu Y, Şahin E, Tekin Ş. New bimetallic dicyanidoargentate (I)-based coordination compounds: Synthesis, characterization, biological activities and DNA-BSA binding affinities. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2017;**173**:1007-1022.
724) Korkmaz, N., Karadağ, A., Aydın, A., Yanar, Y., Karaman, İ., & Tekin, Ş. Synthesis and characterization of two novel dicyanidoargentate (i) complexes containing N-(2-hydroxyethyl) ethylenediamine exhibiting significant biological activity. New J Chem. 2014; **38**(10), 4760-4773.
725) Kumar SS, Kamaraj M. Antimicrobial activity of *Cucumis anguria* L. by agar well diffusion method. Botany Research International. 2011; **4**(2): 41-42.
726) Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmański Ł, Migdał P, Gościniak G. In Vitro Activity of 3-bromopyruvate, an anticancer compound, against antibiotic-susceptible and antibiotic-resistant *Helicobacter pylori* strains. Cancers. 2019;**11**(2):229.
727) Labská K, Plodková H, Pumannová M, Sensch KH. Antiviral activity of propolis special extract GH 2002 against Varicella zoster virus in vitro. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2018;**73**(12):733-6.
728) Lee AR, Niu KM, Kang SK, Han SG, Lee BJ, Kim SK. Antioxidant and antibacterial activities of *Lactobacillus*-fermented Artemisia annua L. as a potential fish feed additive. Journal of Life Science. 2017;**27**(6):652-660.
729) Lekhak B, Singh A, Bhatta DR. Antibacterial and Antifungal Property of *Actinomycetes* Isolates from Soil and Water of Nepal. Journal of Nepal Health Research Council. 2018;**16**(2):136-9.
730) Lima VHMD, Almeida KDCR, Alves CCF, Rodrigues ML, Crotti AEM, Souza JMD, ... & Miranda MLD. Biological properties of volatile oil from Brazilian brown propolis. Revista Brasileira de Farmacognosia. 2019; **29**(6): 807-810.
731) Liu Q, Yu J, Yan J, Qi X, Liu C, Jin H. Antagonism and action mechanism of antifungal metabolites from *Streptomyces rimosus* MY02. Journal of Phytopathology. 2009; **157**(5): 306-310.
732) Maheswari RU, Priya K. Studies on influence of ascorbic acid & correlance with anti-fungal possessions of *Cymbopogan Citratus* treated with various organic manure and its texture analysis using sem. World Journal of Pharmacy and Pharmaceutical Sciences. 2016; **5**(9):1647-1657.
733) Marand SK, Yazdi FT, Mortazavi SA, Babaei AB. Inhibitory and bactericidal effects of artichoke (*Cynara scolymus*) on pathogenic strains and their comparison with antibiotics in vitro. Qom Univ Med Sci J. 2016;**10**(2):31-42.
734) More NV, Kharat KR, Kharat AS. Berberine from *Argemone mexicana* L exhibits a broadspectrum antibacterial activity. Acta Biochimica Polonica. 2017; **64**(4): 653-660.
735) Munir N, Ijaz W, Altaf I, Naz S. Evaluation of antifungal and antioxidant potential of two medicinal plants: Aconitum heterophyllum and Polygonum bistorta. Asian Pacific Journal of Tropical Biomedicine. 2014;**4**:S639-S643.
736) Murali MR, Naveen SV, Son CG, Raghavendran HR. Current knowledge on alleviating *Helicobacter pylori* infections through the use of some commonly known natural products: bench to bedside. Integrative Medicine Research. 2014; **3**(3):111-118.
737) Musa TN, Salih NM, Ulaiwi WS. Detection of some active compounds in aqueous and ethanolic extracts of iraqi propolis and examine their antibacterial effects. Pakistan Journal of Nutrition. 2012; **11**(1): 83-87.
738) Najmadeen HH, Kakamand FAKh. Antimicrobial activity of propolis collected in different regions of Sulaimani province-Kurdistan region/Iraq. J Duhok Univ. 2009; **12**(1, Special Issue): 233-239.
739) Naik GG, Alam MB, Pandey V, Mohapatra D, Dubey PK, Parmar AS, Sahu AN. Multi-Functional Carbon Dots from an Ayurvedic Medicinal Plant for Cancer Cell Bioimaging Applications. Journal of Fluorescence. 2020; 1-12.
740) Nirala SK, Bhadauria M. Propolis reverses acetaminophen induced acute hepatorenal alterations: a biochemical and histopathological approach. Arch Pharm Res. 2008; **31**(4):451-461.
741) Njume C, Afolayan AJ, Clarke AM, Ndip RN. Crude ethanolic extracts of garcinia kola seeds heckel (*Guttiferae*) prolong the lag phase of *Helicobacter pylori*: Inhibitory and bactericidal potential Journal of Medicinal Food. 2011; **14**(7-8): 822-827.
742) Njume C, Afolayan AJ, Samie A, Ndip RN. Inhibitory and bactericidal potential of crude acetone extracts of *Combretum molle (Combretaceae*) on drug-resistant strains of *Helicobacter pylori*. J Health Popul Nutr. 2011; **29**(5):438-445.
743) Njume C, Gqaza BM, George G, Goduka NI. In vitro antimicrobial evaluation of two indigenous functional food-plants (*Chenopodium album* and *Solanum nigrum*) used in the Oliver Reginald (OR) Tambo district municipality of South Africa. African Journal of Microbiology Research. 2014;**8**(41):3612-3616.
744) Njume C, Jide AA, Ndip RN. Aqueous and organic solvent-extracts of selected south african medicinal plants possess antimicrobial activity against drug-resistant strains of *Helicobacter pylori*: inhibitory and bactericidal potential. Int J Mol Sci. 2011; **12**(9), 5652-5665.
745) Nobakht M, Trueman SJ, Wallace HM, Brooks PR, Streeter KJ, Katouli M. Antibacterial properties of flavonoids from Kino of the Eucalypt Tree, *Corymbia torelliana*. Plants. 2017;**6**(3):39.
746) Noel DD, Solomon OO, John NB. Impact of *Vitex doniana* extract in elimination of *Salmonella* infection-a tropical neglected disease. Merit Research Journal of Microbiology and Biological Sciences. 2016; **4**(5): 248-254.
747) Nolkemper S, Reichling J, Sensch KH, Schnitzler P. Mechanism of herpes simplex virus type 2 suppression by propolis extracts Phytomedicine. 2010; **17**(2): 132-138.
748) Nunes LCC, de La Roca MF, Randau KP; Sobrinho JLS, Cito AMGL, Neto PJR. Evaluation of physical chemistry properties and legal aspects of propolis extracts sold in Brazilian markets. Rev Bras Farm. 2008; **89**(1): 59-63.
749) Nyenje, M., Ndip, R.N. In-vitro antimicrobial activity of crude acetone extract of the stem bark of Combretum molle against selected bacterial pathogens. Journal of Medicinal Plant Research. 2011; **5** (21): 5315-5320.
750) Okeleye BI, Bessong PO, Ndip RN. Preliminary phytochemical screening and in vitro anti-*Helicobacter pylori* activity of extracts of the stem bark of *Bridelia micrantha* (Hochst., Baill., Euphorbiaceae). Molecules. 2011;**16**(8):6193-6205.

751) Okeleye BI, Samie A, Bessong PO, Mkwetshana NF, Green E, Clarke AM, Ndip RN. Crude ethyl acetate extract of the stem bark of *Peltophorum africanum* (Sond, Fabaceae) possessing *in vitro* inhibitory and bactericidal activity against clinical isolates of *Helicobacter pylori*. Journal of Medicinal Plants Research 2010; **4**(14): 1432-1440.
752) Pandya K, Parikh V, Patel G, Ukani K. In vitro anti-leucorrhoeal activity of a poly herbal formulation--meryton-l tablet. Pharmanest. 2013; **4**(4):659-663.
753) Park JY, Moon KS, Jeong SH, Kim JM, Oh SH. Visible Light Triggered Chlorhexidine Release of Nitrogen-Doped TiO2 Nanoparticle Dental Desensitizer. In Journal of Nano Research 2016; **43**: 57-62. Trans Tech Publications.
754) Ponmurugan P, Aldhafiri FK, Balakrishnan S. Antibacterial Activity of Green Tea Leaves. Int. J. Curr. Microbiol. App. Sci. 2016; **5**(11):472-477.
755) Pourhojat F, Sohrabi M, Shariati S, Mahdavi H, Asadpour L. Evaluation of poly ε-caprolactone electrospun nanofibers loaded with *Hypericum perforatum* extract as a wound dressing. Research on Chemical Intermediates. 2017;**1**(43):297-320.
756) Prabhakar V. Synthesis and characterization of turmeric powered bio-significant organometallic aluminates. Asian Journal of Biomedical and Pharmaceutical Sciences 2015: 7-14.
757) PrabhaPalanichamy AT, Maruthamuthu M. Ethyl acetate extraction of antibacterial compounds of endophytic fungi isolated from medicinal plants. Chem Sci Rev Lett 2014, **3**(10): 178-182.
758) Pradhan S, Dubey RC. Evaluation of phytochemical, antimicrobial and time-killing assay of *Camellia* species. Vegetos, 2020;33(4), 759-765.
759) Quintino RL, Reis AC, Fernandes CC, Martins CHG, Colli AC, Crotti AEM., ... & Miranda MLD. Brazilian green propolis: chemical composition of essential oil and their in vitro antioxidant, antibacterial and antiproliferative activities. Brazilian Archives of Biology and Technology, 2020; 63.
760) Qu Z, Yu M, Zhang A, Wang A, Shun L. An Experimental bacteriostasis of the banxiaxiexin decoction and 7 kinds of single taste traditional Chinese medicine on *Helicobacter pylori* resistant strains in vitro. American Journal of Internal Medicine. 2020; **8**(3): 138-142.
761) Raeisi M, Hashemi M, Aminzare M, Sadeghi M, Jahani T, Keshavarzi H, Jebelli Javan A, Mirahahidi M, Tepe B. Comparative evaluation of phytochemical, antioxidant, and antibacterial properties from the essential oils of four commonly consuming plants in Iran. Journal of Food Quality and Hazards Control. 2016;3:107-113.
762) Rabie G, Taha M, Youssef K. Antifungal activity of petroleum ether and ethanol extracts of *Moringa Oleifera* seeds. Asian Journal of Applied Sciences: 2019; **7**(1).
763) Rajakumar P, Thirunarayanan A, Raja S. Synthesis and antibacterial activity of novel n-methyl pyrrolidine dendrimers via [3+ 2] cycloaddition. Proceedings of the National Academy of Sciences, India Section A: Physical Sciences. 2014; **84**(3):371-379.
764) Ray A, Jena S, Dash B, Kar B, Halder T, Chatterjee T, Ghosh B, Panda PC, Nayak S, Mahapatra N. Chemical diversity, antioxidant and antimicrobial activities of the essential oils from Indian populations of *Hedychium coronarium* Koen. Industrial Crops and Products. 2018;**112**:353-362.
765) Ray T, Brahma D, Mitra R, Dutta D. Effective decolorization of malachite green using kocuria marina DAGII and its toxicological study Effective decolorization of malachite green using kocuria marina DAGII and its toxicological study. ACM International Conference Proceeding Series. 2018; 113-117.
766) Romero M, Freire J, Pastene E, García A, Aranda M, González C. Propolis polyphenolic compounds affect the viability and structure of *Helicobacter pylori* in vitro. Revista Brasileira de Farmacognosia, 2019; **29**(3): 325-332.
767) Saha R, Karthik S, Balu KS, Suriyaprabha R, Siva P, Rajendran V. Influence of the various synthesis methods on the ZnO nanoparticles property made using the bark extract of *Terminalia arjuna*. Materials Chemistry and Physics. 2018; **209**:208-16.
768) Saha R, Subramani K, Raju SA, Rangaraj S, Venkatachalam R. *Psidium guajava* leaf extract-mediated synthesis of ZnO nanoparticles under different processing parameters for hydrophobic and antibacterial finishing over cotton fabrics. Progress in Organic Coatings. 2018;**124**:80-91.
769) Sahib AM, Jwad SM, Taha TM. Study the protection effect of alcoholic extract of Iraqi propolis on some of liver and kidney functions at male albino rats administered with a combination of amoxicillin/clavulanic acid (augmentin) antibiotic. IJBPAS, June, 2016, **5**(6): 1418-1454.
770) Salman HD. Antibacterial activity of propolis extracted in three different solvents and in three different pH values on some pathogenic bacteria. International Journal of Science and Research.2016; **5**(4):1514-1521.
771) Santhoshkumar A, Kavitha HP, Suresh R. Preparation, Characterization and antibacterial activity of NiO nanoparticles. Asian Journal of Chemistry. 2017; **29**(2):239-241.
772) Sarma MD, Ghosh S. Facile regioselective monobromination of anilines and phenols through green protocol and evaluation of their bioactivity. RASAYAN Journal of Chemistry 2021; 14(01): 19-28.
773) Semerjyan I, Semerjyan G, Semerjyan H, Trchounian A. Antibacterial properties and flavonoids content of some mosses common in Armenia. Iranian Journal of Pharmaceutical Sciences. 2021; **16**(4), 31-42.
774) Sharifi A, Azizi M, Moradi-Choghakabodi P, Aghaei S, Azizi A. In vitro anti-*Helicobacter pylori* activity of aqueous extract from Persian Oak testa. Chinese Herbal Medicines. 2019; **11**(4): 394-399.
775) Schnitzler P, Neuner A, Nolkemper S, Zundel C, Nowack H, Sensch KH, Reichling J. Antiviral activity and mode of action of propolis extracts and selected compounds, Phytother Res. 2010; **24** (S1): S20-S28.
776) Seidel V, Peyfoon E, Watson DG, Fearnley J. Comparative study of the antibacterial activity of propolis from different geographical and climatic zones. J Phytother Res. 2008; **22**(9):1256-1263.
777) Selvaraj C, Sivakamavalli J, Vaseeharan B, Singh P, Singh SK. Examine the characterization of biofilm formation and inhibition by targeting SrtA mechanism in *Bacillus subtilis*: a combined experimental and theoretical study. Journal of molecular modeling. 2014; **20**(8):1-15.
778) Selvaraj, N., Lakshmanan, B.,Mazumder, P.M., Karuppasamy, M.,Jena, S.S., Pattnaik, A.K. Evaluation of wound healing and antimicrobial potentials of Ixora coccinea root extract. Asian Pacific Journal of Tropical Medicine. 2011; **4** (12): 959-963.

779) Sethi, A., Sharma, R.A. Antibacterial and antifungal activity of various whole plant extracts of *Aerva tomentosa* forsk. (*Amaranthaceae*). International Journal of Pharma and Bio Sciences. 2011; **2**(3): 184-192.
780) Shapla UM, Raihan MJ, Islam MA, Alam F, Solayman M, Gan SH, Hossen MS, Khalil MI. Propolis: The future therapy against *Helicobacter pylori*-mediated gastrointestinal diseases. Journal of Applied Biomedicine. 2018; **16**(2):81-99.
781) Singh VK, Upadhyay S. The disappearing brain lesions. Journal of Acute Disease. 2012;**1**(1):65-67.
782) Sökmen B, Kinalioğlu K, Aydin S. Antimicrobial and antioxidant activities of *Pseudevernia furfuracea* (L.) Zopf var. furfuracea and *Evernia prunastri* Lichens collected from Black Sea Region. Gazi University Journal of Science. 2012; **25**(3): 557-565.
783) Sökmen BB, Aydın S, Kınalıoğlu K. Antioxidant and antibacterial properties of a lichen species *Diploschistes scruposus* (Schreb.) Norman. IUFS J Biol 2012, **71**(1):43-51.
784) Soltani EK, Cerezuela R, Charef N, Mezaache-Aichour S, Esteban MA, Zerroug MM. Algerian propolis extracts: Chemical composition, bactericidal activity and in vitro effects on gilthead seabream innate immune responses. Fish & shellfish immunology. 2017;**62**:57-67.
785) Suresh S, Bhuvanesh N, Raman A, Sugumar P, Padmanabhan D, Easwaramoorthi S, ... Nandhakumar R. Experimental and theoretical studies of imidazole based chemosensor for Palladium and their biological applications. Journal of Photochemistry and Photobiology A: Chemistry. 2019; **385**:112092.
786) Takeuchi H, Trang VT, Morimoto N, Nishida Y, Matsumura Y, Sugiura T. Natural products and food components with anti-*Helicobacter pylori* activities. World J Gastroenterol. 2014; **20**(27), 8971-8978.
787) Thakur P, Chawla R, Chakotiya AS, Tanwar A, Narula A , Goel R , Singh N, Arora R, Sharma RK. Antibacterial activity of aquo-alcoholic extract of *Camellia sinensis* against isolates of carbapenem resistant *Escherichia coli* and food borne pathogens. International Journal of Biological & Pharmaceutical Research. 2015; **6**(8):606-616.
788) Thammasit P, Iadnut A, Mamoon K, Khacha-ananda S, Chupradit K, Tayapiwatana C, Kasinrerk W, Tragoolpua Y, Tragoolpua K. A potential of propolis on major virulence factors of Cryptococcus neoformans. Microbial pathogenesis. 2018;**123**:296-303.
789) Thangamuneswari P, Revathi S. In vitro anti-diabetic and antibacterial analysis - "*Erythrina variegata*" leaves. World Journal of Pharmaceutical and Life Sciences. 2017; **3**(2):138-141.
790) Thirumoorthy GS, Balasubramaniam O, Kumaresan P, Muthusamy P, Subramani K. *Tetraselmis indica* mediated green synthesis of zinc oxide (ZnO) nanoparticles and evaluating its antibacterial, antioxidant, and hemolytic activity. BioNanoScience. 2021; **11**(1) 172-181.
791) Uddin B, Hossan T, Paul S, Ahmed T, Nahar T, Ahmed S. Antibacterial activity of the ethanol extracts of *Hibiscus rosa-sinensis* leaves and flowers against clinical isolates of bacteria. Bangladesh J. Life Sci. 2010; **22**(2): 65-73.
792) Valarezo E, Stanzione M, Tammaro L, Cartuche L, Malagón O, Vittoria V. Preparation, characterization and antibacterial activity of poly (ϵ-caprolactone) electrospun fibers loaded with amoxicillin for controlled release in biomedical applications. J. Nanosci. Nanotech. 2013; **13** (3): 1717-1726.
793) Vaz Coelho LG, Bastos EM, Resende CC, Paula e Silva CM, Sanches BS, de Castro FJ, Moretzsohn LD, Vieira WL, Trindade OR. Brazilian green propolis on *Helicobacter pylori* infection. a pilot clinical study. Helicobacter. 2007; **12**(5):572-574.
794) Venegas, A., Touma, J. H., Bravo, J., & Perez-Perez, G. (2016). Progress in use of natural products and their active components against *Helicobacter pylori*. Advances in Microbiology. 2016; **6**(14), 1091.
795) Villanueva M, González M, Fernández H, Wilson M, Manquián N, Otth C, Otth L. Actividad antibacteriana in vitro de propóleos chilenos sobre *Helicobacter pylori*. Revista chilena de infectología, 2015; **32**(5):530-535.
796) Wagh, V.D., Borkar, R.D. Indian propolis: A potential natural antimicrobial and antifungal agent. International Journal of Pharmacy and Pharmaceutical Sciences. 2012; **4** (4): 12-17.
797) Wen, Y.-F., Zhao, J.-Q., Nirala, S.K.,Bhadauria, M. Aluminum-induced toxicity and its response to combined treatment of HEDTA and propolis in rats. Polish Journal of Environmental Studies. 2012; **21** (5): 1437-1443.
798) Wolle K, Malfertheiner P. Treatment of *Helicobacter pylori.* Best Pract Res Clin Gastroenterol., 2007; **21(**2): 315-324.
799) Yasodha A. Puratchikody A. 4-pyrrolidino/morpholino-1-(4-substituted phenylmethyl/2-ethoxy-2- oxoethyl)pyridinium bromide: Synthesis, antimicrobial evaluation and antimrsa studies. International Journal of Pharmacy and Pharmaceutical Sciences. 2014; **6**(5):453-458.
800) Younis K, Ahmad S. Waste utilization of apple pomace as a source of functional ingredient in buffalo meat sausage. Cogent Food & Agriculture. 2015; **1**(1):10.1080/23311932.2015.1119397.
801) Younis K, Ahmad S, Osama K, Malik MA. Optimization of de-bittering process of mosambi (*Citrus limetta*) peel: Artificial neural network, Gaussian process regression and support vector machine modeling approach. Journal of Food Process Engineering. 2019; 42.6: e13185.
802) Zaki MM, Eissa AE, Saeid S. Assessment of the immune status in Nile Tilapia (*Oreochromis niloticus*) experimentally challenged with toxogenic / septicemic bacteria during treatment trial with florfenicol and enrofloxacin. World Journal of Fish and Marine Sciences 2011; **3**(1): 21-36.
803) Zekovič Z, Lepojević Ž, Mujić I. SFE of PMT mixture by supercritical CO_2. CHISA 2006 - 17th International Congress of Chemical and Process Engineering. 27-31 August 2006, Prague, Czech Republic: 5.
804) Zhao J, Han L, Yu M, Cao P, Li D, Guo X, ... Xiang, W. Characterization of *Streptomyces sporangiiformans* sp. nov., a novel soil actinomycete with antibacterial activity against Ralstonia solanacearum. Microorganisms. 2019; 7.9: 360

ЦИТИРАНА: 27А: **Boyanova L**, Nikolov R, Lazarova E, Gergova G, Katsarov N, Kamburov V, Spassova Z, Derejian S, Jelev C, Mitov I, Krastev Z. Antibacterial resistance in *Helicobacter pylori* strains isolated from Bulgarian children and adult patients over 9 years. J Med Microbiol. 2006; **55**: 65-68. **Цитирана от:**

805) Abadi AT, Taghvaei T, Ghasemzadeh A, Mobarez AM. High frequency of A2143G mutation in clarithromycin-resistant *Helicobacter pylori* isolates recovered from dyspeptic patients in Iran. Saudi J Gastroenterol. 2011; 17(6):396-399.
806) Abdel-Raouf M, YousefAbdel-Gleel AE. Study on the role of pet animals for *Helicobacter pylori* transmission. Journal of American Science. 2014; **10**(8s):20-28. http://www.jofamericanscience.org/journals/am-sci/am1008s/002_27437am1008s14_20_28.pdf
807) Agudo, S., Alarcón, T., Cibrelus, L., Urruzuno, P., Martínez, M.J., López-Brea, M. High percentage of clarithromycin and metronidazole resistance in *Helicobacter pylori* clinical isolates obtained from Spanish children. Revista Espanola de Quimioterapia 2009; **22**(2): 88-92.
808) Butenko T, Jeverica S, Orel R, Homan M. Antibacterial resistance and the success of tailored triple therapy in *Helicobacter pylori* strains isolated from Slovenian children. Helicobacter. 2017;e12400:1-6.
809) Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of *Helicobacter pylori* before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol. 2009; **24**(7): 1230-1235.
810) Chisholm SA., Owen RJ. From Nobel to no cure: A case for monitoring antibiotic resistance in the gastric pathogen *Helicobacter pylori*. Expert Rev Anti Infect Ther. 2006; **4**(3):349-351.
811) Chisholm S, Teare E, Davies K, Owen R, . Surveillance of primary antibiotic resistance of *Helicobacter pylori* at centres in England and Wales over a six-year period (2000-2005). Euro Surveill. 2007; **12**(7): E3-E4.
812) Dorta G, Viani F, Vouillamoand combinedz D, Jornod P, Kessler-Brondolo V, Nichita C. Peptic diseases | [Maladies peptiques]. Rev Med Suisse. 2007; **3**(95):192-200.
813) Horvitz G, Gold BD. Gastroduodenal diseases of childhood. Curr Opin Gastroenterol. 2006; **22**(6):632-640.
814) Kalach N, Serhal J, Asmar E, Campeotto F, Bergeret M, Dehecq E, Spyckerelle C, Charkaluk M, Decoster A, Dupont C. *Helicobacter pylori* primary resistant strains over 11 years in French children. Diagn Microbiol Infect Dis . 2007; **59**(2):217-222.
815) Karczewska, E., Wojtas, I., Budak, A. Prevalence of *Helicobacter pylori* primary resistance to antimicrobial agents in Poland and around the world [Występowanie pierwotnej oporności *Helicobacter pylori* na leki przeciwbakteryjne w polsce i na świecie]. Postepy Mikrobiologii. 2009; **48**(1):31-41.
816) Keshavarz ARS, Moniri R, Saffari M, Zadeh MR, Arj A, Abbas Moosavi SG, Ghazi Kalayeh HM. *Helicobacter pylori* resistance to ciprofloxacin in Iran. Int J Antimicrob Agents. 2014;**43**(6):571-572.
817) Keshavarz Azizi Raftar S, Moniri R, Saffari M, Razavi Zadeh M, Arj A, Mousavi SG, Mirzaei Ghazi Kalayeh H, Dastehgoli K. The *Helicobacter pylori* resistance rate to clarithromycin in Iran. Microb Drug Resist. 2015; **21**(1):69-73.
818) Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobialresistance of *Helicobacter pylori* in Korea from 2003 through 2012. Helicobacter. 2013;**18**(3):206-14.
819) Liu, D. S., Wang, Y. H., Zhu, Z. H., Zhang, S. H., Zhu, X., Wan, J. H., ... & Xie, Y. Characteristics of *Helicobacter pylori* antibiotic resistance: data from four different populations. Antimicrobial Resistance & Infection Control. 2019; 8(1), 1-7.
820) Liu, W., Zhu, J., Liu, Y., Wang, Y., Wang, Y., & Wang, X.. Effects of addition of probiotic and/or bismuth to triple therapy of *H. pylori* and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance. Pakistan journal of pharmaceutical sciences. 2019; 32.
821) Machado RS, Silva MR, Viriato A. Furazolidone, tetracycline and omeprazole: a low-cost alternative for *Helicobacter pylori* eradication in children. J. Pediatr. (Rio J.). 2008; **84**(2):160-165.
822) Mourad-Baars P, Chong S. *Helicobacter pylori* infection in pediatrics. Helicobacter 2006; **11**(s1):40-45.
823) Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High *Helicobacter pylori* resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013; **56**(6):645-648.
824) Raftar, S. K. A., Moniri, R., Saffari, M., Zadeh, M. R., Arj, A., Moosavi, S. G. A., & Kalayeh, H. M. G. *Helicobacter pylori* resistance to ciprofloxacin in Iran. International journal of antimicrobial agents. 2014; 43(6), 573-574.
825) Sabbi T, De Angelis, Dall'Oglio L *Helicobacter pylori* infection in children: management and pharmacotherapy. Expert Opin Pharmacother. 2008; **9**(4), 577-585.
826) Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of *Helicobacter pylori* in the East and West. Expert Rev Anti Infect Ther. 2011; **9**(8): 581-588.
827) Seo JH, Woo HO, Youn HS, Rhee KH. Antibiotics resistance of *Helicobacter pylori* and treatment modalities in children with *H. pylori* infection. Korean J Pediatr. 2014;**57**(2):67-71.
828) Shashidhar, Flomenhoft D, Tolia V. *Helicobacter pylori* & beyond: pediatric peptic ulcer disease. Therapy. 2009; **6**(1):65-73.
829) Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of *Helicobacter pylori* to levofloxacin and moxifloxacine in Iran. Intern Emerg Med. 2012; **7**(5):447-452.
830) Shmuely, H., Domniz, N., & Yahav, J. Regional antibiotic resistance of *helicobacter pylori*. JSM Gastroenterol Hepatol. 2016; 4, 1074.
831) Tong Y, Wang Z, Mao M. Detection of clarithromycin-resistant *Helicobacter pylori* by Stool PCR in children: A comprehensive review of literature. Helicobacter. 2013;**18**(2):89-101.
832) Tveit AH, Bruce MG, Bruden DL, Morris J, Hurlburt DA, Hennessy TW, McMahon B. Alaska sentinel surveillance study of *Helicobacter pylori* isolates in Alaska native persons from 2000-2008. J Clin Microbiol. 2011; **49**(10):3638-43.
833) Vakil, N., Megraud, F. Eradication therapy for *Helicobacter pylori*. Gastroenterology. 2007; **133**(3):985-1001.
834) Xiong LJ, Tong Y, Wang Z, Mao M. Detection of clarithromycin-resistant *Helicobacter pylori* by stool PCR in children: a comprehensive review of literature. Helicobacter. 2013;**18**(2):89-101.
835) Zhen-Hua Z, De-Qiang H, Yong X, Lin-Lin L, Nong-Hua L. Characterization of 23S rRNA gene mutation in primary and secondary clarithromycin-resistant *Helicobacter pylori* strains from East China.Turk J Gastroenterol. 2013;**24**(1):5-9. https://pdfs.semanticscholar.org/999f/f2f37f9e34e3fb31952876f6e368fa90430f.pdf

ЦИТИРАНА: 28А: **Boyanova L**, Kolarov R, Gergova G, Deliverska E, Madjarov J, Marinov M, Mitov I. Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillo-Facial Surgery, Sofia, Bulgaria. J. Med. Microbiol. 2006, **55** (Pt 9): 1285-1289. Erratum in: J Med Microbiol. 2006; **55**(Pt 12): 1759-1760. **Цитирана от:**

836) Abdulaziz SM. Occurrence and pattern of antibiotic resistance among dental plaque bacteria from gingivitis patients and their clinical correlation. Journal of baghdad college of dentistry. 2018;**30**(2):51-8.
837) Alegbeleye BJ. Deep neck infection and descending mediastinitis as lethal complications of dentoalveolar infection: two rare case reports. Journal of medical case reports. 2018;**12**(1):195.
838) Ardila Medina, C.M. [Efficacy of moxifloxacin in odontogenic infections]. Avances en Odontoestomatologia 2009; **25**(4): 215-222.
839) Arianto, D. R., & Romdhoni, A. C. Pola Kuman, Hasil Uji Sensitifitas Antibiotik dan Komplikasi Abses Leher dalam di RSUD DR. Soetomo. Jurnal Ilmiah Kedokteran Wijaya Kusuma. 2019; **8**(1), 88-98.
840) Aslam, N., & Masood, S. H. In Vitro Susceptibility Test of Different Clinical Isolates against Ceftriaxone. Oman Medical Journal/ 2010; 100(319), 1-4.
841) Bacalan F, Çakir F, Özcan N, Akpolat N. Identification and antimicrobial susceptibility testing of anaerobic bacteria isolated from clinical samples. Journal of Bacteriology & Mycology: Open Access. 2020. JBMOA-08-00269.pdf
842) Bancescu A, Bancescu G, Didilescu A, Hirjau M. Antibiotic susceptibility testing of some *Prevotella* strains isolated from vestibular abscesses. Farmacia. 2017;**65**(1):132-135.
843) Bancescu G, Didilescu A, Bancescu A, Bari M. Antibiotic susceptibility of 33 *Prevotella* strains isolated from Romanian patients with abscesses in head and neck spaces. Anaerobe. 2015;**35**(Pt A):41-44.
844) Băncescu G, Băncescu AA, Didilescu AC, Constantinescu MV. Antimicrobial susceptibility of *Prevotella* isolates from abscesses of fascial spaces of the face and neck. Revista Romana de Medicina de Laborator. 2009;**17**(4): 37-42.
845) Brotfain E, Koyfman L, Saidel-Odes L, Borer A, Refaely Y, Klein M. Deep neck infection and descending mediastinitis as a complication of *Propionibacterium acnes* odontogenic infection. Case Rep Infect Dis. 2015;**2015**:190134.
846) Celakovsky P, Kalfert D, Smatanova K, Tucek L, Cermakova E, Mejzlik J, Kotulek M, Vrbacky A, Matousek P, Stanikova L, Hoskova T. Bacteriology of deep neck infections: analysis of 634 patients. Australian dental journal. 2015;**60**(2):212-215.
847) Celakovsky P, Kalfert D, Tucek L, Mejzlik J, Kotulek M, Vrbacky A, Matousek P, Stanikova L, Hoskova T, Pasz A. Deep neck infections: risk factors for mediastinal extension. Eur Arch Otorhinolaryngol. 2014;**271**(6):1679-1683.
848) Chan YC, Cheng SW. Mycotic aneurysm of the common carotidartery as a presenting symptom for early colorectal malignancy. Ann Vasc Surg. 2016;**30**:306.e9-e12.
849) Cordesmeyer R, Kauffmann P, Markus T, Sömmer C, Eiffert H, Bremmer F, Laskawi R. Bacterial and histopathological findings in deep head and neck infections: a retrospective analysis. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2017; **124**(1): 11–15.
850) da Silva Junior AF, de Magalhaes Rocha GS. Deep neck infection after third molar extraction: A case report. J Dent Res Dent Clin Dent Prospects. 2017;**11**(3):166-169.
851) de Los Ángeles FM, González P, Mardones MM, Bravo AR. Complicaciones severas de infecciones odontogénicas. Revista Médica Clínica Las Condes. 2014; **25**(3): 529-533.
852) Doležalová H, Zemek J, Tuček L. Deep neck infections of odontogenic origin and their clinical significance. A retrospective study from Hradec Králové, Czech Republic. Acta medica (Hradec Králové) 2015; **58**(3): 86–91. http://actamedica.lfhk.cuni.cz/media/pdf/am_2015058030086.pdf
853) Flynn TR, Paster BJ, Stokes LN, Susarla SM, Shanti RM. Molecular methods for diagnosis of odontogenic infections. Journal of Oral and Maxillofacial Surgery. 2012; **70** (8): 1854-1859.
854) Gaetti-Jardim E Jr, Landucci LF, de Oliveira KL, Costa I, Ranieri RV, Okamoto AC, Schweitzer CM. Microbiota associated with infections of the jaws. Int J Dent. 2012;**2012**:369751.
855) Gaetti-Jardim Junior E, Landucci LF, Lins SA, Vieira EMM, de Oliveira SR. Susceptibility of strict and facultative anaerobes isolated from endodontic infections to metronidazole and b-lactams. J Appl Oral Sci. 2007; **15**(6):539-545.
856) Geraldes AM. Ocorrência de *Porphyromonas gingivalis* na microbiota bucal de pacientes submetidos à radioterapia para tratamento de lesões malignas de cabeça e pescoço. 2010.
857) Igoumenakis D, Gkinis G, Kostakis G, Mezitis M, Rallis G. Severe odontogenic infections: causes of spread and their management. Surg Infect (Larchmt). 2014;**15**(1):64-68.
858) Kaya EE , Medine Ayşin Taşar MA , Yıldız Dallar Bilge Y. Çocukluk yaş grubunda derin boyun enfeksiyonlarinin değerlendirilmesi [Evalution of deep neck infections in pediatric patients]. Türkiye Çocuk Hast Derg / Turkish J Pediatr Dis 2012; **6**(4): 197-205.
859) Kityamuwesi R, Muwaz L, Kasangaki A, Kajumbula H, Rwenyonyi CM. Characteristics of pyogenic odontogenic infection in patients attending Mulago Hospital, Uganda: a cross-sectional study. BMC Microbiol. 2015;**15**:46.
860) Kouassi YM, Janvier B, Dufour X, Bouche G, Klossek J-M. Microbiology of facial cellulitis related to dental infection. Medecine et Maladies Infectieuses. 2011; **41**(10): 540-545.
861) Korivipati, N. K., Irvineti, S., & Mallikarjun Rao, M. Deep neck space infections: our experience. International Journal of Otorhinolaryngology and Head and Neck Surgery. 2018; 4(1), 132.
862) Landucci LF, De Oliveira KL, Costa I, Ranieri RV, Okamoto AC, Schweitzer CM. Microbiota associated with infections of the jaws. International Journal of Dentistry.2012.
863) Loyola-Rodriguez, J. P., Franco-Miranda, A., Loyola-Leyva, A., Perez-Elizalde, B., Contreras-Palma, G., & Sanchez-Adame, O. Prevention of infective endocarditis and bacterial resistance to antibiotics: A brief review. Special Care in Dentistry. 2019; **39**(6), 603-609.
864) Martini MZ, Migliari DA. Epidemiologia das infecções maxilofaciais tratadas num hospital público da cidade de São Paulo. Revista da Associacao Paulista de Cirurgioes Dentistas. 2012;**66**(1):66-73.

865) Masocatto DC, Oliveira MM, de Mendonça JC. Osteomielite crônica mandibular: relato de caso. Archives of Health Investigation. 2017;**6**(2).
866) Masood SH, Aslam N. In vitro susceptibility test of different clinical isolates against ceftriaxone. Oman Medical Journal 2010; **25**(3):199-202.
867) Medina A. Eficacia de la moxifloxacina en infecciones odontogénicas. Avances en Odontoestomatología. 2009; **25**(4):215-222.
868) Millán RE, León JC. Abscesos del periodonto: Conducta odontológica. Acta Odontológica Venezolana. 2008; 46(3): 346-360.
869) Neto NC, Spagnol G, Campos JÁDB, Gabrielli MAC, Pereira Filho VA. Infecções bacterianas da cabeça e pescoço: estudo retrospectivo. Odonto. 2009; **17**(34), 42-48.
870) Patel M, Chettiar TP, Wadee AA. Isolation of *Staphylococcus aureus* and black-pigmented *Bacteroides* indicate a high risk for the development of Ludwig's angina. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2009; **108**(5): 667-672.
871) Pourdanesh, F., Dehghani, N., Azarsina, M., Malekhoseini, Z. Pattern of odontogenic infections at a tertiary hospital in Tehran, Iran: A 10-year retrospective study of 310 patients. J Dent (Tehran). 2013;**10**(4):319-328.
872) Rijal S, Romdhoni AC. Bacteria Pattern, Results of Antibiotic Sensitivity Test, and Complications of Deep Neck Abscess Patients in Dr. Soetomo General Hospital. Biomolecular and Health Science Journal. 2018; **26**;1(2):124-30.
873) Sakarya EU, Kulduk E, Gundogan O, Soy FK, Dundar R, Kilavuz AE, ... & Imre A. Clinical features of deep neck infection: analysis of 77 patients. Kulak Burun Bogaz Ihtis Derg. 2015; **25**(2), 102-8.
874) Salinas M, uni J, Millan I, Ronald E and Leon M, Juan C. The periodontal abscess: Dentist behaviour. Acta odontol. Venez. 2008; **46**(3): 346-360.
875) Santos SG, Diniz CG, Silva VL, Lima FL, Andrade HM, Chapeaurouge DA, Perales J, Serufo JC, Carvalho MA, Farias LM. Differentially regulated proteins in *Prevotella intermedia* after oxidative stress analyzed by 2D electrophoresis and mass spectrometry. Anaerobe. 2012;**18**(1):76-82.
876) Sato FR, Hajala FA, Freire Filho FW, Moreira RW, de Moraes M. Eight-year retrospective study of odontogenic origin infections in a postgraduation program on oral and maxillofacial surgery. J Oral Maxillofac Surg. 2009; **67**(5): 1092-1097.
877) Schaefer EH 4th, Caterson EJ. Antibiotic selection for open reduction internal fixation of mandible fractures. J Craniofac Surg. 2013;**24**(1):85-88.
878) Shejbal D, Grgić M, Trotić R, Ries M.Apsces vrata uzrokovan infekcijom salmonelom – Prikaz slučaja. [Neck abscess caused by salmonella infection – Case report]. Med Jad 2010; **40**(1-2):45-47.
879) Shenoy PA, Vishwanath S, Gawda A, Shetty S, Anegundi R, Varma M, Mukhopadhyay C, Chawla K. Anaerobic bacteria in clinical specimens–frequent, but a neglected lot: a five year experience at a tertiary care hospital. Journal of clinical and diagnostic research: JCDR. 2017;**11**(7):DC44.
880) Suesongtham, P., Charoensombatamorn, S., & Ungkhara, G. Deep Neck Infection in Faculty of Medicine Vajira Hospital, Navamindradhiraj University. Vajira Medical Journal: Journal of Urban Medicine. 2018; 62(5), 365-374.
881) Tent PA, Juncar RI, Onisor F, Bran S, Harangus A, Juncar M. The pathogenic microbial flora and its antibiotic susceptibility pattern in odontogenic infections. Drug metabolism reviews. 2019; **51**(3), 340-355.
882) Vishnoi N, Singh S, Bishnoi RS, Gupta MK. Antibiotic evaluation of odontogenic microbiological spectrum of orofacial infection. Journal of Drug Delivery and Therapeutics. 2018; 2018 (6):179-82.
883) Wiraboonchai B. Deep neck infection in Surin Hospital. Medical Journal of Si Sa Ket Surin Buriram Hospitals. 2011; **24**(1): 173-180.
884) Zeng F, Zhou Q, Zhou P, Wu M, Tang H. A secret path: severe deep neck space infection led to axilla and lateral chest abscesses. Int J Clin Exp Med 2016;**9**(2):5068-5070.
885) Zirk M, Buller J, Goeddertz P, Rothamel D, Dreiseidler T, Zöller JE, Kreppel M. Empiric systemic antibiotics for hospitalized patients with severe odontogenic infections. Journal of Cranio-Maxillofacial Surgery. 2016;**44**(8):1081-1088.
886) Zirk M, Zoeller JE, Peters F, Ringendahl L, Buller J, Kreppel M. Cefazolin versus ampicillin/sulbactam as an empiric antibiosis in severe odontogenic neck infection descending from the lower jaw—retrospective analysis of 350 cases. Clinical Oral Investigations. 2021; **25**(2), 563-570.

ЦИТИРАНА: 29А: **Boyanova L,** Kolarov R, Gergova G, Mitov I. *In vitro* activity of Bulgarian propolis against 94 clinical isolates of anaerobic bacteria. Anaerobe 2006; **12** (4):173-177. **Цитирана от:**

887) Albayrak, S., Albayrak, S. Propolis: Natural antimicrobial matter [Propolis: Doğal antimikrobiyal madde]. Ankara Universitesi Eczacilik Fakultesi Dergisi. 2008; **37**(3): 201-215.
888) Alsayed, M. F. S., Hashem, A., Al-Hazzani, A. A., & Abd_Allah, E. F. Biological control of yeast contamination of industrial foods by propolis. Saudi journal of biological sciences. 2020; 27(3), 935-946.
889) Ambreen S, Maryam R, Tipu HN. Propolis, A Hope for the Future in Treating Resistant Periodontal Pathogens. Cureus. 2016;**8**(7).
890) Badet C, Quero F. The *in vitro* effect of manuka honeys on growth and adherence of oral bacteria. Anaerobe. 2011; **17**(1): 19-22.
891) Bankova V, Atanassov A, Denev R, Shishinjova M. Bulgarian bee products and their health promoting potential. Biotechnol. & Biotechnol. Eq. 2012, **26**(4): 3086-3088.
892) Bartkiene, E., Lele, V., Sakiene, V., Zavistanaviciute, P., Zokaityte, E., Dauksiene, A., ... & Ruzauskas, M. Variations of the antimicrobial, antioxidant, sensory attributes and biogenic amines content in Lithuania-derived bee products. LWT. 2020; 118, 108793.
893) Baumann LS. Less-known botanical cosmeceuticals. Dermatol Ther. 2007; **20**(5): 330–342.
894) Costa, C. L., de Azevedo, C. P., Quesada-Gómez, C., de Castro Brito, G. A., da Silveira Regueira-Neto, M., de Melo Guedes, G. M., ... & Castelo, D. D. S. C. M. Inhibitory effect of Brazilian red propolis on planktonic and biofilm forms of Clostridioides difficile. Anaerobe. 2021; 69, 102322.

895) Demir Özer, E. The effects of propolis and nisin on Listeria monocytogenes in contaminated ice cream. Journal of Food Processing and Preservation. 2020; e14598.
896) Dilebo J. Antibacterial activities of *Microglossa pyrifolia* (Lamk.) Kuntze, Leucas deflexa Hook. and *Indigofera spicata* Forssk. IJPSR. 2015; **6**(5):865-868.
897) Dezmirean, D. S., Paşca, C., Moise, A. R., & Bobiş, O. Plant Sources Responsible for the Chemical Composition and Main Bioactive Properties of Poplar-Type Propolis. Plants. 2021; 10(1), 22.
898) Djauharie N, Kemala N. Antibacterial efficacy of 5% ethanolic extract of propolis (EEP) solution against *Enterococcus faecalis* (Laboratory Experiment). J Int Dent Med Res 2017; **10**(1):19-23.
899) Ebadi, Z., Khodanazary, A., Hosseini, S. M., & Zanguee, N. The shelf life extension of refrigerated Nemipterus japonicus fillets by chitosan coating incorporated with propolis extract. International journal of biological macromolecules. 2019; 139, 94-102.
900) Furiga A, Lonvaud-Funel A, Badet C. In vitro study of antioxidant capacity and antibacterial activity on oral anaerobes of a grape seed extract. Food Chemistry. 2009; **113**(4): 1037-1040.
901) Furiga A, Lonvaud-Funel A, Dorignac G, Badet C. In vitro anti-bacterial and anti-adherence effects of natural polyphenolic compounds on oral bacteria. J Appl Microbiol. 2008; **105**(5):1470-1476.
902) Gajger IT, Pavlović I, Bojić M, Kosalec I, Srečec S, Vlainić T, Vlainić J. The components responsible for the antimicrobial activity of propolis from continental and Mediterranean regions in Croatia. Czech Journal of Food Science. 2017;**35**(5).
903) Ghedira K, Goetz, Le Jeune R. Practical Materia Medica: Propolis [Matière médicale pratique: Propolis]. Phytothérapie. 2009 ; **7**(2):100-105.
904) Hannan A, Batool A, Qamar MU, Khalid F. Propolis as an antibacterial agent against clinical isolates of MDR-*Acinetobacter baumannii*. J Ayub Med Coll Abbottabad. 2015;**27**(1):216-9.
905) Heyman L, Houri-Haddad Y, Heyman SN, Ginsburg I, Gleitman Y, Feuerstein O. Combined antioxidant effects of Neem extract, bacteria, red blood cells and Lysozyme: possible relation to periodontal disease. BMC complementary and alternative medicine. 2017;17(1):399.
906) Iftikhar F, Mahmood R. Propolis an antibacterial agent against clinical isolates of wound infection. IJSRSET. 2015; **1**(6):47-52. http://ijsrset.com/paper/500.pdf
907) Djauharie N, Kemala N. Antibacterial Efficacy of 5% Ethanolic Extract of Propolis (EEP) Solution against Enterococcus faecalis (Laboratory Experiment). Journal of International Dental and Medical Research. 2017;**10**(1):19.
908) Kacániová, M., Vuković, N., Chlebo, R.,Haščík, P., Rovná, K., Cubon, J.,Dzugan, M., Pasternakiewicz, A. The antimicrobial activity of honey, bee pollen loads and beeswax from Slovakia. Archives of Biological Sciences. 2012; **64** (3): 927-934.
909) Kalogeropoulos, N., Konteles, S.J., Troullidou, E., Mourtzinos, I., Karathanos, V.T. Chemical composition, antioxidant activity and antimicrobial properties of propolis extracts from Greece and Cyprus. Food Chemistry. 2009; **116**(2): 452-461.
910) Kita K, Ken IR, Akamine C, Kawada W, Shimura Y, Inamoto T. Influence of propolis residue on the bacterial flora in the cecum of Nanbukashiwa. The Journal of Poultry Science. 2014; **51**(3):275-280.
911) Merck. Life Science: Nutrition Research: Learning Center: Plant Profiler: Propolis (Propolis). https://www.sigmaaldrich.com/life-science/nutrition-research/learning-center/plant-profiler/propolis.html
912) Mohamed WF, Shady HM, Sayed-Ahmed ES, Amer SA. Antibacterial activity of Egyptian propolis and pollen extracts and their synergistic/antagonistic effect with lactic acid bacteria (LAB) against food borne pathogenic bacteria. Egypt J Exp Biol (Bot). 2016; **12**(1):31-43.
913) Moon SH, Roh HS, Kim YH, Kim JE, Ko JY, Ro YS. Antibiotic resistance of microbial strains isolated from Korean acne patients. J Dermatol. 2012;**39**(10):833-7.
914) Num, S. M., Useh, N. M., Suliman, E. S., El Zubeir, I. E., Qumsiyeh, M. B., Zavala, S. S., ... & Ofojekwu, P. C. *Clostridium*: pathogenic roles, industrial uses and medicinal prospects of natural products as ameliorative agents against pathogenic species. Jordan Journal of Biological Sciences. 2014; **7**(2): 81-94.
915) Özen, T., Kiliç, A., Bedir, O., Koru, O., Sorkun, K., Tanyuksel, M., Kiliç, S., Gençay, O., Yildiz, O., Baysallar, M. In vitro activity of Turkish propolis samples against anaerobic bacteria causing oral cavity infections. Kafkas Universitesi Veteriner Fakultesi Dergisi. 2010; **16**(2): 293-298.
916) Peycheva S, Apostolova E, Gardjeva P, Peychev Z, Kokova V, Angelov A, Slavov A, Murdjeva M. Effect of Bulgarian propolis on the oral microflora in adolescents with plaque-induced gingivitis. Revista Brasileira de Farmacognosia. 2019; 29(3), 271-277..
917) Przybyłek, I., & Karpiński, T. M. Antibacterial properties of propolis. Molecules. 2019; 24(11), 2047.
918) Selvaraj N, Lakshmanan B, Mazumder PM, Karuppasamy M, Jena SS, Pattnaik AK. Evaluation of wound healing and antimicrobial potentials of Ixora coccinea root extract. Asian Pac J Trop Med. 2011;**4**(12):959-963.
919) Seibert, J. B., Bautista-Silva, J. P., Amparo, T. R., Petit, A., Pervier, P., dos Santos Almeida, J. C., ... & Dos Santos, O. D. H. Development of propolis nanoemulsion with antioxidant and antimicrobial activity for use as a potential natural preservative. Food chemistry. 2019; 287, 61-67.
920) Shabbir A-, Rashid M, Tipu HN. Propolis, a hope for the future in treating resistant periodontal pathogens. Cureus. 2016; **8**(7): e682. doi:10.7759/cureus.682
921) Shubar H, Gawad MA, Doro B, Sufya N, Alatery A, Mohamed SB, Al Magrha N. Activity of honey and propolis on bacteria isolated from diabetic foot. Journal of Advances in Microbiology. 2018; **16**:1-8.
922) Suarez H, Jiménez Á, Díaz C. Determination of microbiological and sensory parameters of fish fillets with propolis preserved under refrigeration.Rev. MVZ Córdoba. 2014; **19**(3), 4214-4225.
923) Suleman T, van Vuuren S, Sandasi M, Viljoen AM. Antimicrobial activity and chemometric modelling of South African propolis. J Appl Microbiol. 2015;**119**(4):981-90.

924) Suyo JA, de Casalino DP. Actividad antibacteriana in vitro del extracto etanólico de propóleo de Oxapampa-Perú, sobre cepas de *Porphyromonas gingivalis* y *Fusobacterium nucleatum*. Revista Estomatológica Herediana. 2011; **21**(3):125-130.
925) Thamnopoulos IA, Michailidis GF, Fletouris DJ, Badeka A, Kontominas MG, Angelidis AS. Inhibitory activity of propolis against *Listeria monocytogenes* in milk stored under refrigeration. Food Microbiology. 2018;**73**:168-176.
926) Tlak Gajger I, Pavlović I, Bojić M, Kosalec I. The Components Responsible for the antimicrobial activity of propolis from continental and mediterranean regions in Croatia. Czech J Food Sci. 2017; **35**(5):376–385.
927) Useh NM, Num SM. *Clostridium*: pathogenic roles, industrial uses and medicinal prospects of natural products as ameliorative agents against pathogenic species. Jordan Journal of Biological Sciences. 2014; **7**(2):81-94.
928) Vaz Coelho LG, Ferreira Bastos EM, Resende CC, Paula E Silva CM, Fernandes Sanches BS, de Castro FJ, Moretzsohn LD, Dos Santos Vieira WL, Trindade OR. Brazilian green propolis on *Helicobacter pylori* infection. A Pilot clinical study. Helicobacter. 2007; **12**(5):572-574.
929) Victorino, F.R., Bramante, C.M., Watanabe, E., Ito, I.Y., Franco, S.L., Hidalgo, M.M. Antibacterial activity of propolis-based toothpastes for endodontic treatment. Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences. 2009; **45**(4): 795-800.
930) Vras N, EN A, FPCL P, Santos VR. Propolis gel versus benzydamine in preventing oral mucositis for patients irradiated in head and neck: a preliminary study. Cancer Rep Rev, 2017; **1**(2):1-4.
931) Wang X, Sankarapandian K, Cheng Y, Woo SO, Kwon HW, Perumalsamy H, Ahn YJ. Relationship between total phenolic contentsand biological properties of propolis from 20 different regions in South Korea. BMC Complement Altern Med. 2016;**16**:65.
932) Андриасян ЛГ. Использование прополиса в лечебно-профилактической стоматологии и прополис-содержащая зубная паста NZ Propolis & Manuka. К 70-летию со дня рождения и 50-летию творческой жизни в стоматологии. Научно-практический журнал, том 7, випуск 1:
933) Филенко АМ, Омельянюк ВС, Янковский ДС. Спектрофотометрический анализ содержания прополиса в составе мультипробиотика «Апибакт». Biotechnologia Acta. 2009; **2**(3):
934) Хлгатян С.В, Бержец В.М., Хлгатян Е.В. Прополис: состав, биологические свойства и аллергенная активность. Успехи современной биологии, 2008; **128**(1):77-88.

ЦИТИРАНА: 31А: **Boyanova L**, Lazarova E, Jelev C, Gergova G, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in untreated Bulgarian children over a period of 10 years. J Med Microbiol. 2007; **56**(Pt 8):1081-1085. **Цитирана от:**

935) Ali B, Chloë DW, Mehmet A, Sofie DB, Annemieke S, Gökhan T, Tülin GG, Freddy H, Fatih K. Presence of gastric *Helicobacter* species in children suffering from gastric disorders in Southern Turkey. Helicobacter. 2018;**23**(5):e12511.
936) Bahadori, A., De Witte, C., Agin, M., De Bruyckere, S., Smet, A., Tümgör, G., ... & Köksal, F. Presence of gastric Helicobacter species in children suffering from gastric disorders in Southern Turkey. Helicobacter. 2018; 23(5), e12511.
937) Bento-Miranda M, Figueiredo C. *Helicobacter heilmannii* sensu lato: An overview of the infection in humans. World J Gastroenterol.: WJG, 2014; **20**(47): 17779.
938) Bruce, M.G., Maaroos, H.I. Epidemiology of *Helicobacter pylori* infection. Helicobacter 2008; **13**(Suppl 1):1-6.
939) Dimitrova-Dikanarova DK, Lazarov VV, Tafradjiiska-Hadjiolova R, Dimova II, Petkova NU, Krastev ZA. Association between *Helicobacter pylori* infection and the presence of anti-sperm antibodies. Biotechnology & Biotechnological Equipment. 2017;**31**(1):1-8.
940) Gisbert JP, Calvet X. Review article: *Helicobacter pylori*-negative duodenal ulcer disease Aliment Pharmacol Ther. 2009; **30**(8):791-815.
941) Goji, S., Tamura, Y., Sasaki, M., (...), Funaki, Y., Kasugai, K. *Helicobacter suis*-infected nodular gastritis and a review of diagnostic sensitivity for *Helicobacter heilmannii*-like organisms. Case Reports in Gastroenterology. 2015; 9:179-187. http://old.ms.md/_files/14374-PCN-125%2520Gastrita%2520si%2520duodenita%2520la%2520copil.pdf
942) Kivistö, R., Linros, J., Rossi, M., Rautelin, H., Hänninen, M.-L. Characterization of multiple *Helicobacter bizzozeronii* isolates from a Finnish patient with severe dyspeptic symptoms and chronic active gastritis Helicobacter. 2010; **15**(1): 58-66.
943) Kotzev IA, Mirchev MB, Atanasova MV, Stamboliyska MS, Manevska BG, Usheva N, Salme Portinson. The Effect of *L. Reuteri* (ProGastria) on the eradication rate in elderly patients infected with *H. pylori*: a randomized, double-blinded, placebo controlled trial. J Prob Health. 2015; 3:130. doi:10.4172/2329-8901.1000130
944) Leong R. Differences in peptic ulcer between the East and the West. Gastroenterology clinics of North America. 2009; **38**(2): 363-379.
945) Matsui H, Takahashi T, Murayama SY, Uchiyama I, Yamaguchi K, Shigenobu S, Matsumoto T, Kawakubo M, Horiuchi K, Ota H, Osaki T. Development of new PCR primers by comparative genomics for the detection of Helicobacter suis in gastric biopsy specimens. Helicobacter. 2014;**19**(4):260-271.
946) Matsumoto T, Kawakubo M, Akamatsu T, Koide N, Ogiwara N, Kubota S, Sugano M, Kawakami Y, Katsuyama T, Ota H. *Helicobacter heilmannii* sensu stricto-related gastriculcers: a case report. World J Gastroenterol. 2014;**20**(12):3376-3382.
947) Ministerul Sănătăţii Al Republicii Moldova. Gastrita şi duodenita la copil protocol clinic naţional. Chişinău 2013.
948) Moyaert, H., Franceschi, F., Roccarina, D., Ducatelle, R., Haesebrouck, F., Gasbarrini, A. Extragastric manifestations of *Helicobacter pylori* infection: Other Helicobacters. Helicobacter 2008; **13** (Suppl1): 47-57.
949) Ortiz-Princz D, Daoud G, Salgado-Sabel A, Cavazza ME. *Helicobacter pylori* infection in children: should it be carefully assessed? Eur Rev Med Pharmacol Sci. 2016;**20**(9):1798-813.
950) Øverby A, Murayama SY, Michimae H, Suzuki H, Suzuki M, Serizawa H, Tamura R, Nakamura S, Takahashi S, Nakamura M. Prevalence of gastric non-*Helicobacter pylori*-Helicobacters in Japanese patients with gastric disease. Digestion. 2017;**95**(1):61-66.
951) Øverby A, Yamagata Murayama S, Matsui H, Nakamura M. In the aftermath of *Helicobacter pylori*: Other Helicobacters rising up to become the nextgastric epidemic? Digestion. 2016;**93**(4):260-265.

952) Queiroz DM, Saito M, Rocha GA, Rocha AM, Melo FF, Checkley W, Braga LL, Silva IS, Gilman RH, Crabtree JE. *Helicobacter pylori* infection in infants and toddlers in South America: concordance between [13C]urea breath test and monoclonal *H. pylori* stool antigen test. J Clin Microbiol. 2013;**51**(11):3735-40.
953) Shashidhar, H.,Flomenhoft, D., Tolia, V. *Helicobacter pylori* & beyond: pediatric peptic ulcer disease. Therapy. 2009; **6**(1): 65-73.
954) Tarhane, S., & Otlu, S. Investigation of some gastric *Helicobacter* species in saliva and dental plaque of stray cats by cultural and PCR methods. Journal of the Hellenic Veterinary Medical Society. 2019; 70(2), 1573-1578.
955) Valdés, A. Update in Helicobacter Infection World Small Animal Veterinary Association World Congress Proceedings, 2009.
956) Yee EU, Kuo E, Goldsmith JD. Pathologic features of infectious gastritis. Advances in anatomic pathology. 2018; **25**(4):238-53.
957) Zhang, H.-J., Cui, R.-L., Han, Y.-J., (...),Zhang, Y., Jin, Z. Clinical characteristics of *Helicobacter heilmannii*-versus *Helicobacter pylori*-associated gastritis in Chinese patients. World Chinese Journal of Digestology 2013; **21**(3): 244-249.
958) Бельмер СВ, Гасилина ТВ. Неоднозначные ответы на простые вопросы о хроническом гастродуодените у детей. Лечащий врач. 2011(8):57-.
959) Бельмер СВ, Гасилина ТВ. Хронический гастродуоденит у детей. Спорные вопросы. Российский вестник перинатологии и педиатрии. 2009;**54**(3):80-83.
960) Ихсанов, С. Д., Сергиенко, Д. Ф., & Деточкин, А. Н. (2019). Особенности клинического течения язвенной болезни двенадцатиперстной кишки и эрозивных гастродуоденитов у детей. Астраханский медицинский журнал. 2019; 14(2).

ЦИТИРАНА: 32А: **Boyanova L**, Kolarov R, Mitov I. Antimicrobial resistance and the management of anaerobic infections. Expert Rev. Anti Infect. Ther. 2007; **5**(4):685-701. **Цитирана от:**

961) Ahmed MI, Alsammani mA, Ali babiker R. Puerperal sepsis in a rural hospital in Sudan. Mat Soc Med. 2013; **25**(1):19-22.
962) Ahmed MI, Alsammani MA, Babiker RA. Microbial profile in women with puerperal sepsis in Gadarif State, Eastern Sudan. Ann Trop Med Public Health 2013;**6**:460-464.
963) Boscolo-Rizzo P, Stellin M, Muzzi E, Mantovani M, Fuson R, Lupato V, Trabalzini F, Da Mosto MC. Deep neck infections: a study of 365 cases highlighting recommendations for management and treatment. Eur Arch Otorhinolaryngol. 2012;**269**(4):1241-1249.
964) Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev. 2013;**26**(3):526-546.
965) Brook I. Anaerobic bacteria as a cause of mycotic aneurysm of the aorta: microbiology and antimicrobial therapy. Current Cardiology Reviews. 2009; **5**: 36-39.
966) Chen T, Chen L, Li H, Chen Y, Guo H, Shu Y, Chen Z, Cai C, Guo L, Zhang X, Zhou L, Zhong Q. Design and in vitro evaluation of a novelpoly(methacrylic acid)/metronidazole antibacterialnanogel as an oral dosage form. Colloids Surf B Biointerfaces. 2014;**118**:65-71.
967) Fatima N, Muhammad SA, Zaidi SS, Rehman N, Hussain I, Amirzada I, Mannan A. Prioritizing and modelling of putative drug target proteins of *Candida albicans* by system biology approach. Acta Biochimica Polonica. 2018;**65**(2):209-18.
968) Löfmark, S., Edlund, C., Nord, C.E. Metronidazole is still the drug of choice for treatment of anaerobic infections, Clinical Infectious Diseases, 2010; **50** (Suppl 1): S16-S23.
969) Mathur T, Kalia V, Barman TK, Singhal S, Khan S, Upadhyay DJ, Rattan A, Raj VS. Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against *Bacteroides fragilis*. Int J Antimicrob Agents. 2013;**41**(1):36-40.
970) Metcalf III CA, , Li J, Pearson AL. Antibacterial agents for the treatment of gram positive infections US 8507647 B2, US Patent 8,507,647, 2013 - Google Patents
971) Muhammad SA, Ahmed S, Ali A, Huang H, Wu X, Yang XF, Naz A, Chen J. Prioritizing drug targets in *Clostridium botulinum* with a computational systems biology approach. Genomics. 2014; **104**(1):24-35.
972) Polanco N, López T, Urbina G, Carmona O. *Bacteroides fragilis* enterotoxigénico aislado de pacientes con vaginitis. Revista de la Sociedad Venezolana de Microbiología 2008; **28**:43-47.
973) Public Health Agency of Canada. *Clostridium botulinum* Public Health Agency of Canada, 2010. http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/clostridium-eng.php
974) Public Health Agency of Canada. *Fusobacterium* spp.. Public Health Agency of Canada, 2010: http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/fusobacterium-eng.php
975) Tolan RW. Botulism. eMedecine Feb 7, 2008. available online at: http://www.emedicine.com/PED/topic273.htm
976) Tolan RW. Pediatric botulism. Medscape: Drugs, diseases and procedures. 2012: http://emedicine.medscape.com/article/961833-overview#a0101
977) Wexler, H.M. Pump it up: Occurrence and regulation of multi-drug efflux pumps in *Bacteroides fragilis*. Anaerobe. 2012; **18** (2): 200-208.

ЦИТИРАНА: 33А: **Boyanova L.** Detection of *Helicobacter pylori* infection in symptomatic Bulgarian adults. Clin. Microbiol. Infect. 2007; **13** (9): 908-914. **Цитирана от:**

978) Arslan S. [An Opportunity On Peripheral Hospital Impossibilities "Fast Urease Test"]. Abant Med J. 2014; **3**(1):50-54. http://www.journalagent.com/abantmedj/pdfs/ABANT_3_1_50_54.pdf
979) Arslan, Ş. Periferik Hastahane İmkansızlıklarında Bir İmkan;"Hızlı Üreaz Testi". Abant Medical Journal. 2014; 3(1), 50-54.
980) Bruce MG, Maaroos HI. Epidemiology of *Helicobacter pylori* infection. Helicobacter. 2008; **13** (Suppl 1): 1-6.
981) İlktaç M, Öngen B, Pinarbaşi B, Mungan Z. *Helicobacter pylori* Varlığının Kültür, Hızlı Üreaz Testi, PCR ve ELISA Yöntemleriyle Saptanması ve Proton Pompası İnhibitörü Kullanımının Testler Üzerine Etkisinin Araştırılması Türk Mikrobiyol Cem Derg. 2011; 41(1):22-28. http://tmc.dergisi.org/pdf/pdf_TMC_404.pdf

982) Kotzev IA, Mirchev MB, Atanasova MV, Stamboliyska MS, Manevska BG, Usheva N, Salme Portinson. The Effect of *L. Reuteri* (ProGastria) on the eradication rate in elderly patients infected with *H. pylori*: a randomized, double-blinded, placebo controlled trial. J Prob Health. 2015; 3:130. doi:10.4172/2329-8901.1000130
983) Liu, Y.E., Gong, Y.H., Sun, L.P., Xu, Q.,Yuan, Y. The relationship between *H. pylori* virulence genotypes and gastric diseases. Polish Journal of Microbiology. 2012; **61**(2): 147-150.
984) Palácios AC, Carrasco Arroniz MA, Torres TJL, Rojas SB, Silvia Cid Juárez, Troche MR, Dietlen FR. Seroprevalencia del *Helicobacter pylori* en dos comunidades del estado de Veracruz. Revista Investigación en Ciencias de la Salud. 2007; **2** (2): https://issuu.com/revciensalud/docs/vol._2_no._2._julio-diciembre_2007
985) Sudraba A, Funka K, Engstrands L, Jančausks D, Jonaitis L, Kupčinsks L, Lin J-T, Rudzīte D, Leja M, Baltijas–Taivanas atrofiskā gastrīta pētnieku grupas vārdā. [Evaluation of routine *Heliobacter pylori* tests in patients with and without gastric mucosal atrophy]. Latvijas Universitātes raksti. 2009, 750. sēj. Medicīn. 146.–152.

ЦИТИРАНА: 34А: **Boyanova L,** Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of *Helicobacter pylori* resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008; **60(4)**: 409-415.

***Включена в Most Cited Diagnostic Microbiology and Infectious Disease Articles** http://www.journals.elsevier.com/diagnostic-microbiology-and-infectious-disease/most-cited-articles/

986) A El-Zahaby S, A Kassem A, H El-Kamel A. *Helicobacter pylori*: an overview on antimicrobials and drug delivery systems for its eradication. Current drug delivery. 2014; **11**(3):306-312.
987) Adnan M, Tariq A, Bibi R, AbdElsalam NM, Rehman H, Murad W, Ahmad S, Israr M, Sabahat S, Ullah R, Akber A, ud Din J, Aziz MA. Antimicrobial potential of alkaloids and flavonoids extracted from *Tamarix aphylla* leaves against common human pathogenic bacteria. African Journal of Traditional, Complementary and Alternative Medicines. 2015; **12**(2): http://www.ajol.info/index.php/ajtcam/article/view/115514
988) Bertrant, E. B., Danny, T. N. L., Serge, F. C., Agnes, M., Roger, A. M., Roger, K. J., & Brigitte, K. M. L. Evolution of Susceptibilities of *Helicobacter pylori* Strains Circulating in Cameroon to Usual Antibiotics: A Three-year Study. International Journal of Gastroenterology. 2020; 4(2), 63.
989) Bhattamisra SK, Yan VL, Lee CK, Kuean CH, Candasamy M, Liew YK, Sahu PS. Protective activity of geraniol against acetic acid and *Helicobacter pylori*-induced gastric ulcers in rats. J Tradit Complement Med. 2018; **10**;9(3):206-214.
990) Castro Fernández M, Vargas Romero J. Infection with *Helicobacter pylori.* Prevalence, research and impact of antibiotic resistance. Rev Esp Enferm Dig 2009; **101**(11): 743-756.
991) Castro-Fernández M, Lamas-Rojas E, Maraver-Zamora M, Pérez-Pastor MA. Infección por *Helicobacter Pylori*. Pautas de tratamiento erradicador e influencia de la resistencia antibiótica. RAPD online. 2010; 33(6).
992) Cellini L, Di Bartolomeo S, Di Campli E, Genovese S, Locatelli M, Di Giulio M. In vitro activity of Aloe vera inner gel against *Helicobacter pylori* strains. Lett Appl Microbiol. 2014;**59**(1):43-8.
993) Chisholm SA, Owen RJ. Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant *Helicobacter pylori* from gastric infections in the UK. J Med Microbiol. 2009; **58**(Pt 10):1322-1328.
994) Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of *Helicobacter pylori*. World J Gastroenterol. 2012;**18**(32):4386-90.
995) Daugule I, Rowland M. *Helicobacter pylori* infection in children. Helicobacter 2008; **13**(Suppl 1): 41-46.
996) Dorta G, Jornod P, Vouillamoz D, Viani F, Nichita C. Maladies peptiques. Rev Med Suisse 2009; **5**:167-175.
997) Dugina VV, Lebedeva NV, Rudakova GV, Checkalova NG. Influence of the lycopid and immunal immunomodulators on the *Helicobacter pylori* eradication at a treatment of the stomach duodenum ulcerous disease. Sovremennye Tehnologii v Medicine. 2010; **2010** (4):69-72.
998) Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of *Helicobacter pylori* infection. Helicobacter. 2008; **13**(Suppl1): 35-40.
999) El-Zahaby SA, Kassem AA, El-Kamel AH. Formulation and in vitro evaluation of size expandinggastro-retentive systems of levofloxacin hemihydrate. Int J Pharm. 2014 **10**;464(1-2):10-8.
1000) El-Zahaby SA, Kassem AA, El-Kamel AH. Non-antibiotic therapies for treatment of *Helicobacter pylori* infection. Inventi Rapid: Pharm Biotech & Microbio. 2016; **2016**(2):1-5.
1001) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol. 2020; **31**(3): 221.
1002) Falsafi T, Ehsani A, Niknam V. The role of active efflux in antibiotic - resistance of clinical isolates of *Helicobacter pylori*. Indian J Med Microbiol. 2009; **27**(4): 335-340.
1003) Farahmand F, Mohammadi T, Najafi M, Fallahi G, Khodadad A, Motamed F, Mahdi Marashi S, Shoaran M, Nabavizadeh Rafsanjani R. Comparison of ciprofloxacin-based triple therapy with conventional triple regimen for *Helicobacter pylori* eradication in children. Acta Med Iran. 2016; **54**(6):395-400.
1004) Fathi MS, EL-Folly RF, Hassan RA, El-Arab ME. Genotypic and phenotypic patterns of antimicrobial susceptibility of *Helicobacter pylori* strains among Egyptian patients. Egyptian Journal of Medical Human Genetics. 2013;**14**(3): 235-246.
1005) Figueroa M, Cortes A, Pazos Á, Bravo LE. Sensibilidad in vitro a amoxicilina y claritromicina de *Helicobacter pylori* obtenido de biopsias gástricas de pacientes en zona de bajo riesgo para cáncer gástrico. Biomédica [online]. 2012; **32**(1): 32-42 .
1006) Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of *Helicobacter pylori* antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010; **15**(5): 460-466.
1007) González YP, Assef JAC, Hernández DG, Pérez DG. Sequential therapy results in the erradication of the infection by *Helicobacter pylori*. MEDICIEGO 2012; 18 (No. Esp.)

1008) Guarve K, D Gupta G. Formulation and evaluation of extended release asymmetric membrane capsules of atenolol. Current drug delivery. 2011; **8**(2):159-163.
1009) Hafizi M, Shafigh Ardestani MH, Tamadon MR, Kavehzadeh K, Amiri M. Comparison of standard triple therapy regimen with sequential therapy regimen containing levofloxacin used for the eradication of *Helicobacter pylori* in patients with gastrointestinal infection caused by *Helicobacter pylori*. World Family Medicine/Middle East Journal Of Family Medicine. 2017;**15**(6):26-32.
1010) Hashemi SJ, Hajiani ES, Shayesteh A, Masjedizadeh A, Aboali A. Comparison of a triple therapy regimen containing ciprofloxacin and low dose furazolidone with conventional quadruple regimen for *Helicobacter pylori* eradication. Scientific Medical Journal (AJUMS). 2010;**8**(4):445-454.
1011) Hashemi SJ, Sheikh AF, Goodarzi H, Yadyad MJ, Seyedian SS, Aslani S, Assarzadegan MA. Genetic basis for metronidazole and clarithromycin resistance in *Helicobacter pylori* strains isolated from patients with gastroduodenal disorders. Infection and drug resistance. 2019; 12, 535.
1012) Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y. Annual change of primary resistance to clarithromycin among *Helicobacter pylori* isolates from 1996 through 2008 in Japan. Helicobacter. 2009;**14**(5):86-90.
http://nbuv.gov.ua/UJRN/SGastro_2014_4_14
1013) Huang L-P, Zhuang M-L, Gu C-P. Antimicrobial resistance of 36 strains of *Helicobacter pylori* in adolescents. Chinese Journal of Contemporary Pediatrics. 2009; **11**(3): 210-212.
1014) Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change *Helicobacter pylori* treatment: A matter of geography? World J Gastroenterol. 2013;**19**(45):8168-8180.
1015) Jacobson LM, Redd JT, Schneider E, Lu X, Chern SW, Oberste MS, Erdman DD, Fischer GE, Armstrong GL, Kodani M, Montoya J, Magri JM, Cheek JE. Outbreak of lower respiratory tract illness associated with human enterovirus 68 among American Indian children. Pediatr Infect Dis J. 2012;31(3):309-12.
1016) Jeyamani, L., Jayarajan, J., Leelakrishnan, V., & Swaminathan, M. Resistance to Amoxicillin and Clarithromycin in *Helicobacter pylori* isolates in a tertiary care hospital. Indian Journal of Microbiology Research. 2019; 6(4), 294-298.
1017) Jornod P, Vouillamoz D, Viani F, Nichita C, Dorta G. Acid related diseases progress in 2008 [Maladies peptiques]. Rev Med Suisse. 2009; **5**(187): 167-175.
1018) Kalach N, Bontems P, Cadranel S. Advances in the treatment of *Helicobacter pylori* infection in children. Ann Gastroenterol. 2015; **28**(1):10-18. .
1019) Kalem, F., Özdemir, M., Başaranoġlu, M., Toy, H., Baysal, B. *Helicobacter pylori* isolates recovered from antral gastric biopsies of patients with dyspeptic symptoms: Antimicrobial resistance of metronidazole, clarithromycin and amoxicillin | [Dispeptik yakinmalari olan hastalarin antral gastrik biyopsilerinden izole edilen *helicobacter pylori* suşlarinin metranidazol, klaritromisin ve amoksisiline direnci]. Anatolian Journal of Clinical Investigation. 2012; **6** (1): 238-241.
1020) Karczewska E, Wojtas-Bonior I, Sito E, Zwoliñska-Wcisło M, Budak A. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to *Helicobacter pylori* in southern Poland. Pharmacological Reports. 2011; **63**: 799-807.
1021) Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, Chong S, Colletti RB, Casswall T, Elitsur Y, Guarner J, Kalach N, Madrazo A, Megraud F, Oderda G; on behalf of the *H. pylori* working groups of ESPGHAN, NASPGHAN. Evidence-based guidelines from ESPGHAN and NASPGHAN for *Helicobacter pylori* infection in children. J Pediatr Gastroenterol Nutr. 2011; **53**(2): 230-243.
1022) Krasz S, Miehlke S, Berning M, Morgner A, Labenz J. Current value of quinolones in *Helicobacter pylori*/Therapy aktueller stellenwert von fluorchinolonen in der *Helicobacter-pylori*-therapie. Z Gastroenterol 2011; **49**(8): 989-996.
1023) Kupcinskas L, Rasmussen L, Jonaitis L, Kiudelis G, Jørgensen M, Urbonaviciene N, Tamosiunas V, Kupcinskas J, Miciuleviciene J, Kadusevicius E, Berg D, Andersen LP.
Evolution of *Helicobacter pylori* susceptibility to antibiotics during a 10-year period in Lithuania.
APMIS. 2013;**121**(5):431-436.
1024) Massarrat, Sadegh, and Arghavan Sheykholeslami. Increase in resistance rates of *H. pylori* isolates to metronidazole and tetracycline-comparison of three 3-year studies. Archives of Iranian medicine. 2010; (3): 177.
http://www.sid.ir/EN/VEWSSID/J_pdf/86920100301.pdf
1025) Mégraud, F., Corti, R. Bacterial resistance of *Helicobacter pylori* in the world in 2009. [Resistencia bacteriana del *Helicobacter pylori* en el mundo en el año 2009]. Acta Gastroenterologica Latinoamericana 2009; **39**(4): 282-290.
1026) Mi Y, Zheng P-Y, Zhang B-Y, Liu Z-Q, Song C-H, Yang P-C. Role of ABC transporter genes msbA and spab in multidrug resistance of *Helicobacter pylori*. World Chinese Journal of Digestology.. 2011; **19**(14): 1500-1505.
1027) Miendje Deyi VY, Bontems P, Vanderpas J, De Koster E, Ntounda R, Van Den Borre C, Cadranel S, Burette A. Multicenter survey of routine determinations of resistance of *Helicobacter pylori* to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol. 2011; **49**(6): 2200-2209.
1028) Njume C, Afolayan AJ, Ndip RN. An overview of antimicrobial resistance and the future of medicinal plants in the treatment of *Helicobacter pylori* infections. African Journal of Pharmacy and Pharmacology. 2009; **3**(13): 685-699.
1029) Pisegna JR, Surti B, Scott DR. Clinical trial report: Eradication of *Helicobacter pylori* reduces the risk for subsequent gastric cancer. Curr Gastroenterol Rep. 2010;**12**(6): 427-430.
1030) Prechtl J, Deutschmann A, Savic T, Jahnel J, Bogiatzis A, Muntean W, Hauer AC, Hoffmann KM. Monitoring of antibiotic resistance rates of *Helicobacter pylori* in Austrian children, 2002-2009. Pediatr Infect Dis J. 2012;**31**(3):312-314.
1031) Racha S, Wongrattanakamon P, Raiwa A, Jiranusornkul S. Discovery of novel potent small natural molecules able to enhance attenuation of the pathobiology of gastric cancer-associated *Helicobacter pylori* by molecular modeling. International Journal of Peptide Research and Therapeutics. 2018 Jul 17:1-6.

1032) Ramírez-Bulla P, Mercado-Reyes M, Trespalacios-Rangel AA, Avila-Coy J, Otero-Regino W. Estado actual de la resistencia de *Helicobacter pylori* a tetraciclina: revisión sistemática de la literatura. Universitas Scientiarum, 2012; **17**(2): 216-229
1033) Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L. Efficacy of four different moxifloxacin-based triple therapies for first-line *H. pylori* treatment. Dig Liver Dis. 2010; **42**(2): 110-114.
1034) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;**155**(5):1372-82.
1035) Schwarzer A, Urruzuno P, Iwańczak B, Martínez-Gómez MZ, Kalach N, Roma-Giannikou E, Liptay S, Bontem P, Buderus S, Wenzl TG, Koletzko S; ESPGHAN Working Group on *Helicobacter pylori* Infection. New effective treatment regimen for children infected with a double-resistant *Helicobacter pylori* strain. J Pediatr Gastroenterol Nutr. 2011; **52**(4): 424-48.
1036) Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of *H.pylori* isolates to metronidazole and tetracycline-comparison of three 3-year studies. Archives of Iranian Medicine. 2010; **13**(3): 177-187.
1037) Sisto F, Scaltrito MM, Russello G, Bonomi A, Dubini F. Antimicrobial susceptibility testing of *Helicobacter pylori* determined by microdilution method using a new medium. Curr Microbiol. 2009; **58** (6): 559-563.
1038) Srivastava AK, Tewari M, Shukla HS, Roy BK. In silico profiling of the potentiality of curcumin and conventional drugs for CagA oncoprotein inactivation. Arch Pharm (Weinheim). 2015; **348**(8):548-55. doi: 10.1002/ardp.201400438.
1039) Sugimoto M, Yamaoka Y. Virulence factor genotypes of *Helicobacter pylori* affect cure rates of eradication therapy. Archivum Immunologiae et Therapiae Experimentalis. 2009; **57**(1): 45-56.
1040) Suzuki H, Mori H. World trends for *H. pylori* eradication therapy and gastric cancer prevention strategy by *H. pylori* test-and-treat. Journal of gastroenterology. 2018;**53**(3):354-61.
1041) Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of *Helicobacter pylori* to levofloxacin and moxifloxacine in Iran. Intern Emerg Med. 2012;**7**(5):447-452.
1042) Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. *Helicobacter pylori* eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther. 2012; 36(11-12):1076-83.
1043) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016;**43**(4):514-33.
1044) Viani F, Vouillamoz D, Jornod P, Kessler-Brondolo V, Nichita C, Dorta G. [Peptic diseases]. Rev Med Suisse. 2009; **24**; 3(95): 192-194 and 196-200.
1045) Wu, M.-H., Huang, Z.-S., Huang, Y.-Q. Progress in research of *Helicobacter pylori* efflux pumps. World Chinese Journal of Digestology. 2013; **21**(17): 1630-1635.
1046) Zhang, Z., Liu, Z.-Q., Zheng, P.-Y., Tang, F.-A. Effects of efflux pump inhibitors on the multidrug resistance of *Helicobacter pylori.* World Chinese Journal of Digestology 2010; **18**(3): 262-267.
1047) Zhang, Z., Liu, Z.-Q., Zheng, P.-Y., Tang, F.-A., Yang, P.-C. Influence of efflux pump inhibitors on the multidrug resistance of *Helicobacter pylori.* World J Gastroenterol. 2010; **16**(10): 1279-1284.
1048) Бадритдинова, М. Н., & Орзикулова, Ш. (2020). Основные аспекты гастродуоденальной патологии в подростковом возрасте (обзор литературы). Биология и интегративная медицина, (5 (45)).
1049) Воропаева АВ, Воропаев ЕВ, Баранов ОЮ, Платошкин ЭН, Шафранский АА, Пиманов СИ, Макаренко ЕВ. Молекулярно-генетическое тестирование мутаций гена 23S рРНК *Helicobacter pylori*, определяющих резистентность к кларитромицину в Беларуси. Медико-биологические проблемы жизнедеятельности. 2010; 1(3):30-35.
1050) Григориади ГС., Мельник ИВ. Григориади Г.С., Мельник И.В. *Helicobacter pylori*-инфекция и новые возможности ее эрадикации. Илмий-Амалий Тиббиёт Журнали. 2016;1:67-71.
1051) Данильченко П, Токаренко ИИ. Репарант "Доктовит" в лечении гастроэзофагеальной рефлюксной болезни II степени, сопровождающейся эрозивным гастродуоденитом, ассоциированным с *Helicobacter pylori.* Сучасна гастроентерологія. 2014. № 4;85-89.
1052) Бадритдинова Мн, Орзикулова Ш. Gastroduodenal pathology in Smirlik Key features (References)/ Ўсмирлик даврида гастродуоденал патологиянинг асосий хусусиятлари (адабиётлар шарҳи). Биология и интегративная медицина 2020;5:45-59.
1053) Поздеева АО, Морозова ЛГ, Поздеев ОК, Поздняк Александр Олегович. Первичная чувствительность к антибактериальным препаратам среди штаммов *Helicobacter pylori*, выделенных от пациентов с хроническими гастритами и гастродуоденитами. Вестник современной клинической медицины. 2014. №2. URL: http://cyberleninka.ru/article/n/pervichnaya-chuvstvitelnost-k-antibakterialnym-preparatam-sredi-shtammov-helicobacter-pylori-vydelennyh-ot-patsientov-s-hronicheskimi.
1054) Саблин ОА, Ильчишина ТА. Проблема резистентности *Helicobacter pylori* к кларитромицину. Гастроэнтерология. 2009; **2**: 4-8.
1055) Старостин БД. Распространенность первичной кларитромициновой резистентности в различных регионах мира. Гастроэнтерология Санкт-Петербурга. 2011 (№ 2-3): 11-15.
1056) Степченко АА, Филиппенко НГ. Возможности персонализации фармакотерапии язвенной болезни в условиях функционирования стандартов и формулярной системы лечения заболеваний. Архивъ внутренней медицины. 2012(1). https://cyberleninka.ru/journal/n/arhiv-vnutrenney-meditsiny
1057) Успенский ЮП, Барышникова НВ. Использование препаратов нитрофуранового ряда в схемах эрадикационной терапии первой линии. РМЖ. 2012; **20**(35):1694-1696.
1058) Цуканов ВВ, Амельчугова ОС, Буторин НН, Третьякова ОВ, Васютин АВ. Современные аспекты эрадикации *Helicobacter pylori*. Тер. архив. 2013;2:73-75.
1059) Щербаков АП, Щербаков ПЛ. Ведение хеликобактерной инфекции у детей (научно обоснованные рекомендации ESPGHAN и NASPGHAN 2010 года). Лечащий врач. 2011;6:46-58.

ЦИТИРАНА: 33Б: Боянова Л, Панов Вл, Йорданов Д, Марковска Р, Марина М, Гергова Г, Иванова К, Панайотов Ст, Бранкова Н, Левтерова В, Митов И, Кантарджиев Т, Кръстев З. *Helicobacter pylori* в устната кухина–предварителни проучвания. Хепато-гастроентерол. 2008; No.1: 3-10. **Цитирана от:**

1060) Krasteva A, Panov V, Krasteva A, Kisselova A. Oral cavity and systemic diseases – *Helicobacter pylori* and dentistry. Biotechnol. & Biotechnol. Eq. 2011, **25**(3), 2447-2541.

ЦИТИРАНА: 35А: Boyanova L, Ilieva J, Gergova G, Spassova Z, Nikolov R, Davidkov L, Evstatiev I, Kamburov V, Katsarov N, Mitov I. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58**(1):94-100. **Цитирана от:**

1061) Alividza V, Mariano V, Ahmad R, Charani E, Rawson TM, Holmes AH, Castro-Sánchez E. Investigating the impact of poverty on colonization and infection with drug-resistant organisms in humans: a systematic review. Infectious diseases of poverty. 2018;**7**(1):76.
1062) Asfaw T. Prevalence and emergence of drug resistance in *Helicobacter pylori*. Int. Res. J. Microbiol. 2018; **7**(2):056-066.
1063) De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide *H. pylori* antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010; **19**(4): 409-914.
1064) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. The Turk J Gastroenterol. 2020; **31**(3): 221.
1065) Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change *Helicobacter pylori* treatment: A matter of geography? World J Gastroenterol. 2013;**19**(45):8168-8180.
1066) Mabeku LBK, Bille BE, Zemnou CT, Nguefack LDT, Leundji H. Broad spectrum resistance in *Helicobacter pylori* isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. BMC infectious diseases. 2019; 19(1), 1-11.
1067) Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in *Helicobacter pylori* diagnostics in the era of next generation sequencing. World J Gastroenterol. 2019; **25**(32), 4629.
1068) Shi D, Wang Q, Bao Y. Evaluation and risk factors for antibacterial resistance of *Helicobacter pylori*. China Journal of Modern Medicine. 2012; **22**(1): http://eng.med.wanfangdata.com.cn/PaperDetail.aspx?qkid=zgxdyxzz&qcode=zgxdyxzz201201021
1069) Zendedel A, Almasi V, Moradimoghadam F, Zivarifar H. Antibiotic resistance of *Helicobacter pylori* in Mashhad, Iran. Journal of the Pakistan Medical Association. 2013; **63**(3): 336-339.

ЦИТИРАНА: 36А: Boyanova L, Stephanova-Kondratenko M, Mitov I. Anti-*Helicobacter pylori* activity of *Lactobacillus delbrueckii* subsp. *bulgaricus* strains: preliminary report. Lett Appl Microbiol. 2009; **48** (5): 579-584. **Цитирана от:**

1070) Aiba Y, Ishikawa H, Tokunaga M, Komatsu Y. Anti-*Helicobacter pylori* activity of non-living, heat-killed form of lactobacilli including *Lactobacillus johnsonii* No. 1088. FEMS Microbiol Lett. 2017; **364**(11). doi: 10.1093/femsle/fnx102.
1071) Chen X, Tian F, Liu X, Zhao J, Zhang HP, Zhang H, Chen W. *In vitro* screening of lactobacilli with antagonistic activity against *Helicobacter pylori* from traditionally fermented foods. J Dairy Sci. 2010; **93**(12): 5627-5634.
1072) Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016;**69**(3):187-203.
1073) Enany S, Abdalla S. In vitro antagonistic activity of *Lactobacillus casei* against *Helicobacter pylori*. Braz J Microbiol. 2015;**46**(4):1201-6.
1074) Fontana C, Lionetti E, Ierardi E, Maurogiovanni G, Scaccianoce G, Cavallo L, Principi M, La Rosa M, Francavilla R, Sardaro R. Probiotics and *Helicobacter pylori.* European Gastroenterology & Hepatology Review, 2011; **7**(2): 121-128.
1075) Francavilla R, Cavallo L, Sardaro R, Fontana C, Ierardi E, La Rosa M, Maurogiovanni G, Scaccianoce G, Principi M, Lionetti E. Probiotics and *Helicobacter pylori*. European Gastroenterology & Hepatology Review, 2011; **7**(2):121-128.
1076) Gao F, Sui L, Mu G, Zhu X, Qian F. Screening of potential probiotics with anti-*Helicobacter pylori* activity from infant feces through principal component analysis. Food Bioscience. 2021; 101045.
1077) Garault P, Bourdet-Sicard R, Megroud F, inventors; Compagnie Gervais Danone, assignee. *Streptococcus thermophilus* strains for treating *Helicobacter pylori* infection. United States patent application US 14/438,458. 2012 Oct 25.
1078) Garault P, Quere G, Bourdet-Sicard R, Megraud F, inventors; Compagnie Gervais Danone, assignee. Strain of L. bulgaricus capable of inhibiting the adhesion of *H. pylori* strains to epithelial cells. United States patent US 9,272,007. 2016 Mar 1.
1079) Ivanov, I., Petrov, K., Lozanov, V., Hristov, I., Wu, Z., Liu, Z., & Petrova, P. Bioactive Compounds Produced by the Accompanying Microflora in Bulgarian Yoghurt. Processes. 2021; 9(1), 114.
1080) Kanani, B., Khosrowshahi, A., Khaledabad, M. A., & Pourahmad, R. Probiotic Yogurt Formulated with Nettle (Urtica Dioica) Extract, a Compound with Dual Functionalities: Bifidobacterium Growth Promoter and *Helicobacter Pylori* Growth Inhibitor. Biomedical Journal. 2018; 10(1).
1081) Köberl, M., Erschen, S., Etemadi, M., White, R. A., El-Arabi, T. F., & Berg, G. Deciphering the microbiome shift during fermentation of medicinal plants. Scientific reports. 2019; 9(1), 1-11.
1082) Kotzev IA, Mirchev MB, Atanasova MV, Stamboliyska MS, Manevska BG, Usheva N, Salme Portinson. The effect of *L. Reuteri* (ProGastria) on the eradication rate in elderly patients infected with *H. pylori*: a randomized, double-blinded, placebo controlled trial. J Prob Health. 2015; **3**:130. doi:10.4172/2329-8901.1000130
1083) Lim S-m, Kim D-S, Ahn D-H. Anti-*Helicobacter pylori* Activity of Yogurt Fermented with Lactic Acid Bacteria from Baikkimchi. Korean Journal of Microbiology 2014; 50(4): 334-344.
1084) Lin WH, Wu CR, Fang TJ, Guo JT, Huang SY, Lee MS, Yang HL. Anti-*Helicobacter pylori* activity of fermented milk with lactic acid bacteria. J Sci Food Agric. 2011; **91**(8):1424-1431.
1085) Lionetti E, Principi M, Scaccianoce G, Maurogiovanni G, La Rosa M, Ierardi E, Fontana C, Sardaro R, Cavallo L, Francavilla R. Probiotics and *Helicobacter pylori*. European Gastroenterology and Hepatology Review. 2011; **7**(2): 121-128.

1086) Lue BC, inventor; Nubiome, Inc., assignee. Treatment and Prophylaxis for Gastroesophageal Reflux Disease. United States patent application US 14/863,517. 2015 Sep 24.
1087) Opekun AR, Gonzales SA, Al-Saadi MA, Graham DY. Brief report: *Lactobacillus bulgaricus* GLB 44 (Proviotic™) plus esomeprazole for *Helicobacter pylori* eradication: A pilot study. Helicobacter. 2018;**23**(2):e12476.
1088) Pešić-Mikulec D, Niketić GB. Compositional characteristics of commercial yoghurt based on quantitative determination of viable lactic acid bacteria. APTEFF. 2009; **40**(1): 87-94.
1089) Petkov, K., Karsch, M., & Petkov, P. 2018 U.S. Patent No. 9,930,905. Washington, DC: U.S. Patent and Trademark Office.
1090) Sampath, G., Shyu, D. J., Rameshkumar, N., Krishnan, M., & Kayalvizhi, N. In vitro anti-*Helicobacter pylori* and anti-gastric cancer activities of Acacia nilotica aqueous leaf extract and its validation using in silico molecular docking approach. Materials Today: Proceedings. 2020.
1091) Saracino, I. M., Pavoni, M., Saccomanno, L., Fiorini, G., Pesci, V., Foschi, C., ... & Vaira, B. Antimicrobial efficacy of five probiotic strains against *Helicobacter pylori*. Antibiotics. 2020; 9(5), 244.
1092) Sunanliganon C, Thong-Ngam D, Tumwasorn S, Klaikeaw N. *Lactobacillus plantarum* B7 inhibits *Helicobacter pylori* growth and attenuates gastric inflammation. World J Gastroenterol. 2012;**18** (20): 2472-2480.
1093) Zheng PX, Fang HY, Yang HB, Tien NY, Wang MC, Wu JJ. *Lactobacillus pentosus* strain LPS16 produces lactic acid, inhibiting multidrug-resistant *Helicobacter pylori*. Journal of Microbiology, Immunology and Infection. 2016;**49**(2):168-74.
1094) 佩吉, et al. *Helicobacter pylori* Strains can be suppressed to adhere to the Xin Deshi lactobacillus subspecies bulgaricus bacterial strain of epithelial cell. 2016.
1095) 보문. Evaluation of the anti-*Helicobacter pylori* and cytotoxic properties of the antimicrobial substances from Lactobacillus acidophilus BK13 and Lactobacillus paracasei BK57. Korean Journal of Microbiology, 2015, 51.2: 156-168.
1096) 佩吉, et al. *Helicobacter pylori* Strains can be suppressed to adhere to the Xin Deshi lactobacillus subspecies bulgaricus bacterial strain of epithelial cell. 2016.
1097) Гаро, П., Кер, Г., Бурде-Сикар, Р., & Мегро, Ф. Штамм L. bulgaricus, способный ингибировать адгезию штаммов H. pylori к эпителиальным клеткам. RU 2584600 C2, Россия, 2016

ЦИТИРАНА: 37А: **Boyanova L.** Prevalence of multidrug-resistant *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58** (Pt 7): 930-935. **Цитирана от:**

1098) Abdallah EM. Plants: An alternative source for antimicrobials. Journal of Applied Pharmaceutical Science. 2011; **01**(06): 16-20.
1099) Arévalo A, Otero WA, Trespalacios AA. *Helicobacter pylori*: resistencia múltiple en pacientes de Bogotá-Colombia. Biomédica. 2019;39:125-134.
1100) Bachir M, Allem R, Tifrit A, Medjekane M, Drici AE, Diaf M, Douidi KT. Primary antibiotic resistance and its relationship with cagA and vacA genes in *Helicobacter pylori* isolates from Algerian patients. Brazilian Journal of Microbiology. 2018; **49**(3):544-51.
1101) Bedoya-Gómez IJ, Alvarez-Aldana A, Moncayo-Ortiz JI, Guaca-González YM, Santacruz-Ibarra JJ, Arturo-Arias BL, ... & Beltrán-Angarita L. Surveillance of the Antimicrobial Resistance Rates of *Helicobacter pylori* Ten Years Later in the Western Central Region, Colombia. Dig Dis. 2020; **38**(3):196-203.
1102) Ben Mansour K, Burucoa C, Zribi M, Masmoudi A, Karoui S, Kallel L, Chouaib S, Matri S, Fekih M, Zarrouk S, Labbene M, Boubaker J, Cheikh I, Hriz MB, Siala N, Ayadi A, Filali A, Mami NB, Najjar T, Maherzi A, Sfar MT, Fendri C. Primary resistance to clarithromycin, metronidazole and amoxicillin of *Helicobacter pylori* isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study. Ann Clin Microbiol Antimicrob. 2010; **9**: 22.
1103) Bien J, Bozko M, P Malek, N., Bozko P. Editorial (Thematic Issue: *Helicobacter pylori* Eradication Therapy: Advantages and Disadvantages).Current pharmaceutical design. 2014; **20**(28): 4487-4488.
1104) Biernat MM, Poniewierka E, Błaszczuk J, Czapla L, Kempiński R, Ksiądzyna D, Grabińska J, Bińkowska A, Megraud F, Gościaniak G. Antimicrobial susceptibility of *Helicobacter pylori* isolates from Lower Silesia, Poland. Arch Med Sci. 2014; **10**(3):505-509.
1105) Bilgilier C, Stadlmann A, Makristathis A, Thannesberger J, Kastner MT, Knoflach P, Steiner P, Schöniger-Hekele M, Högenauer C, Blesl A, Datz, C., 2017. Prospective, multicenter clinical study on inter-and intra-patient genetic variability for antimicrobial resistance of *Helicobacter pylori*. Clin Microbiol Infect. 2017. pii: S1198-743X(17)30349-X. doi: 10.1016/j.cmi.2017.06.025.
1106) Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of *Helicobacter pylori* in Vietnam. J Clin Gastroenterol. 2013; **47**(3):233-238.
1107) Bolor-Erdene M, Namdag B, Yamaoka Y, Jav S. Antibiotic resistance of *Helicobacter pylori* in Mongolia. The Journal of Infection in Developing Countries. 2017;**11**(11):887-894.
1108) Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, Sevuk EO, Demirci M, Yılmazli O, Akgul O, Kalayci F, Cakan H, Salih B, Bal K, Kocazeybek B.Antimicrobial resistance of *Helicobacter pylori* strains to five antibiotics, includinglevofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop. 2015; **48**(3):278-284.
1109) Cerqueira RM, Correia MR, Vilar H, Manso MC. How effective is the quadruple concomitant *Helicobacter pylori* eradication therapy for obese patients undergoing gastric bypass surgery? Obes Surg. 2016; **26**(6):1163-1166.
1110) Chuah SK, Tai WC, Lee CH, Liang CM, Hu TH. (2014). Quinolone-Containing Therapies in the Eradication of *Helicobacter pylori*. BioMed Research International, 2014 (2014), Article ID 151543. https://www.hindawi.com/journals/bmri/2014/151543.

1111) Farzi, N., Yadegar, A., Sadeghi, A., Asadzadeh Aghdaei, H., Marian Smith, S., Raymond, J., ... & Zali, M. R. High prevalence of antibiotic resistance in Iranian *Helicobacter pylori* isolates: importance of functional and mutational analysis of resistance genes and virulence genotyping. Journal of clinical medicine. 2019; 8(11), 2004.
1112) Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in *Helicobacter pylori*: A recent literature review. World J Methodol. 2015; **5**(3):164-174.
1113) Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change *Helicobacter pylori* treatment: A matter of geography? World J Gastroenterol. 2013;**19**(45):8168-8180.
1114) Kim SY, Choi DJ, Chung JW. Antibiotic treatment for *Helicobacter pylori*: Is the end coming? World J Gastrointest Pharmacol Ther. 2015;**6**(4):183-98.
1115) Kotzev IA, Mirchev MB, Atanasova MV, Stamboliyska MS, Manevska BG, Usheva N, Salme Portinson. The Effect of *L. Reuteri* (ProGastria) on the eradication rate in elderly patients infected with *H. pylori*: a randomized, double-blinded, placebo controlled trial. J Prob Health. 2015; 3:130. doi:10.4172/2329-8901.1000130
1116) Lee JY, Kim N. [Future trends of *Helicobacter pylori* eradication therapy in Korea]. Korean J Gastroenterol. 2014; **63**(3):158-170.
1117) Liu G, Xu X, He L, Ding Z, Gu Y, Zhang J, Zhou L. Primary antibiotic resistance of *Helicobacter pylori* isolated from Beijing children. Helicobacter 2011; **16**(5): 356-362.
1118) Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. *Helicobacter pylori* eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011; **377**(9769): 905-913.
1119) Mohamed ME, Suelam II, Saleh MA. Characterization of *Helicobacter* species isolated from humans and dogs in Sharkia Governorate, Egypt. J. Egypt. Vet. Med. Assoc. 2010; **70**(3):317-325.
1120) Moulaei, H., Namakin, K., Namaei, M. H., & Azarkar, Z. The Effect of Red Rose Extract on *Helicobacter Pylori* Eradication: A Randomized Controlled Clinical Trial. International Journal of Pediatrics. 2019; 7(12), 10473-10480.
1121) Mourad-Baars P, Hussey S, Jones NL. *Helicobacter pylori* infection and childhood. Helicobacter. 2010; **15**(Suppl 1): 53-59.
1122) Njume C, Afolayan AJ, Clarke AM, Ndip RN. Crude ethanolic extracts of *Garcinia kola* Seeds Heckel (*Guttiferae*) prolong the lag phase of *Helicobacter pylori*: inhibitory and bactericidal potential journal of medicinal food. J Med Food. 2011; **14**(7-8): 822-827.
1123) Njume C, Afolayan AJ, Ndip RN. An overview of antimicrobial resistance and the future of medicinal plants in the treatment of *Helicobacter pylori* infections. African Journal of Pharmacy and Pharmacology. 2009; **3**(13): 685-699.
1124) Njume C, Jide AA, Ndip RN. Aqueous and organic solvent-extracts of selected south african medicinal plants possess antimicrobial activity against drug-resistant strains of *Helicobacter pylori*: inhibitory and bactericidal potential. Int J Mol Sci. 2011; **12**(9), 5652-5665.
1125) Ntagirabiri R, Harerimana S, Makuraza F, Ndirahisha E, Kaze H, Moibeni A. *Helicobacter pylori* au Burundi: première évaluation de la prévalence en endoscopie et de l'éradication. Journal Africain d'Hépato-Gastroentérologie. 2014; **8**(4): 217-222.
1126) O'Connor A, Gisbert J, O'Morain C. Treatment of *Helicobacter pylori* infection. Helicobacter. 2009; **14**(Suppl 1): 46-51.
1127) Ramírez-Bulla P, Mercado-Reyes M, Trespalacios-Rangel AA, Avila-Coy J, Otero-Regino W. Estado actual de la resistencia de *Helicobacter pylori* a tetraciclina: revisión sistemática de la literatura. Universitas Scientiarum, 2012 ; **17** (2): 216-229.
1128) Rizvanov, A. A., Haertlé, T., Bogomolnaya, L., & Talebi Bezmin Abadi, A. *Helicobacter pylori* and its antibiotic heteroresistance: A neglected issue in published guidelines. Frontiers in microbiology. 2019; 10, 1796.
1129) Safavi M, Sabourian R, Foroumadi A. Treatment of *Helicobacter pylori* infection: Current and future insights. World J Clin Cases. 2016; **4**(1):5-19.
1130) Schmiloviz-Weiss H, Shalev T, Chechoulin Y, Levi Z, Yishai R, Sehayek-Shabbat V, Niv Y, Shirin H. High eradication rates of *Helicobacter pylori* infection following sequential therapy: the Israeli experience treating naïve patients. Helicobacter. 2011; **16**(3):229-233.
1131) Shiota S, Yamaoka Y. Strategy for the treatment of *Helicobacter pylori* infection. Current pharmaceutical design. 2014; **20**(28):4489-4500.
1132) Shokrzadeh L, Alebouyeh M, Mirzaei T, Farzi N, Zali MR. Prevalence of multiple drug-resistant *Helicobacter pylori* strains among patientswith different gastric disorders in Iran. Microb Drug Resist. 2015; **21**(1):105-110.
1133) Vécsei A, Kipet A, Innerhofer A, Graf U, Binder C, Gizci H, Hammer K, Bruckdorfer A, Huber W-D , Hirschl AM, Makristathis A. time trends of *Helicobacter pylori* resistance to antibiotics in children living in Vienna, Austria. Helicobacter. 2010; **15** (3): 214-220.
1134) Vianna, J.S., Ramis, I.B., Ramos, D.F., Von Groll, A., da Silva, P.E. Drug resistance in *Helicobacter pylori* | [A resistência de *Helicobacter pylori* aos antimicrobianos] Arquivos de Gastroenterologia.2016; **53**(4):215-223.
1135) Wu IT, Chuah SK, Lee CH, Liang CM, Lu LS, Kuo YH, Yen YH, Hu ML, Chou YP, Yang SC, Kuo CM, Kuo CH, Chien CC, Chiang YS, Chiou SS, Hu TH, Tai WC. Five-year sequential changes in secondary antibiotic resistance of *Helicobacter pylori* inTaiwan. World J Gastroenterol. 2015; **21**(37):10669-10674.
1136) Wüppenhorst N, Lenze F, Ross M, Kist M. Isolation and eradication of a clinical isolate of *Helicobacter pylori* resistant to five antimicrobials in Germany. J Antimicrob Chemother. 2011; **66**(1): 222-223.
1137) Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T. Resistance of *Helicobacter pylori* to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol. 2011; **26**(9): 1457-1461.
1138) Yazbek PB, Trindade AB, Chin CM, Dos Santos JL. Challenges to the treatment and new perspectives for the eradication of *Helicobacter pylori*. Dig Dis Sci. 2015; **60**(10):2901-2912.
1139) Yousefi-Avarvand A, Vaez H, Tafaghodi M, Sahebkar AH, Arzanlou M, Khademi F. Antibiotic resistance of *Helicobacter pylori* in Iranian children: a systematic review and meta-analysis. Microbial Drug Resist. 2018; **24**(7):980-986.

1140) Zhang X, Jiang A, Qi B, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Secretion expression of human neutrophil peptide 1 (HNP1) in *Pichia pastoris* and its functional analysis against antibiotic-resistant *Helicobacter pylori*. Applied microbiology and biotechnology. 2018;**102**(11):4817-27.
1141) Zhu R, Chen K, Zheng YY, Zhang HW, Wang JS, Xia YJ, Guo CY. Meta-analysis of the efficacy of probiotics in *Helicobacter pylori* eradication therapy. World J Gastroenterol.: WJG. 2014; **20**(47):18013.
1142) Zullo A, Cristofari F, Bragazzi MC, Hassan C. *Helicobacter pylori* in immigrants: a "foreign" bacterium? Intern Emerg Med. 2011; **6**(1):7-8.
1143) Абдулхаков РА, Абдулхаков СР. Динамика резистентности *Helicobacter pylori* к компонентам схем эрадикационной терапии. Практическая медицина. Общая врачебная практика. Гастроэнтерология. 2011. http://pmarchive.ru/dinamika-rezistentnosti-helicobacter-pylori-k-komponentam-sxem-eradikacionnoj-terapii/
1144) Абдулхаков РА, Абдулхаков СР. От Маастрихта і до Маастрихта IV. Эволюция эрадикационной терапии. Практическая медицина. 2012(58).
1145) Абдулхаков РА, Абдулхаков СР. Современные подходы к эрадикационной терапии. Все ли вопросы решены?. Вестник современной клинической медицины. 2010; **3**(3).
1146) Поздеева АО, Морозова ЛГ, Поздеев ОК, Поздняк Александр Олегович. Первичная чувствительность к антибактериальным препаратам среди штаммов *Helicobacter pylori*, выделенных от пациентов с хроническими гастритами и гастродуоденитами. Вестник современной клинической медицины. 2014. №2. URL: http://cyberleninka.ru/article/n/pervichnaya-chuvstvitelnost-k-antibakterialnym-preparatam-sredi-shtammov-helicobacter-pylori-vydelennyh-ot-patsientov-s-hronicheskimi.
1147) Сорокман ТВ, Сокольник СВ, Попелюк ОМ, Макарова ОВ, Швигар ЛВ. Ефективність різних схем ерадикаційної терапії в дітей, хворих на хелікобактер-асоційовану патологію верхніх відділів шлунково-кишкового тракту. ScienceRise. 2016; **2**(3 (19):58-64.
1148) Чумак ЮВ, Лобань ГА, Фаустова МО, Ананьєва ММ, Войнаш ВА. Мікробіологічні аспекти формування резистентності *H. pylori* до антимікробних препаратів. Актуальні проблеми сучасної медицини: Вісник української медичної стоматологічної академії. 2019; **19**(2 (66)).

ЦИТИРАНА: 38А: **Boyanova L,** Markovska R, Yordanov D, Marina M, Ivanova K, Panayotov S, Gergova G, Mitov I. High prevalence of virulent *Helicobacter pylori* strains in symptomatic Bulgarian patients. Diagn Microbiol Infect Dis. 2009; **64**(4): 374-380. **Цитирана от:**

1149) Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. High prevalence of clarithromycin-resistant *Helicobacter pylori* strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol. 2010; **48**(10):3703-3707.
1150) Aziz, F., Chen, X.,Yang, X., Yan, Q. Prevalence and correlation with clinical diseases of *Helicobacter pylori cagA* and *vacA* genotype among gastric patients from northeast China. BioMed Research International. 2014 (**2014**), Article ID 142980. http://dx.doi.org/10.1155/2014/142980
1151) Ben Mansour K, Fendri C, Zribi M, MasmoudiA, Labbene M, Fillali A, Ben Mami N, Najjar T, Meherzi A, Sfar T, Burucoa C. Prevalence of *Helicobacter pylori vacA, cagA, iceA* and *oipA* genotypes in Tunisian patients. Ann Clin Microbiol Antimicrob. 2010; **9**:10. doi: 10.1186/1476-0711-9-10
1152) Gutef EH. Prevalence of *Helicobacter pylori* infection with peptic ulcer diseases in Iraqi patients. European Journal of Pharmaceutical and Medical Research. 2016; **3**(4): 479-482.
1153) Havaei S A, Mohajeri P, Khashei R, Salehi R, Tavakoli H. Prevalence of *Helicobacter pylori* vacA different genotypes in Isfahan, Iran. Adv Biomed Res 2014;**3**:48. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949348/
1154) Liu, Y.E., Gong, Y.H., Sun, L.P., Xu, Q.,Yuan, Y. The relationship between *H. pylori* virulence genotypes and gastric diseases. Polish Journal of Microbiology. 2012; **61**(2): 147-150.
1155) Padra, M., Adamczyk, B., Flahou, B., (...), Karlsson, N.G., Lindén, S.K. Helicobacter suis infection alters glycosylation and decreases the pathogen growth inhibiting effect and binding avidity of gastric mucins. Mucosal Immunology 2019; 12(3): 784-794.
1156) Ramis, Ivy Bastos, Vianna, Júlia Silveira, Silva Junior, Lande Vieira da, Von Groll, Andrea, & Silva, Pedro Eduardo Almeida da. *cagE* as a biomarker of the pathogenicity of *Helicobacter pylori*. Rev. Soc. Bras. Med. Trop. [online]. 2013; **46**(2):185-189 .
1157) Secka O, Antonio M, Berg DE, Tapgun M, Bottomley C, Thomas V, Walton R, Corrah T, Thomas JE, Adegbola RA. Mixed infection with *cagA* positive and *cagA* negative strains of *Helicobacter pylori* lowers disease burden in The Gambia. PLoS One. 2011;**6**(11):e27954.
1158) Taghvaei T. An investigation of the prevalence of iceA genotypes in *Helicobacter pylori* strains isolated from peptic ulcer patients in Sari (2008). Arak Medical University Journal. 2010;**13**(3):84-90.
1159) Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of *Helicobacter pylori* to levofloxacin and moxifloxacine in Iran. Intern Emerg Med. 2012; **7**(5):447-452.
1160) Yanovich, O., Doroshko, M., Titov, L. *Helicobacter pylori* genotypes among Belarus patients with gastroduodenal disorders and their association with clinical outcome. Acta Microbiologica et Immunologica Hungarica. 2019; 66(3):399-411.

ЦИТИРАНА: 39А: **Boyanova L,** Mitov I. Geographic map and evolution of primary *Helicobacter pylori* resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010; **8**(1):59-70. **Цитирана от:**

1161) Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in *Helicobacter pylori* strains isolated from the northern population of Iran. J Microbiol. 2011;**49**(6):987-993.
1162) Adrych K. Czy każdy chory z zakażeniem *Helicobacter pylori* powinien być leczony? Aktualne stanowisko. Gastroenterologia Kliniczna. Postępy i Standardy. 2018; 10(1): 23-31.
1163) Ahn HJ, Lee DS. *Helicobacter pylori* in gastric carcinogenesis. World Journal of Gastrointestinal Oncology. 2015; **7**(12):455-465.

1164) Alavinejad P, Seiedian SS, Borna KE, Hajiani E, Lajmirnia M, Hesam S. Comparison of furazolidone versus clarithromycin for eradication of Helicobacter pylori infection: A randomized multicenter clinical trial. Afro-Egyptian Journal of Infectious and Endemic Diseases. 2021;11: DOI:10.21608/aeji.2021.50347.1117.
1165) Alfizah, H., Rukman, A.H., Norazah, A.,Hamizah, R., Ramelah, M. Ethnicity association of *Helicobacter pylori* virulence genotype and metronidazole susceptibility. World J Gastroenterol.. 2013; **19** (8):1283-1291
1166) Alihosseini S, Ghotaslou R, Heravi FS, Ahmadian Z, Leylabadlo HE. (2020). Management of antibiotic-resistant *Helicobacter pylori* infection: current perspective in Iran. J Chemother. 2020; **32**(6): 273-285.
1167) Almeida N, Donato MM, Romãozinho JM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Beyond Maastricht IV: are standard empiric triple therapies for *Helicobacter pylori* still useful in a South-European country? BMC Gastroenterol. 2015; **15**:23.
1168) Bari Z, Fakheri H, Taghvaei T, Yaghoobi M. A Comparison between 10-day and 12-day concomitant regimens for *Helicobacter pylori* eradication: A randomized clinical trial. Middle East Journal of Digestive Diseases. 2020; 12(2): 106.
1169) Bertrant EB, Danny TNL, Serge FC, Agnes M, Roger AM, Roger KJ, Brigitte KML. Evolution of susceptibilities of *Helicobacter pylori* strains circulating in cameroon to usual antibiotics: a three-year study. International Journal of Gastroenterology. 2020; 4(2): 63.
1170) Bolor-Erdene M, Namdag B, Yamaoka Y, Jav S. Antibiotic resistance of *Helicobacter pylori* in Mongolia. The Journal of Infection in Developing Countries. 2017;**11**(11):887-894.
1171) Bui D, Brown HE, Harris RB, Oren E. Serologic evidence for fecal-oral transmission of *Helicobacter pylori.* Am J Trop Med Hyg. 2016; **94**(1):82-88.
1172) Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of *Helicobacter pylori* resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014; **109**(4):485-495.
1173) Castro Espinosa J. Aproximación metodológica al consumo ambulatorio de antibióticos. 2018; https://repository.usc.edu.co/handle/20.500.12421/381
1174) Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L. A triple and quadruple therapy with doxycycline and bismuth for first-linetreatment of *Helicobacter pylori* infection: A pilot study. Helicobacter. 2015; **20**(5):390-396.
1175) Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of *Helicobacter pylori*. World J Gastroenterol. 2012; **18**(32):4386-4390.
1176) Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin containing triple therapy and rifabutin with bismuth containing quadrupletherapy for third-line treatment of *Helicobacter pylori* infection: Two pilot studies. Helicobacter. 2016; **21**(5):375-381.
1177) Ciccaglione AF, Di Giulio M, Di Lodovico S, Di Campli E, Cellini L, Marzio L. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of *Helicobacter pylori* infection: an in vitro and in vivo study. J Antimicrob Chemother. 2019; **74**(4): 1069-1077.
1178) Ciccaglione AF, Cellini L, Marzio L. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of *Helicobacter pylori* infection: Two pilot studies. Helicobacter. 2019; 24(5): e12606.
1179) Contreras M, Benejat L, Mujica H, Peña J, García-Amado MA, Michelangeli F, Lehours P. Real-time PCR detection of a 16S rRNA single mutation of *Helicobacter pylori* isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts. J Med Microbiol. 2019; **68**(9): 1287-1291.
1180) Da Hyun Jung JH, Jeong SJ, Park SY, Kang IM, Lee KH, Song YG. Peptide nucleic acid probe-based analysis as a new detection method for clarithromycin resistance in *Helicobacter pylori*. Gut and liver. 2018;**12**(6):641.
1181) De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide *H. pylori* antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010; **19**(4):409-414.
1182) De Francesco V, Giorgio F, Ierardi E, Zotti M, Neri M, Milano A, Varasano V, Luzza F, Suraci E, Marmo R, Marone A, Manta R, Mirante VG, de Matthaeis M, Pedroni A, Manes G, Pallotta S, Usai P, Liggi M, Gatto G, Peri V, Sacco R, Bresci G, Monica F, Hassan C, Zullo A. Primary clarithromycin resistance in *Helicobacter pylori*: the multicentric Italian clarithromycin resistance observational (MICRO) study. J Gastrointestin Liver Dis. 2011; **20**(3):235-239.
1183) De Francesco V, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of *Helicobacter pylori* antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol. 2011; **2**(3): 35-41.
1184) Di Giulio M, Di Campli E, Di Bartolomeo S, Cataldi V, Marzio L, Grossi L, Ciccaglione AF, Nostro A, Cellini L. In vitro antimicrobial susceptibility of *Helicobacter pylori* to nine antibiotics currently used in Central Italy. Scand J Gastroenterol. 2016; **51**(3):263-269.
1185) Diab M, El-Shenawy A, El-Ghannam M, Salem D, Abdelnasser M, Shaheen M, Abdel-Hady M, El-Sherbini E, Saber M. Detection of antimicrobial resistance genes of *Helicobacter pylori* strains to clarithromycin, metronidazole, amoxicillin and tetracycline among Egyptian patients. Egyptian Journal of Medical Human Genetics. 2018;**19**(4):417-23.
1186) Dore MP, Tadeu V, Are B, Mura I, Fanciulli G, Massarelli G, Piana A. Efficacy of a "rescue" ciprofloxacin-based regimen for eradication of *Helicobacter pylori* infection after treatment failures. Gastroenterol Res Pract. 2012; **2012**:484591.
1187) Eed EM, Hawash YA, Khalifa AS, Alsharif KF, Alghamdi SA, Saber T, ... & Shehab-Eldeen SA. Molecular diagnosis of *Helicobacter pylori* antibiotic resistance in the Taif region, Saudi Arabia. Microbiology and immunology. 2019; 63(6): 199-205.
1188) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol. 2020; **31**(3): 221.
1189) Eslami G, Taheri S, Baseri N, (...), Zahirnia Z, Azargashb A. Prevalence of *helicobacter pylori* and determination of antibiotic resistance in patients with gastritis referred to Shahid Beheshti University of Medical Sciences Hospitals in Tehran between 2010 and 2011. Archives of Clinical Infectious Diseases. 2013; **8**(1): 18-22

1190) Fakheri H, Bakhshi Z, Bari Z, Alhooei S. Effects of clarithromycin-containing quadruple therapy on *Helicobacter pylori* eradication after nitroimidazole-containing quadruple therapy failure. Middle East J Dig Dis. 2016; **8**(1):51-56.
1191) Fakheri H, Bari Z, Aarabi M, Malekzadeh R. *Helicobacter pylori* eradication in West Asia: A review. World J Gastroenterol. 2014 ; **20**(30): 10355.
1192) Fakheri H, Firoozi MS, Bari Z. Eradication of *Helicobacter pylori* in Iran: A Review. Middle East Journal of Digestive Diseases (MEJDD). 2018;**10**(1):5-17.
1193) Fan C, Zhao C, Jiang H, (...), Zhao Y, Wang L. Analysis of antibiotic resistance of *Helicobacter pylori* isolates in Changchun area. 2019. Chinese Journal of Gastroenterology 2019; **24**(3): 169-172.
1194) Farshad S, Alborzi A, Japoni A, Ranjbar R, Hosseini Asl K, Badiee P, Amin Shahidi M, Hosseini M. Antimicrobial susceptibility of *Helicobacter pylori* strains isolated from patients in Shiraz, Southern Iran. World J Gastroenterol. 2010; **16**(45): 5746-5751.
1195) Fasciana T, Calà C, Bonura C, Di Carlo E, Matranga D, Scarpulla G, Manganaro M, Camilleri S, Giammanco A. Resistance to clarithromycin and genotypes in *Helicobacter pylori* strains isolated inSicily. J Med Microbiol. 2015; **64**(11):1408-1414.
1196) Fathi MS, EL-Folly RF, Hassan RA, El-Arab ME. Genotypic and phenotypic patterns of antimicrobial susceptibility of *Helicobacter pylori* strains among Egyptian patients. Egyptian Journal of Medical Human Genetics. 2013;**14**(3): 235-246
1197) Gallardo Padilla, M., León Falconi, J.L., Sánchez-Nebreda Arias, R., (...), Muñoz Egea, M.D.C., la Orden Izquierdo, E. Impact of the use of molecular techniques (PCR) on detection and eradication success against *Helicobacter pylori* | [Impacto del uso de las técnicas moleculares (PCR) en la detección y el éxito erradicador frente a *Helicobacter pylori*] 2021; Anales de Pediatria (in press)
1198) Gasparetto M, Pescarin M, Guariso G. *Helicobacter pylori* Eradication Therapy: Current Availabilities. ISRN Gastroenterol. 2012; **2012**:186734.
1199) Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J,Ghosh P, Das R. Low prevalence of clarithromycin-resistant *Helicobacter pylori* isolates with A2143G point mutation in the 23S rRNA gene in North India. J Glob Antimicrob Resist. 2016; **6**: 39-43.
1200) Gisbert JP. Rescue Therapy for *Helicobacter pylori* Infection 2012. Gastroenterol Res Pract. 2012; **2012**: 974594.
1201) Gisbert JP. Treatment of refractory *Helicobacter pylori* infection. European Gastroenterology & Hepatology Review, 2012; **8**(1):54-60
1202) Gościniak G, Biernat M, Grabińska J, Bińkowska A, Poniewierka E, Iwańczak B. The antimicrobial susceptibility of *Helicobacter pylori* strains isolated from children and adults with primary infection in the lower Silesia Region. Poland Polish Journal of Microbiology 2014; **63**(1):57-61.
1203) Haddadi MH, Negahdari B, Asadolahi R, Bazargani A. *Helicobacter pylori* antibiotic resistance and correlation with cagA motifs and homB gene. Postgraduate medicine. 2020; 132(6) : 512-520.
1204) Hou LX, Han BX, Li S, Hong YS, Gou XJ. Clinical study on the timing of emergency gastroscopy in liver cirrhotic patients with esophageal variceal bleeding. American Journal of Biomedical Research. 2018;**6**(1):11-9.
1205) Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change *Helicobacter pylori* treatment: A matter of geography? World J Gastroenterol. 2013; **19**(45):8168-8180.
1206) Jaka H, Rhee JA, Östlundh L, Smart L, Peck R, Mueller A, Kasang C, Mshana SE. The magnitude of antibiotic resistance to *Helicobacter pylori* in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis. BMC infectious diseases. 2018;**18**(1):193.
1207) Jukic IR. *Helicobacter pylori* i antibiotska rezistencija. PLIVAmed.net. 2011: http://www.plivamed.net/aktualno/clanak/5500/Helicobacter-pylori-i-antibiotska-rezistencija.html
1208) Jukic IR. Liječenje peptičke ulkusne bolesti kod gerijatrijske populacije. 2011, http://www.plivamed.net
1209) Kalbina I, Engstrand L, Andersson S, Åke Strid Å. Expression of *Helicobacter pylori* TonB Protein in Transgenic Arabidopsis thaliana: Toward Production of Vaccine Antigens in Plants. Helicobacter. 2010; **15**(5): 430-437.
1210) Karpiński TM, Andrzejewska E, Eder P, Linke K, Szkaradkiewicz A. Evaluation of antimicrobial resistance of *Helicobacter pylori* in the last 15 years inWest Poland. Acta Microbiol Immunol Hung. 2015; **62**(3):287-293.
1211) Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, Jung K, Heo JJ. Effect of 7-day bismuth quadruple therapy versus 14-day moxifloxacin triple therapy for second-line *Helicobacter pylori* eradication therapy. The Korean Journal of Gastroenterology. 2019;**73**(1):26-34.
1212) Kim SY, Chung JW. Best *Helicobacter pylori* eradication strategy in the era of antibiotic resistance. Antibiotics. 2020; 9(8): 436.
1213) Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, ... & Heo JJ. (2019). Effect of 7-day bismuth quadruple therapy versus 14-day moxifloxacin triple therapy for second-line *Helicobacter pylori* eradication therapy. The Korean Journal of Gastroenterology. 2019; 73(1): 26-34.
1214) Kocazeybek B, Sakli MK, Yuksel P, Demirci M, Caliskan R, Sarp TZ, Saribas S, Demiryas S, Kalayci F, Cakan H, Uysal HK. Comparison of new and classical point mutations associated with clarithromycin resistance in *Helicobacter pylori* strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. J Med Microbiol. 2019; **68**(4): 566-573.
1215) Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. The efficacy of moxifloxacin-containing triple therapy after hybrid therapy failure in *Helicobacter pylori* eradication. Korean J Gastroenterol. 2017;**70**(2):72-80.
1216) Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. The efficacy of bismuth-containing quadruple therapy after moxifloxacin-based sequential therapy failure in *Helicobacter pylori* eradication. The Korean Journal of Gastroenterology. 2018;**71**(4):196-203.
1217) Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth

quadruple therapy for the first-line eradication of *Helicobacter pylori*: a prospective, multi-center, randomized clinical trial. BMC Gastroenterol. 2016; **16**(1):79.
1218) Lee JY, Kim N. [Future trends of *Helicobacter pylori* eradicationtherapy in Korea]. Korean J Gastroenterol. 2014; **63**(3):158-170.
1219) Lee JY, Park KS. Optimal first-line treatment for *Helicobacter pylori* infection: recent strategies. Gastroenterol Res Pract. 2016; **2016**: Article ID 9086581
1220) Lee SM, Kim N, Kwon YH, Nam RH, Kim JM, Park JY, Lee YS, Lee DH. rdxA, frxA, and efflux pump in metronidazole-resistant *Helicobacter pylori*: Their relation to clinical outcomes. J Gastroenterol Hepatol. 2018;**33**(3):681-8.
1221) Lee KH, Park SY, Jeong SJ, Jung DH, Kim JH, Jeong SH, ... & Song YG. Can aminoglycosides be used as a new treatment for *Helicobacter pylori*? In vitro Activity of Recently Isolated *Helicobacter pylori*. Infection & chemotherapy. 2019; 51(1): 10.
1222) Liechti G, Goldberg JB. Outer membrane biogenesis in *Escherichia coli, Neisseria meningitidis*, and *Helicobacter pylori*: paradigm deviations in *H. pylori* Front Cell Infect Microbiol. 2012; **2**: 29.
1223) Liu G, Xu X, He L, Ding Z, Gu Y, Zhang J, Zhou L. Primary antibiotic resistance of *Helicobacter pylori* isolated from Beijing children. Helicobacter 2011; **16**(5): 356-362.
1224) Mahant S, Sharma AK, Gehlot V, Mukhopadhyay AK, Chhawchharia A, Dutta S, ... & Das R. Geographically distinct North-East Indian *Helicobacter pylori* strains are highly sensitive to clarithromycin but are levofloxacin resistant. Indian journal of medical microbiology. 2019; 37(3), 337-344.
1225) Markovič S. *Helicobacter pylori*, uspešnost zdravljenja in odpornost bakterije. Ali izgubljamo bitko? Zdravniski Vestnik 2010; **79**(1): 1-4.
1226) Marshall BJ. Study Title: Surveillance of antibiotic resistance, treatment effectiveness, treatment side effects, and bacterial genotypic/phenotypic analyses on clinical *Helicobacter pylori* isolates. 2013-007. http://www.anzctr.org.au/AnzctrAttachments/368419-Study%20protocol%20040713.pdf
1227) Miendje Deyi VY, Burette A, Bentatou Z, Maaroufi Y, Bontems P, Lepage P, Reynders M. Practical use of GenoType® HelicoDR, a molecular test for *Helicobacter pylori* detection and susceptibility testing. Diagn Microbiol Infect Dis. 2011; **70**(4):557-560.
1228) Miftahussurur M, Cruz M, Subsomwong P, Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-based triple therapy is still useful as an initial treatment for *Helicobacter pylori* infection in the Dominican Republic. The American Journal of Tropical Medicine and Hygiene. 2017; **96**(5):1050-1059.
1229) Min S, Kim N, Kwon YH, Hee R, Kim JM, Youn J, Lee YS, Lee DH. RdxA, frxA and efflux pump in metronidazole-resistant *Helicobacter pylori*: their relation to clinical outcomes. J Gastroenterol Hepatol. 2017 Jul 27. doi: 10.1111/jgh.13906.
1230) Njume C, Jide AA, Ndip RN. Aqueous and organic solvent-extracts of selected South African medicinal plants possess antimicrobial activity against drug-resistant strains of *Helicobacter pylori*: inhibitory and bactericidal potential. Int J Mol Sci. 2011; **12**(9), 5652-5665.
1231) Oleastro M, Furtado C, Santos A, Benoliel J, Ratilal P, Liberato M. Resistência primária de *Helicobacter pylori* em doentes sintomáticos de dois hospitais da região de Lisboa Boletim Epidemiológico Observações. 2014; **3**(8):25-29.
1232) Oporto M, Pavez M, Troncoso C, Cerda A, Hofmann E, Sierralta A, ... & Barrientos L. Prevalence of infection and antibiotic susceptibility of *Helicobacter pylori*: An evaluation in public and private health systems of Southern Chile. Pathogens. 2019; 8(4) : 226.
1233) Padilla MG, Falconi JLL, Arias RSN, Santos CG, Egea MDCM, la Orden Izquierdo E. (2021, January). Impacto del uso de las técnicas moleculares (PCR) en la detección y el éxito erradicador frente a *Helicobacter pylori*. In Anales de Pediatría. Elsevier Doyma. https://doi.org/10.1016/j.anpedi.2020.11.016
1234) Papastergiou V, Georgopoulos SD, & Karatapanis S. Treatment of *Helicobacter pylori* infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol. 2014; **20**(29) : 9898.
1235) Papastergiou V,Georgopoulos SD,Karatapanis S. Current and future insights in *H. pylori* eradication regimens: The need of tailoring therapy Current Pharmaceutical Design. 2014; **20** (28) : 4521-4532.
1236) Park JY, Kim JG. New *Helicobacter pylori* eradication therapies. The Korean Journal of Gastroenterology. 2018;**72**(5):237-44.
1237) Rizwan M, Fatima N, Alvi A. Epidemiology and pattern of antibiotic resistance in *Helicobacter pylori*: Scenario from Saudi Arabia. Saudi Journal of Gastroenterology. 2014; **20**(4): 212-218.
1238) Schmitt BH, Regner M, Mangold KA, Thomson RB Jr, Kaul KL. PCR detection of clarithromycin-susceptible and -resistant *Helicobacter pylori* from formalin-fixed, paraffin-embedded gastric biopsies. Mod Pathol. 2013; **26**(9):1222-1227. doi: 10.1038/modpathol.2013.48.
1239) Seck A, Burucoa C, Dia D, Mbengue M, Onambele M, Raymond J, Breurec S. Primary antibiotic resistance and associated mechanisms in *Helicobacter pylori* isolates from Senegalese patients. Ann Clin Microbiol Antimicrob. 2013; **12**(1):3.
1240) Selgrad M, Malfertheiner P. Treatment of *Helicobacter pylori*. Curr Opin Gastroenterol. 2011; **27**(6):565-570.
1241) Sereni G, Azzolini F, Camellini L, Formisano D, Decembrino F, Iori V, Tioli C, Cavina M, Di Mario F, Bedogni G, Sassatelli R. Efficacy of a therapeutic strategy for eradication of *Helicobacter pylori* infection.World J Gastroenterol. 2012; **18**(33):4542-4548.
1242) Shi D, Wang Q, Bao Y. Evaluation and risk factors for antibacterial resistance of *Helicobacter pylori*. China Journal of Modern Medicine. 2012; **22** (1): http://eng.med.wanfangdata.com.cn/PaperDetail.aspx?qkid=zgxdyxzz&qcode=zgxdyxzz201201021
1243) Shin JE, Park KS, Nam K. Chronic functional constipation. The Korean journal of gastroenterology= Taehan Sohwagi Hakhoe chi.2019; 73(2): 92-98.

1244) Siminski T, de Souza JS, , de Araujo CFL, da Silva Añez RB, Nunes RA. Avaliação da atividade antimicrobiana das espécies Aspidosperma nitidum, *Annona crassiflora* e *Annona mucosa* frente a cepas ATCC. Enciclopédia Biosfera, Centro Científico Conhecer - Goiânia, 2015;11(22): 2015.
1245) Smiley R, Bailey J, Sethuraman M, Posecion N, Showkat Ali M. Comparative proteomics analysis of sarcosine insoluble outer membrane proteins from clarithromycin resistant and sensitive strains of *Helicobacter pylori*. J Microbiol. 2013;**51**(5):612-8.
1246) Solomon OA, Ajayi AO, Adegun PT, Gabriel OE, Afolabi O, Solomon OO. Effectiveness of triple therapy regimens in the eradication of *Helicobacter pylori* in patients with uninvestigated dyspepsia in Ekiti state, Nigeria. British Journal of Medicine and Medical Research. 2015; **6**.3: 278-285.
1247) Soni KK, Kondalkar A. Formulation and evaluation of cytoprotective gastroretentive floating tablets of clarithromycin. Int. J. of Pharm. Life Sci.2016; **7**(4): 5002-5009.
1248) Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of *Helicobacter pylori* isolated in the Southeast coastal region of China. Helicobacter. 2013; **18**(4):274-279.
1249) Suzuki RB, Almeida CM, Sperança MA. Absence of *Helicobacter pylori* high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. BMC Gastroenterol. 2012; **12**:49.
1250) Swar SO, Alzubaidy Z. M. Detection of *Helicobacter pylori* in leafy vegetables by pcr and determination of the antibacterial activity of green tea and garlic extracts against isolated bacteria. Plant Archives. 2020; 20(2): 7373-7381
1251) Tay A. (Supervisor who works with Nobel Laureate, Professor Barry Marshall). Typing of *Helicobacter pylori* clinical strains. Projects for the 2013 UWA-USTC/NANJING research training program. http://www.research.uwa.edu.au/__data/assets/pdf_file/0006/2268177/projects-for-2013-china-program-feb-24th.pdf
1252) Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. *Helicobacter pylori* eradication in Western Australia using novelquadruple therapy combinations. Aliment Pharmacol Ther. 2012; **36**(11-12):1076-1083.
1253) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016; **43**(4):514-533.
1254) Vekens, K.,Vandebosch, S., De Bel, A., Urbain, D.,Mana, F. Primary antimicrobial resistance of *Helicobacter pylori* in Belgium. Source of the Document Acta Clinica Belgica. 2013; **68**(3): 183-187.
1255) Vilaichone RK, Gumnarai P, Ratanachu-Ek T, Mahachai V. Nationwide survey of *Helicobacter pylori* antibiotic resistance in Thailand. Diagn Microbiol Infect Dis. 2013; **77**(4):346-349.
1256) Vilaichone RK, Ratanachu-Ek T, Gamnarai P, Chaithongrat S, Uchida T, Yamaoka Y, Mahachai V. Extremely high prevalence of metronidazole-resistant *Helicobacter pylori* strains inmountain people (Karen and Hmong) in Thailand. Am J Trop Med Hyg. 2016; **94**(4):717-720.
1257) Wani FA, Bashir G, Khan MA, Zargar SA, Rasool Z, Qadri Q. Antibiotic resistance in *Helicobacter pylori*: a mutational analysis from a tertiary care hospital in Kashmir, India. Indian journal of medical microbiology. 2018;**36**(2):265.
1258) Weerasekara D, DMBT Dissanayake, GIDDAD Athukorala, MM Weerasekara, SSN Fernando Antibiotic resistance in *Helicobacter pylori*: Recent insights. Sri Lankan Journal of Infectious Diseases. 2014; 4 (1). www.sljol.info/index.php/SLJID/article/view/5986
1259) WHO, IARC, *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric CancerWorking Group Reports, volume 8, WHO-IARC-Report-2014.pdf
1260) Yahaghi E, Khamesipour F, Mashayekhi F, Safarpoor Dehkordi F, Sakhaei MH, Masoudimanesh M, & Khameneie MK. *Helicobacter pylori* in Vegetables and Salads: Genotyping and Antimicrobial Resistance Properties. BioMed research international, 2014. **2014** (2014), Article ID 757941
1261) Yang JC, Lee PI, Hsueh PR. *In vitro* activity of nemonoxacin, tigecycline, and other antimicrobial agents against *Helicobacter pylori* isolates in Taiwan, 1998-2007. Eur J Clin Microbiol Infect Dis. 2010; **29**(11):1369-1375.
1262) Yang Y, Ouyang R, Xu L, Guo N, Li W, Feng K, Ouyang L, Yang Z, Zhou S, Miao Y. Review: Bismuth complexes: Synthesis and applications in biomedicine. Journal of Coordination Chemistry. 2015; **68**(3):1-32.
1263) Yoon K, Kim N, Nam RH, Suh JH, Lee S, Kim JM, Lee JY, Kwon YH, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. Ultimate eradication rate of *Helicobacter pylori* after first, second, or third-line therapy in Korea. J Gastroenterol Hepatol. 2015; **30**(3):490-495.
1264) Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH. (2020). Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for *Helicobacter pylori* infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter. 2020; 25(3): e12685.
1265) Успенский ЮП, Барышникова НВ, Суворов АН. Анализ мировых данных по резистентности *Helicobacter pylori* к кларитромицину. Вестник практического врача. 2012; **1**(2):20-27.

ЦИТИРАНА: 40А: **Boyanova L,** Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, Panteleeva E, Spasova Z, Mitov I. Two-decade trends in primary *H. pylori* resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010; **67**: 319-326.

Цитирана от:

1266) Baltas N, Karaoglu SA, Tarakci C, Kolayli S. Effect of propolis in gastric disorders:inhibition studies on the growth of *Helicobacter pylori* and production of itsurease. J Enzyme Inhib Med Chem. 2016; **27**:1-5.
1267) Boltin D, Ben-Zvi H, Perets TT, Kamenetsky Z, Samra Z, Dickman R, Niv Y. Trends in secondary antibiotic resistance of *Helicobacter pylori* from 2007 to 2014: has the tide turned? J Clin Microbiol. 2015; **53**(2):522-527.
1268) Egli, K., Wagner, K., Keller, P. M., Risch, L., Risch, M., & Bodmer, T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in *Helicobacter pylori*. Frontiers in cellular and infection microbiology. 2020; 10.

1269) Elad, D., Blum, S., Fleker, M., Zukin, N., Weissblit, L. and Shlomovitz, S. Analysis of long term (1990-2009) in vitro susceptibility to antibacterial drugs of the most prevalent animal bacterial pathogens isolated in Israel. Part 1: Trends and Fluctuations. Israel Journal of Veterinary Medicine. 2011; **66** (4):134-142.
1270) Gunnarsdottir AI, Gudjonsson H, Hardardottir H, Jonsdottir KD, Bjornsson ES. Antibiotic susceptibility of *Helicobacter pylori* in Iceland. Infectious Diseases. 2017; **49**(9):1-8.
1271) Hojsak I, Kos T, Dumančić J, Mišak Z, Jadrešin O, Jaklin Kekez A, Lukić Grlić A, Kolaček S. Antibiotic resistance of *Helicobacter pylori* in pediatric patients - 10 years' experience. Eur J Pediatr. 2012; **171**(9):1325-1330.
1272) Hu J, Chen L, Yang W, Li B, Sun H, Wei S, He Y, Zhao Z, Yang S, Zou Q, Chen W, Guo H, Wu C. Systematic identification of immunodominant $CD4^+$ T cell responses to HpaA in *Helicobacter pylori* infected individuals Oncotarget. 2016; **7** (34): 54380-54391.
1273) Kudo, H., Takeuchi, H., Shimamura, T.,Kadota, Y., Sugiura, T., Ukeda, H. In Vitro Anti-*Helicobacter pylori* Activity of Chinese Chive (*Allium tuberosum*). Food Science and Technology Research. 2011; **17** (6):505-513.
1274) Kupcinskas L, Rasmussen L, Jonaitis L, Kiudelis G, Jørgensen M, Urbonaviciene N, Tamosiunas V, Kupcinskas J, Miciuleviciene J, Kadusevicius E, Berg D, Andersen LP.
Evolution of *Helicobacter pylori* susceptibility to antibiotics during a 10-year period in Lithuania. APMIS. 2013; **121**(5):431-436.
1275) Liu G, Xu X, He L, Ding Z, Gu Y, Zhang J, Zhou L. Primary antibiotic resistance of *Helicobacter pylori* isolated from Beijing children. Helicobacter 2011; **16**(5):356-362.
1276) Manyi-Loh CE, Clarke AM, Ndip RN. Detection of phytoconstituents in column fractions of n-hexane extract of Goldcrest honey exhibiting anti-*Helicobacter pylori* activity. Arch Med Res. 2012; **43**(3):197-204.
1277) Matongo F, Nwodo UU. In vitro assessment of *Helicobacter pylori* ureases inhibition by honey fractions. Archives of medical research. 2014; **45**(7):540-546.
1278) Miendje Deyi VY, Bontems P, Vanderpas J, De Koster E, Ntounda R, Van Den Borre C, Cadranel S, Burette A. Multicenter survey of routine determinations of resistance of *Helicobacter pylori* to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol. 2011; **49**(6): 2200-2209.
1279) Mori, H., Suzuki, H., Matsuzaki, J., Masaoka, T., & Kanai, T. 10-Year trends in *Helicobacter pylori* eradication rates by Sitafloxacin-based third-line rescue therapy. Digestion. 2020; 101(5), 644-650.
1280) Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in *Helicobacter pylori* diagnostics in the era of next generation sequencing. World J Gastroenterol. 2019; **25**(32), 4629.
1281) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;**155**(5):1372-82.
1282) Sayadi S, Darboue M, Dabiri H,Shokrzadeh L, Mirzaee T, Alebouyeh M, Mirsatari D, (...), Zali MR. Study of antibiotic resistant *H. pylori* isolated from Iranian patients during 2009-2010. HealthMED. 2011; **5 (6 Suppl. 1)**: 1970-1976.
1283) Shokrzadeh L, Alebouyeh M, Mirzaei T, Farzi N, Zali MR. Prevalence of multiple drug-resistant *Helicobacter pylori* strains among patients with different gastric disorders in Iran. Microbial Drug Resist. 2015, **21**(1):105-110.
1284) Sýkora J, Rowland M. *Helicobacter pylori* in Pediatrics. Helicobacter 2011; **16** (Suppl. 1): 59-64.
1285) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016; **43**(4):514-533.
1286) Vekens, K.,Vandebosch, S., De Bel, A., Urbain, D.,Mana, F. Primary antimicrobial resistance of *Helicobacter pylori* in Belgium. Source of the DocumentActa Clinica Belgica. 2013; **68** (3):183-187.
1287) Yang WC, Chen L, Li HB, Li B, Hu J, Zhang JY, Yang SM, Zou QM, Guo H, Wu C.
Identification of two novel immunodominant UreB CD4(+) T cell epitopes in *Helicobacter pylori* infected subjects. Vaccine. 2013; **31**(8):1204-1209.
1288) Yue JY, Yue J, Wang MY, Song WC, Gao XZ. CagA status & genetic characterization of metronidazole resistant strains of *H. pylori* from a region at high risk of gastric cancer. Pak J Med Sci 2014; **30**(4):804-808.

ЦИТИРАНА: 41А: **Boyanova L,** Yordanov D, Gergova G, Markovska R, Mitov I. Association of *iceA* and *babA* genotypes in *Helicobacter pylori* strains with patient and strain characteristics. Antonie Van Leeuwenhoek. 2010; **98** (3):343-350. **Цитирана от:**

1289) Almeida N, Donato MM, Romãozinho JM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Sofia C. Correlation of *Helicobacter pylori* genotypes with gastric histopathology in the central region of a South-European country. Dig Dis Sci. 2015;**60**(1):74-85.
1290) Ansari S, Yamaoka Y. *Helicobacter pylori* BabA in adaptation for gastric colonization. World J Gastroenterol. 2017;**23**(23):4158-4169.
1291) Baj, J., Forma, A., Sitarz, M., Portincasa, P., Garruti, G., Krasowska, D., & Maciejewski, R. *Helicobacter pylori* Virulence Factors—Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment. Cells. 2021; 10(1), 27.
1292) Bartpho, T. S., Wattanawongdon, W., Tongtawee, T., Paoin, C., Kangwantas, K., & Dechsukhum, C. Precancerous Gastric Lesions with *Helicobacter pylori* vacA+/babA2+/oipA+ Genotype Increase the Risk of Gastric Cancer. BioMed research international, 2020; 2020.
1293) Biernat MM, Gościniak G, & Iwańczak B. Prevalence of *Helicobacter pylori cagA, vacA, iceA, babA2* genotypes in Polish children and adolescents with gastroduodenal disease. Postepy Hig Med Dosw (online). 2014;**68**:1015-1021.
1294) Buzás, G.M. *Helicobacter pylori* - 2012. Orvosi Hetilap. 2012; **153** (36): 1407-1418.
1295) Cervantes-García, E. *Helicobacter pylori*: mecanismos de patogenicidad. Revista Mexicana de Patología Clínica y Medicina de Laboratorio. 2016; 63(2), 100-109.
1296) Chen Q, Belmonte I, Buti M, Nieto L, Garcia-Cehic D, Gregori J, Perales C, Ordeig L, Llorens M, Soria ME, Esteban R. New real-time-PCR method to identify single point mutations in hepatitis C virus. World J Gastroenterol. 2016; **22**(43): 9604–9612.

1297) Chen YL, Mo XQ, Huang GR, Huang YQ, Xiao J, Zhao LJ, Wei HY, Liang Q. Gene polymorphisms of pathogenic *Helicobacter pylori* inpatients with different types of gastrointestinal diseases. World J Gastroenterol. 2016; **22**(44):9718-9726.
1298) da Costa DM, Pereira Edos S, Rabenhorst SH. What exists beyond *cagA* and *vacA*? *Helicobacter pylori* genes in gastric diseases. World J Gastroenterol. 2015;**21**(37):10563-10572.
1299) Dabiri H, Jafari F, Baghaei K, Shokrzadeh L, Abdi S, Pourhoseingholi MA, Mohammadzadeh A. Prevalence of *Helicobacter pylori vacA, cagA, cagE, oipA, iceA, babA2* and *babB* genotypes in Iranian dyspeptic patients. Microb Pathog. 2017;**105**:226-230.
1300) El-Shenawy A, Diab M, Shemis M, El-Ghannam M, Salem D, Abdelnasser M, Shahin M, Abdel-Hady M, El-Sherbini E, Saber M. Detection of *Helicobacter pylori vacA, cagA* and *iceA1* virulence genes associated with gastric diseases in Egyptian patients. Egyptian Journal of Medical Human Genetics. 2017;**18**(4):365-371.
1301) Feliciano O, Gutierrez O, Valdés L, Fragoso T, Calderin AM, Valdes AE, Llanes R. Prevalence of *Helicobacter pylori vacA,cagA,* and *iceA* genotypes in Cuban patients with upper gastrointestinal diseases. Biomed Res Int. 2015; **2015**:753710.
1302) Homan M, Sterbenc A, Kocjan BJ, Luzar B, Zidar N, Orel R, Poljak M. Prevalence of the *Helicobacter pylori babA2* gene and correlation with the degree of gastritis in infected Slovenian children. Antonie Van Leeuwenhoek. 2014;**106**(4):637-645.
1303) Huang, J.-J., Zhan, S.-H., Dong, Q.-J.,Dong, K.-X. Characteristics of geographical distribution of the *Helicobacter pylori iceA1* gene. World Chinese Journal of Digestology. 2011; **19** (29): 3058-3063.
1304) Imkamp, F., Lauener, F. N., Pohl, D., Lehours, P., Vale, F. F., Jehanne, Q., ... & Wagner, K. Rapid characterization of virulence determinants in *Helicobacter pylori* isolated from non-atrophic gastritis patients by next-generation sequencing. Journal of clinical medicine. 2019; 8(7), 1030.
1305) Karabiber H, Selimoglu MA, Otlu B, Yildirim O, Ozer A. Virulence factors and antibiotic resistance in children with *Helicobacter pylori* gastritis. J Pediatr Gastroenterol Nutr. 2014;**58**(5):608-12.
1306) Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of *H. pylori* in Turkey: a systematic review. Helicobacter. 2016;**21**(4):251-260.
1307) Korona-Glowniak, I., Cichoz-Lach, H., Siwiec, R., Andrzejczuk, S., Glowniak, A., Matras, P., & Malm, A. Antibiotic resistance and genotypes of *Helicobacter pylori* Strains in Patients with Gastroduodenal disease in Southeast Poland. Journal of clinical medicine. 2019; 8(7), 1071.
1308) Latifi-Navid S, Mohammadi S, Maleki P, Zahri S, Yazdanbod A, Siavoshi F, Massarrat S. *Helicobacter pylori vacA* d1/-i1 genotypes andgeographic differentiation between high and low incidence areas of gastric cancer in Iran. Arch Iran Med. 2013;**16**(6):330-337.
1309) Li N, Xie C, Lu NH. Transforming growth factor-β: an important mediator in *Helicobacter pylori*-associated pathogenesis. Front Cell Infect Microbiol. 2015;**5**:77.
1310) MalekiMSc, P., & SiavoshiPhD, F. *Helicobacter pylori* vacA d1/-i1 Genotypes and Geographic Differ-entiation between High and Low Incidence Areas of Gastric Can-cer in Iran. Archives of Iranian Medicine. 2013; 16(6), 330.
1311) Neumoina, N. V., Efimov, E. I., Perfilova, K. M., Shutova, I. V., Neumoina, M. V., Troshina, T. A., ... & Semaka, M. A. Genetic variants of *H. pylori* in different forms of chronic gastritis. Opera Medica et Physiologica, 2020; 7(3).
1312) Ramis, Ivy Bastos, Vianna, Júlia Silveira, Silva Junior, Lande Vieira da, Von Groll, Andrea, & Silva, Pedro Eduardo Almeida da. *cagE* as a biomarker of the pathogenicity of *Helicobacter pylori*. Rev. Soc. Bras. Med. Trop. [online]. 2013;**46** (2):185-189.
1313) Shuang, L. N. Transforming growth factor-β: an important mediator in *Helicobacter pylori*-associated pathogenesis. Frontiers in cellular and infection microbiology. 2015; 5, 77.
1314) Sohrabi M, Khashei R, Alizadeh M, Asl MK, Nejati MA, Dara M, Bazargani A. Low Rate of *babA2* genotype among Iranian *Helicobacter pylori* clinical isolates. Journal of clinical and diagnostic research: JCDR. 2017;11(7):DC32.
1315) Soliman, HM; Elseweidy MM, Taha MM. Effect of *Nigella sativa* oil versus amoxicillin in induced chronic fundic gastritis in adult female albino rats: a histological, immunohistochemical, and biochemical study. The Egyptian Journal of Histology. 2011; **34** (1): 674-686.
1316) Šterbenc A, Jarc E, Poljak M, Homan M. *Helicobacter pylori* virulence genes. World J Gastroenterol. 2019; **25**(33), 4870.
1317) Šterbenc A, Lunar MM, Homan M, Luzar B, Zidar N, Poljak M. Prevalence of the *Helicobacter pylori* babA2 gene in children mainly depends on the PCR primer set used. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020; 2020.
1318) Tourkochristou E, Aggeletopoulou I, Konstantakis C, Triantos C. Role of NLRP3 inflammasome in inflammatory bowel diseases. World J Gastroenterol. 2019; **25**(33): 4796.
1319) Yazdanbod A, Massarrat S. *Helicobacter pylori* vacA d1/-i1 Genotypes and Geographic Differentiation between High and Low Incidence Areas of Gastric Cancer in Iran. Arch Iran Med. 2013; **16**(6): 330-337.
1320) Zhang SH, Xie Y, Li BM, Liu DS, Wan SH, Luo LJ, ... & Zhu X. Prevalence of *Helicobacter pylori cagA*, *vacA*, and *iceA* genotypes in children with gastroduodenal diseases. Zhongguo dang dai er ke za zhi= Chinese journal of contemporary pediatrics. 2016; **18**(7), 618-624.
1321) Калашникова ВА, Барышникова НВ, Успенский ЮП. Популяционно-генетические характеристики *Helicobacter pylori* у низших приматов и людей. Гастроэнтерология Санкт-Петербурга. 2014 (1-2):31-34.
1322) Орлов СВ, Калашникова ВА, Барышникова НВ, Успенский ЮП. Генетические особенности инфекции *Helicobacter pylori* у низших приматов и человека. Дневник казанской медицинской школы. 2015(1):15-20.
1323) (2013) .صادق & ... ,پریچهر ,ملکی ,شیوا ,محمدی ,سعید ,نوید لطیفی. *Helicobacter pylori* vacA d1/-i1 genotypes and geographic differentiation between high and low incidence areas of gastric cancer in Iran. Archives of Iranian medicine, 16(6), 330-337.

ЦИТИРАНА: **41Б**: Zhelezova, G., L. Boyanova. Stool antigen test for diagnosis of *Helicobacter pylori* infection. Probl Infec Parasit Dis 2006; 34 (2): 16-18. **Цитирана от:**

1324) Best, L.M.J., Takwoingi, Y., Siddique, S., (...), Yaghoobi, M., Gurusamy, K.S. Non-invasive diagnostic tests for *Helicobacter pylori* infection. Cochrane Database of Systematic Reviews. 2018(3),CD012080
1325) Gurusamy, K. S., Yaghoobi, M., & Davidson, B. R. Non-invasive diagnostic tests for *Helicobacter pylori* infection. Cochrane Database of Systematic Reviews. 2016; (2).

ЦИТИРАНА: 42A: Boyanova L, Kolarov R, Gergova G, Dimitrova L, Mitov I. Trends in antibiotic resistance in *Prevotella* species from patients of the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in 2003-2009. Anaerobe. 2010; **16**(5): 489-492.
Цитирана от:

1326) Alauzet C, Lozniewski A, Marchandin H. Metronidazole resistance and *nim* genes in anaerobes: a review. Anaerobe. 2019; **55**:40-53.
1327) Amissah-Arthur KN, Farooq TA, Dhillon N, Cunliffe IA, Bansal A. Rare case of post-cataract-surgery *Prevotella* endophthalmitis diagnosed by polymerase chain reaction DNA sequencing. J Cataract Refract Surg. 2013;**39**(3):463-466.
1328) Blomgren, K. JE Wikstén, S. Laakso, M. Mäki, AA Mäkitie, A. Pitkäranta &. Eur J Clin Microbiol Infect Dis. 2015; 34, 905-911.
1329) Bostwick DG, Woody J, Hunt C, Budd W. Antimicrobial resistance genes and modelling of treatment failure in bacterial vaginosis: Clinical study of 289 symptomatic women. J. Med. Microbiol. 2016; **65**(5): 377-286.
1330) Carey DE, Zitomer DH, Hristova KR, Kappell AD, McNamara PJ. Triclocarban influences antibiotic resistance and alters anaerobic digester microbial community structure. Environ Sci Technol. 2016; **50**(1):126-134.
1331) Carruth BP, Wladis EJ. Orbital abscess from dacryocystitis caused by *Morganella morganii*. Orbit. 2013; **32**(1):39-41.
1332) Engberg, J., Larsen, T., & Edlund, C. Antibiotikabehandling och dess konsekvenser. Tandläkartidningen 2019, 4.
1333) Guo J, Zhi Y, He L, Lü L, Qiang S, Wu W. A case of bloodstream infection caused by *Prevotella oralis* through operation. Laboratory Medicine. 2015; **30**(9):958-961.
1334) Heim N, Faron A, Wiedemeyer V, Reich R, Martini M. Microbiology and antibiotic sensitivity of head and neck space infections of odontogenic origin. Differences in inpatient and outpatient management. Journal of Cranio-Maxillo-Facial Surgery. 2017;**45**(10):1731-1735. http://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2015.09.021#
1335) Katoumas, K., Anterriotis, D., Fyrgiola, M., (...), Triantafylou, D., Dimopoulos, I. Epidemiological analysis of management of severe odontogenic infections before referral to the emergency department. Journal of Cranio-Maxillofacial Surgery. 2019; 47(8): 1292-1299.
1336) Kim B-S, Kim JN, Yoon S-H, Chun J, Cerniglia CE. Impact of enrofloxacin on the human intestinal microbiota revealed by comparative molecular analysis. Anaerobe. 2012; **18**(3): 310-320.
1337) Kinoshita Y, Niwa H, Katayama Y,Hariu K. Dominant obligate anaerobes revealed in lower respiratory tract infection in horses by 16S rRNA gene sequencing. Journal of Veterinary Medical Science 2014;**76** (4):587-591.
1338) Kinoshita Y, Niwa H, Katayama Y. Use of loop-mediated isothermal amplification to detect six groups of pathogens causing secondary lower respiratory bacterial infections in horses. Microbiol Immunol. 2015;59(6):365-70.
1339) Liang, Z., Zhang, Y., He, T., (...), Li, G., An, T. The formation mechanism of antibiotic-resistance genes associated with bacterial communities during biological decomposition of household garbage. Journal of Hazardous Materials. 2020; 398,122973.
1340) Lloreda Rey, L. P. Efecto antibacteriano de una nanoemulsión de ftalocianina de aluminio clorada sobre periodontopatógenos relevantes en el paciente diabético tipo 2: Estudio in vitro. 2019
1341) Samantaray, S., Biswas, R., & Sasidharan, G. M. Intracranial abscess due to *Prevotella bivia*: First case report from India. Anaerobe. 2020; 65, 102249.
1342) Shilnikova II, Dmitrieva NV. (2014). Evaluation of antibiotic susceptibility of *Bacteroides, Prevotella* and *Fusobacterium* species isolated from patients of the N. N. Blokhin Cancer Research Center, Moscow, Russia. Anaerobe. 2015; 31:15–18.
1343) Shweta Prakash SK. Dental abscess: A microbiological review. Dent Res J (Isfahan). 2013;**10**(5):585-591.
1344) Stojković, D., Kostić, M., Smiljković, M., Aleksić, M., Vasiljević, P., Nikolić, M., & Soković, M.. Linking antimicrobial potential of natural products derived from aquatic organisms and microbes involved in Alzheimer's disease-a review. Current medicinal chemistry. 2020; 27(26), 4372-4391.
1345) Tent, P. A., Juncar, R. I., Onisor, F., Bran, S., Harangus, A., & Juncar, M. The pathogenic microbial flora and its antibiotic susceptibility pattern in odontogenic infections. Drug metabolism reviews. 2019; 51(3), 340-355.
1346) Toprak NU, Veloo AC, Urban E, Wybo I, Justesen US, Jean-Pierre H, Morris T, Akgul O, Kulekci G, Soyletir G, Nagy E. A multicenter survey of antimicrobial susceptibility of *Prevotella* species as determined by Etest methodology. Anaerobe. 2018;**52**:9-15.
1347) Toprak, N. U., Akgul, O., Sóki, J., Soyletir, G., Nagy, E., Leitner, E., ... & Morris, T. Detection of beta-lactamase production in clinical Prevotella species by MALDI-TOF MS method. Anaerobe. 2020; 65, 102240.
1348) Ülger Toprak, N. İstanbul'da İki Merkeze ait *Prevotella* Türlerinin Gradiyent Test Yöntemiyle Belirlenen Antimikrobiyal İlaç Duyarlılığı. Mikrobiyol Bul, 2020; 54(2), 246-256.
1349) Wikstén JE, Laakso S, Mäki M, Mäkitie AA, Pitkäranta A, Blomgren K. Microarray identification of bacterial species in peritonsillar abscesses. Eur J Clin Microbiol Infect Dis. 2015; **34**(5): 905-911.
1350) Захарова ИН, Сугян НГ, Шаммас К, Антониадес А, Николау Э, Камилари Е, Титарев СИ, Сергеев АА, Мнафки НА. Влияние антибактериальной терапии на состояние желудочно-кишечного тракта у детей. Медицинский совет. 2017(19). https://cyberleninka.ru/article/n/vliyanie-antibakterialnoy-terapii-na-sostoyanie-zheludochno-kishechnogo-trakta-u-detey

ЦИТИРАНА: 43A: Medeiros JA, Gonçalves TM, **Boyanova L**, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM. Evaluation of *Helicobacter pylori* eradication by triple therapy plus *Lactobacillus acidophilus* compared to triple therapy alone. Eur J Clin Microbiol Infect Dis. 2011; **30** (4):555-559. **Цитирана от:**

1351) Ameen AM, Abdulridha MK, Najeeb AA. Comparative effectiveness of probiotics timing regimen in *Helicobacter pylori*-induced peptic ulcer disease patients. Journal of Pharmaceutical Sciences and Research. 2019;**11**(1):75-83.

1352) Bagirova M, Allahverdiyev AM, Abamor ES, Aliyeva H, Unal G, Tanalp TD. An overview of challenges to eradication of *Helicobacter pylori* infection and future prospects. Eur Rev Med Pharmacol Sci. 2017; **21**(9):2199-2219.
1353) Barbuti RC, Oliveira MN, Perina NP, Haro C, Bosch P, Bogsan CS, Eisig JN, Navarro-Rodriguez T. *Bifidobacterium lactis* fermented milk was not effective for *Helicobacter pylori* eradication: a prospective, randomized, double-blind, controlled study. World Academy of Science, Engineering and Technology. 2015; **9**(3), https://www.researchgate.net/profile/M_Oliveira2/publication/280490861_
1354) Braun, L. What role for Coenzyme Q10 with statin drugs? Australian Journal of Pharmacy. 2012; **93** (1100): 38-39.
1355) Choi JY, Shim K-N, Kong KA, Kwon K-J, Song E-M, Kim S-E, Jung H-K, Jung S-A. Meta-analysis: the effect of *Lactobacillus* supplementation on *Helicobacter pylori* eradication rates and side effects during treatment. Korean J Helicobacter Up Gastrointest Res. 2012; **12**(2):88-95. Korean.
1356) Costa M. Microbiology Area. Center for Neuroscience and Cell Biology. Annual Report. 2011. http://www.cnbc.pt/pdf/relatorioCNC2011.pdf
1357) Dang, Y., Reinhardt, J. D., Zhou, X., & Zhang, G. The effect of probiotics supplementation on *Helicobacter pylori* eradication rates and side effects during eradication therapy: A meta-analysis. PloS one. 2014; **9**(11):e111030.
1358) Dharmani, P., De Simone, C., Chadee, K. The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor. PLoS ONE 2013; **8** (3) , art. no. e58671
1359) Du YQ, Su T, Fan JG, Lu YX, Zheng P, Li XH, Guo CY, Xu P, Gong YF, Li ZS. Adjuvant probiotics improve the eradication effect of triple therapy for *Helicobacter pylori* infection. World J Gastroenterol. 2012; **18**(43):6302-6307.
1360) Fahey JW, Stephenson KK, Wallace AJ. Dietary amelioration of *Helicobacter* infection. Nutr Res. 2015**; 35**(6):461-473.
1361) Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on *Helicobacter pylori* infection]. Gastroenterol Hepatol. 2013; **36**(5):340-374.
1362) Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate *Helicobacter pylori*: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; **8**(4):6530-6543.
1363) Hongying F, Xianbo W, Fang Y, Yang B, Beiguo L. Oral immunization with recombinant *Lactobacillus acidophilus* expressing the adhesin Hp0410 of *Helicobacter pylori* induces mucosal and systemic immune responses. Clin Vaccine Immunol. 2014;**21**(2):126-132.
1364) Hwang YJ, Kim N, Yun CY, Kwon MG, Baek SM, Kwon YJ, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia: a long-term prospective clinical study. The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 2018;18(3):186-97.
1365) Kim TW, Ban WH, Kim SJ, Ryu SJ, Ha SE, Rho JW, Kong BH, Kim JH, Kim EH, Oh JH. The Antisecretory therapy improves anxiety and depression symptoms in patients with symptomatic gastroesophageal reflux disease. Korean J Helicobacter Up Gastrointest Res. 2013; **13**(1):30-35.
1366) Lau CSM., Ward A, Chamberlain RS. Probiotics improve the efficacy of standard triple therapy in the eradication of *Helicobacter pylori*: A meta-analysis. Infection and Drug Resistance 2016; **9**:275-289.
1367) Lee C-Y, Shih H-C, Yu M-C, (...), Kuan Y-H, Lin C-C. Evaluation of the potential inhibitory activity of a combination of *L. acidophilus, L. rhamnosus* and *L. sporogenes* on *Helicobacter pylori*: A randomized double-blind placebo-controlled clinical trial. Chinese Journal of Integrative Medicine. 2017; **23**(3):176-182.
1368) Lo J, Ramos J. Eficacia de probióticos para la disminución de los efectos adversos del tratamiento y la erradicación de *Helicobacter pylori*.Revista de Gastroenterología del Perú, 2014; **34**(3):257-257.
1369) Lu C, Sang J, He H, Wan X, Lin Y, Li L, Li Y, Yu C. Probiotic supplementation does not improve eradication rate of *Helicobacter pylori* infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep. 2016; **6**:23522.
1370) Lv, Z., Wang, B., Zhou, X., Wang, F., Xie, Y., Zheng, H., Lv, N. Efficacy and safety of probiotics as adjuvant agents for *Helicobacter pylori* infection: A meta-analysis". Experimental and Therapeutic Medicine. 2015; **9**.3:707-716.
1371) Manfredi M, Bizzarri B, Sacchero RI, Maccari S, Calabrese L, Fabbian F, De'Angelis GL. *Helicobacter pylori* infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter. 2012; **17**(4):254-263.
1372) Mehling H, Busjahn A. Non-viable *Lactobacillus reuteri* DSMZ 17648 (Pylopass™) as a new approach to *Helicobacter pylori* control in humans. Nutrients. 2013; **5**(8):3062-3073.
1373) Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for *Helicobacter pylori* in the era of antibiotic resistance. World J Gastroenterol. 2014; **20**(30):10338.
1374) Molina-Infante J, Shiotani A. Practical aspects in choosing a *helicobacter pylori* therapy. Gastroenterol Clin North Am. 2015; **44**(3):519-535.
1375) Molina-Infante J,Gisbert JP. Probióticos en el tratamiento erradicador de *Helicobacter pylori*: Sin evidencia para su uso generalizado | [Probiotics for *Helicobacter pylori* eradication therapy: Not ready for prime time] Revista Espanola de Enfermedades Digestivas. 2013; **105**(8): 441-444.
1376) Navarro-Rodriguez T, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, Bogsan CS, Chinzon D, Eisig JN. Association of a probiotic to a *Helicobacter pylori* eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013;**13**:56. doi: 10.1186/1471-230X-13-56.
1377) O'Connor A, Gisbert JP, Mcnamara D, O'Morain C. Treatment of *Helicobacter pylori* infection 2011. Helicobacter 2011; **16**(SUPPL. 1):53-58.
1378) Oh JH. *Helicobacter pylori* and Gastric Microbiota. Korean J Helicobacter Up Gastrointest Res. 2016; **16**(2):59-67.

1379) Park HK, Kim N, Lee SW, Park J-J, Kim JI, Lee S-Y, Cha H-M et al. The distribution of endoscopic gastritis in 25,536 heath check-up subjects in Korea. The Korean Journal of *Helicobacter* and Upper Gastrointestinal Research, 2012; **12**(4):237-243.
1380) Pazos A, Bravo LE, Betancourt AM, Astudillo M. Caracterización de la microbiota láctica gástrica asociada a gastritis crónica. Rev Univ. salud. 2012; **15**(1): 7-20.
1381) Ruggiero, P. *Helicobacter pylori* infection: What's new. Current Opinion in Infectious Diseases. 2012; **25** (3):337-344.
1382) Shahraki T, Shahraki M, Shahri ES, Mohammadi M. No significant impact of *Lactobacillus reuteri* on eradication of *Helicobacter pylori* in children (double-blind randomized clinical trial). Iranian Red Crescent Medical Journal. 2017; **19**(3) e42101.
1383) Shi, X., Zhang, J., Mo, L., Shi, J., Qin, M., & Huang, X. Efficacy and safety of probiotics in eradicating *Helicobacter pylori*: A network meta-analysis. Medicine. 2019; 98(15).
1384) Song HJ. Future of *Helicobacter pylori* eradication-new trials. Korean J Helicobacter Up Gastrointest Res. 2012; **12**(4):232-236. Korean.
1385) Store M. *Lactobacillus acidophilus*. MY STORE. St. Laurent Centre (613) 842-4116. http://www.nutritionhouse.com/Library/WellnessItem.aspx?ID=68546
1386) Talebi Bezmin Abadi A. *Helicobacter pylori* treatment: New perspectives using current experience. J Glob Antimicrob Resist. 2017; **8**:123-130.
1387) Tolone S, Pellino V, Vitaliti G, Lanzafame A, Tolone C. Evaluation of *Helicobacter pylori* eradication in pediatric patients by tripletherapy plus lactoferrin and probiotics compared t o triple therapy alone. Ital J Pediatr. 2012; **38**:63. doi: 10.1186/1824-7288-38-63.
1388) Urgesi, R., Cianci, R., Riccioni, M.E. Update on triple therapy for eradication of *Helicobacter pylori*: Current status of the art. Clinical and Experimental Gastroenterology. 2012; **5**(1):151-157.
1389) Vitali Čepo, D., Prusac, M., Velkovski Škopić, O., & Tatarević, A. Preporuke o primjeni probiotika u ljekarničkoj praksi. Medicus. 2020; 29(1 Hepatologija danas), 115-134.
1390) Weiss G, Forster S, Irving A, Tate M, Ferrero RL, Hertzog P, Frøkiær H, Kaparakis-Liaskos M. *Helicobacter pylori* VacA suppresses *Lactobacillus acidophilus*-induced interferon beta signaling in macrophages via alterations in the endocytic pathway. MBio. 2013; **4**(3):e00609-12. doi: 10.1128/mBio.00609-12.
1391) Yu, M., Zhang, R., Ni, P., Chen, S., & Duan, G. Efficacy of Lactobacillus-supplemented triple therapy for *H. pylori* eradication: A meta-analysis of randomized controlled trials. PloS one. 2019; 14(10), e0223309.
1392) Zhang, W.-D. Investigations on a new approach to treat *Helicobacter pylori* infection. Journal of Dalian Medical University. 2012, **34**(5):417-423.
1393) Zhang, M., Zhang, C., Zhao, J., Zhang, H., Zhai, Q., & Chen, W. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of *H. pylori* and incidence of therapy-associated side effects. Microbial Pathogenesis. 2020; 147, 104403.
1394) Zheng X, Lyu L,Mei Z. *Lactobacillus*-containing probiotic supplementation increases *Helicobacter pylori* eradication rate: Evidence from a meta-analysis Revista Espanola de Enfermedades Digestivas. 2013; **105**(8):445-453.
1395) Zhu R, Chen K, Zheng YY, Zhang HW, Wang JS, Xia YJ, ... & Guo CY. Meta-analysis of the efficacy of probiotics in *Helicobacter pylori* eradication therapy. World J Gastroenterol.*:* WJG, 2014; **20**
1396) Zhu XY, Liu F. Probiotics as an adjuvant treatment in *Helicobacter pylori* eradication therapy. J Dig Dis. 2017; **18**(4):195-202.
1397) Бусяхн А, Джордан Д, Мелинг Х, Хольц К, Ария С, Ланг К. Уменьшение количества *Helicobacter pylori* с помощью *Lactobacillus reuteri* DSMZ17648. Лечащий врач. 2015(2):52-56.
1398) Вдовиченко ВІ, Меренцова ОО, Демидова АЛ. Ефективність антигелікобактерної терапії ерозивновиразкових уражень гастродуоденальної зони з використанням препаратів «Проксіум» та «Лаціум». Лікарські Засоби. 2012; **5**(67):100-102.
1399) Плотникова, Е. Ю., & Захарова, Ю. Место пробиотиков в антихеликобактерной терапии. Эффективная фармакотерапия. 2020; 16(15), 40-47.

ЦИТИРАНА: 44A: Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I. Benefits of *Helicobacter pylori cagE* genotyping in addition to *cagA* genotyping. A Bulgarian study. Antonie Van Leeuwenhoek. 2011; **100**(4):529-35.DOI: 10.1007/s10482-011-9608-8. **Цитирана от:**

1400) Bridge, D.R., Scott Merrell, D. Polymorphism in the *Helicobacter pylori* CagA and VacA toxins and disease. Gut Microbes. 2013; **4**(2):101-117.
1401) Brkić DV, Katičić M, Bedenić B, Stanko AP, Plečko V. Detection of virulence gene belonging to cag pathogenicity island in *Helicobacter pylori* isolates after multiple unsuccessful eradication therapy in Northwest Croatia. Periodicum Biologorum. 2016; **118** (1):45-52.
1402) El Khadir M, Boukhris SA, Zahir SO, Benajah DA, Ibrahimi SA, Chbani L, ... & Bennani B. *cagE*, *cagA* and *cagA* 3′ region polymorphism of *Helicobacter pylori* and their association with the intra-gastric diseases in Moroccan population. Diagn Microbiol Infect Dis. 2021; **100**(3): 115372.
1403) Hefzy EM, Algameel AA, Mohamed WS, Kamel AS.. Non-invasive detection of *Helicobacter pylori* virulence genotypes *ureA, vacA, cagA* and *babA2* among asymptomatic Egyptian infants. African Journal of Microbiology Research, 2014; **8**(35):3276-3283.
1404) Ozbey G, Dogan Y, Demiroren K. Prevalence of *Helicobacter pylori* virulence genotypes among children in Eastern Turkey. World J Gastroenterol. 2013;**19**(39):6585-9. doi: 10.3748/wjg.v19.i39.6585.
1405) Peña J, Rojas H, Reyes N, Fernández-Delgado M, García-Amado MA, Michelangeli F, Contreras M. Multiple *cag* genotypes of *Helicobacter pylori* isolates colonize the oesophagus in individual hosts in a Venezuelan population. J Med Microbiol. 2017; **66**(2):226-235.

1406) Vaziri F, Najar Peerayeh S, Alebouyeh M, Mirzaei T, Yamaoka Y, Molaei M, Maghsoudi N, Zali MR. Diversity of *Helicobacter pylori* genotypes in Iranian patients with different gastroduodenal disorders. World J Gastroenterol. 2013; **19**(34):5685-5692.

ЦИТИРАНА: 45A: Boyanova L. Role of *Helicobacter pylori* virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiol. 2011; **6** (8): 843-846. **Цитирана от:**

1407) Afsar MNA, Jhinu ZN, Bhuiyan MAI, Islam Z, Siddiqua TJ. *Helicobacter pylori* infection and micronutrient deficiency in pregnant women: a systematic review and meta-analysis. BMJ open gastroenterology. 2020; **7**(1): e000490.
1408) Asi DH, Farivar TN, Rahmani B, Hajmanoochehri F, Razavi ANE, Jahanbin B, Dodaran MS, Peymani A.. The role of transferrin receptor in the *Helicobacter pylori* pathogenesis; L-ferritin as a novel marker for intestinal metaplasia. Microbial pathogenesis. 2019; 126:157-164.
1409) Banić M, Franceschi F, Babić Z, Gasbarrini A. Extragastric Manifestations of *Helicobacter pylori* Infection. Helicobacter. 2012;**17** Suppl 1:49-55.
1410) Campuzano-Maya G. Hematologic manifestations of *Helicobacter pylori* infection. World J Gastroenterol. 2014; **20**(36):12818.
1411) Campuzano-Maya, G. La anemia como manifestación de la infección por *Helicobacter pylori*. Medicina & Laboratorio, 2020; 20(03-04), 111-134.
1412) Ge R, Sun X. Iron trafficking system in *Helicobacter pylori*. Biometals. 2012; **25**(2):247-258.
1413) Hamedi Asl, D., Naserpour Farivar, T., Rahmani, B., (...), Soleimani Dodaran, M., Peymani, A. The role of transferrin receptor in the *Helicobacter pylori* pathogenesis; L-ferritin as a novel marker for intestinal metaplasia. Microbial Pathogenesis 2019; 126:157-164.
1414) Hartl, K., & Sigal, M. Microbe-driven genotoxicity in gastrointestinal carcinogenesis. International journal of molecular sciences. 2020; 21(20), 7439.
1415) Jee, S. R. *Helicobacter pylori* and Hematologic Diseases. The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 2020; 20(1), 11-20.
1416) Kaminski ZJ, Relich I, Konieczna I, Kaca W, Kolesinska B. Cross-Reactivity of polyclonal antibodies against *Canavalia ensiformis* (Jack Bean) urease and *Helicobacter pylori* urease subunit A fragments. Chemistry & biodiversity. 2018; **15**(1):e1700444.
1417) Kell DB, Pretorius E. No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. Biological Reviews. 2018;**93**(3):1518-57.
1418) Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD. The role of *Helicobacter pylori* infection in hematological disorders. Eur J Intern Med. 2013; **24**(8):685–690.
1419) Roesler BM. *Helicobacter pylori* infection and hematologic disorders: what do we really know? Arch Clin Gastroenterol 2015; **1**(2):035-037. DOI: 10.17352/2455-2283.000007
1420) Tsay FW, Hsu PI. *H. pylori* infection and extra-gastroduodenal diseases. Journal of biomedical science. 2018;**25**(1):65.
1421) Ulasoglu C, Temiz HE, Sağlam ZA. The Relation of Cytotoxin-Associated Gene-A Seropositivity with Vitamin B12 Deficiency in *Helicobacter pylori*-Positive Patients. BioMed research international. 2019, 2019.
1422) Voropaev EV. Molecular and genetic factors for realization of the pathogenic potential of *helicobacter pylori*: personified techniques for assessment of manifestations, laboratory diagnosis and prognosis. Проблемы здоровья и экологии. 2018; 55(1): 16-20.
1423) Wong F, Rayner-Hartley E, Byrne MF. Extraintestinal manifestations of *Helicobacter pylori*: A concise review. World J Gastroenterol. 2014; **20**(34): 11950-11961.
1424) Zhang W, Lu H, Graham DY. An Update on *Helicobacter pylori* as the Cause of Gastric Cancer. Gastrointestinal Tumors, 2014; **1**(3):155-165.
1425) Воропаев ЕВ. Молекулярно-генетические факторы реализации патогенного потенциала *Helicobacter pylori*: персонифицированные технологии оценки проявлений, лабораторной диагностики и прогноза. Проблемы здоровья и экологии. 2018(1 (55)).
1426) Воропаев ЕВ, Осипкина ОВ, Баранов ОЮ, Зятьков АА, Бонда НА, Платошкин ЭН, Воропаева АВ, Беляковский ВН, Ачинович СЛ, Шафорост АС, Зайцева ВИ. Анализ канцерогенного потенциала *Helicobacter pylori* на основании определения степени фосфорилирования CagA-белка бактерии. Проблемы здоровья и экологии. 2018(4 (58).

ЦИТИРАНА: 46A: Markovska R, **Boyanova L**, Yordanov D, Gergova G, Mitov I. *Helicobacter pylori oipA* genetic diversity and its associations with both disease and *cagA*, *vacA* s, m and i alleles among Bulgarian patients. Diagn Microbiol Infect Dis. 2011; **71**(4):335-340. **Цитирана от:**

1427) Abadi ATB. *Helicobacter pylori* infection in Iran: a new perspective. Journal of Gastroenterology and Hepatology Research, 2014; **3**(8):1181-1185.
1428) Aghdam SM, Sardari Z, Safaralizadeh R, Bonyadi M, Abdolmohammadi R, Moghadam MS, Khalilnezhad A. Investigation of Association between *oipA* and *iceA1/iceA2* genotypes of *Helicobacter pylori* and gastric cancer in Iran. Asian Pacific Journal of Cancer Prevention, 2014; **15**(19):8295-8299.
1429) Al-Maleki AR, Loke MF, Lui SY, Ramli NS, Khosravi Y, Ng CG, Venkatraman G, Goh KL, Ho B, Vadivelu J. *Helicobacter pylori* Outer Inflammatory Protein A (OipA) suppresses apoptosis of AGS gastric cells in vitro. Cellular microbiology. 2017 Dec 1.
1430) Al-Essa SHF, Al-Ghazawi GJ, Wahab ADA. A comparative study of diagnosis methods of *Helicobacter pylori* in patients with gastroenteritis in Basrah province. Biochem. Cell. Arch. 2020; **20**(1):957-962.
1431) Baj, J., Forma, A., Sitarz, M., Portincasa, P., Garruti, G., Krasowska, D., & Maciejewski, R. *Helicobacter pylori* Virulence Factors—Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment. Cells. 2021; 10(1), 27.
1432) Braga LL, Batista MH, de Azevedo OG, da Silva Costa KC, Gomes AD, Rocha GA, Queiroz DM. oip A "on" status of *Helicobacter pylori* is associated with gastric cancer in North-Eastern Brazil. BMC cancer. 2019;**19**(1):48.

1433) Bridge DR, Scott Merrell DS. Polymorphism in *the Helicobacter pylori* CagA and VacA toxins and disease. Gut Microbes. 2013; **4**(2):101-117.
1434) Buzás GM. *Helicobacter pylori* - 2012 [*Helicobacter pylori* - 2012]. Orvosi Hetilap 2012; **153**(36):1407-1418.
1435) Chen M-Y, Yuan Y. *Helicobacter pylori* virulence factors that act at different stages of infection**.** World Chinese Journal of Digestology 2012; **20**(30):2937-2943.
1436) El Khadir M, Alaoui Boukhris S, Benajah DA, El Rhazi K, Ibrahimi SA, El Abkari M, Harmouch T, Nejjari C, Mahmoud M, Benlemlih M, Bennani B. VacA and CagA status as biomarker of two opposite end outcomes of *Helicobacter pylori* infection (gastric cancer and duodenal ulcer) in a Moroccan population. PLoS One. 2017; 12(1):e0170616.
1437) El-Sayed, M. S., Musa, N., Eltabbakh, M., Abdelhamid, D. H., Mostafa, S. M. I., Salah, M. M., ... & Hassan, R. A. Detection of *Helicobacter pylori* oipA and dupA genes among dyspeptic patients with chronic gastritis. Alexandria Journal of Medicine. 2020; 56(1), 105-110.
1438) El-Shenawy A, Diab M, Shemis M, El-Ghannam M, Salem D, Abdelnasser M, Shahin M, Abdel-Hady M, El-Sherbini E, Saber M. Detection of *Helicobacter pylori vacA, cagA* and *iceA1* virulence genes associated with gastric diseases in Egyptian patients. Egyptian Journal of Medical Human Genetics. 2017: **18**(4):365-371.
1439) Farzi N, Yadegar A, Aghdaei HA, Yamaoka Y, Zali MR. Genetic diversity and functional analysis of *oipA* gene in association with other virulence factors among *Helicobacter pylori* isolates from Iranian patients with different gastric diseases. Infection, Genetics and Evolution. 2018;**60**:26-34.
1440) Feili, O., Bakhti, S. Z., Latifi-Navid, S., Zahri, S., & Yazdanbod, A. Contrasting association of *Helicobacter pylori* oipA genotype with risk of peptic ulceration and gastric cancer. Infection, Genetics and Evolution. 2021; 89, 104720.
1441) Kalali B, Mejías-Luque R, Javaheri A, Gerhard M. *H. pylori* virulence factors: influence on immune system and pathology. Mediators Inflamm. 2014; **2014**:426309.
1442) Li, N, She F-F, Lin X. Application of recombinant *Helicobacter pylori* outer inflammatory protein a peptide for diagnosis of high virulent *Helicobacter pylori* infection. World Chinese Journal of Digestology.2015; **23**(16):2549-2554.
1443) Liu J, He C, Chen M, Wang Z, Xing C, Yuan Y. Association of presence/absence and on/off patterns of *Helicobacter pylori oipA* gene with peptic ulcer disease and gastric cancer risks: a meta-analysis. BMC Infect Dis. 2013;**13**:555.
1444) Liu X, He B, Cho WC, Pan Y, Chen J, Ying H, Wang F, Lin K, Peng H, Wang S. A systematic review on the association between the *Helicobacter pylori vacA* i genotype and gastric disease. FEBS Openbio. 2016; **6**(5):409-417.
1445) Mostafa Abd El-Hamid, M., Ahmed, A. E. A., & Zakaria Abu Amer, M. A novel three drug rigemen (moxifloxacin–omeprazole-nitazoxanide) in comparison to traditional triple therapy for treatment and eradication of naïve and resistant *H. pylori* infection in dyspeptic patients. Al-Azhar Medical Journal. 2020; 49(3), 1163-1172.
1446) Matsuo Y, Kido Y, Yamaoka Y. *Helicobacter pylori* outer membrane protein-related pathogenesis. Toxins (Basel). 2017; **9**(3):101.
1447) Oleastro M, Ménard A. The Role of *Helicobacter pylori* Outer membrane proteins in adherence and pathogenesis. Biology. 2013, **2**(3):1110-1134.
1448) Posselt G, Backert S, Wessler S. The functional interplay of *Helicobacter pylori* factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal. 2013;**11**:77.
1449) Ranjbar R, Khamesipour F, Jonaidi-Jafari N, Rahimi E. *Helicobacter pylori* in bottled mineral water:genotyping and antimicrobial resistance properties. BMC Microbiol. 2016; **16**:40.
1450) Sedaghat H, Moniri R, Jamali R, Arj A, Zadeh MR, Moosavi SGA, Rezaei M, Pourbabaee M. Prevalence of *Helicobacter pylori vacA, cagA, cagE, iceA, babA2*, and *oipA* genotypes in patients with upper gastrointestinal diseases. Iranian Journal of Microbiology. 2014; **6**(1):14-21.
1451) Sohrabi M, Khashei R, Alizadeh M, Asl MK, Nejati MA, Dara M, Bazargani A. Low Rate of *babA2* genotype among Iranian *Helicobacter pylori* clinical isolates. J Clin Diagn Res. 2017;**11**(7):DC32-DC36.
1452) Šterbenc A, Jarc E, Poljak M, Homan M. *Helicobacter pylori* virulence genes. World J Gastroenterol. 2019; **25**(33): 4870.
1453) Tonkic A, Tonkic M, Lehours P, Mégraud F. Epidemiology and diagnosis of *Helicobacter pylori* infection. Helicobacter. 2012; **17**(SUPPL.1): 1-8.
1454) Torres Izarraa KE, Moran Borgesa YH, Valderrama Rios EJ, Chiurillo Siervo MÁ. Variantes del motivo EPIYA de la proteína CagA de *Helicobacter pylori* en biopsias gástricas de pacientes con gastritis crónica de la región centroccidental de Venezuela. Revista de la Sociedad Venezolana de Microbiología. 2013; **33**(1):18-33.
1455) Torres K, Valderrama E, Sayegh M, Ramírez JL, Chiurillo MA. Study of the oipA genetic diversity and EPIYA motif patterns in cagA-positive Helicobacter pylori strains from Venezuelan patients with chronic gastritis. Microb Pathog. 2014;76:26-32.
1456) Tourkochristou E, Aggeletopoulou I, Konstantakis C, Triantos C. Role of NLRP3 inflammasome in inflammatory bowel diseases. World J Gastroenterol. 2019; **25**(33): 4796.
1457) Vidal CEB, Gutiérrez-Escobar AJ, Castiblanco Robayo LP. Membrana externa de *Helicobacter pylori* y su papel en la adhesión al epitelio gástrico. Pontificia Universidad javeriana. 2015; **56**(1)
1458) Whitmire JM, Merrell DS. *Helicobacter pylori* genetic polymorphisms in gastric disease development. *Helicobacter pylori* in Human Diseases. 2019: 173-194.
1459) Zhang J, Qian J, Zhang X, Zou Q. Outer membrane inflammatory protein A, a new virulence factor involved in the pathogenesis of *Helicobacter pylori*. Mol Biol Rep. 2014; **41**(12):7807-7814.

ЦИТИРАНА: 47A: Boyanova L, Mitov I. Coadministration of probiotics with antibiotics: why, when and for how long? Expert Rev Anti Infect Ther. 2012; **10**(4):407-409. **Цитирана от:**.

1460) Ameen AM, Abdulridha MK, Najeeb AA. Comparative effectiveness of probiotics timing regimen in *helicobacter pylori*-induced peptic ulcer disease patients. Journal of Pharmaceutical Sciences and Research. 2019;**11**(1):75-83.
1461) Bendini S. Can you take probiotics and antibiotics at the same time? Probiotics Gazette. 2018: https://www.probioticsgazette.com/can-take-probiotics-antibiotics-time/

1462) Blog RL. CPE Monthly: Probiotics may prevent and treat *Clostridium difficile* By Mary Rodavich, MS, RD, LDN Today's Dietitian. 2015: **17**(11):46.
1463) Deka B, Bhattacharjee B, Shakya A, Ikbal AMA, Goswami C, Sarma S. Mechanism of action of wound healing activity of *Calendula officinalis*: A comprehensive review. Pharmaceutical and Biosciences Journal. 2021: 28-44.
1464) Deka B, Dash B, Saud B, Bhattacharjee B, Ikbal AMA. Critical overview of probiotics efficacy on health and its safety. Pharmaceutical and Biosciences Journal. 2021: 01-15.
1465) Ferreira ECMF, Ferreira TRF, Mascarenhas TS, Costa JPL, Brito LMO, Chein MBC, Brito HO. [Recurrent bacterial vaginosis: updates in therapeutic management.] Rev Pesq Saúde. 2013; **14**(1):55-58.
1466) Fleet M, Rahman PK. Probiotics and their health benefits. Microbial Functional Foods and Nutraceuticals. 2017; 267-279.
1467) Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acutepancreatitis: a systematic review and meta-analysisof randomized controlled trials. Crit Care. 2014;**18**(2):R57.
1468) Guridi CB, Serena AR, Cabrera SG, Fernández IA, Hernández CR, Vivanco BM, ... & Nieto-Magro C. Clinical evaluation of the synbiotic Prodefen Plus® in the prevention of the antibiotic-associated diarrhoea in subjects requiring antibiotic treatment. Beneficial Microbes. 2020; **11**(6), 535-545.
1469) Gurney S, Carvalho L, Gonzalez C, Galaviz E, Sonstein F. An efficacious and cost-effective pharmacologic treatment for *Helicobacter pylori*. The Journal for Nurse Practitioners. 2014; **10**(1):22-29.
1470) Hanson L, VandeVusse L, Jermé M, Abad CL, Safdar N. Probiotics for treatment and prevention of urogenital infections in women: asystematic review. J Midwifery Womens Health. 2016;**61**(3):339-355.
1471) Javaloyas M. Infecció per *Clostridium difficile*. Circular Farmaceutica. 2012; **70**(3):30-34.
1472) Jimeno, M. E. Microbiota, probióticos, prebióticos y simbióticos en pediatría. Boletín de la Sociedad de Pediatría de Aragón, La Rioja y Soria. 2016; 46(3), 77-83.
1473) Ju, A., Duan, A., Zhang, Y., Qin, Y., Xue, L., Ma, X., ... & Yang, S. Effects Of Orally Administered Recombinant Lactobacillus Casei Expressing HN Protein On Early Growth Performance, Intestinal Health And Protection Against NDV Challenge In Chickens. 2020.
1474) Lendrum JE, Seebach B, Klein B, Liu S. Sleep and the gut microbiome: antibiotic-induced depletion of the gut microbiota reduces nocturnal sleep in mice. bioRxiv. 2017:199075.
1475) Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for *Helicobacter pylori* infection: A meta-analysis. Experimental and Therapeutic Medicine. 2015**; 9**(3): 707-716.
1476) Medscape today news: 2021: http://www.medscape.com/viewarticle/763157 (Medscape republishing our article 47A)
1477) Osita EC, Philip BD, Harrison GT, Sylvester NC, Okechukwu EC. Effects of *Lactobacillus* spp. isolated from the sap of palm tree *Elaeis guineensis* (palm wine) on cellular and innate immunity. African Journal of Microbiology Research. 2019;**13**(2):33-9.
1478) Pérez C. Probióticos en la diarrea aguda y asociada al uso de antibióticos en pediatría [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. Nutr Hosp. 2015; **31**(Suppl 1):64-67.
1479) Pts, W. P., Codes, W. P., Points, M., & Voucher, B. M. D. Home/Articles/Gastroenterology/Restoring Gut Health with Hexbio® In the Course of Antibiotics. Urology, 2019.
1480) Rodavich M. Probiotics may prevent and treat *Clostridium difficile.* Today's Dietitian. 2015; 17(11):46.
1481) Rowles HL. How are probiotics affected by antibiotics. Ann Clin Lab Res. 2017;**5**(2):163.
1482) Rowles HL. Increasing antibiotic therapy compliance through concurrent probiotic consumption. International Journal of Probiotics & Prebiotics. 2017;**12**(2):83-88.
1483) Rowles, H. L. Probiotics Slow the Growth of Pathogenic Bacteria. International Journal of Probiotics & Prebiotics. 2019; 14, 28-32.
1484) Shi, X., Zhang, J., Mo, L., Shi, J., Qin, M., & Huang, X. Efficacy and safety of probiotics in eradicating *Helicobacter pylori*: A network meta-analysis. Medicine. 2019; 98(15).
1485) Tomaro-Duchesneau C, Saha S, Prakash S. Modification of the gut microbiota to promote human health. Probiot Prebiot Gut Heal. 2014:15-34.
1486) Zhang W, Guo H, Cao C, Li L, Kwok LY, Zhang H, Sun Z. Adaptation of *Lactobacillus casei* zhang to gentamycin involves an alkaline shock protein. Front Microbiol. 2017;**8**:2316.

ЦИТИРАНА: 48A: Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for *Helicobacter pylori* antibiotic resistance revealed by extended anamnesis. A Bulgarian study. J Med Microbiol. 2012; **61**(Pt 1):85-93. **Цитирана от:**

1487) Bayati, S., Amirmozafari, N., Alebouyeh, M., Farzi, N., Ebrahimi Daryani, N., & Zali, M. R. Antibiotic resistance among *Helicobacter pylori* strains isolated from patients with histopathological changes of the gastric tissue towards metronidazole, clarithromycin, and ciprofloxacin. Archives of Clinical Infectious Diseases. 2019; 14(1).
1488) Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of *Helicobacter pylori* inVietnam. J Clin Gastroenterol. 2013; **47**(3):233-238.
1489) Buzás GM. *Helicobacter pylori* - 2012 [*Helicobacter pylori* - 2012]. Orvosi Hetilap 2012; **153** (36):1407-1418.
1490) Cheng A, Sheng WH, Liou JM, Wang HP, Wu MS, Lin JT, Chang SC. Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against *Helicobacter pylori* isolates in Taiwan. J Microbiol Immunol Infect. 2015; **48**(1):72-79.
1491) Cui R, Song Z, Suo B, Tian X, Xue Y, Meng L, ... & Zhou L. Correlation analysis among genotype resistance, phenotype resistance and eradication effect of *Helicobacter pylori*. Infection and Drug Resistance. 2021; **14:** 1747.
1492) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol. 2020; **31**(3): 221-233.
1493) Examine.com. Garlic. https://examine.com/supplements/garlic/research/

1494) Fathi MS, EL-Folly RF, Hassan RA, El-Arab ME. Genotypic and phenotypic patterns of antimicrobial susceptibility of *Helicobacter pylori* strains among Egyptian patients. Egyptian Journal of Medical Human Genetics. 2013;**14**(3):235-246
1495) Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in *Helicobacter pylori*: A recent literature review. World J Methodol. 2015; **26**;5(3):164-174.
1496) Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A, Ierardi E. Primary clarithromycin resistance to *Helicobacter pylori*: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol. 2013; **4**(3):43-46.
1497) Howden CW, Chey WD, Vakil NB. Clinical rationale for confirmation testing after treatment of *Helicobacter pylori* infection: implications of rising antibiotic resistance. Gastroenterol Hepatol (N Y). 2014; **10**(7 Suppl 3):1-19.
1498) Krzyżek P, Pawełka D, Iwańczak B, Kempiński R, Leśniakowski K, Mégraud F, Łaczmański Ł, Biernat M, Gościniak G. High primary antibiotic resistance of *Helicobacter pylori* strains isolated from pediatric and adult patients in Poland during 2016-2018. Antibiotics (Basel). 2020;9(5):228.
1499) Lyu T, Cheung KS, Ni L, Guo J, Mu P, Li Y, ... & Seto WK. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line *Helicobacter pylori* therapy in southern China: a municipality-wide, multicentre, prospective cohort study. J Antimicrob Chemother. 2020; **75**(11), 3391-3394.
1500) Maysaa El Sayed Zaki, Walaa Othman, Mahmoud Abdelwahab Ali, Ahmed Shehta. Fluoroquinolone-resistant *Helicobacter pylori* strains isolated from one Egyptian University Hospital: Molecular Aspects. Journal of Microbiology and Antimicrobial Agents. 2016; **2**(1). http://jmaa.co.uk/ojs-2.4.7-1/index.php/JMAA/article/view/41
1501) Morilla, A. M., Álvarez-Argüelles, M. E., Duque, J. M., Armesto, E., Villar, H., & Melón, S. Primary antimicrobial resistance rates and prevalence of *Helicobacter pylori* infection in the north of Spain. A 13-year retrospective study. Gastroenterología y Hepatología (English Edition). 2019; 42(8), 476-485.
1502) Navarro-Jarabo JM, Fernández-Sánchez F, Fernández-Moreno N, Hervas-Molina AJ, Casado-Caballero F, Puente-Gutierrez JJ, Pallares-Manrique H, Rodríguez-Ramos C, Fernández-Gutierrez C, Pérez-Aisa A, Rivas-Ruiz F, Montiel Quezel-Guerraz N. Prevalence of primary resistance of *Helicobacter pylori* to clarithromycin and levofloxacin in Southern Spain. Digestion. 2015; **92**(2):78-82.
1503) Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of *Helicobacter pylori* infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol. 2014; **20**(29):9898–9911.
1504) Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of *Helicobacter pylori* infection: Past, present and future. World J Gastrointest Pathophysiol. 2014; **5**(4):392–399.
1505) Paul B, Adimoolam S, Qureshi Mj, Ismail Ne. A review of *Helicobacter pylori* infection diseases, antibiotic resistance and diagnosis. Asian J Pharm Clin Res. 2018;**11**(12):566-71.
1506) Shiota S, Yamaoka Y. Strategy for the treatment of *Helicobacter pylori* infection. Current Pharmaceutical Design. 2014; **20**(28):4489-4500.
1507) Vakil, N. B. Antibiotic resistance in patients with *Helicobacter pylori* infection. Gastroenterol Hepatol. 2014; 10(7 Suppl 3), 9-13.
1508) Vilaichone R, Yamaoka Y, Shiota S, Ratanachu-ek T, Tshering L, Uchida T, Fujioka T, Mahachai V. Antibiotics resistance rate of *Helicobacter pylori* in Bhutan. World J Gastroenterol. 2013; **19**(33):5508-5512.
1509) Wang, D., Guo, Q., Yuan, Y., & Gong, Y. The antibiotic resistance of *Helicobacter pylori* to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer. BMC microbiology. 2019; 19(1), 1-10.
1510) Williams, K., Colquhoun, A., Munday, R., & Goodman, K. J. Antibiotic dispensation rates among participants in community-driven health research projects in Arctic Canada. BMC public health. 2019; 19(1), 1-8.
1511) Wüppenhorst N, Draeger S, Stüger HP, Hobmaier B, Vorreiter J, Kist M, Glocker EO; on behalf of the ResiNet Study Group. Prospective multicentre study on antimicrobial resistance of *Helicobacter pylori* in Germany. J Antimicrob Chemother. 2014; **69**(11):3127-33.
1512) Zaki MES, Othman W, Ali Ma, Shehta A. Fluoroquinolone-resistant *Helicobacter pylori* strains isolated from one Egyptian university hospital: molecular aspects. Journal of Microbiology and Antimicrobial Agents. 2016;**2**(1). http://jmaa.co.uk/ojs-2.4.7-1/index.php/JMAA/article/view/41
1513) Андреев ДН, Маев ИВ, Кучерявый ЮА. Оценка влияния сопутствующих анамнестических и клинических факторов на эффективность и безопасность антихеликобактерной терапии. Архивъ внутренней медицины. 2016; **1**(27): http://cyberleninka.ru/article/n/otsenka-vliyaniya-soputstvuyuschih-anamnesticheskih-i-klinicheskih-faktorov-na-effektivnost-i-bezopasnost-antihelikobakternoy
1514) Маев ИВ, Андреев ДН. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017;**89**(8):5-12.
1515) Самсонов АА, Андреев ДН, Гречушников ВБ, Айвазова РА. Резистентность *Helicobacter pylori* к компонентам эрадикационной терапии и пути ее преодоления. Фарматека, 2015 , №2. http://www.pharmateca.ru/ru/archive/article/30793
1516) Шульгина, Е. М.; Караулова, Л. В.; Симонова, Ж. Г. Оценка вероятности инфицированности *Helicobacter pylori* у больных с гастродуоденальной патологией в зависимости от факторов риска с использованием модели логит-регрессии. Вятский медицинский вестник, 2019, 3 (63).

ЦИТИРАНА: 49A: Boyanova L, Mitev A, Gergova G, Mateev G, Mitov I. High prevalence and resistance rates to antibiotics in anaerobic bacteria in specimens from patients with chronic balanitis. Anaerobe. 2012; 18: 414-416. **Цитирана от:**.

1517) Beran V, Chmelar D, Vobejdova J, Konigova A, Nemec J, Tvrdik J. Sensitivity to antibiotics of *Clostridium difficile* toxigenic nosocomial strains. Folia Microbiol (Praha). 2014; **59**(3):209-215.
1518) Chao CT, Lee SY, Yang WS, Chen HW, Fang CC, Yen CJ, Chiang CK, Hung KY, Huang JW. Peritoneal dialysis peritonitis by anaerobic pathogens: a retrospective case series. BMC Nephrol. 2013;**14**(1):111.

ЦИТИРАНА: 50A: Yordanov D, Boyanova L, Markovska R, Gergova G, Mitov I. Significance of *Helicobacter pylori vacA* intermediate region genotyping—a Bulgarian study, Diagn Microbiol Infect Dis 2012; **74**(3):253-257. **Цитирана от:**

1519) Aftab H, Miftahussurur M, Subsomwong P, Ahmed F, Khan AA, Matsumoto T, Suzuki R, Yamaoka Y. Two populations of less-virulent *Helicobacter pylori* genotypes in Bangladesh. PloS one. 2017;**12**(8):e0182947.
1520) Alderete, A. D., Caballero, R. L., Sarmiento, O. F., Márquez, R. F., Bernal, M. E. F., & Cordero, M. A. Correlation between the presence of pathogenicity factors of *Helicobacter pylori* and digestive diseases in patients with digestive symptoms. 2012-2016. Panorama Cuba y Salud. 2018; 13(2), 40-47.
1521) Bakhti, S. Z., Latifi-Navid, S., & Zahri, S. Unique constellations of five polymorphic sites of *Helicobacter pylori* vacA and cagA status associated with risk of gastric cancer. Infection, Genetics and Evolution. 2020; 79, 104167.
1522) Bridge DR, Scott Merrell D. Polymorphism in the *Helicobacter pylori* CagA and VacA toxins and disease. Gut Microbes. 2013; **4**(2):101-117.
1523) Braga LL, Oliveira MA, Gonçalves MH, Chaves FK, Benigno TG, Gomes AD, Silva CI, Anacleto C, Batista Sde A, Queiroz DM. CagA phosphorylation EPIYA-C motifs and the *vacA* i genotype in *Helicobacter pylori* strains of asymptomatic children from a high-risk gastric cancer area in northeastern Brazil. Mem Inst Oswaldo Cruz, Rio de Janeiro, 2014; **109**(8):1045-1049.
1524) El Khadir M, Alaoui Boukhris S, Benajah DA, El Rhazi K, Ibrahimi SA, El Abkari M, Harmouch T, Nejjari C, Mahmoud M, Benlemlih M, Bennani B. VacA and CagA status as biomarker of opposite end outcomes of *Helicobacter pylori* infection (gastric cancer and duodenal ulcer) in a Moroccan population. PLoS One. 2017; **12**(1):e0170616.
1525) Keikha M, Ali-Hassanzadeh M, Karbalaei M. Association of *Helicobacter pylori* vacA genotypes and peptic ulcer in Iranian population: a systematic review and meta-analysis. BMC gastroenterology. 2020; **20**(1): 1-11.
1526) Liu X, He B, Cho WC, Pan Y, Chen J, Ying H, Wang F, Lin K, Peng H, Wang S. A systematic review on the association between the *Helicobacter pylori vacA* i genotype and gastric disease. FEBS Openbio. 2016; **6**(5):409–417.
1527) Miernyk KM, Bruden D, Rudolph KM, Hurlburt DA, Sacco F, McMahon BJ, Bruce MG. Presence of *cag*PAI genes and characterization of *vacA* s, i and m regions in *Helicobacter pylori* isolated from Alaskans and their association with clinical pathologies. J Med Microbiol. 2020; **69**(2): 218-227.
1528) Miftahussurur M, Yamaoka Y. *Helicobacter pylori* virulence genes and host genetic polymorphisms as risk factors forpeptic ulcer disease. Expert Rev Gastroenterol Hepatol. 2015; **9**(12):1535-1547.
1529) Miftahussurur, M., Yamaoka, Y., & Graham, D. Y. *Helicobacter pylori* as an oncogenic pathogen, revisited. Expert reviews in molecular medicine. 2017; 19, e4.
1530) Paredes-Osses E, Sáez K, Sanhueza E, Hebel S, González C, Briceño C, Cancino AG. Association between *cagA, vacA*i, and *dupA* genes of *Helicobacter pylori* and gastroduodenal pathologies in Chilean patients. Folia Microbiol (Praha). 2017; **62**(5):437-444.
1531) Trang T, Thanh Binh T, Yamaoka Y. Relationship between *vacA* types and development of gastroduodenal diseases.Toxins (Basel). 2016; **8**(6). pii: E182. doi:10.3390/toxins8060182
1532) Winter JA, Letley DP, Cook KW, Rhead JL, Zaitoun AA, Ingram RJ, Amilon KR, Croxall NJ, Kaye PV, Robinson K, Atherton JC. A Role for the vacuolating cytotoxin, VacA, in colonization and *Helicobacter pylori*-induced metaplasia in the Stomach. J Infect Dis. 2014; 210(6):954-963.
1533) Whitmire JM, Merrell DS. *Helicobacter pylori* genetic polymorphisms in gastric disease development. *Helicobacter pylori* in Human Diseases. 2019;173-194.

ЦИТИРАНА: 51A: Boyanova L, Mitov I. Antibiotic resistance rates in causative agents of infections in diabetic patients. Rising concerns. Expert Rev. Anti Infect. Ther. 2013; **11** (4): 411-420. **Цитирана от:**

1534) Abbas Hisham A. Diabetic Foot Infection. Research Journal of Pharmacy and Technology. 2015; **8**(5): 575-579.
1535) Al-Bakri, A. G., Bulatova, N. R., Younes, N. A., Othman, G., Jaber, D., Schleimer, N., ... & Becker, K. Characterization of staphylococci sampled from diabetic foot ulcer of Jordanian patients. Journal of applied microbiology. 2021; https://doi.org/10.1111/jam.15096
1536) Alhazzani W, Smith O, Muscedere J, Medd J, Cook D. Toothbrushing for critically ill mechanically ventilated patients: a systematic review and meta-analysis of randomized trials evaluating ventilator-associated pneumonia. Crit Care Med. 2013; **41**(2):646-655.
1537) Amaral L, Martins A, Spengler G, Hunyadi A, Molnar J. The mechanism by which the phenothiazine thioridazine contributes to cure problematic drug-resistant forms of pulmonary tuberculosis: recent patents for "new use". Recent Pat Antiinfect Drug Discov. 2013; **8**(3):206-212.
1538) Arenas I, Ibarra MA, Santana FL, Villegas E, Hancock RE, Corzo G. In vitro and in vivo antibiotic capacity of two host defense peptides. Antimicrob Agents Chemother. 2020; **64**(7).
1539) Bhandari K, Zamora JA. *Actinomyces naeslundii* bacteremia in an elderly woman with type 2 diabetes mellitus. Infectious Diseases in Clinical Practice. 2017;**25**(6):e23.
1540) Choi WH, Jiang MH. Evaluation of antibacterial activity of hexanedioic acid isolated from *Hermetia illucens* larvae. Journal of Applied Biomedicine, 2014; **12**(3): 179-189.
1541) Critchley JA, Restrepo BI, Ronacher K, Kapur A, Bremer AA, Schlesinger LS, Basaraba R, Kornfeld H, van Crevel R. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: Part 1: Epidemiology and clinical management. Chest. 2017; **152**(1):165-173.
1542) De A, Pasquantonio G, Cerroni L, Petrelli D, Lauro D, Longhi M, Vitali LA. Genotypic and phenotypic heterogeneity in *Streptococcus mutans* isolates from diabetic patients in Rome, Italy. Springerplus. 2016; **5**(1):1794.
1543) Fazeli Farsani S, Souverein PC, van der Vorst MM, Knibbe CA, de Boer A, Mantel-Teeuwisse AK. Anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents: a population-based cohort study. Antimicrob Agents Chemother. 2014; **58**(8):4666-4674.
1544) Fejfarová V, Jirkovská A, Dubský M, Game F, Vydláková J, Sekerková A, Franeková J, Kučerová M, Stříž I, Petkov V, Bém R, Wosková V, Němcová A, Skibová J. An alteration of lymphocytes subpopulations and immunoglobulins levels in patients with diabetic foot ulcersinfected particularly by resistant pathogens. J Diabetes Res. 2016; **2016**:2356870.

1545) Grint D, Alisjhabana B, Ugarte-Gil C, Riza AL, Walzl G, Pearson F, Ruslami R, Moore DA, Ioana M, McAllister S, Ronacher K. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. Bulletin of the World Health Organization. 2018;**96**(11):738.
1546) Hadi SA. An update on antibiotic resistance and DFUs. Podiatry today. 2016; **29**(3): http://www.podiatrytoday.com/update-antibiotic-resistance-and-dfus
1547) Haghighi, M., Kariman, H., & Sistanizad, M. Evaluating Association between Glycosylated Hemoglobin and the Spectrum and Antibiotic Resistance of Uropathogens: A Cross Sectional Study. Journal of Pharmaceutical Care. 2019; 67-71.
1548) He, K., Hemmila, M. R., Cain-Nielsen, A. H., Machado-Aranda, D. A., Frydrych, L. M., & Delano, M. J. Complications and resource utilization in trauma patients with diabetes. PloS one. 2019; 14(8), e0221414.
1549) Heimbuck, A. M., Priddy-Arrington, T. R., Padgett, M. L., Llamas, C. B., Barnett, H. H., Bunnell, B. A., & Caldorera-Moore, M. E. Development of responsive chitosan–Genipin hydrogels for the treatment of wounds. ACS Applied Bio Materials, 2019; 2(7), 2879-2888.
1550) Korbel L, Easterling RS, Punja N, Spencer JD. The burden of common infections in children and adolescents with diabetes mellitus: A Pediatric Health Information System study. Pediatric diabetes. 2018;**19**(3):512-9.
1551) Kurup, R., & Ansari, A. A. A study to identify bacteriological profile and other risk factors among diabetic and non-diabetic foot ulcer patients in a Guyanese hospital setting. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;, 13(3), 1871-1876.
1552) Lipsky BA, Aragón-Sánchez J, Diggle M, Embil J, Kono S, Lavery L, Senneville É, Urbančič-Rovan V, Van Asten S; International Working Group on the Diabetic Foot. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev. 2016; **32 Suppl 1**:45-74.
1553) Lubis VA, Katar Y, Bahar E. Identifikasi bakteri infeksi saluran pernafasan bawah non tuberkulosis (Non TB) dan pola resistensinya pada penderita diabetes melitus di RSUP M. Djamil. Jurnal Kesehatan Andalas. 2016; **5**(3):692-696.
1554) Mahbub, S., Akter, S., Akter, P., Hoque, M. A., Rub, M. A., Kumar, D., ... & Džudžević-Čančar, H. Effects of temperature and polyols on the ciprofloxacin hydrochloride-mediated micellization of sodium dodecyl sulfate. RSC Advances. 2020; 10(25), 14531-14541.
1555) Markakis K, Faris AR, Sharaf H, Faris B, Rees S, Bowling FL. Local Antibiotic Delivery Systems: Current and Future Applications for Diabetic Foot Infections. The International Journal of Lower Extremity Wounds. 2018;**17**(1):14-21.
1556) Martins IJ. Antibiotic resistance involves antimicrobial inactivation in global communities. SAJ Pharma Pharmacol. 2017;**2**:102.
1557) Martins IJ. Diabetes and Clinical Studies. J Diab Clin Stud. 2018; **2**(1):1-3.
1558) Navarro-Flores, E., Pérez-Ros, P., Martínez-Arnau, F. M., Julían-Rochina, I., & Cauli, O. Neuro-psychiatric alterations in patients with diabetic foot syndrome. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2019; 18(8), 598-608.
1559) Opara JK, Onwuliri FC, Agumah NB, Njoku OM, Onwuliri EA. Evaluation antibacterial effects of *Garcinia Kola* and *Vernonia Amygdalina* on *Staphylococcus aureus* isolated from residents of Abuja. Nigeria. World Journal of Pharmaceutical Research. 2017; **6**(15):95-104.
1560) Opara JK, Onwuliri FC, Agumah NB, Njoku OM, Onwuliri EA. Incidence of multidrug resistant (MDR) *Staphylococcus aureus* isolated from urban population and private health clinics in the federal capital territory; Abuja, Nigeria. Ijppr.Human, 2017; **10**(4): 1-14
1561) Osawa H, Orii K, Terunuma H, Abraham SJ. Combining autologous peripheral blood mononuclear cells with fibroblast growth factor therapy along with stringent infection control leading to successful limb salvage in diabetic patient with chronic renal failure and severe toe gangrene. Int J Stem Cells. 2014; **7**(2):158-161.
1562) Pavlicek RL, Zurawski DV, Thompson MG, Black CC, inventors. Murine wound model for testing pathogen viruence and therapeutic efficacy. United States patent application US 14/570,424. 2014 Dec 15.
1563) Pontes, D. G., Silva, I. T. D. C. E., Fernandes, J. J., Monteiro, A. D. F. G., Gomes, P. H. D. S., Ferreira, M. G. M., ... & Cavalcante, L. P. Perfil microbiológico e de resistência bacteriana no pé diabético infectado. Revista do Colégio Brasileiro de Cirurgiões. 2020; 47.
1564) Pragash DS, Girija S, Sekar U, Rayapu V, Sheriff DS. Uropathogens and diabetes mellitus-a perspective. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). 2017; **16**(5): 29-32.
1565) Qu Z, Yu J, Ma K, Chen Y. Characteristics of bacterial infection in patients with diabetic foot and its relationship with degree of vascular lesions in lower extremities. Biomedical Research. 2018;**28**(22):10181-10185.
1566) Rajana VM. Immune dysfunction in diabetes mellitus (DM). Int J Health Sci Res. 2017; **7**(12):256-275.
1567) Sanchez-Jimenez R, Ceron E, Bernal-Alcántara D, Castillejos-López M, Gonzalez-Trujano E, Negrete-García MC, Alvarado-Vasquez N. Association between IL-15 and insulin plasmatic concentrations in patients with pulmonary tuberculosis and type 2 diabetes. Tuberculosis. 2018;**111**:114-20.
1568) Sekhar S, Unnikrishnan MK, Rodrigues GS, Vyas N, Mukhopadhyay C. Antimicrobial susceptibility pattern of aerobes in diabetic foot ulcers in a South-Indian tertiary care hospital. The Foot. 2018;**37**:95-100.
1569) Simonsen JR, Harjutsalo V, Järvinen A, Kirveskari J, Forsblom C, Groop PH, Lehto M; FinnDianeStudy Group. Bacterial infections in patients with type 1 diabetes: a 14-year follow-up study. BMJ Open Diabetes Res Care. 2015; **3**(**1**):e000067.
1570) Sowmya AV, Jayalakshmi G, Agatha D. Community acquired pneumonia-current scenario among immunocompromised patients in a tertiary care hospital. International Journal of Bioassays. 2016; **5**(01):4715-4719.
1571) Shivekar SS, Manikandan R. Incidence of MDR surgical ward patients in rural te Puducherry. International Journal of Recent Trends in Science a http://www.statperson.com. 2015; **16**(2):478-481.

1572) Tayyab, M., Hanif, M., Rafey, A., Mohibullah, M., Rasool, S., ul Mahmood, F., ... & Amin, A. UHPLC, ATR-FTIR Profiling and Determination of 15 LOX, α-Glucosidase, Ages Inhibition and Antibacterial Properties of Citrus Peel Extracts. Pharmaceutical Chemistry Journal. 2021; 1-11.
1573) Thompson MG, Black CC, Pavlicek RL, Honnold CL, Wise MC, Alamneh YA, Moon JK, Kessler JL, Si Y, Williams R, Yildirim S, Kirkup BC Jr, Green RK, Hall ER, Palys TJ, Zurawski DV. Validation of a novel murine wound model of *Acinetobacter baumannii* infection. Antimicrob Agents Chemother. 2014; **58**(3):1332-1342.
1574) Uçkay I, Gariani K, Pataky Z, Lipsky BA. Diabetic foot infections: state-of-the-art. Diabetes, Obesity and Metabolism. 2014; **26**(4):305-316.
1575) Waked, R., Jaafar, D., Chedid, M., Saliba, G., Haddad, E., & Choucair, J. Impact of the inpatient infectious disease consultations at a tertiary care university hospital. The International Arabic Journal of Antimicrobial Agents. 2020; 10(2).
1576) Xie, M., Yu, J., Li, L., Jia, R., Song, X., Wang, Y., & Fan, X. Nomogram for Preoperative Estimation of Orbit Invasion Risk in Periocular Squamous Cell Carcinoma. Frontiers in oncology. 2020; 10, 564.
1577) Zemlianoi A.B., Zelenina T.A., Salukhov V.V. Parallels of infections of diabetic foot syndrome at inpatient and outpatient stages of treatment. Meditsinskiy Sovet, 2021(7): 68-76.
1578) Земляной, А. Б., Зеленина, Т. А., & Салухов, В. В. Параллели особенностей инфекций синдрома диабетической стопы на стационарном и амбулаторном этапах лечения. Вестник Национального медико-хирургического Центра им. НИ Пирогова. 2020; 15(4).

ЦИТИРАНА: 52A Boyanova L, Ilieva J, Gergova G, Evstatiev I, Nikolov R, Mitov I. Living in Sofia is associated with a risk for antibiotic resistance in *H. pylori*. A Bulgarian study. Folia Microbiol (Praha). 2013; **58** (6):587-591. **Цитирана от:**

1579) Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in *Helicobacter pylori*: A recent literature review. World J Methodol. 2015; **5**(3):164-174.
1580) Karpiński TM, Andrzejewska E, Eder P, Linke K, Szkaradkiewicz A. Evaluation of antimicrobial resistance of *Helicobacter pylori* in the last 15 years inWest Poland. Acta Microbiol Immunol Hung. 2015; **62**(3):287-293.
1581) Yang XT, Liu ZJ. Antimicrobial activities of four antibiotics against clinical isolates of *Helicobacter pylori*. Shijie Huaren Xiaohua Zazhi. 2014; **22**(26): 4041-4044. https://www.wjgnet.com/1009-3079/full/v22/i26/4041.htm

ЦИТИРАНА: 53A:Boyanova L, Panov V, Yordanov D, Gergova G, Mitov I. Characterization of oral *Helicobacter pylori* strain by 4 methods. Diagn Microbiol Infect Dis 2013; **77** (4): 287-288. **Цитирана от:**

1582) Ansari SA, Khan TA, Kazmi SU. Association of oral *Helicobacter pylori* with gastric complications. Life sciences. 2018;**205**:125-30.
1583) Cellini L. *Helicobacter pylori*: A chameleon-like approach to life. World J Gastroenterol. 2014; **20**(19): 5575-5582.
1584) Lou, X.-J., Shen, L.-N.,Chen, J., Li, L. Correlation of oral *Helicobacter pylori* infection with gastric *Helicobacter pylori* infection: Implications for eradication. World Chinese Journal of Digestology. 2016; **24**(18): 2918-2922.
1585) Mao, X., Jakubovics, N. S., Bächle, M., Buchalla, W., Hiller, K. A., Maisch, T., ... & Cieplik, F. Colonization of *Helicobacter pylori* in the oral cavity–an endless controversy?. Crit Rev Microbiol. 2021; 1-18.
1586) Veiga N, Pereira C, Resende C, Amaral O, Ferreira M, Nelas P, Chaves C, Duarte J, Cirnes L, Machado JC, Ferreira P, Correia IJ. Oral and gastric *Helicobacter pylori*: effects and associations. PLoS One. 2015; **10**(5):e0126923.
1587) Yacoubi A, Hassn MS, Almogbel E, Makhrelouf L, Bouziane D, Saleh AM. The Relationship of *Helicobacter pylori* and Dental Plaques with Gastric Dyspepsia. Ibnosina Journal of Medicine and Biomedical Sciences. 2017; **9**(1):12-16.
1588) Yee JK. *Helicobacter pylori* colonization of the oral cavity: A milestone discovery. World J Gastroenterol. 2016; **22**(2):641-648.
1589) Zaric S, Bojic B, Popovic B, Milasin J. Eradication of gastric *Helicobacter pylori* ameliorates halitosis and tongue coating. J Contemp Dent Pract. 2015; **16**(3):205-209.
1590) Щербак ВА, Щербак НМ. Новые данные об этиологии и патогенезе хронических гастродуоденитов у детей. Забайкальский медицинский вестник. 2014(3):148-155.

ЦИТИРАНА: 54A: Markovska R, Schneider I, Stoeva T, Bojkova K, **Boyanova L,** Bauernfeind A, Mitov I. First identification of KPC-2 and VIM-1 producing *Klebsiella pneumoniae* in Bulgaria. Diagn Microbiol Infect Dis. 2013;**77**(3):252-253. **Цитирана от:**

1591) Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL; European Survey of Carbapenemase-Producing *Enterobacteriaceae* (EuSCAPE) working group. Carbapenemase-producing *Enterobacteriaceae* in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill. 2015;**20**(45). doi: 10.2807/1560-7917.ES.2015.20.45.30062. Erratum in: Euro Surveill.2015; **20**(49).
1592) Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA. Multiyear, multinational survey of the incidence and global distribution of metallo-β-lactamase-producing *Enterobacteriaceae* and *Pseudomonas aeruginosa*. Antimicrob Agents Chemother. 2015; **60**(2):1067-1078.
1593) Poirel L, Savov E, Nazli A, Trifonova A, Todorova I, Gergova I, Nordmann P. Outbreak caused by NDM-1- and RmtB-producing *Escherichia co*li in Bulgaria. Antimicrob Agents Chemother. 2014; **58**(4):2472-2474.
1594) Sabtcheva S, Ivanov IN, Todorova B, Simeonov Y, Dobreva E, Ivanova K, Velinov T, Kantardjiev T. Detection and characterization of OXA-48-producing *Klebsiella pneumoniae* originated in Bulgaria. J Chemother. 2016; **28**(5):450-453.
1595) Thomson GK, Snyder JW, McElheny CL, Thomson KS, Doi Y. Coproduction of KPC-18 and VIM-1 carbapenemases by *Enterobacter cloacae*:implications for newer β-lactam-β-lactamase inhibitor combinations. J Clin Microbiol. 2016; **54**(3):791-794.
1596) Todorova B, Sabtcheva S, Ivanov IN, Lesseva M, Chalashkanov T, Ioneva M, Bachvarova A, Dobreva E, Kantardjiev T. First clinical cases of NDM-1-producing *Klebsiella pneumoniae* from two hospitals in Bulgaria. J Infect Chemother. 2016; **22**(12): 837-840.
1597) Trudić A, Jelesić Z, Mihajlović-Ukropina M, Medić D, Zivlak B, Gusman V, Đilas, M. Carbapenemase production in hospital isolates of multidrug-resistant *Klebsiella pneumoniae* and *Escherichia coli* in Serbia. Vojnosanitetski pregled, 2017; **74**(8):715-21.

ЦИТИРАНА: 54B: Adrian G. McNicholl AG, Tepes B, Gasbarrini A, Aisa AP, Vaira D, Bordin DS, Lerang F, Castro-Fernandez M, Bujanda L, Leja M, Vujasinovic M, Rokkas T, Kupcinskas L, Veijola L, Shvets O, Buzás GM, Machado JC, **Boyanova L**, …, Megraud F, O'Morain CA, Gisbert JP. Tu1328 Pan-European Registry on *H. pylori* Management (HP-EuReg): Interim Analysis of First- and Second-Line Treatments. Gastroenterology. 2016; 150 (4 Supplement 1): Page S875. **Цитирана от:**

1598) Cosme A, Torrente Iranzo S, Montes Ros M, Fernández-Reyes Silvestre M, Alonso Galán H, Lizasoain J, Bujanda L. *Helicobacter pylori* antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies. Helicobacter. 2019 Feb 1:e12557.
1599) Ramírez FB, Núñez CG, Mas MT, Jiménez NR, Caballero FL. Criterios para la erradicación de *Helicobacter pylori*. FMC: Formación Médica Continuada en Atención Primaria. 2018;**25**(1):43-53.
1600) Сафина ДД, Абдулхаков СР, Абдулхаков РА. Эрадикационная терапия *Helicobacter pylori*: настоящее и будущее. Экспериментальная и клиническая гастроэнтерология. 2016(11):84-93.

ЦИТИРАНА: 55A: Boyanova L. Comparative evaluation of the activity of plant infusions against *Helicobacter pylori* strains by three methods. World J Microbiol Biotechnol. 2014; **30** (5):1633-1637. **Цитирана от:**

1601) Krynicka P, Ochmanek R, Strojewska P, Brzeska M, Frydrych A. Wpływ składników pokarmowych na leczenie *Helicobacter pylori*. Nauki Przyrodnicze i Medyczne: Najnowsze doniesienia dotyczące nauk medycznych i biotechnologicznych.:50-68.
1602) Lee SM, Park SY, Kim MJ, Cho EA, Jun CH, Park CH, Kim HS, Choi SK, Rew JS. Key lime (*Citrus aurantifolia*) inhibits the growth of triple drug resistant *Helicobacter pylori*. Gut Pathog. 2018;**10**(1):16.
1603) Malm A, Glowniak-Lipa A, Korona-Glowniak I, Baj T. Anti-*Helicobacter pylori* activity in vitro of chamomile flowers, coneflower herbs, peppermint leaves and thyme herbs – a preliminary report. Current Issues in Pharmacy and Medical Sciences. 2015; **28**(1):30-32.
1604) Menegazzi, M., Masiello, P., & Novelli, M. Anti-Tumor Activity of Hypericum perforatum L. and Hyperforin through Modulation of Inflammatory Signaling, ROS Generation and Proton Dynamics. Antioxidants. 2021; 10(1), 18.
1605) Nash LA, Ward WE. Tea and bone health: findings from human studies, potential mechanisms, and identification of knowledge gaps. Crit Rev Food Sci Nutr. 2015; **57**(8): 1603-1617.
1606) Sarnowska M, Gawron-Gzella A. Rooibos (*Aspalathus linearis* (Burm. f.) R. Dahlgren) – substancje biologicznie aktywne i działanie farmakologiczne [Rooibos (*Aspalathus linearis* (Burm. f.) R. Dahlgren) – biological active substances and farmacological activity]. Borgis - Postępy Fitoterapii. 2016; 3:189-199. http://www.czytelniamedyczna.pl/5803,rooibos-aspalathus-linearis-burm-f-r-dahlgren-substancje-biologicznie-aktywne-i.html
1607) Venegas, A., Touma, J. H., Bravo, J., & Perez-Perez, G. Progress in use of natural products and their active components against *Helicobacter pylori*. Advances in Microbiology. 2016; **6**(14):1091.
1608) Zea D, Bayona M. Actividad antimicrobiana de productos naturales contra *Helicobacter pylori*. Revista Venezolana de Salud Pública. 2017;**5**(2):19-26.

ЦИТИРАНА: 56A: Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I. *Helicobacter pylori* susceptibility to fosfomycin, rifampin and five usual antibiotics for *H. pylori* eradication. Diagn Microbiol Infect Dis 2014; **79**:358–361. **Цитирана от:**

1609) Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in *Helicobacter pylori* infection. World J Gastroenterol. 2017; **23**(16):2854-2869.
1610) Bedoya-Gómez IJ, Alvarez-Aldana A., Moncayo-Ortiz JI, Guaca-González YM, Santacruz-Ibarra JJ, Arturo-Arias BL, ... & Beltrán-Angarita L. Surveillance of the antimicrobial resistance rates of *Helicobacter pylori* ten years later in the Western Central Region, Colombia. Dig Dis. 2020; **38**(3), 196-203.
1611) Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, Sevuk EO, Demirci M, Yılmazli O, Akgul O, Kalayci F, Cakan H, Salih B, Bal K, Kocazeybek B. Antimicrobial resistance of *Helicobacter pylori* strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop. 2015; **48**(3):278-284.
1612) Elmesky, M. M., Deghady, A. A., Ellakany, A. S., & Saad, N. A. Comparison Between Triple Therapy Versus Salvage Therapy in the Treatment of *Helicobacter Pylori* Infection in Some Egyptian Patients. Alexandria journal. 2016; XXI:
1613) Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin. Microbiol. Rev. 2016; **29**(2):321-347.
1614) Goudarzi M, Heidary M, Azad M, Fazeli M, Goudarzi H. Evaluation of antimicrobial susceptibility and integron carriage in *Helicobacter pylori* isolates from patients. Gastroenterol Hepatol Bed Bench. 2016; **9**(Suppl1):S47-S52.
1615) Güven, B., Gülerman, F., & Kaçmaz, B. *Helicobacter pylori* resistance to clarithromycin and fluoroquinolones in a pediatric population in Turkey: A cross-sectional study. Helicobacter. 2019;, 24(3), e12581.
1616) Hays C, Burucoa C, Lehours P, Tran CT, Leleu A, Raymond J. Molecular characterization of *Helicobacter pylori* resistance to rifamycins. Helicobacter. 2018;**23**(1). doi: 10.1111/hel.12451
1617) Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of *H. pylori* in Turkey: A systematic review. Helicobacter. 2016; **21**(4):251-260.
1618) Naik DG. *Helicobacter pylori* mediated gastritis, peptic ulcer and gastric cancer. International Journal of Biochemistry and Biomolecules. 2016; **1**(1-2):36-42.
1619) Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for *Helicobacter pylori* eradication in Italy. World J Gastroenterol. 2015; **21**(21):6698-6705.
1620) Sarfo FS, Eberhardt KA, Dompreh A, Kuffour EO, Soltau M, Schachscheider M, Drexler JF, Eis-Hübinger AM, Häussinger D, Oteng-Seifah EE, Bedu-Addo G, Phillips RO, Norman B, Burchard G, Feldt T. *Helicobacter pylori* infection is associated with higher CD4 T cell counts and lower HIV-1 viral loads in ART-naïve HIV-positivepatients in Ghana. PLoS One. 2015; **10**(11):e0143388.
1621) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;**155**(5):1372-82.

1622) Silvan, J. M., Gutiérrez-Docio, A., Moreno-Fernandez, S., Alarcón-Cavero, T., Prodanov, M., & Martinez-Rodriguez, A. J. Procyanidin-rich extract from grape seeds as a putative tool against *Helicobacter pylori*. Foods. 2020; 9(10), 1370.
1623) Talebi Bezmin Abadi A. *Helicobacter pylori* treatment: New perspectives using current experience. J Glob Antimicrob Resist. 2017;**8**:123-130.
1624) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016; **43**(4):514-533.
1625) Xu Z, Yan A. Multidrug efflux systems in microaerobic andanaerobic bacteria. Antibiotics (Basel). 2015; **4**(3):379-396.
1626) Zdzieblo M. , Andrzejczuk S. , Chudzik-Rzad B. , Juda M. , Malm A. Fosfomycin as an alternative therapeutic option for treatment of infections caused by multi-resistant Gram-negative bacteria. Journal of Pre-Clinical and Clinical Research. 2014; **08**(2):51-54.
1627) Zollner-Schwetz I, Leitner E, Plieschnegger W, Semlitsch G, Stepan V, Reiter L, Reicht G, Mörth E, Pavek J, Parsché P, Betterklieber C, Atzmüller D, Krause R, Högenauer C. Primary resistance of *Helicobacter pylori* is still low in Southern Austria. Int J Med Microbiol. 2016; **306**(4):206-211.
1628) Ахметова, Д. Г., Балтабекова, А. Ж., & Шустов, А. В. Устойчивость к антибиотикам *Helicobacter pylori*: обзор эпидемиологических тенденций и проблемы терапии. Русский медицинский журнал. Медицинское обозрение. 2018; 2(7-1), 13-18.

ЦИТИРАНА: 57A:Boyanova L, Sabov R, Kolarov R, Mitov I. Chronic odontogenic osteomyelitis and facial actinomycosis of six-month duration. JMM Case Reports. 2014 DOI 10.1099/jmmcr.0.000729 **Цитирана от:**

1629) Thukral R, Shrivastav K, Mathur V, Barodiya A, Shrivastav S. Actinomyces: a deceptive infection of oral cavity. Journal of the Korean Association of Oral and Maxillofacial Surgeons. 2017;**43**(4):282-285.

ЦИТИРАНА: 58A: Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015, **31**: 4-10. **Цитирана от:**

1630) Abdu, A. R., Egbagba, J., Fente, B. G. Identification and antimicrobial susceptibility profile of bacterial pathogens isolated from wound infections in a tertiary hospital, Bayelsa South southern, Nigeria. Trop J Path Micro. 2019; 5(12), 966-975.
1631) Al-Hamdoni, S. A. S., & Al-Rawi, A. M. M. Assessment the Effect of Some Reagents on the Planktonic Cells and Biofilms of Red Complex Periodontal Pathogens. International Journal of Sciences: Basic and Applied Research (IJSBAR). 2020; 51(2): 1-13
1632) Akhi MT, Ghotaslou R, Alizadeh N, Yekani M, Beheshtirouy S, Asgharzadeh M, Pirzadeh T, Memar MY. *nim* gene-independent metronidazole-resistant *Bacteroides fragilis* in surgical site infections. GMS hygiene and infection control. 2017;**12**:Doc13-.
1633) Albrecht, J., Barbaric, J., & Nast, A. Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? Reply from the authors. The British journal of dermatology, 2019;180(5), 1262-1263.
1634) Allenspach, K. Bacteria involved in acute haemorrhagic diarrhoea syndrome in dogs. Veterinary Record. 2015; **176**(10): 251-252.
1635) Andersen JM, Shoup M, Robinson C, Britton R, Olsen KE, Barrangou R. CRISPR diversity and in *Clostridium difficile*. Genome Biol Evol. 2016; **8**(9):2841-2855.
1636) Badr, M. T., Blümel, B., Baumgartner, S., Komp, J., & Häcker, G. Antimicrobial Susceptibility Patterns and Wild-Type MIC Distributions of Anaerobic Bacteria at a German University Hospital: A Five-Year Retrospective Study (2015–2019). Antibiotics. 2020; 9(11), 823.
1637) Bhat, K. G., Ingalagi, P., Patil, S., Patil, S., & Pattar, G. Antimicrobial susceptibility pattern of oral gram negative anaerobes from Indian subjects. Anaerobe. 2021; 70, 102367.
1638) Cherkaoui A, Fischer A, Azam N, Riat A, Schrenzel J. A comparison of Sensititre™ Anaerobe MIC plate with ATB ANA® test for the routine susceptibility testing of common anaerobe pathogens. European Journal of Clinical Microbiology & Infectious Diseases. 2018;**37**(12):2279-84.
1639) Cobo, F., Rodríguez-Granger, J., Pérez-Zapata, I., Sampedro, A., Aliaga, L., & Navarro-Marí, J. M. Antimicrobial susceptibility and clinical findings of significant anaerobic bacteria in southern Spain. Anaerobe. 2019; 59, 49-53.
1640) Cobo, F., Pérez-Carrasco, V., Gómez-Vicente, E., Martín-Hita, L., García-Salcedo, J. A., & Navarro-Marí, J. M. First case of abdominal infection caused by Bacteroides fluxus. Anaerobe. 2021; 69, 102363.
1641) Colney, Z., Antony, B., & Kanthaje, S. Genotyping of multi drug resistant *Bacteroides fragilis* group of clinical isolates from mangalore, south India. Indian journal of medical microbiology. 2021; 39(1), 19-23.
1642) Cooley L, Teng J. Anaerobic resistance: should we be worried?. Current opinion in infectious diseases. 2019; 32(6), 523-530.
1643) Dahlen G, Preus HR. Low antibiotic resistance among anaerobic Gram-negative bacteria in periodontitis 5 years following metronidazole therapy. Anaerobe. 2017; **43**:94-98.
1644) de Sá Almeida, J. S., de Oliveira Marre, A. T., Teixeira, F. L., Boente, R. F., Domingues, R. M., de Paula, G. R., & Lobo, L. A. Lactoferrin and lactoferricin B reduce adhesion and biofilm formation in the intestinal symbionts *Bacteroides fragilis* and Bacteroides thetaiotaomicron. Anaerobe. 2020; 64, 102232.
1645) Dellinger EP. Cephalosporin plus metronidazole for surgical prophylaxis. Surgical infections. 2018;**19**(4):359-61.
1646) Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 2018;**73**(2):265-279.
1647) Dumont Y, Michon AL, Laurens C, Bonzon L, Godreuil S, Jean-Pierre H. Rôle du laboratoire de biologie médicale dans le diagnostic microbiologique des bactéries anaérobies. Revue Francophone des Laboratoires. 2018;**2018**(505):40-7.
1648) El Badawy NE, El shabrawy RM, Ghonaim RA, Allam Z. Identification and detection of antibiotic susceptibility of the most common anerobes causing infection in surgical hospital, Faculty of Medicine Zagazig University, Egypt. African Journal of Clinical and Experimental Microbiology. 2016; **17**(2): 140-150.

1649) Gaetti-Jardim Jr E, Correia ASC, Schweitzer CM. Mecanismos de resistência aos antibióticos e quimioterápicos com antimicrobiana empregados no tratamento das infecções de cabeça e pescoço. Revista Visão Universitária. 2015; **2**(1): http://www.visaouniversitaria.com.br/ojs/index.php/home/article/view/69
1650) Gajdács M, Spengler G, Urbán E. Identification and antimicrobial susceptibility testing of anaerobic bacteria: Rubik's cube of clinical microbiology?. Antibiotics. 2017;**6**(4):25.
1651) Gajdács, M., Terhes, G., & Urbán, E. Az anaerob baktériumok által okozott véráramfertőzések gyakorisága 2005–2009 és 2013–2017 között egy egyetemi központban. Retrospektív összehasonlító vizsgálat. Orvosi Hetilap. 2020; 161(19), 797-803.
1652) Galliguez, T., Tsou, P. Y., Cabrera, A., & Fergie, J. Next-generation sequencing-based clinical metagenomics identifies Prevotella pleuritidis in a diabetic adolescent with large parapneumonic effusion and negative growth of pleural fluid culture: a case report. British Journal of Biomedical Science. 2021; 78(2), 101-105.
1653) García-Bayona L, Comstock LE. Streamlined genetic manipulation of diverse *Bacteroides* and *Parabacteroides* isolates from the human gut microbiota. MBio. 2019] 10(4).
1654) Gilarranz-Luengo R, Chamizo-López FJ, Horcajada-Herrera I, Bordes-Benítez A. Trends in antimicrobial susceptibility among anaerobes in Gran Canaria: Analysis of 15-years data. Enferm Infecc Microbiol Clin. 2016; **34**(3):210-211.
1655) Gil-Tomás JJ, Jover-García J, Colomina-Rodríguez J. Vigilancia de la sensibilidad antibiótica de anaerobios gramnegativos: RedMiVa 2010-2016. Enfermedades Infecciosas y Microbiología Clínica. 2018;**36**(3):200-1.
1656) Gustafson CT, Boakye-Agyeman F, Brinkman CL, Reid JM, Patel R, Bajzer Z, Dadsetan M, Yaszemski MJ. Controlled delivery of vancomycin via charged hydrogels. PLoS One. 2016; **11**(1):e0146401.
1657) Haidar YM, Tripathi PB, Tjoa T, Walia S, Zhang L, Chen Y, Nguyen DV, Mahboubi H, Armstrong WB, Goddard JA. Antibiotic prophylaxis in clean-contaminated head and neck cases with microvascular free flap reconstruction: A systematic review and meta-analysis. Head & neck. 2018;**40**(2):417-27.
1658) Hansen KCM, Schwensen SAF, Henriksen DP, Justesen US, Sydenham TV. Antimicrobial resistance in the *Bacteroides fragilis* group in faecal samples from patients receiving broad-spectrum antibiotics. Anaerobe. 2017; **47**:79-85.
1659) Hastey CJ, Boyd H, Schuetz AN, Anderson K, Citron DM, Dzink-Fox J, Hackel M, Hecht DW, Jacobus NV, Jenkins SG, Karlsson M, Knapp CC, Koeth LM, Wexler H, Roe-Carpenter DE; From the Ad Hoc Working Group on Antimicrobial Susceptibility Testing of Anaerobic Bacteria of CLSI. Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology. Anaerobe. 2016; **42**:27-30.
1660) Ho PL, Yau CY, Ho LY, Lai EL, Liu MC, Tse CW, Chow KH. Antimicrobial susceptibility of *Bacteroides fragilis* group organisms in Hong Kong by the tentative EUCAST disc diffusion method. Anaerobe. 2017; **47**:51-56. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.819.3234&rep=rep1&type=pdf
1661) Hwang, S., Jo, M., Hong, J. E., Park, C. O., Lee, C. G., Yun, M., & Rhee, K. J. Zerumbone suppresses enterotoxigenic *Bacteroides fragilis* infection-induced colonic inflammation through inhibition of NF-κB. International journal of molecular sciences. 2019; 20(18), 4560.
1662) Ishak, N., Wahab, Z. A., Nordin, S. A., & Ibrahim, R. Susceptibility patterns of anaerobes isolated from clinical specimens in tertiary Hospital, Malaysia. The Malaysian Journal of Pathology. 2020; 42(2), 245-252.
1663) Jasemi S, Emaneini M, Ahmadinejad Z, Fazeli MS, Sechi LA, Heravi FS, Feizabadi MM. Antibiotic resistance pattern of *Bacteroides fragilis* isolated from clinical and colorectal specimens. Annals of Clinical Microbiology and Antimicrobials. 2021; **20**(1), 1-8.
1664) Jayasimhan D, Wu L,Huggan P. Fusobacterial liver abscess: a case report and review of the literature. BMC Infect Dis. 2017;**17**(1):440.
1665) Jeverica S, Kolenc U, Mueller-Premru M, Papst L. Evaluation of the routine antimicrobial susceptibility testing results of clinically significant anaerobic bacteria in a Slovenian tertiary-care hospital in 2015. Anaerobe. 2017; **47**:64-69.
1666) József S. The clinically important anaerobic, human pathogenic Bacteroides species and their antibiotic resistance levels in Central and Southeast Europe. Bulletin of Medical Sciences. 2018;**91**(1):19-25.
1667) Kierzkowska M, Majewska A, Sawicka-Grzelak A, Mlynarczyk A, Chmura A, Kwiatkowski A, Durlik M, Paczek L, Mlynarczyk G. Antibiotic resistance profiles of strictly anaerobic Gram-negative *Bacteroides* spp. and *Parabacteroides* spp. bacilli isolated from infected inpatients on surgical wards. J Glob Antimicrob Resist. 2016; **7**:128-129. .
1668) Kierzkowska M, Majewska A, Szymanek-Majchrzak K, Sawicka-Grzelak A, Mlynarczyk A, Mlynarczyk G. In vitro effect of clindamycin against *Bacteroides* and *Parabacteroides* isolates in Poland. J Glob Antimicrob Resist. 2017:128.
1669) Kierzkowska M, Majewska A, Szymanek-Majchrzak K, Sawicka-Grzelak A, Młynarczyk A, Młynarczyk G. Oporność typu MLSB u klinicznych izolatów *Bacteroides* i *Parabacteroides* MLSB resistance in clinical isolates of *Bacteroides* and *Parabacteroides*. Organ narodowego instytutu zdrowia publicznego, 49. Med. Dośw. Mikrobiol., 2018, 70: 49 - 56
1670) Kierzkowska M, Majewska A, Mlynarczyk G. Trends and impact in antimicrobial resistance among *Bacteroides* and *Parabacteroides* species in 2007–2012 compared to 2013–2017. Microbial Drug Resist. 2020; **26**(12):1452-1457.
1671) Kim YA. The importance of the early and appropriate treatment of anaerobic bacteremia patients. Infect Chemother. 2016; **48**(2):143-144.
1672) Kim, M., Kim, H. S., Song, Y. J., Lee, E., Song, K. H., Choe, P. G., ... & Kim, H. B. Redundant combinations of antianaerobic antimicrobials: Impact of pharmacist-based prospective audit and feedback and prescription characteristics. European Journal of Clinical Microbiology & Infectious Diseases. 2020; 39(1), 75-83.
1673) Kierzkowska, M., Majewska, A., Szymanek-Majchrzak, K., Sawicka-Grzelak, A., Mlynarczyk, A., & Mlynarczyk, G. The presence of antibiotic resistance genes and bft genes as well as antibiotic susceptibility testing of *Bacteroides fragilis* strains isolated from inpatients of the Infant Jesus Teaching Hospital, Warsaw during 2007–2012. Anaerobe. 2019; 56, 109-115.
1674) Langerman A, Ham SA, Pisano J, Pariser J, Hohmann SF, Meltzer DO. Laryngectomy complications are associated with perioperative antibiotic choice. Otolaryngol Head Neck Surg. 2015; **153**(1):60-68.
1675) Litterio MR, Cejas D, Gutkind G, Radice M. Identification of CfiA coding genes in *Bacteroides fragilis* isolates recovered in Argentina. Inconsistencies in CfiA organization and nomenclature. Anaerobe. 2017;**48**:257-261.

1676) Man MY, Shum HP, Wu A, Lee RA, Yan WW. A case of severe empyema with acute respiratory distress syndrome caused by *Slackia exigua* requiring veno-venous extracorporeal membrane oxygenation. Anaerobe. 2017; **48**:7-11.
1677) Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, Chang PK, O'Neill PJ, Mollen KP, Huston JM, Diaz JJ Jr, Prince JM. The Surgical Infection Society Revised Guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;**18**(1):1-76.
1678) Memar, M. Y., Yekani, M., Aghazadeh, M., & Baghi, H. B. Antibiotic Treatment of Anaerobic Infections: Uncharted Land in Iran. Iranian journal of public health. 2019; 48(11), 2103-2104.
1679) Merchan C, Parajuli S, Siegfried J, Scipione MR, Dubrovskaya Y, Rahimian J. Multidrug-resistant *Bacteroides fragilis* bacteremia in a US resident: an emerging challenge. Case Reports in Infectious Diseases. 2016, Article ID 3607125, doi:10.1155/2016/3607125
1680) Nagy E, Schuetz A. Is there a need for the antibiotic susceptibility testing of anaerobic bacteria? Anaerobe. 2015; **31**:2-3.
1681) Niestępski S, Harnisz M, Korzeniewska E, Aguilera-Arreola MG, Contreras-Rodríguez A, Filipkowska Z, Osińska A. The emergence of antimicrobial resistance in environmental strains of the Bacteroides fragilis group. Environment international. 2019;**124**:408-19.
1682) Oller I, Ruiz-Tovar J, Cansado P, Zubiaga L, Calpena R. Effect of lavage with gentamicin vs. clindamycin vs. physiologic saline on drainage discharge of the axillary surgical bed after lymph node dissection. Surg Infect (Larchmt). 2015; **16**(6):781-784.
1683) Peeters AB. Critically Appraised Topic. A clinically orientated procedure for the workup of anaerobic bacteria in the era of MALDI-TOF: feasible or fiction? 2015: https://www.uzleuven.be/sites/default/files/Laboratoriumgeneeskunde/CAT%20150519_anaeroben.pdf
1684) Peeters B, Magerman K, Waumans L, Cartuyvels R. Laboratory survey and literature review of anaerobic bacteriology: foundations of aclinically orientated and evidence-based workup for anaerobic cultures. Diagn Microbiol Infect Dis. 2016; **86** (1):15-22.
1685) Petersen MW, Perner A, Bahador M, Sjövall F, Møller MH. Empirical metronidazole for patients with severe bacterial infection: protocol for a systematic review. Acta Anaesthesiologica Scandinavica. 2018;**62**(5):724-30.
1686) Rams TE, Sautter JD, van Winkelhoff AJ. Antibiotic resistance of human periodontal pathogen *Parvimonas micra* over 10 years. Antibiotics. 2020; **9**(10), 709.
1687) Rodloff AC, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European collection of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST) 2010–2016. Anaerobe. 2018;**51**:78-88.
1688) Sárvári KP, Sóki J, Kristóf K, Juhász E, Miszti C, Latkóczy K, Melegh SZ, Urbán E. A multicentre survey of the antibiotic susceptibility of clinical *Bacteroides* species from Hungary. Infectious Diseases. 2018 ; **50**(5):372-80.
1689) Sayın E. Türkiye'deki Bir Üniversite Eğitim ve Araştırma Hastanesinde Elde Edilen Toksijenik *Clostridioides difficile* İzolatlarına Antimikrobiyallerin İn Vitro Etkisi. Mikrobiyol Bul. 2020; **54**(3), 368-377.
1690) Schwensen SA, Henriksen DP, Justesen US, Sydenham TV. Antimicrobial resistance in the *Bacteroides fragilis* group in faecal samples from patients receiving broad-spectrum antibiotics. Anaerobe. 2017;**47**:79-85.
1691) Shafquat Y, Jabeen K, Farooqi J, Mehmood K, Irfan S, Hasan R, Zafar A. Antimicrobial susceptibility against metronidazole and carbapenem in clinical anaerobic isolates from Pakistan. Antimicrobial Resistance & Infection Control. 2019; **8**(1), 1-7.
1692) Sóki J, Székely E. A klinikailag fontos humán patogén anaerob *Bacteroides* fajok és antibiotikumérzékenységi szintjeik Közép-és Délkelet-Európában. Bulletin of medical sciences/orvostudományi értesítő. 2018; **91**(1), 19-25.
1693) Steininger C, Willinger B. Resistance patterns in clinical isolates of pathogenic *Actinomyces* species. J Antimicrob Chemother. 2016; **71**(2):422-427.
1694) Sydenham TV, Jensen BH, Petersen AM, Krogfelt KA, Justesen US. Antimicrobial resistance in the *Bacteroides fragilis* group in faecal microbiota from healthy Danish children. Int J Antimicrob Agents. 2017; **49**(5):573-578.
1695) Sydenham TV, Sóki J, Hasman H, Wang M, Justesen US. Identification of antimicrobial resistance genes in multidrug-resistant clinical *Bacteroides fragilis* isolates by whole genome shotgun sequencing. Anaerobe. 2015; **31**:59-64.
1696) Tan TY, Ng LS, Kwang LL, Rao S, Eng LC. Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital. Anaerobe. 2017; **43**:69-74.
1697) Teng JC, Dreyer L. Antimicrobial susceptibility patterns of anaerobic bacteria in Victoria, Australia. bioRxiv. 2018 Jan 1:308023.
1698) Terheyden H. Komplexe Augmentationen. Der MKG-Chirurg. 2016; **9**: 35. doi:10.1007/s12285-015-0035-0
1699) Toprak NU, Alida V, Urban E, Wybo I, Justesen US, Jean-Pierre H, Morris T, Akgul O, Kulekci G, Soyletir G, Nagy E. Performance of mass spectrometric identification of clinical *Prevotella* species using the VITEK MS system: A prospective multi-center study. Anaerobe. 2018; **54**:205-209.
1700) Toprak NU, Veloo AC, Urban E, Wybo I, Justesen US, Jean-Pierre H, Morris T, Akgul O, Kulekci G, Soyletir G, Nagy E. A multicenter survey of antimicrobial susceptibility of *Prevotella* species as determined by Etest methodology. Anaerobe. 2018;**52**:9-15.
1701) Tunckanat, F., Sancak, B., Altun, B., Dursun, E., & Akdogan-Kittana, F. N.. Investigation of Antibiotic Susceptibilities of Anaerobic Bacteria Isolated From Patients With Chronic Periodontitis/Kronik Periodontitli Hastalardan Izole Edilen Anaerop Bakterilerin Antibiyotik Duyarlilik Durumlarinin Arastirilmasi. KLIMIK Journal. 2019; 32(3), 240-245.
1702) Ugarte-Torres A, Gillrie MR, Griener TP, Church DL. *Eggerthella lenta* bloodstream infections are associated with increased mortality following empiric piperacillin-tazobactam (TZP) monotherapy: A population-based cohort study. Clinical Infectious Diseases. 2018; **67**(2):221-8.
1703) Ülger Toprak N. İstanbul'da İki Merkeze ait *Prevotella* Türlerinin Gradiyent Test Yöntemiyle Belirlenen Antimikrobiyal İlaç Duyarlılığı. Mikrobiyol Bul, 2020; 54(2), 246-256.
1704) Večeřová R, Panáček A, Kolář M. Effect of silver nanoparticles on anaerobic bacteria | [Účinek nanočástic stříbra na anaerobní bakterie]. Klinicka Mikrobiologie a Infekcni Lekarstvi. 2017; **23**(1):17-20.

1705) Veloo ACM, van Winkelhoff AJ. Antibiotic susceptibility profiles of anaerobic pathogens in The Netherlands. Anaerobe. 2015; **31**:19-24.
1706) Veloo ACM, Tokman HB, Jean-Pierre H, Dumont Y, Jeverica S, Lienhard R, ... & ESGAI study group. Antimicrobial susceptibility profiles of anaerobic bacteria, isolated from human clinical specimens, within different European and surrounding countries. A joint ESGAI study. Anaerobe. 2020; **61**, 102111.
1707) Zhang J, Liang H, Zheng Y, Wang D, Xia J, Peng W, Cheng K, Wang L, Liu Y, Peng W, Li Q. Photodynamic therapy versus systemic antibiotic for the treatment of periodontitis in a rat model. Journal of periodontology. 2019 Jan 11.
1708) Zhang X, Bai Y, Zhang L, Draz MS, Ruan Z, Zhu Y. Antimicrobial susceptibility and clonality of vaginally derived multidrug-resistant *Mobiluncus* isolates in China. Antimicrob Agents Chemother. 2020; **64**(8).
1709) Zhang CY, Li MH, Guo MQ. A phase conversion headspace technique for the determination of anti-anaerobic activity of drug candidate based on the metabolic acidity change in culture medium. Journal of Chromatography A. 2020; 1621: 461024.
1710) Zhao-Fleming H, Dissanaike S, Rumbaugh K. Are anaerobes a major, underappreciated cause of necrotizing infections? Anaerobe. 2017; **45**:65-70.
1711) Zhou XJ, Gong LJ, Li J, Liu QC, Zhu DS. Intestinal flora changes in a mouse model of transverse aortic constriction. Medical Journal of Chinese People's Liberation Army. 2016; **41**(10):808-812.

ЦИТИРАНА: 59A: Boyanova L. Susceptibility of anaerobes to fusidic acid and fosfomycin. Int J Antimicrob Agents. 2015; **45**(5):560-561. **Цитирана от:**

1712) Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D. Activity of fosfomycin when tested against US contemporary bacterial isolates. Diagn Microbiol Infect Dis. 2019;**93**(2):143-6.
1713) Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ, Shortridge D. Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against gram-negative bacterial strains by using time-kill curves. Antimicrob Agents Chemother. 2019: **63(**5).
1714) Grabein B, Graninger W, Baño JR, Dinh A, Liesenfeld DB. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017; **23(**6):363-372.
1715) Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732-9.
1716) Williams PC, Waichungo J, Gordon NC, Sharland M, Murunga S, Kamau A, Berkley JA. The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria. J Med Microbiol. 2019; **68**(5): 711.

ЦИТИРАНА: 60A: Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. Diagn Microbiol Infect Dis 2015; **82**(1):85-86. **Цитирана от:**

1717) Abdel-Latif MM, Abouzied MM. Molecular mechanisms of natural honey against *H. pylori* infection via suppression of NF-κB and AP-1 activation in gastric epithelial cells. Arch Med Res. 2016; **47**(5):340-348.
1718) Aleixo MLM, Galbiati C, Lemos LMS. Produtos naturais anti - *Helicobacter pylori*: revisão. Revista Ibero-Americana de Ciências Ambientais. 2018;9(1). http://www.sustenere.co/index.php/rica/article/view/CBPC2179-6858.2018.001.0005/1049
1719) Butler J. Honey–the new hope or the new hype?. Energy (kcal).; **318**(298):257. https://www.vivahealth.org.uk/healthfeatures/honey-hope-or-hype
1720) Chiu HF, Venkatakrishnan K, Golovinskaia O, Wang CK. Gastroprotective effects of polyphenols against various gastro-intestinal disorders: A Mini-Review with Special Focus on Clinical Evidence. Molecules. 2021; **26**(7), 2090. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038706/
1721) Coșarcă S, Tanase C, Muntean DL. Therapeutic aspects of catechin and its derivatives–an update. Acta Biologica Marisiensis. 2019; **2**(1): 21-29. https://abmj.ro/wp-content/uploads/2019/07/26685124-Acta-Biologica-Marisiensis-Therapeutic-Aspects-of-Catechin-and-Its-Derivatives-%E2%80%93-An-Update.pdf
1722) Debraekeleer A, Remaut H. Future perspective for potential *Helicobacter pylori* eradication therapies. Future Microbiology. 2018;**13**(06):671-87.
1723) Ebrahimpour S, Esmaeili H, Ghadimi R. Food bioactive components, a possible adjuvant for *H. pylori* eradication. Caspian J Intern Med 2017; **8(**2): 130-131.
1724) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. The Turkish Journal of Gastroenterology, 2020; **31**(3): 221.
1725) Farzaei MH, Abdollahi M, Rahimi R. Role of dietary polyphenols in themanagement of peptic ulcer. World J Gastroenterol. 2015; **21**(21):6499-6517.
1726) Hołubiuk Ł, Imiela J. Diet and *Helicobacter pylori* infection. Przeglad gastroenterologiczny. 2016; **11**(3):150.
1727) Hroncová Z, Konopásková K, Volštátová T, Killer J. Quantification of Firmicutes, Actinobacteria, and Gammaproteobacteria from Bohemian Honey. Scientia Agriculturae Bohemica. 2018;**49**(3):192-200.
1728) Kolaylı S , Baltas N , Sahin H, Karaoglu S. Evaluation of anti-*Helicobacter pylori* activity and urease inhibition by some Turkish authentic honeys. Journal of Food Science and Engineering 2017;**7**: 67-73.
1729) Maris H, PlaceboNocebo H. Honing & thee beschermen tegen *Helicobacter pylori*.
1730) Mitchell D. 8 Ways to Heal Gut Bacteria Naturally. https://naturallysavvy.com/care/8-ways-to-heal-gut-bacteria-naturally/
1731) Mohtashami R, Huseini HF, Heydari M, Amini M, Sadeqhi Z, Ghaznavi H, Mehrzadi S. Efficacy and safety of honey based formulation of *Nigella sativa* seed oil infunctional dyspepsia: A double blindrandomized controlled clinical trial. J Ethnopharmacol. 2015;**175**:147-152.
1732) Naveed M, BiBi J, Kamboh AA, Suheryani I, Kakar I, Fazlani SA, FangFang X, Yunjuan L, Kakar MU, El-Hack ME, Noreldin AE. Pharmacological values and therapeutic properties of black tea (*Camellia sinensis*): A comprehensive overview. Biomedicine & Pharmacotherapy. 2018;**100**:521-31.
1733) Özturan A, Bilici S, Sargin Zg, Karakan T. *Helicobacter pylori* enfeksiyonu olan bireylerde tedavi öncesi ve sonrasi beslenme durumlarinin değerlendirilmesi üzerine bir araştirma. Gazi Sağlık Bilimleri Dergisi. 2017;**2**(2):20-31.

1734) Puścion-Jakubik A, Borawska MH, Socha K. Modern methods for assessing the quality of bee honey and botanical origin identification. Foods. 2020; **9**(8): 1028.
1735) Puścion-Jakubik A, Socha K, Borawska MH. Comparative study of labelled bee honey from Poland and the result of the melissopalynological analysis. Journal of Apicultural Research. 2020; **59**(5), 928-938.
1736) Quraisiah A, Fazalda A, Alfizah H, Azlina MFN. In vitro Study of Anti-*Helicobacter pylori* Activity of Honey: A systematic review. Sains Malaysiana. 2020; **49**(2): 411-420.
1737) Rezaeimanesh N, Farzi N, Pirmanesh S, Emami S, Yadegar A. Management of multi-drug resistant *Helicobacter pylori* infection by supplementary, complementary and alternative medicine; a review. Gastroenterology and Hepatology from bed to bench. 2017;**10**(Suppl1):S8.
1738) Samanta S. Potential bioactive components and health promotional benefits of tea (*Camellia sinensis*). Journal of the American College of Nutrition. 2020; 1-29.
1739) Serafim C, Araruna ME, Júnior EA, Diniz M, Hiruma-Lima C, Batista L. A Review of the role of flavonoids in peptic ulcer (2010–2020). Molecules. 2020; **25**(22), 5431.
1740) Venegas A, Touma JH, Bravo J, Perez-Perez G. Progress in use of natural products and their active components against *Helicobacter pylori*. Advances in Microbiology. 2016; **6**(14):1091-1129.

ЦИТИРАНА: 61A: Boyanova L, Kolarov R, Mateva L, Markovska R, Mitov I. Actinomycosis- a frequently forgotten disease. Future Microbiol. 2015; **10**(4): 613–628. **Цитирана от:**

1741) Abo-Zed A, Yassin M, Phan T. A rare case of polymicrobial brain abscess involving Actinomyces. Radiology case reports. 2021; **16**(5), 1123-1126.
1742) Ahmadi A, Salem MM, Safdarian M, Ilkhani S, Hamidian R, Cheraghipour M, Daneshvar A, Izadi F. Management of Laryngocutaneous Fistula following Chondroradionecrosis of the Larynx in a Patient with Laryngeal Actinomycosis. Iranian Journal of Otorhinolaryngology. 2017;**29**(3):154.
1743) Aini RI, Ratunanda SS, Wijana W, Permana AD, Mahdiani S. Aktinomikosis di tonsil lingualis dan supraglotis sebagai manifestasi klinis pertama pada pasien imunokompromais. Oto Rhino Laryngologica Indonesiana. 2017;**47**(1):81-88.
1744) Alsohime F, Assiri RA, Al-Shahrani F, Bakeet H, Elhazmi M, Somily AM. Premature labor and neonatal sepsis caused by *Actinomyces neuii*. Journal of infection and public health. 2018; **12**(2), 282-284.. https://www.sciencedirect.com/science/article/pii/S1876034118300376
1745) Azadi, D., Motallebirad, T., Ghaffari, K., Shokri, D., & Rezaei, F. Species Diversity, Molecular Characterization, and Antimicrobial Susceptibility of Opportunistic Actinomycetes Isolated from Immunocompromised and Healthy Patients of Markazi Province of Iran. Infection and drug resistance. 2020; **13**, 1.
1746) Bacharewicz-Szczerbicka, J., Serwin, A. B., Kozłowska, D., & Flisiak, I. Case Report/Opis Przypadku. Dermatol Rev/Przegl Dermatol 2019, 106, 522–528.
1747) Bacharewicz-Szczerbicka, J., Serwin, A. B., Kozłowska, D., & Flisiak, I. Metastasis of laryngeal cancer or cervical actinomycosis-the importance of early differential diagnosis. Dermatology Review/Przeglad Dermatologiczny. 2019; **106**(5).
1748) Balis, E., Kakavas, S., Kompogiorgas, S., Kotsifas, K., & Boulbasakos, G. Presentation of pulmonary tuberculosis and actinomyces co-infection as a lung mass: a literature review and unique case report. Monaldi Archives for Chest Disease. 2019; **89**(3).
1749) Bonifaz, A., Buitrón-García, R., Ramírez-Galván, A., & Tirado-Sánchez, A. Actinomyces-like Organisms on Intrauterine Devices from Asymptomatic Users. International Journal of TROPICAL DISEASE & Health. 2017; 1-3.
1750) Bortoluzzi, P., Nazzaro, G., Giacalone, S., & Veraldi, S. Cervicofacial actinomycosis: a report of 14 patients observed at the Dermatology Unit of the University of Milan, Italy. International journal of dermatology. 2020; **59**(10), 1222-1225.
1751) Carrara, J., Hervy, B., Dabi, Y., Illac, C., Haddad, B., Skalli, D., ... & Vaysse, C. Added-value of endometrial biopsy in the diagnostic and therapeutic strategy for pelvic actinomycosis. Journal of clinical medicine. 2020; **9**(3), 821.
1752) Cherni I, Hentati H, Hadhri R, Bouguezzi A, Chokri A, Selmi J. L´ intérêt de la piézochirurgie dans le traitement d'une dysplasie cémento-osseuse surinfectée par actinomycose: à propos d'un cas. The Pan African Medical Journal, 2021:**38**.
1753) Córdoba IE, Irazábal MCY, Chaveli CD, Moreno JC, Beortegui RM, Murua MCM. *Actinomyces odontolyticus*, an uncommon cause of intraabdominal infection after a gastric bypass. Bmi journal. www.bmi-journal.com (ISSN: 2250-737X)
1754) Crisafulli, E., Bernardinello, N., Alfieri, V., Pellegrino, F., Lazzari, C., Gnetti, L., & Chetta, A. A pulmonary infection by *Actinomyces odontolyticus* and *Veillonella atypica* in an immunocompetent patient with dental caries. Respirology case reports. 2019; **7**(9), e00493.
1755) Dagher, R., Riaz, T., Tande, A. J., Osmon, D. R., Jagtiani, A., Steckelberg, J. M., ... & Berbari, E. F. Prosthetic Joint Infection due to Actinomyces species: A case series and review of literature. Journal of bone and joint infection. 2019; **4**(4), 174-180.
1756) de Oca, G. M., Simón-Díaz, P., Torres-Haro, J., Macías-Jiménez, J. B., Araiza, J., & Bonifaz, A. Actinomicosis cérvico-facial tratada con amoxicilina-clavulanato. Dermatología Revista Mexicana. 2016; **60**(6), 526-530.
1757) Ding X, Sun G, Fei G, Zhou X, Zhou L, Wang R. Pulmonary actinomycosis diagnosed by transbronchoscopic lung biopsy: A case report and literature review. Experimental and therapeutic medicine. 2018;**16**(3):2554-8.
1758) Dioguardi, M., Crincoli, V., Laino, L., Alovisi, M., Sovereto, D., Lo Muzio, L., & Troiano, G. Prevalence of Bacteria of Genus Actinomyces in Persistent Extraradicular Lesions—Systematic Review. Journal of clinical medicine. 2020; **9**(2), 457.
1759) Doğan, B. İ., Ceyda, A. N. A. R., Sertogullarindan, B., & Turan, O. COVİD-19 Pandemi Döneminde Multiple Nodüllerle Gelen Hastada Nadir Görülen Bir Enfeksiyon Etkeni: Aktinomikoz Odontoliticus. İzmir Göğüs Hastanesi Dergisi 2020;**34**(3):129-34
1760) Elzein, F., Kharraz, R., Arab, N., Alotaibi, F., Almohaya, A., & Almutairy, A. A case series of actinomycosis from a single tertiary care center in Saudi Arabia. IDCases. 2019; **15**, e00521.
1761) e Monteiro, E. V., Gaspar, J., Paiva, C., Correia, R., Valente, V., Coelho, A., & Lamas, N. J. Abdominal Actinomycosis misdiagnosed as liposarcoma. Autopsy & case reports. 2020; **10**(1).

1762) Gajdács, M., Urbán, E., & Terhes, G. Microbiological and clinical aspects of cervicofacial actinomyces infections: an overview. Dentistry journal. 2019; **7**(3), 85.
1763) Gajdács, M., & Urbán, E. The Pathogenic Role of *Actinomyces* spp. and Related Organisms in Genitourinary Infections: Discoveries in the New, Modern Diagnostic Era. Antibiotics. 2020; **9**(8), 524.
1764) Gandhi K., van der Woerd B.D., Graham M.E., Barton M., Strychowsky J.E. Cervicofacial Actinomycosis in the Pediatric Population: Presentation and Management. Annals of Otology, Rhinology and Laryngology. 2021.
1765) García-García A, Coronel-Martínez J, Cantú-de Leon D, del Socorro Romero-Figueroa M, Caballero-Pantoja YE, Manzanares-Leal GL, Rodriguez-Morales M, Sandoval-Trujillo H, Ramírez-Durán N. Detection of *Actinomyces* spp. in cervical exudates from women with cervical intraepithelial neoplasia or cervical cancer. J Med Microbiol. 2017; **66**(6):706-712.
1766) Gaspar, J., Paiva, C., Correia, R., Valente, V., Coelho, A., & Lamas, N. J. Abdominal Actinomycosis misdiagnosed as liposarcoma. Autopsy and Case Reports. 2020; **10**(1).
1767) Gupta, N., Aggarwal, A., Ramteke, P., & Soneja, M. Mandibular osteomyelitis due to Actinomyces spp. BMJ case reports. 2020; **13**(5).
1768) Granier, S., Zarrouk, V., Mauillon, J., Hammel, P. Granier, S., Zarrouk, V., Mauillon, J., Hammel, P. Gastrointestinal actinomycosis | [Actinomycose digestive] Hepato-Gastro et Oncologie Digestive. 2018; **25**(1), pp. 21-29
1769) Hartert, M., Wolf, M., Ferber, J., & Huertgen, M. Thoracoabdominal actinomycosis–Chameleon through kaleidoscope. Respiratory Medicine Case Reports. 2020; **31:** 101281.
1770) Jabi, R., Ramdani, H., Elmir, S., Elmejjati, F., Serji, B., El Harroudi, T., & Bouziane, M. Pseudotumoral actinomycosis mimicking malignant colic disease: A case report and literature review. Visceral Medicine. 2020; **36**(4), 333-337.
1771) Knežević, S., Slavuljica, I., Cekinović Grbeša, Đ., Gorup, L., Škrobonja, I., Poljak, I., ... & Trošelj Vukić, B. Aktinomikoza temporalne kosti, aktinomikotični meningitis i limfadenitis vrata-prikaz bolesnice. Infektološki glasnik. 2018; **38**(3), 81-85.
1772) Łanowy, P., Ślusarz, K., Pyka, W., Dzindzio, J., Bichalski, M., Blaszkowska, M., ... & Jaroszewicz, J. Actinomycosis-forgotten disease as a diagnostic challenge. Journal of Education, Health and Sport. 2019; **9**(5), 256-264.
1773) Lee, S. Z., Syed, M. T., & Kumar, P. Actinomycosis or malignancy: A diagnostic dilemma. Int J Case Rep Images. 2019; **10**, 101055Z01SL2019.
1774) López-Casillas N, Cuevas-González A. Actinomicosis primaria de pared abdominal: presentación de un caso con fístula enterocutánea y revisión de la bibliografía Primary actinomycosis of the abdominal wall: presentation of a case with enterocutaneous fistula. Rev Hispanoam Hernia. 2018;**6**(1):45-49
1775) Loth-Bouketala A, Graziani J, Fakhry N. Actinomicosis cervicofacial. EMC-Otorrinolaringología. 2017;**46**(3):1-5.
1776) Lynch T, Gregson D, Church DL. Species-level identification of Actinomyces isolates causing invasive infections:multiyear comparison of Vitek MS (Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry) to partial sequencing of the 16S rRNA gene. J Clin Microbiol. 2016; **54**(3):712-717.
1777) Manterola, C., Grande, L., & Otzen, T. Actinomicosis de Pared Abdominal con Infiltración Hepática Simulando una Neoplasia Maligna. Reporte de un Caso. International Journal of Morphology. 2019; **37**(3), 1033-1037.
1778) Millet, A., Bachelet, A., & Croguennec, M. Actinomycose pelvienne. Annales françaises de médecine d'urgence. 2020; **10**(1), 41-42.
1779) Montes de Oca G, Simón-Díaz P, Torres-Haro J, (...), Araiza J, Bonifaz A. Cervicofacial actinomycosis treated with amoxicillin/clavulanate | [Actinomicosis cérvico-facial tratada con amoxicilina-clavulanato]. Dermatologia Revista Mexicana. 2016; **60** (6): 526-530. http://www.medigraphic.com/pdfs/derrevmex/rmd-2016/rmd166k.pdf
1780) Mousavi SA, Mojahed M, Shahcheraghi SH. Actinomycosis of hand: a case report. Reviews in Medical Microbiology: 2016; **27**(3):85–86.
1781) Nahum A, Filice G, Malhotra A. A Complicated thread: abdominal actinomycosis in a young woman with Crohn disease. Case Reports in Gastroenterology. 2017;**11**(2):377-381.
1782) Nakahira ES, Maximiano LF, Lima FR, Ussami EY. Abdominal and pelvic actinomycosis due to longstanding intrauterine device: a slow and devastating infection. Autops Case Rep. 2017;**7**(1):43-47.
1783) Ocampo-Verdeja AE, Damián-Zapién A, Gallegos-Fernández AA, Soto-Ortiz JA, Mayorga J. Actinomycosis: 11-years clinical-epidemiological study. Dermatología Revista Mexicana. 2018;**62**(1):3-10.
1784) Oikonomidis, P., Fousekis, F., Kotsaftis, P., Pilios, I., Dimas, D., & Giannoulis, G. A case of pulmonary actinomycosis presented with endobronchial involvement. Respiratory medicine case reports. 2019; **28**, 100930.
1785) Palmitessa, V., Cuppone, R., Monno, R., Fumarola, L., & Lippolis, A. A case report of esophageal actinomycosis in an immunocompetent patient and review of the literature. New Microbiol. 2019; **42**(1), 55-60.
1786) Puspitasari, T., Ratunanda, S. S., Poerwana, R. A., & Wijana, W. Penatalaksanaan Aktinomikosis Oroservikofasial dengan Berbagai Faktor Risiko. Jurnal Sistem Kesehatan. 2020; **5**(4).
1787) Regino, C. A., Navarro, K., García, A., Bacca, J., & Uribe, N. Abdominopelvic actinomycosis mimicking a malignant ovarian neoplasia: case report and review of literature. Cureus. 2020; **12**(12).
1788) Rojas, S. A., Ortega, J. G. O., Quintanilla, M. P., & Cabrejos, R. D. I. Abdominal actinomycosis: differential diagnosis of ovarian malignant tumor. Anales Médicos de la Asociación Médica del Centro Médico ABC. 2019; **64**(2), 144-148.
1789) Rousseau C, Piroth L, Pernin V, Cassuto E, Etienne I, Jeribi A, Kamar N, Pouteil-Noble C, Mousson C. Actinomycosis: An infrequent disease in renal transplant recipients?. Transplant Infectious Disease. 2018;**20**(6):e12970.
1790) Saeed A, Paściak M, Drab M, Gamian A. Cell surface of *Actinomyces israelii*, its impact on adhesion properties and identification by MALDI-TOF MS. Proceedings of XVIConference DIAGMOL 2015 Molecular biology in diagnostics of infectious diseases and biotechnology" 28 November 2015, WULS-SGGW in Warsaw, Poland.
1791) Salami, A., Assouan, C., N'dah, J. K., Zegbeh, N., Mourtada, D., & Konan, E. A rare case of nasosinusal actinomycosis with cerebral extension. J. TUN ORL – 2021; N45 2021:73-75.

1792) Sandoval-Mallma, E., & Caballero-Silva, J. Actinomicosis diseminada en un paciente inmunocompetente: Reporte de caso. Horizonte Médico (Lima). 2019; **19**(3), 89-95.
1793) Sawtelle AL, Chappell NP, Miller CR. Actinomyces-related tubo-ovarian abscess in a poorly controlled type II diabetic with a copper intrauterine device. Military Medicine. 2017;**182** (3), e1874-e1876.
1794) Scheifer C, Bor C, Debray MP, Chanson N, Chauveheid MP, Gombert B, Papo T, Sacré K. A 27-Year-Old Man With Multiple Cavitary Lung Lesions. Chest. 2018; **155**(2): e43- e46.
1795) Siavashifar, M., Rezaei, F., Motallebirad, T., Azadi, D., Absalan, A., Naserramezani, Z., ... & Ghaffari, K. Species diversity and molecular analysis of opportunistic *Mycobacterium*, *Nocardia* and *Rhodococcus* isolated from the hospital environment in a developing country, a potential resources for nosocomial infection. Genes and Environment. 2021; **43**(1), 1-12.
1796) Sousa DE, Wilson TM, Machado M, Pereira AA, Costa GR, Dutra V, Castro MB. Pulmonary actinomycosis in a free-living black-tufted marmoset (Callithrix penicillata). Primates. 2019 Jan 12:1-5. https://link.springer.com/article/10.1007/s10329-018-00713-w
1797) Stájer, A., Ibrahim, B., Gajdács, M., Urbán, E., & Baráth, Z. Diagnosis and management of cervicofacial actinomycosis: lessons from two distinct clinical cases. Antibiotics. 2020; **9**(4), 139.
1798) Stájer, A., Ibrahim, B., Gajdács, M., Baráth, Z., & Urbán, E. A cervicofaciális actinomycosisok jellemzői és korszerű diagnosztikája: összefoglaló az irodalmi adatok alapján. Fogorvosi Szemle. 2020; **113**(3), 96-104.
1799) Sugrue, I., O'Connor, P. M., Hill, C., Stanton, C., & Ross, R. P. *Actinomyces* produces defensin-like bacteriocins (actifensins) with a highly degenerate structure and broad antimicrobial activity. Journal of bacteriology. 2020; **202**(4).
1800) Urbán, E., & Gajdács, M. Microbiological and Clinical Aspects of *Actinomyces* Infections: What Have We Learned? Antibiotics 2021, 10(2), 151; https://doi.org/10.3390/antibiotics10020151
1801) Wang, L., Zhang, H., Di Wu, M. F., Yang, P., Hu, X., Tattevin, P., ... & Qiu, C. Pulmonary lesions associated with sputum culture-positive actinomycetes: Report of one case. Annals of translational medicine. 2019; **7**(23).
1802) Zayed, Y., Osterholzer, D., Armstrong, E., Azher, Q., & Bachuwa, G. Pulmonary actinomycosis and tracheal squamous cell carcinoma: A rare simultaneous presentation of both in a single patient. Respiratory medicine case reports. 2019; 27, 100855.
1803) Zhang M, Zhang XY, Chen YB. Primary pulmonary actinomycosis: a retrospective analysis of 145 cases in mainland China. The International Journal of Tuberculosis and Lung Disease. 2017; **21**(7):825-831.
1804) Zhang AN, Guss D, Mohanty SR. Esophageal stricture caused by *Actinomyces* in a patient with no apparent predisposing factors. Case reports in gastrointestinal medicine. 2019; 2019. Article ID 7182976
1805) Lee D, Hyun CL, Yoo JR. Fish bone of *Branchiostegus Japonicas* causing actinomycosis in the cecum in male on Jeju island. Korean J Gastroenterol. 2021; **77**(2): 92-94.

ЦИТИРАНА: 62A: Kotsilkov K, Popova C, **Boyanova L**, Setchanova L , Mitov I. Comparison of culture method and real-time PCR for detection of putative periodontopathogenic bacteria in deep periodontal pockets. Biotechnol. Biotechnol. Equip. 2015; **DOI:** 10.1080/13102818.2015.1058188 http://www.tandfonline.com/doi/abs/10.1080/13102818.2015.1058188#.Vco9c_ntmko **Цитирана от:**

1806) AL-Bdery, A. S. J., & Al-Yasseen, A. K. Genotypic and phenotypic detection of some virulence factors among *Porphyromonas gingivalis* related with period ontitis in Al-Najaf Al-Ashraf city, Iraq. Plant Archives. 2018; **18**(2), 2345-2353.
1807) Al-Hamdoni, S. A. S., & Al-Rawi, A. M. M. Assessment the Effect of Some Reagents on the Planktonic Cells and Biofilms of Red Complex Periodontal Pathogens. International Journal of Sciences: Basic and Applied Research (IJSBAR). 2020; **51**(2: 1-13.
1808) Bravo, P. O., León, K. C., Tacuri, C. A., & Feijóo, D. S. Sensitivity and specificity of molecular tests in dentistry. Revista de la Asociación Dental Mexicana. 2021; 78(2), 90-94.
1809) Couper L, Swei A. Tick Microbiome Characterization by Next-Generation 16S rRNA Amplicon Sequencing. JoVE (Journal of Visualized Experiments). 2018; **25**(138):e58239.
1810) Cuenca M, Marín MJ, OConnor A, Sánchez MDC, Blanco Carrión J, Limeres Posse J, ... & Herrera D. Periodontal condition and subgingival microbiota characterization in subjects with Down syndrome. Appl. Sci. 2021, **11**: 778. https://doi.org/ 10.3390/app11020778.
1811) Feijóo DS, Tacuri CA, León KC, Bravo PO. Sensibilidad y especificidad de pruebas moleculares en odontología. Revista ADM. 2021; **78**(2), 90-94.
1812) Hasriati, E., Anggani, H. S., Purbiati, M., & Bachtiar, E. W. Antibacterial effect of 0.2% chlorhexidine and 1% chitosan mouthwash on bacteria during orthodontic miniscrew use. International Journal of Applied Pharmaceutics. 2020; 8-12.
1813) Jassim AL-Bdery AS, Al-Yasseen AK. Genotypic and phenotypic detection of some virulence factors among Porphyromonas gingivalis related with period ontitis in Al-Najaf al-Ashraf city, Iraq Plant Archives. 2018; **18**(2): 2345-2353.
1814) Li, L. F., Wei, R., Liu, H. B., Jiang, B. G., Cui, X. M., Wei, W., ... & Hu, Y. L. Characterization of Microbial Communities in *Ixodes persulcatus* (Ixodida: Ixodidae), a Veterinary and Medical Important Tick Species in Northeastern China. Journal of medical entomology. 2020; 57(4), 1270-1276.
1815) Marín, M. J., Ambrosio, N., O'Connor, A., Herrera, D., Sanz, M., & Figuero, E. Validation of a multiplex qPCR assay for detection and quantification of Aggregatibacter actinomycetemcomitans, *Porphyromonas gingivalis* and *Tannerella forsythia* in subgingival plaque samples. A comparison with anaerobic culture. Archives of oral biology. 2019; 102, 199-204.
1816) Monyama, M. C., Onyiche, E. T., Taioe, M. O., Nkhebenyane, J. S., & Thekisoe, O. M. Bacterial pathogens identified from houseflies in different human and animal settings: A systematic review and meta-analysis. Veterinary Medicine and Science. 2021; 00:1-18.
1817) Nastych, O., Goncharuk-Khomyn, M., Foros, A., Cavalcanti, A., Yavuz, I., & Tsaryk, V. Usporedba parametara bakterijskog opterećenja u subgingivalnom plaku kod parodontitisa i periimplantitisa metodom RT-PCR. Acta stomatologica Croatica. 2020; 54(1), 32-43.

1818) Ng E, Byun R, Spahr A, Divnic-Resnik T. The efficacy of air polishing devices in supportive periodontal therapy: A systematic review and meta-analysis. Quintessence International. 2018;**49**(6):453-467.
1819) Nwaokorie, F. O., & Ayanbadejo, P. O. Detection of Six Periodontopathogens in the Subgingival Plaque of Patients with Chronic Periodontitis in Lagos, Nigeria. Nigerian Journal of Dental Research. 2020; 5(2), 145-154.
1820) Pahumunto, N., Sophatha, B., Piwat, S., & Teanpaisan, R. Increasing salivary IgA and reducing Streptococcus mutans by probiotic Lactobacillus paracasei SD1: a double-blind, randomized, controlled study. Journal of dental sciences. 2019; 14(2), 178-184.
1821) Pawlaczyk-Kamieńska, T., Śniatała, R., Batura-Gabryel, H., Borysewicz-Lewicka, M., & Cofta, S. Periodontal status and subgingival biofilms in cystic fibrosis adults. Polish journal of microbiology. 2019; 68(3), 377.
1822) Shahi S, Vahed SZ, Fathi N, Sharifi S. Polymerase chain reaction (PCR)-based methods: Promising molecular tools in dentistry. International journal of biological macromolecules. 2018; **117**(1):983-992.
1823) Trtić, N., Bošnjak, A. P., Arbutina, R., Nikolić, T., Marin, S., Veselinović, V., ... & Dolić, O. Subgingival air-polishing treatment in patients with aggressive periodontitis. Vojnosanitetski pregled. 2021; 78(1).
1824) Tomás I, Regueira-Iglesias A, López M, Arias-Bujanda N, Novoa L, Balsa-Castro C, Tomás M. Quantification by qPCR of Pathobionts in Chronic Periodontitis: Development of Predictive Models of Disease Severity at Site-Specific Level. Frontiers in microbiology. 2017;**8**:1443.
1825) Vakhitov D, Tuomisto S, Martiskainen M, Korhonen J, Pessi T, Salenius JP, Suominen V, Lehtimäki T, Karhunen PJ, Oksala N. Bacterial signatures in thrombus aspirates of patients with lower limb arterial and venous thrombosis. Journal of vascular surgery. 2017 Aug 26.
1826) Wendland, N., Opydo-Szymaczek, J., Mizgier, M., & Jarząbek-Bielecka, G. Subgingival microflora in adolescent females with polycystic ovary syndrome and its association with oral hygiene, gingivitis, and selected metabolic and hormonal parameters. Clinical Oral Investigations. 2021; 25(3), 1485-1496.
1827) Zang X, Tang H, Jiao X, Huang J. Can a visual loop-mediated isothermal amplification assay stand out in different detection methods when monitoring *Campylobacter jejuni* from diverse sources of samples? Food Control. 2017; **75**: 220-227.

ЦИТИРАНА: 63A: Markovska R, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015;**123**(10):887-94. **Цитирана от:**

1828) Berglund, B., Hoang, N. T. B., Tärnberg, M., Le, N. K., Nilsson, M., Khu, D. T. K., ... & Hanberger, H. Molecular and phenotypic characterization of clinical isolates belonging to a KPC-2-producing strain of ST15 *Klebsiella pneumoniae* from a Vietnamese pediatric hospital. Antimicrobial Resistance & Infection Control. 2019; 8(1), 1-8.
1829) Chi, X., Berglund, B., Zou, H., Zheng, B., Börjesson, S., Ji, X., ... & Nilsson, L. E. Characterization of clinically relevant strains of extended-spectrum β-lactamase-producing *Klebsiella pneumoniae* occurring in environmental sources in a rural area of China by using whole-genome sequencing. Frontiers in microbiology. 2019; 10, 211.
1830) Ferrari, C., Corbella, M., Gaiarsa, S., Comandatore, F., Scaltriti, E., Bandi, C., ... & Sassera, D. Multiple *Klebsiella pneumoniae* KPC clones contribute to an extended hospital outbreak. Frontiers in microbiology. 2019; 10, 2767.
1831) Flores C, Bianco K, de Filippis I, Clementino MM, & Romão CMC. Genetic relatedness of NDM-producing *Klebsiella pneumoniae* co-occurring VIM, KPC, and OXA-48 enzymes from surveillance cultures from an Intensive care unit. Microbial Drug Resist. 2020; **26**(10), 1219-1226.
1832) Friedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-resistant *Enterobacteriaceae*: a strategic road map for infection control. Infect Control Hosp Epidemiol. 2017; **38**(5):580-594.
1833) Han, Y., Huang, L., Liu, C., Huang, X., Zheng, R., Lu, Y., ... & Liu, G. Characterization of Carbapenem-Resistant *Klebsiella* pneumoniae ST15 Clone Coproducing KPC-2, CTX-M-15 and SHV-28 Spread in an Intensive Care Unit of a Tertiary Hospital. Infection and drug resistance. 2021; 14, 767.
1834) Jones-Dias D, Manageiro V, Ferreira E, Barreiro P, Vieira L, Moura IB, Caniça M. Architecture of Class 1, 2, and 3 integrons from Gram negative bacteria recovered among fruits and vegetables. Front Microbiol. 2016;**7**:1400.
1835) Kittinger C, Lipp M, Folli B, Kirschner A, Baumert R, Galler H, Grisold AJ, Luxner J, Weissenbacher M, Farnleitner AH, Zarfel G. *Enterobacteriaceae* isolated from the river Danube: antibiotic resistances, with a focus on the presence of ESBL and carbapenemases. PLoS One. 2016;**11**(11):e0165820.
1836) Ku YH, Chuang YC, Chen CC, Lee MF, Yang YC, Tang HJ, Yu WL. *Klebsiella pneumoniae* isolates from meningitis: epidemiology, virulence and antibiotic resistance. Scientific reports. 2017;**7**(1):6634.
1837) Lagacé-Wiens PR, Adam HJ, Poutanen S, Baxter MR, Denisuik AJ, Golden AR, ... & Zhanel GG. Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007–16. J Antimicrob Chemother. 2019; **74**(Suppl 4), iv22-iv31.
1838) Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global dissemination of carbapenemase-producing *Klebsiella pneumoniae*: epidemiology, genetic context, treatmentoptions, and detection methods. Front Microbiol. 2016;**7**:895.
1839) Lomonaco S, Crawford MA, Lascols C, Timme RE, Anderson K, Hodge DR, Fisher DJ, Pillai SP, Morse SA, Khan E, Hughes MA. Resistome of carbapenem-and colistin-resistant *Klebsiella pneumoniae* clinical isolates. PloS one. 2018;**13**(6):e0198526.
1840) Loucif L, Kassah-Laouar A, Saidi M, Messala A, Chelaghma W, Rolain JM. Outbreak of OXA-48-producing *Klebsiella pneumoniae* involving a sequence type 101 clone in Batna university hospital, Algeria. Antimicrob Agents Chemother. 2016;**60**(12):7494-7497.
1841) Machuca J, Lopez-Cerero L, Fernandez-Cuenca F, Mora-Navas L, Mediavilla-Gradolph C, López-Rodríguez I, Pascual Á. OXA-48-like-producing *Klebsiella pneumoniae* in southern Spain in 2014–2015. Antimicrob Agents Chemother. 2019; **63**(1):e01396-18.

1842) Martins WM, Nicolas MF, Yu Y, Li M, Dantas P, Sands K, ... & Andrey DO. Clinical and Molecular Description of a high-copy IncQ1 KPC-2 plasmid harbored by the international ST15 *Klebsiella pneumoniae* Clone. Msphere. 2020; **5**(5).
1843) Moradigaravand D, Martin V, Peacock SJ, Parkhill J. Evolution and epidemiology of multidrug-resistant *Klebsiella pneumoniae* in the United Kingdom and Ireland. MBio. 2017;**8**(1). pii: e01976-16.
1844) Oteo J, Pérez-Vázquez M, Bautista V, Ortega A, Zamarrón P, Saez D, Fernández-Romero S, Lara N, Ramiro R, Aracil B, Campos J; Spanish Antibiotic Resistance Surveillance Program Collaborating Group. The spread of KPC-producing *Enterobacteriaceae* in Spain: WGS analysisof the emerging high-risk clones of *Klebsiella pneumoniae* ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. J Antimicrob Chemother. 2016;**71**(12):3392-3399.
1845) Su S, Zhang J, Zhao Y, Yu L, Wang Y, Wang Y, ... & Zhang X. Outbreak of KPC-2 carbapenem-resistant *Klebsiella pneumoniae* ST76 and carbapenem-resistant K2 hypervirulent *Klebsiella pneumoniae* ST375 strains in Northeast China: molecular and virulent characteristics. BMC Infectious Diseases. 2020; **20**(1): 1-14.
1846) Sui W, Zhou H, Du P, Wang L, Qin T, Wang M, Ren H, Huang Y, Hou J, Chen C, Lu X. Whole genome sequence revealed the fine transmission map of carbapenem-resistant *Klebsiella pneumoniae* isolates within a nosocomial outbreak. Antimicrobial Resistance & Infection Control. 2018;**7**(1):70.
1847) Tekeli A, Dolapci İ, Evren E, Oguzman E, Karahan ZC. Characterization of *Klebsiella pneumoniae* coproducing KPC and NDM-1 Carbapenemases from Turkey. Microbial Drug Resist. 2020; **26**(2), 118-125.
1848) Tokajian S, Moghnieh R, Salloum T, Arabaghian H, Alousi S, Moussa J, Abboud E, Youssef S, Husni R. Extended-spectrum β-lactamase-producing *Escherichia coli* in wastewaters and refugee camp in Lebanon. Future microbiology. 2018;**13**(1):81-95.
1849) Xiao SZ, Wang S, Wu WM, Zhao SY, Gu FF, Ni YX, Guo XK, Qu JM, Han LZ. The resistance phenotype and molecular epidemiology of *Klebsiella pneumoniae* in bloodstream infections in Shanghai, China, 2012-2015. Front Microbiol. 2017;**8**:250.
1850) Yousfi H, Hadjadj L, Dandachi I, Lalaoui R, Merah A, Amoura K, ... & Rolain JM. Colistin-and carbapenem-resistant *Klebsiella pneumoniae* clinical_isolates: Algeria. Microbial Drug Resist. 2019; **25**(2): 258-263.

ЦИТИРАНА: 65A: Boyanova L, Evstatiev I**, Gergova G, Yaneva P**, Mitov I. Linezolid susceptibility *in Helicobacter pylori*, including strains with multidrug resistance. Int J Antimicrob Agents. 2015;**46**(6):703-706. **Цитирана от:**

1851) Arévalo A, Otero WA, Trespalacios AA. *Helicobacter pylori*: resistencia múltiple en pacientes de Bogotá-Colombia. Biomédica. 2019;39.
1852) Bayati S, Alebouyeh M, Amirmozafari N, Ebrahimi Daryani N, Talebi M, Zali MR. Histological changes in refractory *Helicobacter pylori* infection and its relationship with increased levels of resistance to antibiotics and therapeutic regimens: one-year follow-up. APMIS. 2020; **128**(1), 25-34.
1853) Goudarzi M, Heidary M, Azad M, Fazeli M, Goudarzi H. Evaluation of antimicrobial susceptibility and integron carriage in *Helicobacter pylori* isolates from patients. Gastroenterol Hepatol Bed Bench. 2016;**9**(Suppl1):S47-S52.
1854) Goudarzi M, Seyedjavadi SS, Fazeli M, Roshani M, Azad M, Heidary M, Navidinia M, Goudarzi H. Identification of a novel cassette array in integron-bearing *Helicobacter pylori* strains isolated from Iranian Patients. Asian Pac J Cancer Pr. 2016; **17**:3309-3315.
1855) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-82.
1856) Shi J, Jiang Y, Zhao Y. Promising in vitro and in vivo inhibition of multidrug-resistant *Helicobacter pylori* by linezolid and novel oxazolidinone analogues. J Glob Antimicrob Resist. 2016;7:106-109.
1857) Tang Q, Zhao Y, Xu B, Gong P, Wang D. An Update on the Structure of Oxazolidinone Analogs and a Comparison with Linezolid in terms of in vitro and intracellular efficacy against clinically relevant bacterial species. Japanese journal of infectious diseases. 2017;**70**(6):678-681.
1858) Zhang S, Huang J, Xie X, He Y, Mo F, Luo Z. Quercetin from *Polygonum capitatum* protects against gastric inflammation and apoptosis associated with *Helicobacter pylori* infection by affecting the levels of p38MAPK, BCL-2 and BAX. Molecules. 2017;**22**(5):744. doi: 10.3390/molecules22050744.

ЦИТИРАНА: 66A: Boyanova L, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, Markovska R, Mitov I. *Helicobacter pylori* resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infect Dis (Lond). 2016;**48**(1):56-62. **Цитирана от:**

1859) Alarcón T, Urruzuno P, Martínez MJ, Domingo D, Llorca L, Correa A, López-Brea M. Antimicrobial susceptibility of 6 antimicrobial agents in *Helicobacter pylori* clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enferm Infecc Microbiol Clin. 2017; **35**(5):278-282..
1860) Alba C, Blanco A, Alarcón T. Antibiotic resistance in *Helicobacter pylori*. Current opinion in infectious diseases. 2017; **30**(5):489-497.
1861) Alhammad MA, Hadir EK, Hamed Y. Clarithromycin resistance and genetic pattern Of *Helicobacter Pylori* in a group of patients with peptic ulcer disease in Alexandria, Egypt. International Journal of Scientific & Technology Research. 2019; **8**:3-5.
1862) Bedoya-Gómez IJ, Alvarez-Aldana A, Moncayo-Ortiz JI, Guaca-González YM, Santacruz-Ibarra JJ, Arturo-Arias BL, ... & Beltrán-Angarita L. Surveillance of the antimicrobial resistance rates of *Helicobacter pylori* ten years later in the Western central region, Colombia. Digestive Diseases. 2020; **38**(3): 196-203.
1863) Biernat MM, Bińkowska A, Łaczmański Ł, Biernat P, Krzyżek P, Gościniak G. Phenotypic and genotypic analysis of resistant *Helicobacter pylori* strains isolated from children with gastrointestinal diseases. Diagnostics. 2020; **10**(10): 759.
1864) Byambajav TO, Bira N, Choijamts G, Davaadorj D, Gantuya B, Sarantuya T, ... & Oyuntsetseg K. Initial trials with susceptibility-based and empiric anti-*H. pylori* therapies in Mongolia. Frontiers in pharmacology. 2019; **10**: 394.

1865) Dang NQH, Ha TMT, Nguyen ST, Le ND K, Nguyen TMT, Nguyen TH, Pham TTH. High rates of clarithromycin and levofloxacin resistance of *Helicobacter pylori* in patients with chronic gastritis in the south east area of Vietnam. J Glob Antimicrob Resist. 2020; **22**:620-624.
1866) Dekhnich N, Ivanchik N, Kozlov R, Alimov A, Steshits A, Kirsov P, Pandav K. Dynamics of antimicrobial resistance of *Helicobacter pylori* isolates in the Smolensk region of Russian Federation. Helicobacter. 2018;**23**(6):e12545.
1867) Famouri F, Emadoleslami MS, Riahi R, Saneian H, Nasri P. The sensitivity of *H. pylori* in gastric tissue samples of children and adolescents to various antibiotics in center of Iran. International Journal of Pediatrics. 2018;**6**(12):8685-96.
1868) García G, Betancourt E, Corrales R. Analisis de resonancia de plasmon superficial en *Helicobacter pylori*. Investigación clínica. 2020; **61**(1): 525-530.
1869) Gudra, D., Pupola, D., Skenders, G., Leja, M., Radovica-Spalvina, I., Gorskis, H., ... & Fridmanis, D. Lack of significant differences between gastrointestinal tract microbial population structure of *Helicobacter pylori*-infected subjects before and 2 years after a single eradication event. Helicobacter. 2020; 25(5), e12748.
1870) Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for *Helicobacter pylori* eradication treatment. PloS one. 2018;**13**(1):e0189888.
1871) Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of *Helicobacter pylori* infection-the MaastrichtV/Florence Consensus Report. Gut. 2017; **66**(1):6-30.
1872) Mihai, C., Mihai, B. M., Dranga, M., Cardoneanu, A., & Prelipcean, C. C. *Lactobacillus reuteri*–an alternative in the first-line of *Helicobacter pylori* eradication. Farmacia. 2019; 67(5), 871-876.
1873) Ni, C., & Jiang, D. Three-Dimensional Numerical Simulation of Particle Focusing and Separation in Viscoelastic Fluids. Micromachines. 2020; 11(10), 908.
1874) Rojas García, P., van der Pol, S., van Asselt, A. D. I., Postma, M., Rodríguez-Ibeas, R., Juárez-Castelló, C. A., ... & Antoñanzas, F. Efficiency of Diagnostic Testing for *Helicobacter pylori* Infections—A Systematic Review. Antibiotics 2021, 2021, 10, 55.
1875) Talebi Bezmin Abadi A. *Helicobacter pylori* treatment: New perspectives using current experience. J Glob Antimicrob Resist. 2017;**8**:123-130.
1876) van der Pol, S., van Asselt, A. D. I., Postma, M., Rodríguez-Ibeas, R., Juárez-Castelló, C. A., González, M., & Antoñanzas, F. Efficiency of Diagnostic Testing for *Helicobacter pylori* Infections-A Systematic Review. Antibiotics (Basel, Switzerland). 2021; 10(1).
1877) Xu, G., Shi, Y., Zhang, X., (...), Zhang, N., Li, Z. Correlation Analysis of Pathways and Operons of *Helicobacter pylori* Resistance Genes Using Bibliometrics. Clinical Laboratory. 2019; 65(5): 673-683.
1878) Yang, L., Zhang, J., Xu, J., Wei, X., Yang, J., Liu, Y., ... & Gai, Z. *Helicobacter pylori* infection aggravates dysbiosis of gut microbiome in children with gastritis. Frontiers in cellular and infection microbiology. 2019; 9, 375.
1879) Дехнич НН, Иванчик НВ, Козлов РС, Алимов АВ, Стеших АС, Кирсов ПП. Распространенность антимикробной резистентности *Helicobacter pylori* в Смоленской области в 2015-2017 гг. Вестник Смоленской государственной медицинской академии. 2018;**17**(1).
1880) Дехнич НН, Иванчик НВ, Козлов РС, Алимов АВ, Стеших АС, Кирсов ПП. Антибиотикорезистентность *Helicobacter pylori* в Смоленске. КМАХ, 2018; **20**(1):42-48.

ЦИТИРАНА: 67А: Boyanova L, Markovska R, Yordanov D, Gergova G, Mitov I. Clarithromycin resistance mutations in *Helicobacter pylori* in association with virulence factors and antibiotic susceptibility of the strains. Microb Drug Resist. 2016;**22**(3):227-232. **Цитирана от:**

1881) Akramovich AA, Akbarovna DD, Utkurovna TS. Study of mutations in the 23 s rRNA gene are associated with clarithromycin resistance in *H. pylori*. European science review. 2018; №. 9-10-1.
1882) Alavifard H, Mirzaei N, Yadegar A, Baghaei K, Smith SM, Sadeghi A, Zali MR. Investigation of clarithromycin resistance-associated mutations and virulence genotypes of *Helicobacter pylori* isolated from Iranian population: a cross-sectional study. Current Microbiol. 2021; **78**(1), 244-254.
1883) Alba C, Blanco A, Alarcón T. Antibiotic resistance in *Helicobacter pylori*. Current opinion in infectious diseases. 2017; **30**(5):489-497.
1884) Baroni MR, Bucci P, Giani RN, Giusti A, Tedeschi FA, Salvatierra E, Barbaglia Y, Jimenez F, Zalazar FE. Usefulness of rapid urease test samples for molecular analysis of clarithromycin resistance in *Helicobacter pylori*. Revista Argentina de microbiologia. 2018;**50**(4):359-64.
1885) Bastia F. Method for determining *Helicobacter pylori*. 2016 . https://patents.google.com/patent/WO2017134627A1/fi
1886) Brennan DE, Dowd C, O'Morain C, McNamara D, Smith SM. Can bacterial virulence factors predict antibiotic resistant *Helicobacter pylori* infection? World J Gastroenterol. 2018;**24**(9):971.
1887) Choi YI, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, Seo JY. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line *Helicobacter pylori* eradication: A comparative, open trial. World J Gastroenterol. 2019; **25**(46): 6743.
1888) Eed EM, Hawash YA, Khalifa AS, (...), Ismail KA, Shehab-Eldeen SA. Molecular diagnosis of *Helicobacter pylori* antibiotic resistance in the Taif region, Saudi Arabia. Microbiology and Immunology. 2019; 63(6): 199-205.
1889) Gong Y, Yuan Y. Resistance mechanisms of *Helicobacter pylori* and its dual target precise therapy. Crit Rev Microbiol. 2018;**44**(3):371-92.
1890) Haddadi, M. H., Negahdari, B., Asadolahi, R., & Bazargani, A. *Helicobacter pylori* antibiotic resistance and correlation with cagA motifs and homB gene. Postgraduate medicine. 2020; 132(6), 512-520.
1891) Hanafiah, A., Binmaeil, H., Ali, R. A. R., Rose, I. M., & Lopes, B. S. Molecular characterization and prevalence of antibiotic resistance in *Helicobacter pylori* isolates in Kuala Lumpur, Malaysia. Infection and drug resistance. 2019; 12, 3051.

1892) Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among *H. pylori* infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC infectious diseases. 2019; 19(1), 1-7.
1893) Kalach N, Bontems P, Raymond J. *Helicobacter pylori* infection in children. Helicobacter. 2017;22(S1).
1894) Khashei R, Dara M, Bazargani A, Bagheri Lankarani K, Taghavi A, Moeini M, Dehghani B, Sohrabi M. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian *Helicobacter pylori* clinical isolates. APMIS. 2016;**124**(9):787-793.
1895) Kim, S. Y., Park, J. M., Lim, C. H., Lee, H. A., Shin, G. Y., Choe, Y., ... & Choi, M. G. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for *Helicobacter pylori*. Gut and Liver. 2020.
1896) Kwon YH, Jeon SW, Nam SY, Lee HS, Park J. H. Efficacy of tailored therapy for *Helicobacter pylori* eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. Helicobacter. 2019; 24(4): e12585.
1897) Matta AJ, Zambrano DC, Pazos AJ. Punctual mutations in 23S rRNA gene of clarithromycin-resistant *Helicobacter pylori* in Colombian populations. World J Gastroenterol. 2018; **24**(14):1531.
1898) Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic resistance and genotypic study of the *vacA, cagA, iceA, oipA* and *babA* genotypes of the *Helicobacter pylori* strains isolated from raw milk. Antimicrobial Resistance & Infection Control. 2018;**7**(1):115.
1899) Wang D, Li Q, Gong Y, Yuan Y. The association between *vacA* or *cagA* status and eradication outcome of *Helicobacter pylori* infection: A meta-analysis. PLoS One. 2017;**12**(5):e0177455.
1900) Zerbetto De Palma G, Mendiondo N, Wonaga A, Viola L, Ibarra D, Campitelli E, Salim N, Corti R, Goldman C, Catalano M. Occurrence of mutations in the antimicrobial target genes related to levofloxacin, clarithromycin, and amoxicillin resistance in *Helicobacter pylori* isolates from Buenos Aires city. Microb Drug Resist. 2017;**23**(3):351-358.

ЦИТИРАНА: 68A: Boyanova L, Ilieva J, Gergova G, Mitov I. Levofloxacin susceptibility testing against *Helicobacter pylori*: evaluation of a modified disk diffusion method compared to E test. Diagn Microbiol Infect Dis. 2016; **84**(1):55-56.**Цитирана от:**

1901) Alba C, Blanco A, Alarcón T. Antibiotic resistance in *Helicobacter pylori*. Current opinion in infectious diseases. 2017; **30**(5):489-97.
1902) Ganta D, Chavez J, Lopez A. Disposable Chronoamperometric Sensor Coated with Silver Nanowires for Detecting Levofloxacin. Analytical Letters. 2020; **53**(12), 1992-2001.
1903) Liu C, Xie D, Liu P, Xie S, Wang S, Cheng F, Zhang M, Wang L. Voltammetric determination of levofloxacin using silver nanoparticles deposited on a thin nickel oxide porous film. Microchimica Acta. 2019;**186**(1):21.
1904) Parra-Sepúlveda C, Merino JS, Sáez-Carrillo K, González C, García-Cancino A. Antibiotic resistance surveillance of *Helicobacter pylori* at the Biobío region (Chile) in a decade. Arquivos de gastroenterologia. 2019; **56**(4), 361-366.
1905) Sharma TSK, Hwa KY. Facile Synthesis of Ag/AgVO3/N-rGO Hybrid Nanocomposites for Electrochemical Detection of Levofloxacin for Complex Biological Samples Using Screen-Printed Carbon Paste Electrodes. Inorg. Chem. 2021, **60**, 9: 6585–6599.
1906) Yahya, E., & Abdulsamad, M. A. In-vitro Antibacterial Activity of Carbopol-Essential Oils hydrogels. Journal of Applied Science & Process Engineering. 2020; **7**(2), 564-571.

ЦИТИРАНА:69A: Boyanova L, Evstatiev I, Yordanov D, Markovska R, Mitov I. Three unsuccessful treatments of *Helicobacter pylori* infection by a highly virulent strain with quadruple antibiotic resistance. Folia Microbiol (Praha). 2016; **61**(4):307-310. **Цитирана от:**

1907) González A, Fillat MF, Lanas Á. Transcriptional regulators: valuable targets for novel antibacterial strategies. Future medicinal chemistry. 2018;**10**(5):541-60.
1908) González A, Salillas S, Velázquez-Campoy A, Angarica VE, Fillat MF, Sancho J, Lanas Á. Identifying potential novel drugs against *Helicobacter pylori* by targeting the essential response regulator HsrA. Scientific reports. 2019; **9**(1): 1-13.
1909) Moghadam MT, Chegini Z, Norouzi A, Dosari AS, Shariati A. Three-decade failure to eradication of refractory *Helicobacter pylori* infec-tion and recent efforts to eradicate the infection. Curr Pharm Biotechnol. 2020 Aug 6.
1910) Rezaei S, Abadi ATB, Mobarez AM. Metronidazole-resistant *Helicobacter pylori* isolates without *rdxA* mutations obtained from Iranian dyspeptic patients. New microbes and new infections. 2020; **34**:100636.

ЦИТИРАНА 70A: Boyanova L, Markovska R, Mitov I. Review article: virulence arsenal of the most pathogenic species among the Gram positive anaerobic cocci, *Finegoldia magna.* Anaerobe. 2016;**42**:145-151. **Цитирана от:**

1911) Alsubaie S, Dolgum S, Binkhamis K, Alweijri I, Bugshan A, Alzamil F. *Finegoldia magna* causing intramedullary thoracic spinal cord abscess in an infant. Anaerobe. 2019; **56**, 57-60.
1912) Brüggemann H, Jensen A, Nazipi S, Aslan H, Meyer RL, Poehlein A, Brzuszkiewicz E, Al-Zeer MA, Brinkmann V, Söderquist B. Pan-genome analysis of the genus *Finegoldia* identifies two distinct clades, strain-specific heterogeneity, and putative virulence factors. Scientific reports. 2018;**8**(1):266.
1913) Byeon J, Blizinsky KD, Persaud A, Findley K, Lee JJ, Buscetta AJ, ... & Grice EA. Insights into the skin microbiome of sickle cell disease leg ulcers. Wound Repair and Regeneration. 2021. https://doi.org/10.1111/wrr.12924
1914) Chien S, Gorman D, Koutsogiannidis CP, Ravishankar R, Kamath G, Zamvar V. The novel use of oral antibiotic monotherapy in prosthetic valve endocarditis caused by *Finegoldia magna*: a case study. Journal of cardiothoracic surgery. 2019; **14**(1), 1-5.
1915) Corvec S, Seiler E, Wang L, Moreno MG, Trampuz A. Characterization of medical relevant anaerobic microorganisms by isothermal microcalorimetry. Anaerobe. 2020; **66**: 102282.
1916) Dahal N, Nowitzke J, Eis A, Popa I. Binding-induced stabilization measured on the same molecular protein substrate using single-molecule magnetic tweezers and heterocovalent attachments. The Journal of Physical Chemistry B, 2020; **124**(16), 3283-3290.
1917) De Donder L, Uyttebroek O, Van Cleven S, Berrevoet F. A subcutaneous infection mimicking necrotizing fasciitis due to *Butyricimonas virosa*. Acta Chirurgica Belgica. 2020; **120**(6), 425-428.
1918) Dehkordi SH, Osorio G. Case of pacemaker pocket infection caused by *Finegoldia magna*. Anaerobe. 2017;**47**:135-136.

1919) González Ruiz L, Flores-Terry MÁ, Franco-Muñoz M, García-Arpa M. A common skin infection due to a rare microorganism | [Una infección cutánea frecuente por un germen poco común]. Piel, 2018; 34(5)
1920) Guérin, F., Lachaal, S., Auzou, M., Le Brun, C., Barraud, O., Decousser, J. W., ... & Cattoir, V. Molecular basis of macrolide-lincosamide-streptogramin (MLS) resistance in *Finegoldia magna* clinical isolates. Anaerobe. 2020; 64, 102220.
1921) Söderquist B, Björklund S, Hellmark B, Jensen A, Brüggemann H. *Finegoldia magna* isolated from orthopedic joint implant-associated infections. Journal of clinical microbiology. 2017;**55**(11):3283-3291.
1922) Szymczak, Z., Michalski, P., Dudek, J., Płusa, T., Baranowski, P., Burczy, M., & Burczy, J. A. C. E. K. *Finegoldia magna* the cause of hip revision surgery-a two case report. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego. 2019; 47(279), 99-102.

ЦИТИРАНА 72А: Markovska R, Stoeva T, **Boyanova L**, Stankova P, Pencheva D, Kaneva R, Mitev V, Mitov I. Isolation of *Escherichia coli* ST131 producing KPC-2 in Bulgaria. Infect Dis (Lond). 2017; **49**(5): 429-431. **Цитирана от:**

1923) Du X, Huang J, Wang D, Zhu Y, Lv H, Li X. Whole genome sequence of an Escherichia coli ST131 strain isolated from a patient with bloodstream infection in China co-harbouring blaKPC-2, blaCTX-M-3, blaCTX-M-14, qnrS1, aac(3)-IIa and aac(6')-Ib-cr genes. J Glob Antimicrob Resist 2020; **22**: 700-702.
1924) Yair Y, Gophna U. Pandemic bacteremic *Escherichia coli* strains: Evolution and emergence of drug-resistant pathogens. Current Topics in Microbiology and Immunology. 2018; **416**: 163-180.

ЦИТИРАНА 73А: Boyanova L. Stress hormone epinephrine (adrenaline) and norepinephrine (noradrenaline) effects on the anaerobic bacteria. Anaerobe. 2017; **44**:13-19. **Цитирана от:**

1925) AbdElnapi NMM, Omran NF, Ali AA, Omara FA. Modelling a smart non-invasive adrenaline sensor. International Journal of Sensor Networks 2020; **32**(2): 96-106.
1926) Anderson CJ, Kendall MM. *Salmonella enterica* serovar *Typhimurium* strategies for host adaptation. Frontiers in microbiology. 2017;**8**:1983.
1927) Alauzet C, Cunat L, Wack M, Lanfumey L, Legrand-Frossi C, Lozniewski A, Agrinier N, Cailliez-Grimal C, Frippiat JP. Impact of a model used to simulate chronic socio-environmental stressors encountered during spaceflight on murine intestinal microbiota. International Journal of Molecular Sciences. 2020; **21**(21):7863.
1928) Beitollahi H, Dourandish Z, Tajik S, Ganjali MR, Norouzi P, Faridbod F. Application of graphite screen printed electrode modified with dysprosium tungstate nanoparticles in voltammetric determination of epinephrine in the presence of acetylcholine. Journal of Rare Earths. 2018; **36**(7):750-7.
1929) Beitollahi H, Tajik S, Aflatoonian MR, Makarem A. Nife2 O4 nanoparticles modified screen printed electrode for simultaneous determination of serotonin and norepinephrine. Analytical and Bioanalytical Electrochemistry. 2018; **10**(11): 1399-1413.
1930) Borrel V, Thomas P, Catovic C, Racine PJ, Konto-Ghiorghi Y, Lefeuvre L, Duclairoir-Poc C, Zouboulis CC, Feuilloley MG. Acne and stress: impact of catecholamines on *Cutibacterium acnes*. Frontiers in medicine. 2019;**6**:155.
1931) Buduneli N. Environmental factors and periodontal microbiome. Periodontology 2000. 2021;**85**(1):112-25.
1932) Cambronel M, Nilly F, Mesguida O, Boukerb AM, Racine PJ, Baccouri O, Borrel V, Martel J, Fécamp F, Knowlton R, Zimmermann K. Influence of catecholamines (epinephrine/norepinephrine) on biofilm formation and adhesion in pathogenic and probiotic strains of *Enterococcus faecalis*. Frontiers in microbiology. 2020;**11**:1501.
1933) Chekabab SM, Rehman MA, Yin X, Carrillo C, Mondor M, Diarra MS. Growth of *Salmonella enterica* Serovars *Typhimurium* and *Enteritidis* in iron-poor media and in meat: Role of catecholate and hydroxamate siderophore transporters. Journal of food protection. 2019;**82**(4):548-60.
1934) Danilova ND, Solovyeva TV, Mart'yanov SV, Zhurina MV, Gannesen AV. Stimulatory effect of epinephrine on biofilms of Micrococcus luteus C01. Microbiology. 2020;**89**(4):493-497.
1935) de Lima PO, Nani BD, Almeida B, (...), Franz-Montan M, Cogo-Müller K. Stress-related salivary proteins affect the production of volatile sulfur compounds by oral bacteria. Oral Diseases. 2018; **24**(7):1358-1366.
1936) Dubar M, Frippiat JP, Remen T, Boufenzer A, Alauzet C, Baumann C, Gibot S, Bisson C. Comparison of sTREM-1 and associated periodontal and bacterial factors before/after periodontal therapy, and impact of psychosocial factors. Journal of Clinical Periodontology. 2020; **47**(9):1064-78.
1937) Hampelska K, Jaworska MM, Babalska ZŁ, Karpiński TM. The role of oral microbiota in intra-oral halitosis. Journal of Clinical Medicine. 2020; **9**(8):2484.
1938) Hampl R, Bičíková M, Stárka L. Gut microbiome and brain | [Střevní mikrobiota a mozek] Diabetologie Metabolismus Endokrinologie Vyziva 2019; **22**(1): 43-48.
1939) Harrold D, Saunders R, Bailey J. Dietary putrescine supplementation reduces faecal abundance of *Clostridium perfringens* and markers of inflammation in captive azure-winged magpies. Journal of Zoo and Aquarium Research. 2020;**8**(2):114-23.
1940) Horn N, Bhunia AK Food-associated stress primes foodborne pathogens for the gastrointestinal phase of infection. Frontiers in Microbiology. 2018; **9**(AUG),1962.
1941) Huang X, Le W, Chen Q, Chen J, Zhu Y, Shi D, Chen B, Cui Z. Suppression of the innate cancer-killing activity in human granulocytes by stress reaction as a possible mechanism for affecting cancer development. Stress. 2020;23(1):87-96.
1942) Jumina J, Harizal H. Dermatologic toxicities and biological activities of chromium. intrace metals in the environment-new approaches and recent advances 2019 Dec 3. IntechOpen.
1943) chandra HD, M, Kumara Swamy, BE. Development of electrochemical sensor for adrenaline at poly (allura red) modified carbon paste electrode: A voltammetric study Chemical Data Collections 2020; **28**:100447
1944) Mart'yanov SV, Botchkova EA, Plakunov VK, Gannesen AV. The Impact of Norepinephrine on Mono-Species and Dual-Species Staphylococcal Biofilms. Microorganisms. 2021;**9**(4):820.
1945) Memmert S, Damanaki A, Nogueira AV, Nokhbehsaim M, Götz W, Cirelli JA, Rath-Deschner B, Jäger A, Deschner J. Regulation of tyrosine hydroxylase in periodontal fibroblasts and tissues by obesity-associated stimuli. Cell and tissue research. 2018 Oct 25:1-0.

1946) Purnamasari KD, Rohita T, Zen DN, Ningrum WM. The effect of deep breathing exercises on menstrual pain perception in adolescents with primary dysmenorrhea. Pertanika Journal of Science and Technology. 2020; **28**(2), pp. 649-657
1947) Safaei M, Beitollahi H, Shishehbore MR. Synthesis and characterization of NiFe2O4 nanoparticles using the hydrothermal method as magnetic catalysts for electrochemical detection of norepinephrine in the presence of folic acid. Journal of the Chinese Chemical Society. 2019;**66**(12):1597-603.
1948) Sarkodie EK, Zhou S, Baidoo SA, Chu W. Influences of stress hormones on microbial infections. Microbial pathogenesis. 2019;**131**:270-6.
1949) Sviridova AA, Kabaeva AR, Rogovskii VS, (...), Melnikov MV, Boyko AN. Norepinephrine and intestinal microbiome in the early stages of demyelination: Clinical-immunological parallels. Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova. 2019; **119**(10): 28-34.
1950) Swamy BK. Development of electrochemical sensor for adrenaline at poly (allura red) modified carbon paste electrode: A voltammetric study. Chemical Data Collections. 2020;**28**:100447.
1951) Van Riet, N., & Luyckx, B. Novel way of promoting and maintaining gut health in pro-athletes. Whitepaper 4Gold https://4gold.eu/wp-content/uploads/2019/08/whitepaper-gut-health_4gold.pdf
1952) Volgers C, Savelkoul PH, Stassen FR. Gram-negative bacterial membrane vesicle release in response to the host-environment: different threats, same trick?. Crit Rev Microbiol. 2017; **24**:1-6. DOI: 10.1080/1040841X.2017.1353949
1953) Wang F, Tang Y. The Role of monoamine system in core affects and basic emotions. Arch Neurol & Neurosci. 2019: **3**(1):. ANN.MS.ID.000553. https://irispublishers.com/ann/fulltext/the-role-of-monoamine-system-in-core-affects-and-basic-emotions.ID.000553.php
1954) Werbner M, Barsheshet Y, Werbner N, Zigdon M, Averbuch I, Ziv O, Brant B, Elliott E, Gelberg S, Titelbaum M, Koren O. Social-stress-responsive microbiota induces stimulation of self-reactive effector T helper cells. Msystems. 2019;**4**(4).
1955) Yang Qian, et al. QseC inhibition as a novel antivirulence strategy for the prevention of acute hepatopancreatic necrosis disease (AHPND)-causing *Vibrio parahaemolyticus*. Frontiers in Cellular and Infection Microbiology, 2021, **10**: 867.
1956) Zschocke AK. Mikrobiom: Worauf Sie bei Ihren Patienten achten sollten. Osteopathische Medizin. 2017; **18** (2): 36–39.
1957) Горобец СМ, Романенко ИГ, Бобкова СА, Джерелей АА, Крючков ДЮ, Горобец ОВ. Факторы риска развития галитоза (обзор). Крымский терапевтический журнал. 2017;**3**:13-18
1958) Свиридова АА, Кабаева АР, Роговский ВС, Кожиева МХ, Мельников МВ, Бойко АН. Норадреналин и микробиом кишечника на ранних стадиях демиелинизирующего процесса: клинико-иммунологические параллели. Журнал неврологии и психиатрии им. СС Корсакова. Спецвыпуски. 2019;**119**(10):28-34.

ЦИТИРАНА:74А: Yordanov D, **Boyanova L**, Markovska RD, Ilieva J, Andreev N, Gergova G, Mitov IG. Influence of dietary factors on *Helicobacter pylori* and CagA seroprevalence in Bulgaria. Gastroenterol Res Pract. 2017;**2017**: Article ID 9212143, doi:10.1155/2017/9212143 https://www.hindawi.com/journals/grp/2017/9212143/ **Цитирана от:**

1959) Ali, M., Almal, N. B., & Mohammed, M. Study of Immuno-physiological Alterations Induced by *Helicobacter Pylori* Infection Among Population in El-Baida City, Libya.2021: https://doi. org/10.5281/zenodo. 4425526--AJMAS.
1960) El Kady, H. Screening for *Helicobacter pylori* Infection among Asymptomatic University Students in Alexandria, Egypt, Using Non Invasive Laboratory Techniques. Int. J. Curr. Microbiol. App. Sci. 2018; 20187(6), 2136-2155.
1961) Li Z, Ying X, Shan F, Ji J. The association of garlic with *Helicobacter pylori* infection and gastric cancer risk: A systematic review and meta-analysis. Helicobacter. 2018; **23**(5):e12532.
1962) Mentis, A. F. A., Boziki, M., Grigoriadis, N., & Papavassiliou, A. G. *Helicobacter pylori* infection and gastric cancer biology: tempering a double-edged sword. Cellular and Molecular Life Sciences. 2019; 76(13), 2477-2486.
1963) Monno, R., De Laurentiis, V., Trerotoli, P., Roselli, A. M., Ierardi, E., & Portincasa, P. *Helicobacter pylori* infection: association with dietary habits and socioeconomic conditions. Clinics and research in hepatology and gastroenterology. 2019; 43(5), 603-607.
1964) Shalapour, S., & Karin, M. Cruel to be kind: epithelial, microbial, and immune cell interactions in gastrointestinal cancers. Annual review of immunology. 2020; 38, 649-671.
1965) Sjomina O, Pavlova J, Niv Y, Leja M. Epidemiology of *Helicobacter pylori* infection. Helicobacter. 2018; 23:e12514.
1966) Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of *Helicobacter pylori* infection. Aliment Pharmacol Ther. 2018; 47(7):868-876.

ЦИТИРАНА: 75А. Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. Diagn Microbiol Infect Dis. 2017; 88(3): 264-267.

1967) Deyi VYM, Burette A, Ntounda R, Elkilic O, Cadranel S, Bontems P, Hallin M. Update of primary *Helicobacter pylori* resistance to antimicrobials in Brussels, Belgium. Diagn Microbiol Infect Dis. 2019; **95**(4): 114875.
1968) Pateria P, Chin M, Goodheart R, McCullough C, Raby E, Robinson JO, Ingram PR. Increasing secondary resistance to fluoroquinolones amongst *Helicobacter pylori* in Western Australia. Tasman Medical Journal. 2020; **2**(1): 15-19.
1969) Yan T-L, Gao J-G, Wang J-H, Chen D, Lu C, Xu C-F. Current status of *Helicobacter pylori* eradication and risk factors for eradication failure. World J Gastroenterol. 2020; **26**(32): 4846-4856.
1970) Zendehdel, A., & Roham, M. Role of *Helicobacter pylori* infection in the manifestation of old age-related diseases. Molecular genetics & genomic medicine. 2020; 8(4), e1157.

ЦИТИРАНА: 76А. Markovska R, Stoeva T, **Boyanova L**, Stankova P, Pencheva D, Keuleyan E, Murjeva M, Sredkova M, Ivanova D, Lazarova G, Nedelcheva G, Kaneva R, Mitov I. Dissemination of successful international clone ST15 and clonal complex 17 among Bulgarian CTX-M-15 producing *K. pneumoniae* isolates. Diagn Microbiol Infect Dis. 2017; 89(4):310-313.

1971) Abumettleq IS, Bayraktar N. Nurses' awareness on hospital acquired infection risks of the geriatric patients: A descriptive and cross-sectional study. The Journal of Infection in Developing Countries. 2021; **15**(04), 552-558.

1972) Benbrahim C, Barka MS, Benmahdi L, Zatout A, Khadir A. *Klebsiella pneumoniae* producing extended spectrum β-lactamase in Regional Military University Hospital of Oran, Algeria: antibiotic resistance, biofilm formation, and detection of *bla*CTX-M and *bla*TEM genes. African Journal of Clinical and Experimental Microbiology. 2021; **22**(1): 28-37.
1973) Domokos J, Damjanova I, Kristof K, Ligeti B, Kocsis B, Szabo D. Multiple benefits of plasmid-mediated quinolone resistance determinants in *Klebsiella pneumoniae* ST11 high-risk clone and recently emerging ST307 clone. Frontiers in microbiology. 2019; 10, 157.
1974) Horváth M, Kovács T, Koderivalappil S, Ábrahám H, Rákhely G, Schneider G. Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant *Klebsiella pneumoniae* isolates. Scientific reports. 2020; **10**(1), 1-11.
1975) Marianna, H., Tamás, K., Sarshad, K., Hajnalka, Á., Gábor, R., & Schneider, G. Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant Klebsiella pneumoniae isolates. Scientific Reports (Nature Publisher Group). 2020; 10(1).
1976) Nesporova, K., Valcek, A., Papagiannitsis, C., Kutilova, I., Jamborova, I., Davidova-Gerzova, L., ... & Dolejska, M. Multi-Drug Resistant Plasmids with ESBL/AmpC and mcr-5.1 in Paraguayan Poultry Farms: The Linkage of Antibiotic Resistance and Hatcheries. Microorganisms. 2021; 9(4), 866.
1977) Strydom KA, Chen L, Kock MM, Stoltz AC, Peirano G, Nobrega DB, ... & Pitout JDD. *Klebsiella pneumoniae* ST307 with OXA-181: threat of a high-risk clone and promiscuous plasmid in a resource-constrained healthcare setting. J Antimicrob Chemother. 2020; **75**(4), 896-902.
1978) Wang Y, Luo C, Du P, Hu J, Zhao X, Mo D, ... & Zhou H. Genomic epidemiology of an outbreak of *Klebsiella pneumoniae* ST471 producing extended-spectrum β-Lactamases in a neonatal intensive care unit. Infection and drug resistance. 2020; **13**, 1081.

ЦИТИРАНА:77A: Boyanova L, Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. Lett Appl Microbiol. 2017;**65**(6):469-474.doi: 10.1111/lam.12807

1979) Andreev, D.N., Maev, I.V., Samsonov, A.A. The importance of probiotics in optimizing the efficacy and safety of *helicobacter pylori* infection eradication therapy Meditsinskiy Sovet 2020(5):. 9-16.
1980) Bravo D, Hoare A, Soto C, Valenzuela MA, Quest AF. *Helicobacter pylori* in human health and disease: Mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018; **24**(28): 3071-3089.
1981) Bruno G, Rocco G, Zaccari P, (...), Mascellino MT, Severi C. *Helicobacter pylori* infection and gastric dysbiosis: Can probiotics administration be useful to treat this condition? Canadian Journal of Infectious Diseases and Medical Microbiology. 2018; **2018**,6237239.
1982) Ezequiel S, Zaily L, Ángela F. Estudio Micrográfico de Electrones en Indígenas *Lactobacillus delbrueckii* subsp. *fagos* de *bulgaricus*. Acta Microscopica . 2020; 29**(**4):1927-1934.
1983) Ivanov I, Petrov K, Lozanov V, Hristov I, Wu Z, Liu Z, Petrova P. Bioactive compounds produced by the accompanying Microflora in bulgarian yoghurt. Processes. 2021; **9**(1):114. https://doi.org/10.3390/pr9010114
1984) Ji J, Yang H. Using probiotics as supplementation for *Helicobacter pylori* antibiotic therapy. International journal of molecular sciences, 2020, 21.3: 1136.
1985) Layus BI.; Gerez CL.; Rodriguez AV. Antibacterial activity of *Lactobacillus plantarum* CRL 759 against methicillin-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa*. Arabian Journal for Science and Engineering, 2020, 45.6: 4503-4510.
1986) Le VM, Asyakina LK, Velichkovitch NS, Kozlova OV, Milentyeva IS, Pozdnyakova AV, Prosekov AY. Screening and characterization of the antagonistic properties of microorganisms isolated from natural sources. Open Access Maced J Med Sci [Internet]. 2020; **8**(A):195-202. Available from: https://oamjms.eu/index.php/mjms/article/view/3573
1987) Multivitamins, T. F. Consumer's Health Report. https://consumershealthreport.com/lactobacillus-bulgaricus/
1988) O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA.Treatment of *Helicobacter pylori* infection in 2018. Helicobacter. 2018; **23**,e12519.
1989) Opekun AR, Gonzales SA, Al-Saadi MA, Graham DY. Brief report: *Lactobacillus bulgaricus* GLB44 (Proviotic™) plus esomeprazole for *Helicobacter pylori* eradication: A pilot study. Helicobacter. 2018; 23(2),e12476.
1990) Pero, Raffaela, et al. A novel view of human *Helicobacter pylori* infections: Interplay between microbiota and beta-defensins. Biomolecules, 2019, 9.6: 237.
1991) Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. *Helicobacter pylori* treatment in the post-antibiotics era—searching for new drug targets. Applied Microbiology and Biotechnology, 2020, 1-15.
1992) Shehata HR; Chandler RA, Newmaster SG. Draft genome sequences of Lactobacillus delbrueckii subsp. bulgaricus strains CBC-LB69 and CBC-LB8, isolated from homemade dairy foods in Bulgaria. Microbiology Resource Announcements, 2020, 9.45.
1993) Velikova P, Petrov K, Lozanov V, Tsvetanova F, Stoyanov A, Wu Z, Liu Z, Petrova P. Microbial diversity and health-promoting properties of the traditional Bulgarian yogurt. Biotechnology & Biotechnological Equipment. 2018 May 1:1-3.

ЦИТИРАНА: 79A: Markovska R, **Boyanova L**, Yordanov D, Stankova P, Gergova G, Mitov I. Status of *Helicobacter pylori cag* pathogenicity island (*cag*PAI) integrity and significance of its individual genes. Infect Genet Evol. 2018;**59**: 167-171..

1994) Ansari S, Yamaoka Y. *Helicobacter pylori* virulence factors exploiting gastric colonization and its pathogenicity. Toxins. 2019; **11**(11): 677.
1995) Ansari S, Yamaoka Y. *Helicobacter pylori* virulence factor cytotoxin-associated gene A (*cagA*)-mediated gastric pathogenicity. International Journal of Molecular Sciences. 2020; **21**(19): 7430.
1996) dos Santos Pereira E, Albuquerque LM, de Queiroz Balbino V, da Silva Junior WJ, Burbano RMR, Gomes JPP, Rabenhorst SHB. *Helicobacter pylori cagE*, *cagG*, and *cagM* can be a prognostic marker for intestinal and diffuse gastric cancer. Infection. Genetics and Evolution. 2020; **84**:104477.

1997) El Khadir M, Boukhris SA, Zahir SO, Benajah DA, Ibrahimi SA, Chbani L, ... & Bennani B. *cagE*, *cagA* and *cagA* 3′ region polymorphism of *Helicobacter pylori* and their association with the intra-gastric diseases in Moroccan population. Diagn Microbiol Infect Dis. 2021; **100**(3): 115372.
1998) Haddadi MH, Negahdari B, Asadolahi R, Bazargani A. *Helicobacter pylori* antibiotic resistance and correlation with *cagA* motifs and *homB* gene. Postgraduate medicine. 2020; **132**(6): 512-520.
1999) Yanovich O, Doroshko M, Titov L. *Helicobacter pylori* genotypes among Belarus patients with gastroduodenal disorders and their association with clinical outcome. Acta microbiologica et immunologica Hungarica. 2019; 66(3): 399-411.
2000) Сорокман ТВ, Попелюк НА, Колесник ДИ. Инфекция *Helicobacter pylori*: современный взгляд на факторы вирулентности и патогенности. Актуальная инфектология. 2019; **7**(4).
ЦИТИРАНА:78A: Boyanova L. Direct Gram staining and its various benefits in the diagnosis of bacterial infections. Postgrad Med. 2018;**130**(1):105-110. doi: 10.1080/00325481.2018.1398049.
2001) Ako SE, Akum EA, Nkenfou CN, Pokam TB, Assob JCN. Fecal Gram stain morphotype and their distribution patterns in a Cameroonian cohort with and without HIV infection. Scientific African, 2020; 8, e00376.
2002) Gutiérrez-Arenas EG, Tavera-Valdez AN, Niderhauser-García A, Jaramillo-Rangel G, Ortega-Martínez MG. Optimización de la tinción de gram para su aplicación en tejidos. Revista de Ciencias Farmaceúticas y Biomedicina 2020; (ISSN: 2448-8380), 10.
2003) Haddad G., Bellali S., Takakura T., (...), Bou Khalil J., Raoult D. Scanning electron microscope: A new potential tool to replace gram staining for microbe identification in blood cultures. Microorganisms. 2021; 9(6): art. no. 1170.
2004) Hassan Y, Abdullahi SA, Than LT. *Candida albicans* interdigital foot infection: A case report highlighting the importance of antifungal susceptibility testing. Afr. J. Microbiol. Res. 2018; **12**(36): 889-896.
2005) Karsiyakali N, Yucetas U, Karatas A, Karabay E, Okucu E, Erkan E. Renal pelvis urine Gram stain as a traditional, but new marker in predicting postoperative fever and stone culture positivity in percutaneous nephrolithotomy: an observational, prospective, non-randomized cohort study. World J Urol. 2020 Jul 28. doi: 10.1007/s00345-020-03381-y.
2006) Kolbeck L, Haertlé M, Graulich T, Ettinger M, Suero EM, Krettek C, Omar M. Leukocyte Esterase and Glucose Reagent Test Can Rule in and Rule out Septic Arthritis. In Vivo. 2021 ;35(3):1625-1632.
2007) Li H, Li L, Chi Y, Tian Q, Zhou T, Han C, ... & Zhou Y.. Development of a standardized Gram stain procedure for bacteria and inflammatory cells using an automated staining instrument. MicrobiologyOpen. 2020; 9(9), e1099.
2008) Nawijn F, Houwert RM, van Wessem KPJ, Simmermacher RKJ, Govaert GAM, van Dijk MR, de Jong MB, de Bruin IGJ, Leenen LPH, Hietbrink F. A 5-Year Evaluation of the Implementation of Triple Diagnostics for Early Detection of Severe Necrotizing Soft Tissue Disease: A Single-Center Cohort Study. World J Surg. 2019;43(8):1898-1905.
2009) Rehman A, Ahmad S, Mateen A, Qamar H, Mubashar MA, Raza A, ... & Arshad A. Mechanistic Study of Antibacterial Properties of Chemically Synthesize Zinc Oxide Nanoparticles. Advanced Nano Research. 2019; 2(1), 42-52.
2010) Rodríguez PA, Arenas R. Hans Christian Gram y su tinción. Dermatología Cosmética, Médica y Quirúrgica. 2018;**16**(2):166-167.
2011) Sharma N K, Gautam DK, Khan MR. (2020, July). Comparative Analysis on Multiplier. In 2020 11th International Conference on Computing, Communication and Networking Technologies (ICCCNT) (pp. 1-5). IEEE.
2012) Süzük Yıldız, S. "In-House" Tween® 80 Yöntemi ile Pozitif Kan Kültürlerinden Mikroorganizmaların MALDI-TOF MS Yöntemi ile Doğrudan Tanımlanması: Deneysel ve Klinik Çalışma. Mikrobiyol Bul. 2020; 54(4), 523-534.
2013) Teixeira, P. M., Vital, W. C., Lima, A. A., Silva, N. N. T., Carneiro, C. M., de Medeiros Teixeira, L. F., & da Silva, G. N. Bacterial vaginosis: prevalence, risk profile and association with sexually transmitted infections. Revista de Epidemiologia e Controle de Infecção. 2020; 10(3).
ЦИТИРАНА:80A: Nagy E, **Boyanova L**, Justesen US; ESCMID Study Group of Anaerobic Infections. How to isolate, identify and determine antimicrobial susceptibility of anaerobic bacteria in routine laboratories? Clin Microbiol Infect. 2018;**24**(11):1139-1148. doi: 10.1016/j.cmi.2018.02.008.
2014) Acuña-Amador L, & Barloy-Hubler F. *Porphyromonas* spp. have an extensive host range in ill and healthy individuals and an unexpected environmental distribution: A systematic review and meta-analysis. Anaerobe. 2020;102280.
2015) Al Hag, W. A., Elbadawi, H., & Hamid, M. A. (2020). Use of 16s rRNA to identify non-lactose-fermenting bacilli and molecular detection of ESBL resistance genes associated with hospital-acquired infection in Soba University Hospital, Sudan. *F1000Research.* 2020;**9**(1311):1311.
2016) Aoki K, Ishii Y, Tateda K. Detection of associated bacteria in aspiration pneumonia and lung abscesses using partial 16S rRNA gene amplicon sequencing. Anaerobe. 2021;69:102325.
2017) Bavelaar, H., Justesen, U.S., Morris, T.E., (...), Kahlmeter, G., Matuschek, E. Development of a EUCAST disk diffusion method for the susceptibility testing of rapidly growing anaerobic bacteria using Fastidious Anaerobe Agar (FAA): a development study using Bacteroides species. Clinical Microbiology and Infection 2021 (in press)
2018) Bharath Kumar N. Halophilic Abilities of Bacteria in Selected Locations of Tamil Nadu. International Journal of Microbiology Research, 2019:0975-5276.
2019) Bhat KG, Ingalagi P, Patil S, Patil S, Pattar G. Antimicrobial susceptibility pattern of oral Gram negative anaerobes from Indian subjects. Anaerobe. 2021:102367.
2020) de Oliveira BFR, Cavalcanti MDA, de Oliveira Nunes S, Lobo LA, Domingues RMCP, Muricy G, Laport MS. *Paraclostridium* is the main genus of anaerobic bacteria isolated from new species of the marine sponge Plakina in the Brazilian Southeast coast. Curr microbiol. 2019;**76**(6):713-722.
2021) Deusenbery C, Wang Y, Shukla A. Recent innovations in bacterial infection detection and treatment. ACS Infectious Diseases. 2021;**7**(4):695-720.
2022) Dubreuil L, Jehl F, Cattoen C, Bonnet R, Bru JP, Caron F, ... & Weber P. Improvement of a disk diffusion method for antibiotic susceptibility testing of anaerobic bacteria. French recommendations revisited for 2020. *Anaerobe*, 2020;*64:*102213.

2023) Dumont Y, Michon AL, Laurens C, Bonzon L, Jean-Pierre H, Godreuil S. Rôle des bactéries anaérobies en clinique humaine. Revue Francophone des Laboratoires. 2018;**2018**(505):32-9.
2024) Enault, C., Aujoulat, F., Pantel, A., (...), Lavigne, J.-P., Marchandin, H. Surgical site infection after hip replacement due to a novel Peptoniphilus species, provisionally named 'Peptoniphilus nemausus' sp. nov. Anaerobe 2020, **61**:102071
2025) Erdélyi E, Ambrus A, Szabó L, Kiricsi Á, Nagy E, Rovó L, Bella Z. A mikrobiológiai vizsgálatok szerepe a peritonsillaris tályog kezelésében hat év anyagának retrospektív elemzése alapján. Orvosi Hetilap. 2020 Nov 1;161(44):1877-83.
2026) Eszter, E., Andrea, A., Linda, S., (...), László, R., Zsolt, B. The role of microbiological examination in treating peritonsillar abscess based on the retrospective analysis of data from six years | [A mikrobiológiai vizsgálatok szerepe a peritonsillaris tályog kezelésében hat év anyagának retrospektív elemzése alapján] Orvosi Hetilap. 2020; 161(44), pp. 1877-1883
2027) Gajdács, M. Anaerobes and laboratory automation: Like oil and water?. Anaerobe, 2019;**59***:*112-114.
2028) Gajdács M, Urbán E, Terhes G. Microbiological and clinical aspects of cervicofacial *actinomyces* infections: an overview. Dentistry journal, 2019:**7**(3): 85.
2029) Gajdács M, Urbán E. Relevance of anaerobic bacteremia in adult patients: A never-ending story?. European Journal of Microbiology and Immunology. 2020;
2030) Gajdács M, Urbán E. The Pathogenic Role of *Actinomyces* spp. and Related Organisms in Genitourinary Infections: Discoveries in the New, Modern Diagnostic Era. Antibiotics, 2020; **9**(8):524.
2031) Jepsen K, Falk W, Brune F, Fimmers R, Jepsen S, Bekeredjian-Ding I. Prevalence and antibiotic susceptibility trends of periodontal pathogens in the subgingival microbiota of German periodontitis patients: A retrospective surveillance study. Journal of Clinical Periodontology. 2021 May 2.
2032) Jeverica S, Sóki J, Premru MM, Nagy E, Papst L. High prevalence of division II (*cfiA* positive) isolates among blood stream *Bacteroides fragilis* in Slovenia as determined by MALDI-TOF MS. Anaerobe. 2019 Feb 1.
2033) Kierzkowska M, Majewska A, Młynarczyk G. Five years prospective survey of antibiotic resistance in *Bacteroides* and *Parabacteroides* isolated from inpatients of clinical hospital in Warsaw, Poland Pięcioletnie prospektywne badanie oporności na antybiotyki bakterii z rodzajów Bacteroides i Parabacteroides izolowanych od chorych. Organ Narodowego Instytutu Zdrowia Publicznego.: Med. Dośw. Mikrobiol. 2020; **72**:13-19.
2034) Klug TE, Greve T, Andersen C, Hahn P, Danstrup C, Petersen NK, ... & Kjeldsen A. Microbiology of parapharyngeal abscesses in adults: in search of the significant pathogens. European Journal of Clinical Microbiology & Infectious Diseases. 2021;1-10.
2035) Korb A, Silveira AM. The practice of disinfection of finger oximeters performed by nursing professionals. Rev Rene. 2021;**22**:e61222.
2036) Li-Geng T, Geraci TC, Narula N (...), Sterling S, Zacharioudakis IM. Recognizing *Cutibacterium acnes* as a cause of infectious pericarditis: A case report and review of literature. Anaerobe. 2021; **69**,102359.
2037) Maier L, Goemans CV, Pruteanu M, Wirbel J, Kuhn M, Cacace E, ... Typas A. Dissecting the collateral damage of antibiotics on gut microbes. BioRxiv. 2020
2038) Majewska A, Kierzkowska M, Kawecki D. What we actually know about the pathogenicity of *Bacteroides pyogenes*. Medical Microbiology and Immunology. 2021 in press
2039)
2040) Márió G, Gabriella T, Edit U. The incidence of bloodstream infections caused by anaerobic bacteria in a university hospital between 2005-2009 and 2013-2017: A retrospective, comparative study | [Az anaerob baktériumok által okozott véráramfertozések gyakorisága 2005-2009 és 2013-2017 között egy egyetemi központban: Retrospektív összehasonlító vizsgálat] Orvosi Hetilap. 2020; **161**(19), pp. 797-803.
2041) Ombelet S, Barbé B, Affolabi D, Ronat JB, Lompo P, Lunguya O, ... & Hardy L. Best practices of blood cultures in low-and middle-income countries. Frontiers in medicine, 2019;**6:** 131.
2042) Peeters M, Ombelet S, Chung P, Tsoumanis A, Lim K, Long L, ... Jacobs J. Slow growth of *Burkholderia pseudomallei* compared to other pathogens in an adapted blood culture system in Phnom Penh, Cambodia. J Med Microbiol. 2019; **68**(8):1159-1166.
2043) Posteraro P, De Maio F, Menchinelli G, Palucci I, Errico FM, Carbone M, ... Posteraro B. First bloodstream infection caused by *Prevotella copri* in a heart failure elderly patient with Prevotella-dominated gut microbiota: a case report. Gut pathog. 2019; **11**(1):1-6.
2044) Rassolie A, Özenci V. Short-term culture for rapid identification of anaerobic bacteria from blood cultures. Anaerobe. 2019;**57***:* 59-62.
2045) Ryan PM, Morrey BF. *Parvimonas micra* causing native hip joint septic arthritis. Baylor University Medical Center Proceedings 2021: 1-3. Taylor & Francis.
2046) Scherler A, Ardissone S, Moran-Gilad J, Greub G. (2019). ESCMID/ESGMD postgraduate technical workshop on diagnostic microbiology. Microbes and infection, 2019;*21*(8-9): 343-352.
2047) Urbán, E., & Gajdács, M. Microbiological and Clinical Aspects of Actinomyces Infections: What Have We Learned? Antibiotics 2021, **10**(2), 151; https://doi.org/10.3390/antibiotics10020151
2048) Zhang, C. Y., Li, M. H., & Guo, M. Q. (2020). A phase conversion headspace technique for the determination of anti-anaerobic activity of drug candidate based on the metabolic acidity change in culture medium. Journal of Chromatography *A*. 2020;**1621***:* 461024.
2049) Zou J, Yang X, Zeng L, Wang X, Liu Y, Wei D, ... & Hu N. Identification and Antimicrobial Susceptibility of Clinically Isolated Anaerobic Bacteria: A Retrospectively Study in a Jiangxi Tertiary-Care Hospital. Jundishapur Journal of Microbiology, 2019;**12**(10).
ЦИТИРАНА 85А: Boyanova L, Hadzhiyski P, Markovska R, Yaneva P, Yordanov D, Gergova G, Mitov I. Prevalence of *Helicobacter pylori* is still high among symptomatic Bulgarian children. Acta Microbiol Immunol Hung. 2019; **66**(2):255-260.

2050) Gold, B. D., Jones, N. L., & Heyman, M. B. *Helicobacter pylori*: Diagnosis and management in the pediatric patient. 2021. https://www.uptodate.com/contents/helicobacter-pylori-diagnosis-and-management-in-the-pediatric-patient
2051) Seo JH, Bortolin K, Jones NL. *Helicobacter pylori* infection in children. Helicobacter. 2020; 25, e12742.
2052) Поливанова ТВ, Каспаров ЭВ, Вшивков ВА, Перетятько ОВ, Ахметшин ТН. Распространенность гастроэзофагеальной рефлюксной болезни, гастродуоденальных эрозий и язв и их ассоциация у школьников Сибири с семейной предрасположенностью к язвенной болезни. Сибирский научный медицинский журнал. 2020; **40**(5), 113-121.

ЦИТИРАНА 86А: Markovska R, Stoeva T, Boyanova L, Stankova P, Schneider I, Keuleyan E, Mihova K, Murdjeva M, Sredkova M, Lesseva M, Nedelcheva G, Petrova A, Ivanova D, Lazarova G, Kaneva R, Mitov I. Multicentre investigation of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing K. pneumoniae. Infect Genet Evol. 2019; 69:61-67. **Цитирана от:**

2053) Bilal H, Zhang G, Rehman T, Han J, Khan S, Shafiq M, ... & Yang X. First Report of $bla_{\text{NDM-1}}$ bearing IncX3 plasmid in clinically isolated ST11 *Klebsiella pneumoniae* from Pakistan. Microorganisms. 2021; 9(5), 951.
2054) Dziri R, Ayari I, Barguellil F, Ouzari HI, El Asli MS, Klibi N. First report of NDM and VIM coproducing *Klebsiella pneumoniae* in Tunisia and emergence of novel clones. Microbial Drug Resist. 2019; **25**(9): 1282-1286.
2055) Foster-Nyarko, E., Alikhan, N. F., Ravi, A., Thilliez, G., Thomson, N. M., Baker, D., ... & Pallen, M. J. Genomic diversity of Escherichia coli isolates from non-human primates in the Gambia. Microbial genomics. 2020; 6(9).
2056) Papa-Ezdra R, Caiata L, Palacio R, Outeda M, Cabezas L, Bálsamo A, ... & Seija V. Prevalence and molecular characterisation of carbapenemase-producing *Enterobacterales* in an outbreak-free setting in a single hospital in Uruguay. J Glob Antimicrob Resist. 2021; **24**:58-62.
2057) Ripabelli G, Sammarco ML, Salzo A, Scutellà M, Felice V, Tamburro M. New Delhi metallo-β-lactamase (NDM-1)-producing *Klebsiella pneumoniae* of sequence type ST11: first identification in a hospital of central Italy. Lett Appl Microbiol. 2020; **71**(6): 652-659.
2058) Zou, H., Jia, X., Liu, H., Li, S., Wu, X., & Huang, S. Emergence of NDM-5-Producing *Escherichia coli* in a Teaching Hospital in Chongqing, China: IncF-Type Plasmids May Contribute to the Prevalence of blaNDM–5. Frontiers in microbiology. 2020; 11, 334.

ЦИТИРАНА:90А: **Boyanova L,** Kalvatchev N, Yordanov D, Hadzhiyski P, Markovska R, Gergova G, Mitov I. *Clostridioides (Clostridium) difficile* carriage in asymptomatic children since 2010: a narrative review. Biotechnol Biotec Eq. 2019; 33:1, 1228-1236, DOI: 10.1080/13102818.2019.1650666 **Цитирана от:**

2059) Gates V, Best E, Roberts S, Swager T, Voss L. Diagnosis and management of paediatric *Clostridioides difficile* infection in a tertiary centre: A prospective audit. Journal of Paediatrics and Child Health 2021; **57**(4): 500-506.
2060) Khattab RA, Ahmed NA, Ragab YM, Rasmy SA. Bacteria producing antimicrobials against *Clostridium difficile* isolated from human stool. Anaerobe. 2020; 102206.

ЦИТИРАНА:91А: Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in *Helicobacter pylori*: current state and future directions. Expert Rev Clin Pharmacol. 2019;12(9):909-915. doi: 10.1080/17512433.2019.doi: 10.1080/17512433.2019.1654858. **Цитирана от:**

2061) BaniHani MN, Khabour OF, Alzoubi KH, Bashir NA, Shakhatreh MAK, Sabi SH, Alrabadi N. The association between ABCB1 C1236T/C3435T SNPs and *H. pylori* infection among Jordanians. Genes. 2020; **11**(1): 63.
2062) Bedoya-Gómez IJ, Alvarez-Aldana A, Moncayo-Ortiz JI, Guaca-González YM, Santacruz-Ibarra JJ, Arturo-Arias BL, ... & Beltrán-Angarita L. Surveillance of the antimicrobial resistance rates of *Helicobacter pylori* ten years later in the Western Central Region, Colombia. Digestive Diseases,.2020; **38**(3): 196-203.
2063) Cai Y, Wang C, Chen Z, Xu Z, Li H, Li W, Sun Y. Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in *Helicobacter pylori* by enhancing drug efflux. Helicobacter. 2020; **25**(4): e12715.
2064) Cano, A., Ettcheto, M., Espina, M., López-Machado, A., Cajal, Y., Rabanal, F., ... & Souto, E. B. State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. Journal of Nanobiotechnology. 2020; 18(1), 1-24.
2065) Di Fermo P, Di Lodovico S, Amoroso R, De Filippis B, D'Ercole S, Di Campli E, Cellini L, Di Giulio M. Searching for new tools to counteract the *Helicobacter pylori* resistance: The positive action of resveratrol derivatives. Antibiotics. 2020;9(12):891.
2066) Gong, M., Han, Y., Wang, X., Tao, H., Meng, F., Hou, B., ... & Wang, G. Effect of Temperature on Metronidazole Resistance in *Helicobacter pylori*. Frontiers in Microbiology. 2021; 12, 1224.
2067) Gontijo MT, Vidigal PM, Lopez ME, Brocchi M. Bacteriophages that infect Gram-negative bacteria as source of signal-arrest-release motif lysins. Research in Microbiology. 2021;172(2):103794.
2068) Graells T, Heinzel C., Jørgensen PS. The Anthropocene Operating Space for for Antimicrobial Resistance: tipping points in treatability of priority pathogens. OSF preprints. 10.31219/osf.io/s879f; https://osf.io/s879f/
2069) Hwang JY, Kim C, Kwon YH, Lee JE, Jeon SW, Nam SY, Seo AN, Han MH, Park JH. Dual Clarithromycin and Metronidazole Resistance is the Main Cause of Failure in Ultimate *Helicobacter pylori* Eradication. Dig Dis. 2021 Jan 11.
2070) Isaza-Gómez E, Ángel-González MS, Ocampo-Muñoz M, Díaz-Quintero CA, Molina-Céspedes IC, Velásquez-Martínez MA, Posada-Moreno P, Salazar-Ochoa S. Controversies in surgery: Eradication of *Helicobacter pylori*. Therapy for all or according to usual indications? Revista Colombiana de Cirugía. 2020;35(4):665-674.
2071) Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD. Role of antimicrobial susceptibility testing before first-line treatment containing clarithromycin for *Helicobacter pylori* eradication in the clinical setting. Antibiotics 2021, 10, 214.
2072) Kim YM, Lee KH, Kim JH, Park SY, Song YG, Jeon SY, Park H. Is only clarithromycin susceptibility important for the successful eradication of *Helicobacter pylori*?. Antibiotics. 2020;9(9):589.

2073) Kobayashi J, Kawakubo M, Fujii C, Arisaka N, Miyashita M, Sato Y, Komura H, Matoba H, Nakayama J. Cholestenone functions as an antibiotic against *Helicobacter pylori* by inhibiting biosynthesis of the cell wall component CGL. Proceedings of the National Academy of Sciences. 2021;118(16).
2074) Krzyżek P, Paluch E, Gościniak G. Synergistic therapies as a promising option for the treatment of antibiotic-resistant *Helicobacter pylori*. Antibiotics. 2020;9(10):658.
2075) Krzyżek P, Gościniak G, Fijałkowski K, Migdał P, Dziadas M, Owczarek A, Czajkowska J, Aniołek O, Junka A. Potential of bacterial cellulose chemisorbed with anti-metabolites, 3-bromopyruvate or sertraline, to fight against *Helicobacter pylori* Lawn Biofilm. International journal of molecular sciences. 2020;21(24):9507.
2076) Mi M, Wu F, Zhu J, Liu F, Cui G, Wen X, Hu Y, Deng Z, Wu X, Zhang Z, Qi T. Heterogeneity of *Helicobacter pylori* Strains Isolated from Patients with Gastric Disorders in Guiyang, China. Infection and Drug Resistance. 2021;14:535.
2077) Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The prevalence of multidrug resistance of *helicobacter pylori* and its impact on eradication in Korea from 2017 to 2019: A single-center study. Antibiotics. 2020;9(10):646.
2078) Pellicano R, Roldán IJ, Castaño R, Navas MC. Which should be the first-line treatment for *Helicobacter pylori* in Colombia? A lesson from a recent study. Biomédica. 2019; 39(4): 811-815.
2079) Raj R, Agarwal N, Raghavan S, Chakraborti T, Poluri KM, Kumar D. Exquisite binding interaction of 18β-Glycyrrhetinic acid with histone like DNA binding protein of *Helicobacter pylori*: A computational and experimental study. International Journal of Biological Macromolecules. 2020.
2080) Tshibangu-Kabamba, E., & Yamaoka, Y. *Helicobacter pylori* infection and antibiotic resistance—from biology to clinical implications. Nature Reviews Gastroenterology & Hepatology. 2021; 1-17.
2081) Ye ZN, Xia HH, Zhang R, Li L, Wu LH, Liu XJ, Xie WR, He XX. The efficacy of washed microbiota transplantation on *Helicobacter pylori* eradication: A pilot study. Gastroenterol Res Pract. 2020: 8825189.
2082) Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, ... & Xie Y. The effect of antibiotic resistance on *Helicobacter pylori* eradication efficacy: A systematic review and meta-analysis. Helicobacter. 2020; e12714.
2083) Емельянов ИА. Современные подходы к повышению эффективности эрадикации *H. pylori* при высокой антибиотикорезистентности (обзор литературы). Вестник новых медицинских технологий. Электронное издание. 2020;14(5).

ЦИТИРАНА 92А: Boyanova L, Markovska R, Mitov I. Multidrug resistance in anaerobes. FutureMicrobiol. 2019; 14(12):1055–1064.. **Цитирана от:**

2084) Areej, S., Sattar, A., Javeed, A., & Raza, S. Diphenhydramine and levofloxacin combination therapy against antimicrobial resistance in respiratory tract infections. Future microbiology. 2021; 16(6), 409-420.
2085) Kozhakhmetova S, Zholdybayeva E, Tarlykov P, Atavliyeva S, Syzdykov T, Daniyarov A, ... & Ramankulov Y. Determinants of resistance in *Bacteroides fragilis* strain BFR_KZ01 isolated from a patient with peritonitis in Kazakhstan. J Glob Antimicrob Resist.2021; **25**: 1-4.
2086) Kozhakhmetova, S. S., Zholdybayeva, E. V., Mukhtarova, K. E., & Ramankulov, Y. M. Pathogenicity factors and antibiotic resistance of the *Bacteroides fragilis*. Eurasian Journal of Applied Biotechnology. 2020; (1), 3-13.

ЦИТИРАНА 98А: Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of *Helicobacter pylori* infection: a review of recent data. Future Microbiol. 2020;15:1185-1196. **Цитирана от:**

2087) Gisbert JP. Rifabutin for the treatment of *Helicobacter pylori* infection: A Review. Pathogens. 2021;10(1):15.

ЦИТИРАНА: **101А:** Nyssen OP, Pérez-Aisa A, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M,| Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Jurecic NB, Huguet JM, Alcaide N, Voynovan I, Bote JMB, Modolell I, Lasala JP, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Pinto RM, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, **Boyanova L**, … *Helicobacter pylori* first-line and rescue treatments in patients allergic to penicillin: experience from the European Registry on *H. pylori* management (Hp-EuReg). Helicobacter. 2020;00:e12686. https://doi.org/10.1111/hel.12686. **Цитирана от:**

2088) Zhou Y, Ye Z, Lu J, Miao S, Lu X, Sun H, ... & Huang Y. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. *Helicobacter*. 2020: e12721.

ЦИТИРАНА: **102А**: Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, **Boyanova L,** Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on *Helicobacter pylori* management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;**70**(1):40-54. doi: 10.1136/gutjnl-2020-321372. **Цитирана от:**

2089) Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of *H. pylori* infection. Expert Opinion on Pharmacotherapy. 2021; 22(6):729-741.
2090) Graham DY. Molecular-based *Helicobacter pylori* susceptibility testing is almost ready for prime time. Gastroenterology. 2021;160(6): 1936-1937.
2091) Graham DY, El-Serag HB. European Registry on *Helicobacter pylori* management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut. 2021;70(1):1-2.
2092) Graham DY. Transitioning of *Helicobacter pylori* therapy from trial and error to antimicrobial stewardship. Antibiotics. 2020;9(10):671.
2093) Graham DY, Liou JM. Primer for development of guidelines for *Helicobacter pylori* Therapy using antibiotic stewardship. Clinical Gastroenterology and Hepatology. 2021 Mar 26.
2094) Gravina A.G., Priadko K., Granata L., (...), Ciamarra P., Romano M. Single capsule bismuth quadruple therapy for eradication of *H. pylori* infection: A Real-Life Study. Frontiers in Pharmacology. 2021; **12**, art. no. 667584.

2095) Howden CW, Graham DY. Recent developments pertaining to *H. pylori* Infection. Official journal of the American College of Gastroenterology| ACG. 2021 Jan 1;116(1):1-3.
2096) Jukic I, Vukovic J, Rusic D, Bozic J, Bukic J, Leskur D, Seselja Perisin A, Modun D. Adherence to Maastricht V/Florence consensus report for the management of *Helicobacter pylori* infection among primary care physicians and medical students in Croatia: A cross-sectional study. Helicobacter. 2021 Apr;26(2):e12775.
2097) Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of *Helicobacter pylori* in West Flanders–Belgium: an observational cross-sectional study. Acta Clinica Belgica. 2021 Jan 29:1-8.

ЦИТИРАНА 12Б: Keuleyan E, R. Avramova, S. Barzashka, L. Boyanova, R. Gergova, I. Mitov. Analysis of antibiotic susceptibility in orthopedics and traumatology hospital. Probl. Inf. Parasit. Dis. 1998; 26 (1): 24-27. **Цитирана от:**

2098) Avorn, J. L., Davey, J. F., McEwen, P. G., O'Brien, S. A., TF Levy, S. B., & World Health Organization. Antibiotic resistance: sinthesis of recommendations by expert policy groups. Portal Regional da BVS, 2001.
2099) World Health Organization. Antibiotic resistance: synthesis of recommendations by expert policy groups (No. WHO/CDS/CSR/DRS/2001.10). World Health Organization. 2001.

ЦИТИРАНА: 29Б: Петров, Д., Вл. Джамбазов, Петкова, П., **Л. Боянова,** Ц. Минчев, Е. Горанов, М. Плочев. Хирургично лечение на хроничния плеврален емпием - седемгодишен опит. Хирургия 2004; **60** (2): 25-29. **Цитирана от:**

2100) Andrade-Alegre R, Garisto JD, Zebede S. Open thoracotomy and decortication for chronic empyema. Clinics (Sao Paulo). 2008; **63**(6):789-793.

ЦИТИРАНА: 49Б: Боянова Л., Панов Вл., Йорданов Д., Марковска Р., Марина М., Гергова Г., Иванова К., Панайотов Ст., Бранкова Н., Левтерова В., Митов И., Кантарджиев Т., Кръстев З. *Helicobacter pylori* в устната кухина–предварителни проучвания. Хепато-гастроентерол. 2008; No.1: 3-10.

2101) Bagirova M, Allahverdiyev AM, Abamor ES, Aliyeva H, Unal G, Tanalp TD. An overview of challenges to eradication of *Helicobacter pylori* infection and future prospects. Eur Rev Med Pharmacol Sci. 2017; **21**(9):2199-2219.

ЦИТИРАНА: 67Б: Боянова Л., Илиева Ю, Владимиров Б, Гергова Г, Николов Р, Спасова З, Матева Л, Митова Р, Терзиев И, Митов И. Честота на *Helicobacter pylori* при възрастни пациенти с ^{13}C уреен дихателен тест. Обща мед. 2013, XV (4):22-25.

2102) Best, L. M., Takwoingi, Y., Siddique, S., Selladurai, A., Gandhi, A., Low, B., ... & Gurusamy, K. S. Non-invasive diagnostic tests for *Helicobacter pylori* infection. Cochrane Database of Systematic Reviews. 2018; (3).
2103) Gurusamy, K. S., Yaghoobi, M., & Davidson, B. R. Non-invasive diagnostic tests for *Helicobacter pylori* infection. Cochrane Database of Systematic Reviews. 2016; (2).

ЦИТИРАНА 47В: McNicholl AG, Gasbarrini A, Tepes B, Lerang F, Bordin DS, Shvets O, Rokkas T, Kupcinskas L, Leja M, Katicic M, Machado JC, **Boyanova L**, Przytulski K, Simsek I, Buzas GM, Axon T, Beglinger C, Bytzer P, Lamy V, Goldis A, Cappelle LG, Veijola L, Caldas M, Ramas M, F. Megraud F, O'Morain CA, Gisbert JP On Behalf of the Hp-EuReg investigators and the European Helicobacter Study Group.Pan-European Registry on *H. pylori* Management (Hp-EuReg): **Rescue Treatments**. 27th International Workshop on Helicobacter and Microbiota in Chronic Digestive Inflammation and Gastric Cancer. Rome, Italy 10–13 September 2014. Helicobacter, 2014; 19 (suppl 1): Abstract no.: P11.06.

2104) Шептулин, А. А., & Лапина, Т. Л. Современные аспекты диагностики и лечения инфекции *H. pylori* в свете профилактики рака желудка (по итогам XXVII Международного рабочего совещания Европейской группы по изучению Helicobacter). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 25(1), 80-85.

ЦИТИРАНА 51В: McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskas L, Perez-Aisa A, Axon T, Buzas GM, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, **Boyanova L,** Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Huerta A, Perez-Lasala J, Caldas M, Ramas M, Megraud F, O'Morain CA, Gisbert JP. Pan-European Registry on *H. pylori* Management (HP-EuReg): **Bacterial Resistance**. XXVIIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Nicosia, Cyprus, September 24–26, 2015. Gastroenterology, 2015; **148**(4): S-417. **Цитирана от:**

2105) Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of *Helicobacter pylori* infection. The American journal of gastroenterology. 2017;**112**(2):212-239.

ЦИТИРАНА 49В: McNicholl AG, Tepes B, Gasbarrini A, **Boyanova L**, Leja M, Lerang F, Rokkas T, Kupcinskas L, Przytulski K, Katicic M, Machado JC. **Su1173** Pan-European Registry on *H. pylori* Management: Interim Analysis. Gastroenterology. 2014;**146**(5):S-395. **Цитирана от:**

2106) Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY. First-line *Helicobacter pylori* eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut. 2018;**67**(1):20-7.
2107) Бордин, Д. С., О. Б. Янова, И. Н. Войнован, С. Г. Хомерики, В. А. Ким, Е. В. Быстровская, and Э. Р. Валитова. "Эффективность и безопасность пробиотических бактерий *Lactobacillus reuteri* DSMZ17648 у инфицированных *Helicobacter pylori*, не имеющих абсолютных показ. Лечащий врач. 2015: https://www.lvrach.ru/2015/08/15436273/
2108) Лазебник ЛБ, Бордин ДС. Диагностика и лечение инфекции *Helicobacter pylori* в России: результаты проспективной наблюдательной программы «КАЙДЗЕН». Эффективная фармакотерапия. 2016(15):12-23.
2109) Лазебник ЛБ. Диагностика и лечение заболеваний ассоциированных с *Helicobacter pylori* в условиях реальной клинической практики: результаты наблюдательной программы «ПАРАД». Клинический протокол диагностики и лечения: Болезни печени, связанные с беременностью. 2014:73.
2110) МКНЦДЗМ Ц. Эффективность и безопасность *Lactobacillus reuteri* DSMZ17648 у инфицированных *Helicobacter pylori.* Журнал «Лечащий Врач». 2017 (5-2016):106.

ЦИТИРАНА 50В: McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskas L, Perez-Aisa A, Axon T, Buzas GM, Castro M, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, Rodrigo L, **Boyanova L,** Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Bujanda L, Molina-Infante J, Caldas M, Ramas M, Donday MG, Megraud F, O'Morain CA, Gisbert JP. P02.01management (Hp-EuReg): **First-line treatments and interim**

analysis of 11 272 patients. XXVIIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Nicosia, Cyprus, September 24–26, 2015. Helicobacter. 20:91, SEP 2015. **Цитирана от:**

2111) Beaugerie L, Peyrin-Biroulet L. No Excess Cancer Recurrence After Immunosuppressive Drugs in a Meta-analysis of Cohorts of Patients With Immune-mediated Diseases: A Mirage Related to Propensity Bias?. Gastroenterology. 2017; **152**(1):304-306.
2112) Дехнич, Н. Н., Тряпышко, А. А., Трушин, И. В., Кузьменков, А. Ю., & Козлов, Р. С. Нифурател в эрадикации инфекции *Helicobacter pylori* у взрослых: результаты рандомизированного, сравнительного клинического исследования. Клиническая микробиология и антимикробная химиотерапия, 2020; 22(2).
2113) Ивашкин ВТ, Маев ИВ, Лапина ТЛ, Шептулин АА, Трухманов АС, Абдулхаков РА, Алексеенко СА, Дехнич НН, Козлов РС, Кляритская ИЛ, Курилович СА.. Лечение инфекции *Helicobacter pylori:* мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2017; **27**(4):4-21.
2114) Хлынов, И. Б., Акименко, Р. И., Воронова, Е. И., Гаранина, Е. В., Гурикова, И. А., Лосева, М. Э., ... & Фрезе, Е. Б. Роль *Lactobacillus reuteri* DSMZ17648 в эрадикационной терапии инфекции *Helicobacter pylori* у взрослых в реальной клинической практике. Лечащий врач, 2020; (2), 19-22.

ЦИТИРАНА 51В: McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskas L, Perez-Aisa A, Axon T, Buzas GM, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, **Boyanova L,** Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Huerta A, Perez-Lasala J, Caldas M, Ramas M, Megraud F, O'Morain CA, Gisbert JP. Pan-European Registry on *H. pylori* Management (HP-EuReg): **Bacterial Resistance**. XXVIIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Nicosia, Cyprus, September 24–26, 2015. Gastroenterology, 2015; **148**(4): S-417. **Цитирана от:**

2115) Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. ACG clinical guideline: treatment of *Helicobacter pylori* infection. Official journal of the American College of Gastroenterology| ACGл 2017; 112(2), 212-239.
2116) Savoldi, A., Carrara, E., Graham, D. Y., Conti, M., & Tacconelli, E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018; 155(5), 1372-1382.

ЦИТИРАНА: 53В: McNicholl AG, Gasbarrini A, Tepes B, Castro-Fernandez M, Aisa AP, Bujanda L, Molina-Infante J, Lanas A, Vaira D, Rokkas T, Almela P, Medina E, Ortuño J, Michopoulos S, Domínguez-Cajal M, Lucendo AJ,Barrio J, Modolell I, Pozzati L, Ntouli V, Perez-Lasala J, Georgopoulos SD, Rodrigo L, Vujasinovic M, Bordin DS, Machado JC, **Boyanova L,** Caldas M, Ramas M, Donday MG, Megraud F, O'Morain CA, Gisbert JP. Tu1327 Pan-European Registry on *H. pylori* Management (Hp-EuReg): **Interim Analysis of Non-Bismuth Quadruple Concomitant Treatment.** Gastroenterology. 2016; 150 (4 Supplement 1): Page S875. http://www.gastrojournal.org/article/S0016-5085(16)32952-3/abstract

Цитирана от:

2117) Ramírez FB, Núñez CG, Mas MT, Jiménez NR, Caballero FL. Criterios para la erradicación de *Helicobacter pylori*. FMC-Formación Médica Continuada en Atención Primaria. 2018;**25**(1):43-53.
2118) Сафина ДД, Абдулхаков СР, Абдулхаков РА. Эрадикационная терапия *Helicobacter pylori*: настоящее и будущее. Экспериментальная и клиническая гастроэнтерология. 2016(11):84-93.

ЦИТИРАНА: 54В: Adrian G. McNicholl AG, Tepes B, Gasbarrini A, Aisa AP, Vaira D, Bordin DS, Lerang F, Castro-Fernandez M, Bujanda L, Leja M, Vujasinovic M, Rokkas T, Kupcinskas L, Veijola L, Shvets O, Buzás GM, Machado JC, **Boyanova L**, …, Megraud F, O'Morain CA, Gisbert JP. Tu1328 Pan-European Registry on *H. pylori* Management (HP-EuReg): **Interim Analysis of First- and Second-Line Treatments.** Gastroenterology. 2016; 150 (4 Supplement 1): Page S875. **Цитирана от:**

2119) Fallone, C. A., Moss, S. F., & Malfertheiner, P. (2019). Reconciliation of recent *Helicobacter pylori* treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019; 157(1), 44-53.
2120) Jonaitis, P. *Helicobacter pylori* infekcijos gydymo metodų ir jų efektyvumo vertinimas. 2020
2121) Сафина ДД, Абдулхаков СР, Абдулхаков РА. Эрадикационная терапия *Helicobacter pylori*: настоящее и будущее. Экспериментальная и клиническая гастроэнтерология. 2016(11):84-93.

ЦИТИРАНА: 58В: McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskas L, Perez-Aisa A, Axon T, Buzas GM, Castro M, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, **Boyanova L,** Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Huerta A, Perez-Lasala J, Caldas M, Ramas M, Megraud F, O'Morain CA, Gisbert JP. Pan-European Registry on *H. pylori* Management (HP-EuReg): Interim Analysis of 8,271 Patients. Su1136. Gastroenterology. 2015 Apr 1;148(4):S-417. **Цитирана от:**

2122) Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of *Helicobacter pylori* infection. The American journal of gastroenterology. 2017;112(2):212.
2123) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;**155**(5):1372-82.

ЦИТИРАНА: 71В: Marteva-Proevska Y, Velinov T, Markovska R, Dobrikova D, Pavlov I, **Boyanova L**, Mitov I. Antibiotic combinations with colistin against carbapenem-resistant *Klebsiella pneumoniae* - in vitro assessment. J of IMAB. 2018;**24**(4):2258-2266. DOI: 10.5272/jimab.2018244.2258. **Цитирана от:**

2124) Nagy TA, Crooks AL, Quintana JL, Detweiler CS. Clofazimine Reduces the Survival of Salmonella enterica in Macrophages and Mice. ACS infectious diseases. 2020; **6**(5), 1238-1249.

ЦИТИРАНА: 7М: Boyanova L, Setchanova L, Gergova G, Kostianev T, Yordanov D, Popova C, Kotsilkov K, Mitov I. Microbiological diagnosis of the severe chronic periodontitis. Journal of IMAB- Annual Proceeding (Scientific Papers) 2009; 15, Book 2 (Part Dentistry (Oral and Dental Medicine): 89-94. http://www.journal-imab-bg.org/en/vol-15_book-2.htm **Цитирана от**:

2125) Abdulaziz SM, Said AMA, Mustafa SA. The impact of the presence of *Porphyromonas gingivalis* on periodontal health in a group of patients with periodontitis in Erbil. Zanco J Med Sci. 2015; **19**(3):1069-1074.
2126) Al-Hamdonii SA. Some rapid methods for oral treponema detection. Raf. J. Sci. 2012; **23**(3):23-23.
2127) Bankur PK, Nayak A, Bhat K, Bankur R, Naik R, Rajpoot N. Comparison of culture and polymerase chain reaction techniques

in the identification of *Tannerella forsythia* in periodontal health and disease, an in vitro study.J Indian Soc Periodontol. 2014;**18**(2):155-60.
2128) Górski B. Wybrane czynniki ryzyka chorób przyzębia w świetle współczesnej wiedzy (Selected risk factors for periodontal diseases in the light of a contemporary knowledge). Nowa Stomatologia. 2012; **3**:126-129.
2129) Hamdoon, S. M. Prevalence of Anaerobic Bacteria in Periodontitis in Relation to Pocket Depth. Al-Rafidain Dental Journal. 2014; 14(2), 320-328.
2130) Jóźwik M, Kopański Z. Periodontium diseases. Journal of public health, nursing and medical rescue. 2014; 1: 30-34. http://jchc.eu/numery/article.php?idissue=201416
2131) Kazi, M. M., & Bharadwaj, R. Microbiota of Chronic Periodontitis and their Association with Severity of the Disease. International Journal of Current Research and Review. 2017; 9(7), 28.
2132) Omran, M. E., Gomaa, F. A. M., Ibrahim, N. G., Afifi, S. S., & Ashour, M. S. Isolation and Antimicrobial Susceptibility of Aerobic and Anaerobic Bacteria of Periodontitis in Egyptian Diabetic Patients. Egyptian Journal of Medical Microbiology, 2011;20(2).
2133) Rai R. A comparative evaluation of the effect of chlosite & chlorhexidine mouth wash in the management of chronic periodontitis as an adjunct to scaling and root planing - a clinicomicrobiological study. IJPRD. 2013; **5**(09):60-66.
2134) Shehab EY.Antibacterial effect of black and green tea on oral bacteria in pregnant women. International Journal of Enhanced Research in Science Technology & Engineering. 2014; **3**(4): 1-14.: www.erpublications.com
2135) Sindagi, A. S., Anmol, G. K., Bellad, A. S., & Kulkarni, K. In-vitroantibacterial activity of neem, clove, and cinnamon against Actinobacillus sp., isolatedfrom chronic periodontitis patients. Biomedicine. 2020; 40(2), 214-219.

ЦИТИРАНА: 8M: Kotsilkov K, Popova C, **Boyanova L**, Setchanova L, Gergova G, Kostanev T, Yordanov D, Mitov I, Dosseva V. Effectiveness of the target antibiotic administration in the treatment of the severe chronic periodontitis part I – microbiological evaluation. Journal of IMAB- Annual Proceeding (Scientific Papers) 2009; Book 2 Part Dentistry (Oral and Dental Medicine): 95-101. http://www.journal-imab-bg.org/en/vol-15_book-2.htm **Цитирана от:**

2136) Mammdoh J K. Efficacy of azithromycin in comparison with metronidazole in the treatment of chronic periodontitis. Al–Rafidain Dent J. 2011; **11**(2): 323-330.

ЦИТИРАНА: 14M: Boyanova L. *H. pylori* virulence factors. In *Helicobacter pylori*. Boyanova L. (ed.) Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011:71-117. **Цитирана от:**

2137) Nyberg, Tora, 2014. *Helicobacter* : en omvänd zoonos?. First cycle, G2E. Uppsala: SLU, Dept. of Biomedical Sciences and Veterinary Public Health

ЦИТИРАНА: 15M: Boyanova L. Epidemiology of *H. pylori* infection. In *Helicobacter pylori*. Boyanova L. (ed.) Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011: 135-159. **Цитирана от:**

2138) Kudabaeva KI, Bazargaliev YS, Baspacova AM, Darzhanova KB. Atrophic gastritis and peculiaritis *Helicobacter pylori*-colonization in diabetes mellitus type 2. Black Sea Scientific Journal of Academic Research. 2014;**13**(6):69-72.
2139) Bui D, Brown HE, Harris RB, Oren E. Serologic evidence for fecal-oraltransmission of *Helicobacter pylori.* Am J Trop Med Hyg. 2016;**94**(1):82-8.
2140) Seid A, Tamir Z, Kasanew B, Senbetay M. Co-infection of intestinal parasites and *Helicobacter pylori* among upper gastrointestinal symptomatic adult patients attending Mekanesalem Hospital, northeast Ethiopia. BMC research notes. 2018;**11**(1):144.

ЦИТИРАНА 11-17M: Boyanova L. (ed.) *Helicobacter pylori*. Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011. **Цитирана от:**

2141) Al-Balushi MS, Al-Busaidi JZ, Al-Daihani MS, Shafeeq MO, Hasson SS. Sero-prevalence of *Helicobacter pylori* infection among asymptomatic healthy Omani blood donors. Asian Pac J Trop Dis 2013; **3**(2): 146-149.
2142) Algaiat SS, Lal SS. Molecular cloning of *iceA1* gene of *Helicobacter pylori* in relation to gastric cancer. International Journal of Scientific Engineering and Technology Research. 2016; **05**(08): 1613-1619.
2143) Breckan RK, Paulssen EJ, Asfeldt AM, Kvamme JM, Straume B, Florholmen J. The All-Age Prevalence of *Helicobacter pylori* Infection and Potential Transmission Routes. A Population-Based Study. Helicobacter. 2016;21(6):586-595.
2144) Bruno D, Fanny B, Jeremy P, Mathilde G, Amandine F, Allais F, Le Blaye I. Higher levels of exhaled dimethylcyclopropane in patients with small intestinal bowel overgrowth, periodontitis when associated with a medical history of cancer. J Clin Case Stu 2018; 3(4): dx.doi.org/10.16966/2471- 4925.175.
2145) Creative Diagnostics. Mouse Anti-HP Urease B Monoclonal Antibody. Mouse, Monoclonal (HP Urease B). Specification sheet. Cat. No.: DMAB7734. 2011. http://img.creative-diagnostics.com/pdf/DMAB7734,%20Anti-HP%20Urease%20B%20MAb.pdf
2146) Creative Diagnostics. Mouse Anti-HP Urease A Monoclonal Antibody. Mouse, Monoclonal (HP Urease A). Specification sheet. Cat. No.: DMAB7733. 2011. http://img.creative-diagnostics.com/pdf/DMAB7733,%20Anti-HP%20Urease%20A%20MAb.pdf
2147) Dogar T, Khan SA, Jaffer R, Majid S, Qureshy A. Identification of *Helicobacter pylori* in gastric biopsies: a comparison of haematoxylin and eosin staining with immunohistochemistry. Biomedica. 2012; 28: 121- 125.
2148) Elshiekh HRM, Elrabat AMH, Abd EL Mohsen E. EL desoky, Zaky MM. Antibiotic sensitivity to *Helicobacter pylori* growth. Int J Curr Microbiol App Sci. 2017; 6(12):3999-4006.
2149) Gabal SM, Hosni HN, Elsheikh SA, Essa AN. Role of *Helicobacter* bacteria in colitis and colorectal neoplasms: a histopathological and immunohistochemical study. Egyptian Journal of Pathology. 2013;33(1):108-113.
2150) "*Helicobacter pylori*.(Brief article)(Book review). Reference & Research Book News. 2011. HighBeam Research.(March 21, 2013).http://www.highbeam.com/doc/1G1-263161060.html
2151) *Helicobacter pylori.* Sensagent Corporation: Online Encyclopedia, Thesaurus, Dictionary definitions and more. 2012. http://dictionary.sensagent.com/Helicobacter_pylori/en-en/
2152) Horvat RT. Editorial Reviews. http://www.barnesandnoble.com/w/helicobacter-pylori-lyudmila-boyanova/1102267133

2153) Kaewpitoon SJ, Loyd RA, Rujirakul R, Panpimanmas S, Matrakool L, Tongtawee T, Kootanavanichpong N, Pengsaa P, Kompor P, Chavengkun W, Kujapun J, Norkaew J, Ponphimai S, Padchasuwan N, Polsripradist P, Eksanti T, Phatisena T, Kaewpitoon N. *Helicobacter* species are possible risk factors of cholangiocarcinoma. Asian Pac J Cancer Prev. 2016;17(1):37-44.
2154) Kheirallah AK. *H. pylori*: comparison of progressive and regressive Giemsa staining. Biomedical Scientist. 2012; **56** (2): 76-79.
2155) Kholeaf MEAG, Mostafa MK, Saad NM, Hassan MMN. Occurrence of *Helicobacter* species with special priority to *H. pylori* in hen's eggs. Assiut Vet Med J. 2018; 64(158): 22-30.
2156) Lopes-de-Campos D, Pinto RM, Lima SAC, Santos T, Sarmento B, Nunes C, Reis S. Delivering amoxicillin at the infection site - a rational design through lipid nanoparticles. Int J Nanomedicine. 2019;14:2781-2795.
2157) Ombugadu D, Oladele OV, Onuoha SC, Omisope O, Ani A. Prevalence of *Helicobacter pylori* IGG and stool antigen detection from dyspeptic patients in Jos, Nigeria. African journal of clinical and experimental microbiology. 2018; 19(3): 177- 185.
2158) Oti VB, Pennap GR, Dennis O, Ajegena AS, Adoga MP. Prevalence and predictors of *Helicobacter pylori* infection among patients attending a healthcare facility in North-Central Nigeria Asian Pac J Trop Dis 2017; **7**(6):352-355.
2159) Piyush AR, Khan R, Harris H, Maheshwari V. Diagnostic efficacy of different techniques for detection of *Helicobacter pylori* in upper gastrointestinal tract pathologies. International Journal of Contemporary Research and Review. 2017;8(06).
2160) Samson AD, Arend SM, Zwaginga JJ, Schipperus M. *Helicobacter pylori*-geïnduceerde trombocytopenie. Ned Tijdschr Geneeskd. 2012;156:A4799. https://www.ntvg.nl/system/files/publications/a4799.pdf
2161) Sherwani SK, Haider SS, Kazmi SU. *Helicobacter pylori*: Gastric ulcer and cancer causing bug. International Journal of Advanced Research. 2013; 1(4):399-405.
2162) Stollman NH, Graham DY. Rallying community health care providers to close the gap between *H pylori* guidelines and the challenges of eradication. Gastroenterol Hepatol (N Y). 2014;**10**(12):811-814.
2163) Tiwari R, Gore D. Bioinformatics approach for cell surface antigen search of *Helicobacter pylori*. Journal of Pharmacy Research. 2012,**5**(12),5322-5325.
2164) Venkatesh CS, Wong SK, Hassan AKR, Yan YW, Chan CP, Ebernesan B. The prevalence of Helicobacter pylori infection in patients undergoing oesophago-gastro-duodenoscopy in Perak, Malaysia. Asian Journal of Medicine and Health Sciences. 2019; 2(2):11-22.
2165) Wasimuddin, Čížková D, Bryja J, Albrechtová J, Hauffe HC, Piálek J. High prevalence and species diversity of *Helicobacter* spp. detected in wild house mice. Appl Environ Microbiol. 2012; **78**(22): 8158-8160. doi: 10.1128/AEM.01989-12.
2166) Грищенко ЕГ, Петрова ММ, Гилюк АВ, Николаева НН. Генетическая изменчивость *Helicobacter pylori* и особенности гастродуоденальной патологии. ЭНИ Забайкальский медицинский вестник. 2017; № 4: 245- 257.

В ЧУЖДЕСТРАННИ КНИГИ:

ЦИТИРАНА: 1А: Megraud F, Trimoulet P, Lamouliatte H, **Boyanova L**. Bactericidal effect of amoxicillin on *Helicobacter pylori* in an in vitro model using epithelial cells. Antimicrob Agents Chemother. 1991; **35**, (5): 869 - 872. **Цитирана от:**

2167) Clinical pharmacology and therapy of *Helicobacter pylori* infection. C. Scarpignato, Gabriele Bianchi Porro (eds). Karger Medical and Scientific Publishers, 2004: pp.174.
2168) Gastritis. David Y. Graham, Robert M. Genta, Michael F. Dixon (eds.) Lippincott Williams & Wilkins, 1999, pp. 200.
2169) Gastrointestinal and Hepatic Infections. Christina Surawicz, Robert L. Owen (eds.) Saunders, 1995, pp. 69.
2170) Noach LA, Bertola MA, Schwartz MP, Raws EAJ, Tytgat GNJ. Treatment of *Helicobacter pylori* infection: an evaluation of various therapeutic trials and review of the literature. In *Helicobacter pylori* infection. Aspects of pathogenesis and therapy. LA. Noach, GNJ. Tytgat (eds). Yamanouchi Europe B. V., Leiderdorp. Amsterdam, 1994, pp. 83-126.
2171) Treatment of *Actinobacillus actinomycetemcomitans*-associated Periodontitis: Studies into antimicrobial interactions and long-term microbiological and clinical effects: academisch proefschrift. Mile Josef Antoon Marko Patrick Pavičić (eds.). Febodruk BV, 1994, pp. 130.
2172) Peura DA Treatment of *Helicobacter pylori* Infection (Book Chapter) Therapy of Digestive Disorders. 2006, pp. 277-290.

ЦИТИРАНА: 2А: Megraud F, **Boyanova L**, Lamouliatte H. Activity of lansoprazole against *Helicobacter pylori*. Lancet. 1991; **337**: 1486. **Цитирана от:**

2173) *Campylobacters, Helicobacters*, and Related Organisms. Diane G. Newell, Julian M. Ketley, Roger A. Feldman (eds.) Springer Science&Business media, pp 2013:401.
2174) Clinical pharmacology and therapy of *Helicobacter pylori* infection. C. Scarpignato, Gabriele Bianchi Porro (eds). Karger Medical and Scientific Publishers, 2004, pp.164 https://books.google.bg/books?id=Y4TrBwAAQBAJ&dq=Boyanova+L&hl=es&source=gbs_navlinks_s
2175) Galos F, Năstase G, Boboc C, Coldea C, Anghel M, Orzan A, Bălgrădean M. A study of the correlation between bacterial culture and histological examination in children with *Helicobacter pylori* Gastritis. Intech Open. 2018; pp. 79-91. http://dx.doi.org/10.5772/intechopen.80257
2176) Kim J. Culture. In *Helicobacter pylori*. Kim N. (ed.). Springer, 2016, pp.129-134. https://books.google.com/books?isbn=9812877061
2177) Noach LA, Bertola MA, Schwartz MP, Raws EAJ, Tytgat GNJ. Treatment of *Helicobacter pylori*: an evaluation of various therapeutic trials and review of the literature. In *Helicobacter pylori* infection. Aspects of pathogenesis and therapy. LA. Noach, GNJ. Tytgat (eds.) Yamanouchi Europe B. V., Leiderdorp Amsterdam, 1994: 83, pp. 83-126.
2178) Paradise WA, Vesper BJ, Altman KW, Radosevich JA. Systemic implications in the pharmacologic treatment of gastroesophageal reflux disease (GERD) (Book Chapter) Reflux Disease: Causes, Symptoms and Treatment. 2010, pp.37-72.

2179) Proceedings of 1992 Shanghai International symposium on gastroenterology: (with special emphasis on G-I cancers); Shao-ji Jian, Ben-yu Qian, Shu-dong Xiao (eds.) Shanghai Scientific and Technical Literature Publishers, Shanghai, China. 1992, pp. 181
2180) Scandinavian Journal of Gastroenterology (book). Universitetsforlager, 1995, pp. 1056. https://books.google.com/books?id=iFJRAQAAIAAJ

ЦИТИРАНА: 4A: Boyanova L, Andreev N, Bouchard S, Megraud F. *Helicobacter pylori* seroprevalence in Bulgaria. Med Microbiol Lett. 1994; **3**: 107-113. **Цитирана от:**

2181) Buzás GM.Development and current state of *Helicobacter pylori* research in Hungary. *Helicobacter pylori*: a worldwide perspective. Buzás GM (ed.). Bentham Science Publishers, Budapest, Hungary, pp. 484.
2182) Critical Reviews in Microbiology (book)- Volume 33 – 2007, pp 165. https://books.google.com/books?id=WqFNAQAAIAAJ

ЦИТИРАНА: 6A: Boyanova L, Stancheva I, Todorov D, Kumanova R, Petrov S, Vladimirov B, Pehlivanov N, Mitova R, Chakarski I, Churchev I. Comparison of three urease tests for detection of *Helicobacter pylori* in gastric biopsy specimens. Eur J Gastroenterol Hepatol. 1996; **8**(9): 911-914. **Цитирана от:**

2183) Canto MIF. Chromoendoscopy. In Medical Imaging in Gastroenterology and Hepatology. Hagenmüller F, Manns MP, Musmann HG, Riemann JF. (eds). Kluwer Academic Publishers and Falk Foundation e.V, Dordrecht, The Netherland, 2002; pp. 182-
2184) González-Carbajal Pascual M. Capítulo II. Microbiología y patogenia de la infección por *Helicobacter pylori*. In *Helicobacter pylori*: ¿el tercer dogma? Autores Productores Asociados, 2003
2185) Westblom TU, Bhatt BD. Diagnosis of *Helicobacter pylori* infection. In Gastroduodenal disease and *Helicobacter pylori*: pathophysiology, diagnosis and treatment. TU Westblom, SJ Czinn, JG Nedrud (eds.). Springer Science & Business Media, 2012, pp. 227.

ЦИТИРАНА: 10A: Boyanova L, Neshev G. Inhibitory effect of rose oil products on *Helicobacter pylori* growth in vitro: preliminary report. J. Med. Microbiol. 1999; **48**: 705-706. **Цитирана от:**

2186) A proceedings of WOCMAP III: the IIIrd World Congress on Medicinal and Aromatic Plants. Traditional medicine and nutraceuticals, Chiang Mai, Thailand, 2003. UR Palaniswamy, ZE Gardner, LE Craker. 2005. pp. 149. https://books.google.bg/books?id=QV4fAQAAMAAJ
2187) Aromatherapie: Grundlagen-Wirkprinzipien–Praxis. Wabner D, Beier C (eds). Elsevier, Urban& Fischer Verlag, 2008, pp. 70-72.
2188) Aromatherapy for health professionals. Price S, Price L. (eds.) Third edition. Elsevier, 2007, 576 pages.
2189) Battaglia S. ESSENTIAL OIL MONOGRAPH: Rose. 2020. www.salvatorebattaglia.com.au
2190) Evidence-based aromatherapy in nursing practice. In: Clinical Aromatherapy 2e. Buckle J (ed.) Elsevier Science. 2003, pp:127-133.
2191) Yamamoto Y. Anti-*Helicobacter pylori* activity of natural substances. In *Helicobacter pylori* infection and immunity. Yamamoto Y, Friedman F, Hoffman P (eds). Springer (ISBN:0306466589), 2001, pp.105-120.

ЦИТИРАНА: 11A: Petrov S, Churtchev J, Mitova R, **Boyanova L**, Tarassov M. Xanthoma of the stomach-some morphometrical peculiarities and scanning electron microscopy. Hepato- Gastroenterology. 1999; **46**: 1220-1222. **Цитирана от:**

2192) Stolte M. Polypöse Magentumoren. In Pathologie. Springer Berlin Heidelberg. 2013, pp. 215-250.

ЦИТИРАНА: 12A: Boyanova L, Spassova Z, Krastev Z, Petrov S, Stancheva I, Docheva J, Mitov I, Koumanova R. Characteristics and trends in macrolide resistance among *Helicobacter pylori* strains isolated in Bulgaria over four years. Diagn Microbiol Infect Dis. 1999; **34** (4): 309 -313. **Цитирана от:**

2193) Clancy R, Borody T, Clancy C. What role for clarithromycin in the treatment of *Helicobacter pylori* infection? In *Helicobacter pylori*, Springer Netherlands, 2000, pp. 587-591.
2194) *Helicobacter pylori*: Basic Mechanisms to Clinical Cure 2000. RH Hunt, G Tytgat (eds.) Springer Science & Business Media, 2012, pp. 591.
2195) Keuleyan EE. Bulgaria: Hospital Case Studies and National Antibiotic Policy. In Alliance for the Prudent Use of Antibiotics: Avorn JL, Barrett JF, Davey PG, McEwen SA, O'Brien TF, Levy SB. Antibiotic resistance:synthesis of recommendations by expert policy groups. Boston, MA, USA. WHO, 2001. available at: http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_DRS_2001.10.pdf

ЦИТИРАНА: 13A: Boyanova L. Comparative evaluation of two methods for testing metronidazole susceptibility of *Helicobacter pylori* in routine practice. Diagn Microbiol Infect Dis. 1999; **35** (1): 33 - 36. **Цитирана от:**

2196) Mégraud F, Hazell S, Glupczynski Y. Chapter 42. Antibiotic susceptibility and resistance *Helicobacter pylori*: Physiology and genetics. In Mobley HLT, Mendz GL, Hazell SL, editors. Washington (DC): ASM Press; 2001. https://www.ncbi.nlm.nih.gov/books/NBK2469/

ЦИТИРАНА: 14A: Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in *Helicobacter pylori* in Sofia, Bulgaria. J. Med. Microbiol. 2000; **49**: 415–418. **Цитирана от:**

2197) Anuario de investigaciones. Centro de Investigaciones en Ciencias y Humanidades Universidad, Dr. José Matías Delgado. El Salvador. 2003, Volumes 3-4, pp. 293. https://books.google.bg/books?id=uG8SAQAAIAAJ&q=boyanova+l&dq=boyanova+l&hl=en&sa=X&redir_esc=y
2198) Emerging Infectious Diseases. National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Communicable diseases. 2004, pp. 1093. https://books.google.bg/books?id=kxTSkjn4TSAC&q=boyanova+l&dq=boyanova+l&hl=en&sa=X&redir_esc=y
2199) Jenks PJ. Drug-resistant *Helicobacter pylori*. In: Management of drug-resistant infections. S. H. Gillespie (ed.). Humana Press:2004, pp. 141-154.
2200) Keuleyan EE. Bulgaria: Hospital Case Studies and National Antibiotic Policy. In Alliance for the Prudent Use of Antibiotics: Avorn JL, Barrett JF, Davey PG, McEwen SA, O'Brien TF, Levy SB. Antibiotic resistance:synthesis of recommendations by

expert policy groups. Boston, MA, USA. WHO, 2001. available at: http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_DRS_2001.10.pdf

2201) Mégraud F, Hazell S, Glupczynski Y. Chapter 42. Antibiotic susceptibility and resistance *Helicobacter pylori*: Physiology and genetics. In Mobley HLT, Mendz GL, Hazell SL (eds). Washington (DC): ASM Press; 2001.

2202) Samie A, Tanih NF, Ndip RN. Chapter 9. *Helicobacter pylori* Infection - Challenges of Antimicrobial Chemotherapy and Emergence of Alternative Treatments. In Trends in *Helicobacter pylori* Infection. BM Roesler (ed.), ISBN 978-953-51-1239-6, 2014. http://cdn.intechopen.com/pdfs-wm/46489.pdf

2203) Саторов С. *Helicobacter pylori* и хеликобактериоз. Общество с ограниченной ответственностью "Центр развития научного сотрудничества"(Новосибирск). Новосибирск. 2015, pp. 96. https://elibrary.ru/item.asp?id=23376499

ЦИТИРАНА: 16A: Boyanova L, Osmanliev D, Petrov D, Mitov I, I. Usunova, Petrov S, Minchev Tz. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study. Clin. Microbiol. Infect. 2000; **6**: 622-624. **Цитирана от:**

2204) Cabeceran CB, de la Garza JJP. Microbiologia applicada a la Otorrinolaringologia. Terapia antimicrobiana. In: Tratado de Otorrinolaringología y Cirugía de Cabeza y Cuello. Suarez C, Gil-Carcedo LM, Marco J,Medina JE, Ortega P, Trinidad J. (eds). Medica Panamericana, Buenos Aires, Madrid. 2007, 2nd ed., vol. 1.

2205) Kaynak S, Aydın R.. Current concepts and management of severely traumatized eye: Open-globe injury with endophthalmitis. In Current Concepts and Management of Eye Injuries. Springer London. 2016, pp. 155-166.

ЦИТИРАНА: 17A: Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarcheken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M. The status of antimicrobial resistance of *Helicobacter pylori* in eastern Europe. Clin. Microbiol. Infect. 2002; **8** (7): 388-396**. Цитирана от:**

2206) González-Carbajal Pascual M. Capítulo II. Microbiología y patogenia de la infección por *Helicobacter pylori*. In *Helicobacter pylori*: ¿el tercer dogma? Autores Productores Asociados, 2003.

2207) North of England Dyspepsia Guideline Development group. Dyspepsia: Managing dyspepsia in adults in primary care. Evidence-based Clinical Practice Guideline. Centre for Health services Research report No 112. University of Newcastle upon Tyne, 2004, 228 pages. Available at: http://www.nice.org.uk/nicemedia/pdf/CG017fullguideline.pdf

ЦИТИРАНА: 18A: Boyanova L, Koumanova R, Gergova G, Popova M, Mitov I, Kovacheva Y, Derejian S, Katsarov N, Nikolov R, Krastev Z. Prevalence of resistant *Helicobacter pylori* isolates in Bulgarian children. J. Med. Microbiol. 2002; **51**:786-790. **Цитирана от:**

2208) Ampicillin, amoxicillin and other ampicillin-like penicillins. In Kucers' the use of antibiotics a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA (eds). Edward Arnold (Publishers) Ltd. Vol. 1, 6th ed. 2010. pp. 84. https://books.google.com/books?isbn=1444147528

2209) Кудрявцева ЛВ, Щербаков ПЛ, Иваников ИО, Говорун ВМ. *Helicobacter pylori*- инфекция: современные аспекты диагностики и терапии (пособие для врачей). НИИ Физико-Химической Медицины Министерства здравоохранения РФ Москва - 2004, 41 стр.

ЦИТИРАНА: 19A: Boyanova L, Derejian S, Koumanova R, Katsarov N, Gergova G, Mitov I, Nikolov R, Krastev Z. Inhibition of *Helicobacter pylori* growth in vitro by Bulgarian propolis: preliminary report. J. Med. Microbiol. 2003; **52**: 417-419. **Цитирана от:**

2210) Ali S, Majid S, Yatoo AM, Ali MN, Rasool S, Ali S, ... &Rasool S. Clinico-Pharmacological Perspective of honey and propolis. In Therapeutic Applications of Honey and its Phytochemicals. Springer, Singapore. 2020, pp. 165-193.

2211) Almodovar MA. La formula Almodovar. Los 10 supplementos nutricionales imprescindible a partir de los 40. Ediciones Nowtilus SL. Madrid, 2009.

2212) Farooqui T, Farooqui AA. Beneficial effects of propolis on human health: In Pharmacological and molecular aspects Phytochemicals and Human Health: Pharmacological and Molecular Aspects - A Tribute to Late Professor Bimal Kumar Bachhawat 2011; pp. 219-239.

2213) Henderson, DJ. Antioxidants. In Why America Is Sick: But You Don't Have to Be. Tate Publishing, 2010.

2214) Natural Standard Herb & Supplement Handbook: The Clinical Bottom Line. Basch EM, Ulbricht CE (eds). Elsevier Mosby, 2005: pp. 526.

2215) Shetty K, Lin Y-T. Phenolic antimicrobials from plants for plants for control of bacterial pathogens. In Food Biotechnology, Second Edition. Shetty K, Paliyath G, Pometto AL, Levin RE (eds). CRC press, Taylor&Francis: 2006, pp. 286-302.

ЦИТИРАНА: 23A: Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev Z. *Campylobacter* infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease and other chronic intestinal diseases. Diagn Microbiol Infect Dis. 2004; **49** (1): 71-74. **Цитирана от:**

2216) Backert S, Tegtmeyer N, Croinin TO, Boehm M, Heimesaat MM. Human *campylobacter*iosis. In *Campylobacter*: Features, Detection, and Prevention of Foodborne Disease. Günter Klein (ed.) Elsevier, 2017, pp. 1-26.

2217) Butcher J, Flint A, Stahl M, Stintzi A. *Campylobacter* Fur and PerR regulons. In Iron uptake and chomeostasis in microorganisms. Cornelis P and Andrews SC (eds). Caister Academic Press, Norfolk, UK, 2010, pp. 167-202.

2218) Guérin A, Sulaeman S, Coquet L, Ménard A, Barloy-Hulter F, Dé E, Tresse O. Membrane proteocomplexome of *Campylobacter jejuni* using 2-D blue native/SDS-PAGE combined to bioinformatics analysis. In Developments in *Campylobacter, Helicobacter* & Related Organisms Research – CHRO 2019. Ozan Gundogdu, Nicolae Corcionivoschi, Stuart A. Thompson (eds) Frontiers Media SA, 2021.

2219) Kaakoush NO, Mitchell HM. *Campylobacter concisus*- a new player in intestinal disease. In: Research Advances in the Study of *Campylobacter, Helicobacter* & related organisms. Merrell DS and Stintzi A (eds). Frontiers in cellular and infection Microbiology. 2013.

2220) Mandrell RE, Miller WG. Chapter 18: *Campylobacter*. In: Emerging foodborne pathogens. Motarjemi Y, Adams M (eds). CRC Press, USA, 2006, pp. 476-521.

2221) Sederdahl BK, Anderson EJ. Other *Campylobacter* Species. In: Principles and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018, pp. 903-904.
2222) Stojanov I, Tambur Z, Petrović J, Prodanov J, Pušić I. *Campylobacter*isis of Domestic Animals–The Infection Control. In The Second Joint PSU–UNS International Conference on BioScience: Food, Agriculture and the Environment Jun 22–24, Novi Sad, Serbia. 2008 pp. 71-76. file:///C:/Users/07012017/Downloads/Survey_of_amphibians_and_reptiles_in_the%20(1).pdf

ЦИТИРАНА: 24A: Boyanova L, Gergova G, Koumanova R, Jelev C, Lazarova E, Mitov I, Kovacheva Y. Risk factors for primary *Helicobacter pylori* resistance in Bulgarian children. J. Med. Microbiol.; 2004; **53** (Pt 9): 911-914. **Цитирана от:**

2223) McDermott PF, Simala-Grant JL, Taylor DE. Antimicrobial resistance in *Helicobacter* and *Campylobacter*. In Antimicrobial Drug Resistance. Humana Press, 2009, pp. 847-863.

ЦИТИРАНА: 25A: **Boyanova L**, Djambazov V, Gergova G, Iotov D, Petrov D, Osmanliev D, Minchev Z, Mitov I. Anaerobic microbiology in 198 cases of pleural empyema. A Bulgarian study. Anaerobe; 2004; **10** (5): 261-267. **Цитирана от:**

2224) Bartlett JG. ABX guide by PDR& John Hopkins. Posted 12-09-2004. http://hopkins-abxguide.org/download_center/download_center.cfm
2225) Bartlett JG. Empyema. Johns Hopkins poc-it centre. ABX guide. 2007. http://prod.hopkins-abxguide.org/diagnosis/respiratory/full_empyema.html
2226) Chapter 12. Bacterial and mycobacterial diseases. In Lung and Pleural Pathology. Philip Cagle, Timothy Allen (eds.) McGraw Hill Professional, 2015, pp. 281.
2227) Godfrey MS, Bramley KT, Detterbeck F. Medical and surgical management of empyema. In Seminars in respiratory and critical care medicine. Thieme Medical Publishers. 2019, Vol. 40, No. 03, pp. 361-374.
2228) Hedberg M, Nord CE. Anaerobic Gram-positive non-sporeforming rods and anaerobic Gram-positive cocci. In Anaerobic Bacteria**.** © 2010-2017. E-Sun Technologies, http://www.antimicrobe.org/b77.asp
2229) Kononen E, Jalava J. *Peptostreptococcus*. In Molecular Detection of Human Bacterial Pathogens. Dongyou Liu (ed.). Taylor & Francis group, 2011, pp. 423-436.
2230) Meislich D, Feingold AR. Anaerobic Cocci. In: Principles and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018, pp. 1018-1019.
2231) Morelli L, Callegari ML, Patrone V. Prebiotics, Probiotics, and Synbiotics: A Bifidobacterial View. In: The Bifidobacteria and Related Organisms 2018, pp. 271-293.
2232) Part 8. Anaerobic infections. In Molecular Medical Microbiology. Yi-Wei Tang, Max Sussman, Dongyou Liu, Ian Poxton, Joseph Schwartzman (eds). Academic Press, 2014, pp. 894. https://books.google.bg/books?id=rlxzAwAAQBAJ&dq=Boyanova+L&hl=es&source=gbs_navlinks_s
2233) Priyadarshini, P. In Isolation, molecular characterization and immunity enhancement of the probiotic, *Bacillus subtilis* Prbd09 against *Aeromonas hydrophila* in mullet fish, mugil Cephalus Linnaeus, and the proteomic analysis of its extra cellular proteins. 2014.
2234) Strange C. Parapneumonic effusion and empyema in adults. In UpToDate. Section Editors Bartlett JG, Broaddus VC. Deputy Editor Finlay G. 2021 UpToDate, Inc. https://www.uptodate.com/contents/parapneumonic-effusion-and-empyema-in-adults
2235) Weissferdt A. Infectious Diseases of the Pleura. In Diagnostic Thoracic Pathology. Springer, Cham. 2020, pp. 661-675.

ЦИТИРАНА: 26A: Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains *in vitro* by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; **54** (Pt 5):481-483. **Цитирана от:**

2236) Dental Herbalism: Natural therapies for the mouth. Leslie M. Alexander, Ph.D., RH(AHG), Linda A. Straub-Bruce, BS Ed, RDH (rds.) Inner Traditions / Bear & Co, 2014: https://books.google.bg/books?id=lcIPBAAAQBAJ&dq=Boyanova+L&source=gbs_navlinks_s
2237) Fokt H, Pereira A, Ferreira AM, Cunha A, Aguiar C. How do bees prevent hive infections? In The antimicrobial properties of propolis. Current research, technology and education topics in applied microbiology and microbial biotechnology. Mendez-Vilas A (ed). Fotmatex, 2010, pp. 481-493.
2238) Infection en gastro-enterologie. Phytothérapie anti-infectieuse. Paul Goetz, Kamel Ghédira (ed.). Springer-Verlag, Paris, France, 2012, pp. 85-112.
2239) Jothi CEG. Ecotoxnil ® : a potent multi-species and multi- functional probiotic consortium for the efficient revitalization of aquaculture pond bottom ecosystem. Proceedings of National Seminar on Marine Resources NSMR'16. Department of Zoology, The M.D.T. Hindu Collge, 2016, pp.199-204. http://darshanpublishers.com/pdfcopy/FINAL%20NSMR16%20Proceedings.pdf
2240) Rida S, Claesson R, Ennibi O. Chemical composition, antimicrobial activity, in vitro cytotoxicity and leukotoxin neutralization of essential oil from Origanum vulgare against Aggregatibacter actinomycetemcomitans. In *Aggregatibacter actinomycetemcomitans*, Anders Johansson and Joseph M. DiRienzo (eds) 2021.
2241) Ríos J-L. Testing of herbal products used to treat infections. In Evaluation of herbal medicinal products: perspectives on quality, safety and efficacy. Houghton P, Mukherjee PK (eds). Pharmaceutical Press 2009, pp. 133-145.
2242) Santos VR. Propolis: Alternative Medicine for the treatment of oral microbial diseases, Alternative Medicine, H Sakagami (Ed.), 2012; ISBN: 978-953-51-0903-7, InTech, DOI: 10.5772/54003. http://www.intechopen.com/books/alternative-medicine/antifungal-activity-of-propolis-oral-clinical-studies-in-humans
2243) Younis K, Younis K, Ahmad S. Investigating the functional properties of pineapple pomace powder and its incorporation in buffalo meat products, in plant-based natural products: derivatives and applications (ed Shahid-ul-Islam), John Wiley & Sons, Inc., Hoboken, NJ, USA. 2017, pp.175-192.

ЦИТИРАНА: 27A: **Boyanova L**, Nikolov R, Lazarova E, Gergova G, Katsarov N, Kamburov V, Spassova Z, Derejian S, Jelev C, Mitov I, Krastev Z. Antibacterial resistance in *Helicobacter pylori* strains isolated from Bulgarian children and adult patients over 9 years. J. Med. Microbiol. 2006; **55**: 65-68. **Цитирана от:**

2244) McDermott PF, Simala-Grant JL, Taylor DE. Antimicrobial resistance in *Helicobacter* and *Campylobacter*. In Antimicrobial Drug Resistance. Mayers DL (ed). Humana Press, 2009, pp. 847-863.

ЦИТИРАНА: 28A: **Boyanova L**, Kolarov R, Gergova G, Deliverska E, Madjarov J, Marinov M, Mitov I. Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillo-Facial Surgery, Sofia, Bulgaria. J. Med. Microbiol. 2006, **55** (Pt 9): 1285-1289. Erratum in: J Med Microbiol. 2006; **55** (Pt 12): 1759-1760. **Цитирана от:**

2245) Al-Nawas B, Karbach J. Leitlinie odontogene Infektionen 170620. 2017.
2246) Chow, AW. Anaerobic infections. Decker Publishing, 2008. http://74.205.62.209/bcdecker/pdfs/acp/part07_ch05.pdf
2247) Buchingham SC. *Bacteroides*, *Fusobacterium* and *Prevotella*. In Feigin and Cherry's Textbook of Pediatric Infectious Diseases E-Book: 2-Volume Set, Elsevier Health Sciences, 2013, pp.1835.
2248) Infections and infestations. In Scully's Medical Problems in Dentistry E-Book. Crispian Scully (ed.) Elsevier Health Sciences. 2014, p.:558. https://books.google.bg/books?id=OZXdAwAAQBAJ&dq=Boyanova+L&hl=es&source=gbs_navlinks_s
2249) Kuhn-Dall'Magro A, Silva NLNV, Lauxen J, Santos R, Valcanaia TC, Martins Fo SC, Dall'Magro E. Angina de Ludwig: aspectos anatômicos, etiologia e abordagem multidisciplinar. In: Linden MSS, Carli JP, Magro ML, Trentin MS, Silva SO, organizadores. Odonto Science: 53 Anos FOUPF. São José dos Pinhas: Editora Plena; 2014. pp. 55-62. http://faciallmed.com.br/wp-content/uploads/2014/05/FOUPF-final-1.pdf#page=56
2250) Song Y, Finegold SM. *Peptostreptococcus, Finegoldia, Anaerococcus, Peptoniphilus, Veillonella*, and other anaerobic cocci. In Manual of Clinical Microbiology, 10th Edition 2011. American Society of Microbiology. pp. 803-816.

ЦИТИРАНА: 29A: **Boyanova L,** Kolarov R, Gergova G, Mitov I. *In vitro* activity of Bulgarian propolis against 94 clinical isolates of anaerobic bacteria. Anaerobe 2006; **12** (4):173-177. **Цитирана от:**

2251) Santos VR. Propolis: Alternative medicine for the treatment of oral microbial diseases. Alternative Medicine, Hiroshi Sakagami (Ed.), 2012; ISBN: 978-953-51-0903-7, InTech, DOI: 10.5772/54003. http://www.intechopen.com/books/alternative-medicine/antifungal-activity-of-propolis-oral-clinical-studies-in-humans
2252) Sojka M, Horniackova M, Bucekova M, Majtan V, Majtan J. Antibiofilm efficacy of honeybee products against wound biofilm. In: . Recent Clinical Techniques, Results, and Research in Wounds. Springer, Cham. 2018. https://link.springer.com/chapter/10.1007/15695_2018_108#citeas

ЦИТИРАНА: 31A: **Boyanova L**, Lazarova E, Jelev C, Gergova G, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in untreated Bulgarian children over a period of 10 years. J Med Microbiol. 2007; **56**(Pt 8):1081-1085. **Цитирана от:**

2253) Booth TN. Infection and inflammation. In Caffey's Pediatric Diagnostic Imaging E-Book. Brian D. Coley (ed.) Elsevier Health Sciences, 2013, p. 104.
2254) Principles and Practice of Pediatric Infectious Diseases E-Book. Sarah S. Long, Charles G. Prober, Marc Fischer (eds.)- 2017.
2255) Vale FF. *Helicobacter pylori* prevalence and transmission among children attending rural schools: A critical review of evidence. Urban and Rural Schools: Problems, Solutions and Progress: 2013, pp. 123-146.

ЦИТИРАНА: 32A: **Boyanova L**, Kolarov R, Mitov I. Antimicrobial resistance and the management of anaerobic infections. Expert Rev. Anti Infect. Ther. 2007; **5**(4):685-701. **Цитирана от:**

2256) Breathnach SM, Smith CH, Chalmers RJG, Hay RJ. Systemic Therapy. In Rook's Textbook of Dermatology: Eighth Edition 2010. pp. 3835-3887.
2257) Brook I, Long SS. Anaerobic bacteria: classification, normal flora, and clinical concepts. InPrinciples and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018; pp. 987-995.
2258) Brook I. Antimicrobial resistance of anaerobic bacteria. In Antimicrobial Drug Resistance. Mayers D, Sobel J, Ouellette M, Kaye K, Marchaim D. (eds). Springer International Publishing. 2017, pp. 1007-1040. https://link.springer.com/chapter/10.1007/978-3-319-47266-9_15
2259) Brook I. *Bacteroides* and *Prevotella* species and other anaerobic Gram-negative bacilli. InPrinciples and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018; pp. 1012-1014.
2260) Brook I. *Bacteroides* and *Prevotella* species and other anaerobic Gram-negative bacilli. In: Long SS, Pickering LK, Prober CG. Principles and practice of pediatric infectious diseases. 4th ed. Elsevier, 2012: http://www.expertconsultbook.com/expertconsult/ob/book.do?method=display&type=bookPage&decorator=none&eid=4-u1.0-B978-1-4377-2702-9..00194-X--bib3&isbn=978-1-4377-2702-9#lpState=open&lpTab=contentsTab&content=4-u1.0-B978-1-4377-2702-9..C2009-0-41480-6--v1%3Bfrom%3Dtoc%3Btype%3DbookPage%3Bisbn%3D978-1-4377-2702-9&search=none
https://archive.org/stream/HenrysClinicalDiagnosisAndManagementByLaboratoryMethods22ndEd2011/Henry's%20Clinical%20Diagnosis%20and%20Management%20by%20Laboratory%20Methods%2022nd%20ed%202011_djvu.txt
2261) In: Henry's Clinical diagnosis and management by laboratory methods. E-book 22nd edition. McPherson RA, Pincus MR (eds), Saunders 2012.
2262) Part 8. Anaerobic infections. In Molecular medical microbiology. Yi-Wei Tang, Max Sussman, Dongyou Liu, Ian Poxton, Joseph Schwartzman (eds). Academic Press, 2014, pp. 896.

ЦИТИРАНА: 34A: **Boyanova L,** Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of *Helicobacter pylori* resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008; **60 (4)**: 409-415. **Цитирана от:**

2263) Langan K, Van Bambeke F. Clarithromycin. In Kucers' the use of antibiotics a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA (eds). Edward Arnold (Publishers) Ltd. CRC Press. Vol. 1, 6th ed. 2010, pp. 779-800. https://books.google.com/books?isbn=1444147528
2264) Mégraud F. Antimicrobial resistance and approaches to treatment. In *Helicobacter pylori* in the 21st Century. Philip Sutton, Hazel Mitchell (Eds). Cab International, Wallingford, UK. 2010, pp. 45-68.

2265) Quinolones and fluoroquinolones. In Kucers' the use of antibiotics a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA (eds). Edward Arnold (Publishers) Ltd. CRC Press. 2010; pp. 1314. https://books.google.com/books?isbn=1444147528

ЦИТИРАНА: 35A: Boyanova L, Ilieva J, Gergova G, Spassova Z, Nikolov R, Davidkov L, Evstatiev I, Kamburov V, Katsarov N, Mitov I. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58**(1):94-100. **Цитирана от:**

2266) Challa S, Neelapu NRR. Association between horizontal gene transfer and adaptation of gastric human pathogen *Helicobacter pylori* to the host. In Horizontal Gene Transfer 2019: pp. 257-267. Springer, Cham.

2267) Challa S, Dutta T, Bramhachari PV, Reddy NNR. Quorum sensing and multidrug resistance mechanism in *Helicobacter pylori*. In Implication of Quorum Sensing and Biofilm Formation in Medicine, Agriculture and Food Industry. Springer, Singapore, 2019, pp. 101-119.

ЦИТИРАНА: 10B: Boyanova L, Megraud F, Lamouliatte H. Application of a bacterial assay using cell adherent bacteria to test drug combinations in vitro. Ital. J. Gastroenterol., 1991; **23** (suppl. 2, I): 36.IV Workshop Gastroduodenal Pathology and *Helicobacter pylori*, 28-30 Nov. 1991, Bologna, Italy: *Helicobacter pylori* (abstract 283). **Цитирана от:**

2268) Goodwin CS. The susceptibility of *Helicobacter pylori* to antibiotics. In: *Helicobacter pylori*: biology and clinical practice. Goodwin CS., Worsley BW. (eds.), Boca Raton, Florida: CRC Press, 1993, pp. 344-349.

ЦИТИРАНА: 36A: Boyanova L, Stephanova-Kondratenko M, Mitov I. Anti-*Helicobacter pylori* activity of *Lactobacillus delbrueckii* subsp. *bulgaricus* strains: preliminary report. Lett Appl Microbiol. 2009; **48** (5): 579-584. **Цитирана от:**

2269) Francavilla R, Cavallo L, Sardaro R, Fontana C, Ierardi E, La Rosa M, Maurogiovanni G, Scaccianoce G, Principi M, Lionetti E. Probiotics and *Helicobacter pylori*. CRC Press, 2013.

2270) Komatsu Y, Aiba Y, Nakano Y, Yasuhiro Koga Y. Probiotics, prebiotics, and biogenics for the stomach. Chapter 18, 2016, pp. 363-381. https://www.researchgate.net/profile/Yasuhiko_Komatsu2/publication/305392756_Probiotics_Prebiotics_and_Biogenics_for_the_Stomach/links/578cceeb08ae59aa66814750.pdf

2271) Techo, S., De Moreno De Leblanc, A. The Many Benefits of Lactic Acid Bacteria. 2019, pp. 163-193

ЦИТИРАНА: 37A: **Boyanova L.** Prevalence of multidrug-resistant *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58** (Pt 7): 930-935.**Цитирана от:**

2272) Lee JY. Triple therapy. Chapter. *Helicobacter pylori*. Kim N. (ed.) Springer. 2016, pp. 427-436. http://link.springer.com/chapter/10.1007/978-981-287-706-2_41

ЦИТИРАНА: 39A: **Boyanova L,** Mitov I. Geographic map and evolution of primary *Helicobacter pylori* resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010; **8**(1):59-70. **Цитирана от:**

2273) Doron SI, Beaulac KR, Dhand A, Snydman DR. Mechanisms of Resistance in Metronidazole. In: Mayers D., Sobel J., Ouellette M, Kaye K, Marchaim D. (eds) Antimicrobial Drug Resistance. Springer, Cham, 2017. https://link.springer.com/chapter/10.1007/978-3-319-46718-4_19

2274) Epsilonproteobacteria. In Advances in proteobacteria research and application. Scolarity editions. Ashton Acton Q (ed.). Atlanta, Georgia. 2011, pp. 1-51.

2275) Gisbert JP, Greenberg ER. Chapter 3.2 Potential regimens for the mass eradication of *Helicobacter pylori* infection. *Helicobacter pylori* Eradication as Strategy for Preventing Gastric Cancer, International Agency for Research on Cancer, 69372 Lyon Cedex 08, France. 2014, p. 95. https://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/*Helicobacter_pylori*_Eradication.pdf

2276) Greenfield LK, Dang F, Jones NL. *Helicobacter pylori* Infection control by autophagy. autophagy, infection, and the immune response, John Wiley & Sons, Inc. 2014, pp. 171-200.

2277) Kwon YH. Amoxicillin. Chapter *Helicobacter pylori.* Springer. 2016, pp. 387-396. http://link.springer.com/chapter/10.1007/978-981-287-706-2_37

2278) Lee JY. Quadruple therapy. Chapter *Helicobacter pylori.* Springer. 2016, pp. 437-445. http://link.springer.com/chapter/10.1007/978-981-287-706-2_42

2279) Lee JY. Triple therapy. Chapter *Helicobacter pylori.* Springer. 2016, pp. 427-436. http://link.springer.com/chapter/10.1007/978-981-287-706-2_41

2280) Lee SM. Metronidazole. Chapter *Helicobacter pylori.* Springer. 2016, pp. 405-413. http://link.springer.com/chapter/10.1007/978-981-287-706-2_39

2281) Liechti G, Goldberg JB. Outer membrane biogenesis in *Escherichia coli*, *Neisseria meningitidis*, and *Helicobacter pylori*: paradigm deviations in *H. pylori*. research advances in the study of *Campylobacter*, *Helicobacter* & Related Organisms. Frontiers E-books. 2012, pp. 36.

2282) Vale FF, Rosa MR, Oleastro M. *Helicobacter pylori* resistance to antibiotics. In Science against microbial pathogens: communicating current research and technological advances. A. Méndez-Vilas (Ed.) Formatex Research Center, Badajoz, Spain. 2011, pp. 745-756.

ЦИТИРАНА: 40A: **Boyanova L,** Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, Panteleeva E, Spasova Z, Mitov I. Two-decade trends in primary *H. pylori* resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010; **67**: 319-326. **Цитирана от:**

2283) In Amebicides: Advances in research and application: Scolarity editions. Ashton Acton Q (ed.). Scholarly Editions. Atlanta, Georgia. 2012, pp.6.

ЦИТИРАНА: 41A: **Boyanova L,** Yordanov D, Gergova G, Markovska R, Mitov I. Association of *iceA* and *babA* genotypes in *Helicobacter pylori* strains with patient and strain characteristics. Antonie Van Leeuwenhoek. 2010; **98** (3):343-350. **Цитирана от:**

2284) *Helicobacter* infections. In Gram-negative bacterial infections: advances in research and treatment. Ashton Acton Q (ed.). Scolarity editions. Atlanta, Georgia. 2011, pp. 11-96.

2285) Holton J. Chapter 77 - Peptic ulcer disease genomic and personalized medicine. Volunes 1–2. Genomic and Personalized Medicine (Second Edition), Volume 2, 2013, pp. 914-934.
2286) Поливанова, Т. В., Каспаров, Э. В., & Вшивков, В. А. *Helicobacter pylori* инфекция у детей Сибири (монография). 2018. https://www.elibrary.ru/item.asp?id=36538466

ЦИТИРАНА: 42A: Boyanova L, Kolarov R, Gergova G, Dimitrova L, Mitov I. Trends in antibiotic resistance in *Prevotella* species from patients of the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in 2003-2009. Anaerobe. 2010; **16**(5): 489-492. **Цитирана от:**

2287) Metronidazole. In: Nitroimidazoles: advances in Research and applications. Scolarity editions. Atlanta, Georgia. 2011, pp. 1-39.
2288) Brook I. *Bacteroides* and *Prevotella* species and other anaerobic Gram-negative bacilli. In: Long SS, Pickering LK, Prober CG. Principles and practice of pediatric infectious diseases. 4th ed. Elsevier, 2012: http://www.expertconsultbook.com/expertconsult/ob/book.do?method=display&type=bookPage&decorator=none&eid=4-u1.0-B978-1-4377-2702-9..00194-X--bib3&isbn=978-1-4377-2702-9#lpState=open&lpTab=contentsTab&content=4-u1.0-B978-1-4377-2702-9..C2009-0-41480-6--v1%3Bfrom%3Dtoc%3Btype%3DbookPage%3Bisbn%3D978-1-4377-2702-9&search=none
2289) Brook I. *Bacteroides* and *Prevotella* species and other anaerobic Gram-negative bacilli. In: Principles and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018, pp. 1012-1014.
2290) Buchingham SC. *Bacteroides*, *Fusobacterium* and *Prevotella*. In Feigin and Cherry's Textbook of Pediatric Infectious Diseases E-Book: 2-Volume Set, Elsevier Health Sciences 2013; pp. 1833.

ЦИТИРАНА: 43A: Medeiros JA, Gonçalves TM, **Boyanova L**, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM. Evaluation of *Helicobacter pylori* eradication by triple therapy plus *Lactobacillus acidophilus* compared to triple therapy alone. Eur J Clin Microbiol Infect Dis. 2011; **30** (4):555-559. **Цитирана от:**

2291) Molina-Infante J, Shiotani A. *Helicobacter pylori* therapy. In Management of *Helicobacter pylori*-related diseases, an issue of gastroenterology clinics of North America. Akiko Shiotani, David Y. Graham (eds.) Elsevier Health Sciences, 2015, pp. 535. https://books.google.bg/books?id=jaE_CwAAQBAJ&dq=Boyanova+L&hl=es&source=gbs_navlinks_s

ЦИТИРАНА: 44A: Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I. Benefits of *Helicobacter pylori cagE* genotyping in addition to *cagA* genotyping. A Bulgarian study. Antonie Van Leeuwenhoek. 2011 Nov;100(4):529-35.DOI: 10.1007/s10482-011-9608-8. **Цитирана от:**

2292) Chapter 2: Genetics. In *Helicobacter pylori*: New insights for the healthcare professional. Ashton Acton Q (ed.). Scholarly editions. 2012, pp. 5-40.

ЦИТИРАНА: 45A: Boyanova L. Role of *Helicobacter pylori* virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiol. 2011; **6**(8): 843-846. **Цитирана от:**

2293) Cárdenas AJ, Arévalo-Ferro C. Papel de las comunidades bacterianas en sistemas arrecifales. In Investigación en Ciencias del Mar: Aportes de la Universidad Nacional de Colombia. Luz Marina Melgarejo Camilo Bernardo García Ramírez (eds.) Red de Estudios del Mundo Marino, Universidad Nacional de Colombia (Bogotá). Red de Estudios del Mundo Marino (REMAR). 2013, pp. 67-90. https://www.researchgate.net/profile/Jaime_Polania_Vorenberg/publication/259297942_Resea_de_los_aportes_de_la_sede_Medelln_de_la_Universidad_Nacional_de_Colombia_al_conocimiento_de_los_manglares_colombianos/links/00b7d52ae5e124aa4c000000.pdf#page=67
2294) Investigación en ciencias del mar: Aportes de la Universidad Nacional de Colombia. Melgarejo LM, Ramírez CBG (eds.) Universidad Nacional de Colombia (Bogotá). Red de Estudios del Mundo Marino (REMAR). 2013, pp. 89.
2295) Campuzano-Maya G. Chapter 3. *Helicobacter pylori* and hematologic diseases. In Extradigestive manifestations of *Helicobacter pylori* infection-an overview 2016. InTech. Medicine "Extradigestive Manifestations of *Helicobacter pylori* Infection - An Overview", Bruna Maria Roesler (ed.), 2016.

ЦИТИРАНА: 46A: Markovska R, **Boyanova L**, Yordanov D, Gergova G, Mitov I. *Helicobacter pylori oipA* genetic diversity and its associations with both disease and *cagA*, *vacA* s, m and i alleles among Bulgarian patients. Diagn Microbiol Infect Dis. 2011; **71**(4):335-340. **Цитирана от:**

2296) Kabamba ET, Yamaoka Y. *Helicobacter pylori* and related virulence factors for gastrointestinal diseases. In Gastric Cancer. Springer, Singapore 2019, pp. 31-50.
2297) Mishra J, Ruggiero P, Bagnoli F, Rappuoli R, Stein M. *Helicobacter pylori*: the cancer bug. In Infection and Cancer: Bi-Directorial Interactions. Shurin MR, Thanavala Y, Ismail N. (Eds).2015, pp. 171-211. http://link.springer.com/book/10.1007/978-3-319-20669-1

ЦИТИРАНА: 47A: Boyanova L, Mitov I. Coadministration of probiotics with antibiotics: why, when and for how long? Expert Rev Anti Infect Ther. 2012; **10**(4):407-409. **Цитирана от:**.

2298) Fleet M, Rahman PK. Probiotics and their health benefits. In: Microbial Functional Foods and Nutraceuticals. Vijai Kumar Gupta, Helen Treichel, Volha (Olga) Shapaval, Luiz Antonio de Oliveira, Maria G. Tuohy (eds.). John Wiley & Sons, Dec 26, 2017 – Science. 2017, pp. 267-279.
2299) Millar MR, Wilks M. Modulation of the intestinal flora. In Walker's pediatric gastrointestinal disease. 6th edition. Kleinman RE, Goulet O-J, Mieli-vergani G (eds) People's Medical Publishing House. 2018.
2300) Tomaro-Duchesneau C., Saha S, Prakash S. Modification of the gut microbiota to promote human health. In Clinical Insights: Probiotics, Prebiotics and Gut Health. Martin H Floch and Adam Kim (eds). 2014, pp. 15-34.

ЦИТИРАНА: 48A: Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for *Helicobacter pylori* antibiotic resistance revealed by extended anamnesis. A Bulgarian study. J Med Microbiol. 2012; **61**(Pt 1):85-93. **Цитирана от:**

2301) Chapter 5: Therapies and treatments. In *Helicobacter pylori*: New insights for the healthcare professional. Ashton Acton Q (ed.). Scholarly editions. 2012, pp. 62-74.

2302) Vakil NB. Antibiotic resistance in patients with *Helicobacter pylori* infection. In Clinical rationale for confirmation testing after treatment of *Helicobacter pylori* infection: implications of rising antibiotic resistance Clinical Roundtable Monograph. 2014;**10**(7 Supplement 3):9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219329/pdf/GH-10-S3-1.pdf#page=9

ЦИТИРАНА: 49A: Boyanova L, Mitev A, Gergova G, Mateev G, Mitov I. High prevalence and resistance rates to antibiotics in anaerobic bacteria in specimens from patients with chronic balanitis. Anaerobe. 2012; 18: 414-416. **Цитирана от:**.

2303) Metronidazole. In: Nitroimidazoles-Advances in search and applications. Acton QA. (ed.) Scholarly brief. Atlanta, Feorgia. 2013, pp. 19.

2304) Könönen E. Anaerobic cocci and anaerobic Gram-positive nonsporulating bacilli (Book Chapter). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 2014; 2, pp. 2781-2786.

ЦИТИРАНА: 51A: Boyanova L, Mitov I. Antibiotic resistance rates in causative agents of infections in diabetic patients. Rising concerns. Expert Rev. Anti Infect. Ther. 2013; **11** (4): 411-420. **Цитирана от:**

2305) Sharif, H., Rehman, K., Irshad, K., & Akash, M. S. H. (2021). Antibiotic Resistance in EDCs-Induced Metabolic Disorders. In Endocrine Disrupting Chemicals-induced Metabolic Disorders and Treatment Strategies. 2021, pp. 125-133. Springer, Cham.

ЦИТИРАНА: 55A: Boyanova L. Comparative evaluation of the activity of plant infusions against *Helicobacter pylori* strains by three methods. World J Microbiol Biotechnol. 2014; **30** (5):1633-1637. **Цитирана от:**

2306) Chapter 14. Control de *Helicobacter pylori* con extractos vegetales. Andrews, H. E., Carvajal, Z. Y. G., & Márquez, E. G. (eds). Avances en la seguridad y actividad biológica de sustancias bioactivas y probióticos. 2017. Avances%20en%20la%20seguridad%20y%20actividad%20biologica%20de%20sustancias.pdf

2307) Krynicka, P., Ochmanek, R., Strojewska, P., Brzeska, M., & Frydrych, A. Effect of nutrients on the treatment of helicobacter pylorI/Wpływ składników pokarmowych na leczenie *helicobacter pylori*. Nauki Przyrodnicze i Medyczne: Najnowsze doniesienia dotyczące nauk medycznych i biotechnologicznych, IPKIN, Lublin, 2018, pp. 50. (159 pages)

ЦИТИРАНА: Boyanova L. (ed.) *Helicobacter pylori*. Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011 **Цитирана от:**

2308) Chapter 5. Definitions of common terminologies used in nuclear medicine. In Nuclear medicine. A guide for healthcare professionals and patients. Prakash D (ed). Springer India. 2014, pp. 117-149.

2309) Testerman TL. *Helicobacter pylori*. In Vascular Responses to Pathogens. Felicity NE. Gavins, Karen Y. Stokes (eds.) Academic Press, UK, 2016, pp. 102.

ЦИТИРАНА: 58A: Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015, **31**: 4-10. **Цитирана от:**

2310) Auwaerter PG. *Bacteroides* species. Johns Hopkins ABX Guide. 2019. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540053/3.0/Bacteroides_species

2311) Avdic E, Pham PA. Clindamycin. Johns Hopkins ABX Guide. 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540131/all/Clindamycin

2312) Brook I. Antibiotic-Resistant Pathogens in ear, nose, and throat infections. In Infections of the ears, nose, throat, and sinuses Springer, Cham. 2018, pp. 15-29.

2313) Charnot-Katsikas A, Beavis KG. In vitro testing of antimicrobial agents. McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods E-Book. Elsevier, St Louis, Missouri. 2017, pp. 1153-1170.

2314) Hauser AR. Antibiotic basics for clinicians: The ABCs of choosing the right antibacterial agent (Book) Antibiotic Basics for Clinicians: The ABCs of Choosing the Right Antibacterial Agent. 2018, pp. 1-336.

2315) Lowman W. The value and interpretation of microbiological specimens in the management of cIAI. InAbdominal Sepsis 2018 (pp. 301-317). Springer, Cham.

2316) Pham PA, John G. Bartlett JG. Clindamycin. Johns Hopkins ABX Guide. Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, Unbound Medicine. 2015.

2317) Поляк МС. Антибиотики в лечении анаэробных заболеваний. Нестор-История, 2017. 192 стр. ISBN 978-5-4469-1149-3. https://www.labirint.ru/books/585245/

ЦИТИРАНА: 60A: Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. Diagn Microbiol Infect Dis 2015; **82**(1):85-86. **Цитирана от:**

2318) Bogdanov S. Honey in Medicine. Chapter 9. In Book of Honey. Bee Product Science, www.bee-hexagon.net April 2016

2319) Chakravorty S, Bhattacharya S, Bhattacharya D, Sarkar S, Gachhui R. Kombucha: a promising functional beverage prepared from tea. In Non-alcoholic beverages. Woodhead Publishing. 2019; pp. 285-327.

2320) Szweda P. Antimicrobial activity of honey. Chapter 10. In Agricultural and Biological Sciences "Honey Analysis", Vagner de Alencar Arnaut de Toledo. 2017. ISBN 978-953-51-2880-9: https://www.intechopen.com/books/honey-analysis/antimicrobial-activity-of-honey

2321) Wani RA, Bhat AA, Rasool I, Yousuf SM, Rasool S, Wani HA. Properties of honey: its mode of action and clinical outcomes. In Therapeutic Applications of Honey and its Phytochemicals. 2020, pp. 299-314.

ЦИТИРАНА: 61A: Boyanova L, Kolarov R, Mateva L, Markovska R, Mitov I. Actinomycosis- a frequently forgotten disease. Future Microbiol. 2015; **10**(4): 613–628. **Цитирана от:**

2322) Bonifaz A, Armas-Vázquez A, Tirado-Sánchez A. Fungal infections in diabetics. In: Dermatology and Diabetes. Springer, Cham, 2018, pp. 117-132.

2323) Feingold AR, Meislich D. Anaerobic Gram-positive nonsporulating bacilli (including *Actinomyces*). In: Principles and practice of pediatric infectious diseases (Fifth Edition) 2018, pp. 1019-1022.

2324) Müller S. Non-neoplastic lesions of the oral cavity. In Head and neck pathology (Third Edition) 2019, pp. 175-196.

2325) Principles and practice of pediatric infectious diseases. E-Book. Sarah S. Long, Charles G. Prober, Marc Fischer (eds.). 2017. https://books.google.com/books?isbn=0323461328

ЦИТИРАНА: 63А: Markovska R, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015;**123**(10):887-94. **Цитирана от:**

2326) Li J, Li XZ. Antimicrobial resistance and drug efflux pumps in *Helicobacter*. In Efflux-mediated antimicrobial resistance in bacteria. Adis, Cham. 2016, pp. 489-513.
2327) Fuzi M Chang-Ro Lee, Jung Hun Lee, Kwang Seung Park, Young Bae Kim, Byeong Chul Jeong, Sang Hee Lee. The Global Challenge Posed by the Multiresistant International Clones of Bacterial Pathogens. Fuzi M, Margaret Ip (eds). Frontiers. (e-book) 2017, pp:156.

ЦИТИРАНА: 65А: Boyanova L, Evstatiev I**, Gergova G, Yaneva P**, Mitov I. Linezolid susceptibility *in Helicobacter pylori*, including strains with multidrug resistance. Int J Antimicrob Agents. 2015 Dec;**46**(6):703-706. **Цитирана от:**

2328) Geddes AM, Gould IM, Roberts JA, Lindsay Grayson M, Cosgrove SE. Ampicillin and amoxicillin (Book Chapter). In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition, 2017, pp. 100-135.
2329) Li J, Li X-Z. Antimicrobial resistance and drug efflux pumps in *Helicobacter*. In Efflux-mediated antimicrobial resistance in bacteria. Springer International Publishing, 2016, pp. 489-513.
2330) Sparham SJ, Howden BP. Linezolid (Book Chapter) In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition, 2017, pp. 1293-1347.

ЦИТИРАНА: 66А: Boyanova L, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, Markovska R, Mitov I. *Helicobacter pylori* resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infect Dis (Lond). 2016;**48**(1):56-62. **Цитирана от:**

2331) Angelov TA, Kovacheva-Slavova MD, Iliev HI, Valkov HY, Vladimirov BG. *Helicobacter pylori* Infection. In Gastritis-New Approaches and Treatments. IntechOpen. 2019.

ЦИТИРАНА 73А: Boyanova L. Stress hormone epinephrine (adrenaline) and norepinephrine (noradrenaline) effects on the anaerobic bacteria. Anaerobe. 2017; **44**:13-19. **Цитирана от:**

2332) Anderson CJ, Kendall MM. *Salmonella enterica* serovar *Typhimurium* strategies for host adaptation. In Recent discoveries in human serious foodborne pathogenic bacteria: resurgence, pathogenesis, and control strategies. Chen L, Alali W (eds). 2019.
2333) Murillo-Tovar MA, Saldarriaga-Noreña H, Saeid A. Trace metals in the environment- new approaches and recent advices. BoD – Books on Demand. IntechOpen. 2021, pp. 141.
2334) Plewig G, Melnik B, Chen W. Distinctive acne entities. In Plewig and Kligman´s Acne and Rosacea. Springer, Cham. 2019, pp. 191-215.
2335) Winter G, Hart RA, Charlesworth RP, Sharpley C. Gut Microbiome and Depression. The Oxford Handbook of the Microbiome-Gut-Brain Axis. Philip WJ Burnet (ed). 2020.

ЦИТИРАНА: 75А. Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. Diagn Microbiol Infect Dis. 2017; 88(3): 264-267.

2336) Aldana AA, Trujillo OMH. Línea de investigación en *Helicobacter pylori* para la formación de recurso humano en ciencia, tecnología e innovación en el programa de microbiología. A Alvarez Aldana, OM Henao Trujillo (eds.) Risaralda, Colombia, Pereira. 2020.

ЦИТИРАНА:77А: Boyanova L, Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. Lett Appl Microbiol. 2017;**65**(6):469-474.doi: 10.1111/lam.12807

2337) Oyeniran A, Gyawali R, Aljaloud SO, Krastanov AIbrahim SA. Probiotic Characteristics and Health Benefits of the Yogurt Bacterium *Lactobacillus delbrueckii* sp. *bulgaricus*, Current Issues and Challenges in the Dairy Industry, Salam A. Ibrahim, Tahl Zimmerman and Rabin Gyawali, IntechOpen, DOI: 10.5772/intechopen.86939. 2020.

ЦИТИРАНА: 79А: Markovska R, **Boyanova L**, Yordanov D, Stankova P, Gergova G, Mitov I. Status of *Helicobacter pylori cag* pathogenicity island (*cag*PAI) integrity and significance of its individual genes. Infect Genet Evol. 2018;**59**: 167-171..

2338) Vellozzi EM, Giugliano ER. The Genus *Helicobacter*. In Practical Handbook of Microbiology. CRC Press. 2021, pp. 375-398.

ЦИТИРАНА 11-17М: Boyanova L. (ed.) *Helicobacter pylori*. Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011. **Цитирана от:**

2339) Lopes D, Nunes C, Martins MCL, Sarmento B, Reis S. Chapter 13.Targeting strategies for the treatment of *Helicobacter pylori* infections. In Nanobiotechnology in Diagnosis, Drug Delivery and Treatment. John Wiley & Sons, 2020. http://iapc-obp.com/assets/files/165115_08_NBDD_13.pdf
2340) Testerman TL. Chapter 8 - *Helicobacter pylori*. In Vascular Responses to Pathogens. Academic Press, 2016: pp. 87-109.
2341) Лоранская ИД, Болдырева МН, Лаврентьева ОА, Мулухова ЭВ. Пристеночная микрофлора кишечника. «Прима Принт», Москва, 2015 г.

В ЧУЖДЕСТРАННИ ДИСЕРТАЦИИ:

ЦИТИРАНА: 1А: Megraud F, Trimoulet P, Lamouliatte H, **Boyanova L**. Baciericidal effect of amoxicillin on *Helicobacter pylori* in an vitro model using epithelial cells. Antimicrob Agents Chemother. 1991; **35** (5): 869 -872. **Цитирана от:**

2342) Brown JC. Activities of muscadine grape skin and polyphenolic constituents against *Helicobacter pylori.* Graduate School of Clemson University, Sc, USA. 2011. PhD Thesis.
2343) Črnič A. The release of amoxicillin from bilayer floating tablets based on xanthan gum. Diplomska naloga. Univerza v Ljubljani, Fakulteta za Farmacijo. Ljubljana, Slovenia. 2008.

2344) Houben MHMG. Clinical aspects in *Helicobacter pylori* infections. Dissertation. Universiteit van Amsterdam, the Netherlands. 2000.
2345) Schmidt-Petri T. Analyse der Topologie und Funktion der c-Untereinheit der F1F0-ATPase von *Helicobacter pylori.* Dissertation. Fachbereich für Biologie, Universität Konstanz, Germany. 22. Oktober 2003: 109 pages.
2346) Thamphiwatana S. Antimicrobial nanotherapeutics against *Helicobacter pylori* infection. University of California, San Diego. Phd dissertation. 2014:
2347) Белова ИВ. Конструирование нового многокомпонентного пробиотика и использование его в комплексной терапии хеликобактер-ассоциированных заболеваний. кандидат биологических наук. Нижний Новгород, 2005.

ЦИТИРАНА: 2A: Megraud F, **Boyanova L**, Lamouliatte H. Activity of lansoprazole against *Helicobacter pylori*. Lancet. 1991; **337**: 1486. **Цитирана от:**

2348) Bekada DE. Intérêt des tests microbiologiques dans le cas de la gastrite B, maladie de Crohn et rectocolite hémorragique. Université d'Oran. 2019.
2349) Cogo LL. Caracterização molecular de genes de virulência de isolados clínicos de *Helicobacter pylori* e determinação da atividade antimicrobiana in vitro de diferentes fitoterápicos utilizados na medicina popular brasileira. Tese. Curitiba, 2008.
2350) Maukonen J. Characterization of the human predominant fecal microbiota - With special focus on the Clostridial clusters IV and XIVa. Department of Biotechnology and Chemical Technology. Finland..2012.
2351) Macleod K. The effect of the proton pump inhibitor pantoprazole on the biology of *Campylobacter jejuni*. PhD thesis. University of Glasgow. 2016.
2352) Miendje Deyi V-Y. Contribution au management de l'infection à *Helicobacter pylori* en Belgique. Doctorat en Sciences biomédicales et pharmaceutiques. Universite libre de Bruxelles. Faculte de pharmacie. Bruxelles, Belgique. 2011.
2353) Okeleye BI. In vitro activity of bioactive compounds of selected south african medicinal plants on clinical isolates of *Helicobacter pylori.* DMSc Dissertation. University of Fort Hare. 2011. file:///C:/Users/07012017/Downloads/Okoleye+%2528M+Sc%2529+Microbiology.pdf
2354) Riediger C. Lansoprazol und Azithromycin: Antibakterielle Aktivität allein und in Kombination gegen *Helicobacter pylori in vitro*. Dissertation Universität Ulm, Germany. 2000: 89 pages.
2355) Бондаренко ОЮ. Эффективность эрадикационной терапии инфекции Хеликобактер Пилори на основе антибиотиков макролидов при язвенной болезни двенадцатиперстной кишки. кандидат медицинских наук. Москва. 2002.
2356) Усанкова ИН. Влияние компонентов пищи, ингибиторов протонной помпы и блокаторов H_2-рецепторов гистамина на суточный уровень интрагастральной кислотности у больных язвенной болезнью. кандидат медицинских наук. Москва, 2003.

ЦИТИРАНА: 4A: Boyanova L, Andreev N, Bouchard S, Megraud F. *Helicobacter pylori* seroprevalence in Bulgaria. Med Microbiol Lett. 1994; **3**: 107-113. **Цитирана от:**

2357) Vilarinho SMSQ. Colonização adeno-amigdalina por *Helicobacter pylori*, facto ou ficção? Dissertação de Candidatura ao Grau de Mestre. Universidade do Porto. Porto, Portugal, 2009.

ЦИТИРАНА: 10A: Boyanova L, Neshev G. Inhibitory effect of rose oil products on *Helicobacter pylori* growth in vitro: preliminary report. J. Med. Microbiol. 1999; **48**: 705-706. **Цитирана от:**

2358) El Gharbaoui A. Evolución y contraste del conocimiento etnofarmacológico (tradicional de plantas y usos medicinales) con perspectiva histórica en Marruecos oriental y Andalucía oriental, usando como base 'El Tratado de los Simples' de Ibn al-Baytar del siglo XIII. Universidad de Granada. 2017.
2359) Jeba WC. A comparative study on phytochemical, antimicrobial and immunomodulatory activity of *Ocimum* species. PhD Thesis. Educational and research institute university. Chennai. 2011.
2360) Wang X. *Helicobacter pylori* infection in a mouse model. Development, optimization and inhibitory effects of antioxidants. Doctoral dissertation, Lund University, Sweden. 2001; 128 pages.

ЦИТИРАНА: 12A: Boyanova L, Spassova Z, Krastev Z, Petrov S, Stancheva I, Docheva J, Mitov I, Koumanova R. Characteristics and trends in macrolide resistance among *Helicobacter pylori* strains isolated in Bulgaria over four years. Diagn Microbiol Infect Dis. 1999; **34** (4): 309 -313. **Цитирана от:**

2361) Aronson J. Macrolide antibiotics. Meyler's Side Effects of Antimicrobial Drugs. Elsevier Science 2009.
2362) Stais P. Verfügbarkeit von geschlechterbezogenen daten zu arzneimittelwirkungen in informationsquellen der ärztlichen praxis. dissertation. Institut für Toxikologie der Heinrich-Heine-Universität Düsseldorf, Germany. 2007.
2363) Абдулхаков РА. Оптимизация методов диагностики и лечения больных язвенной болезнью желудка и двенадцатиперстной кишки, ассоциированной с *Helicobacter pylori* (региональные особенности). доктор медицинских наук. Казань, Россия, 2006, 192 стр.

ЦИТИРАНА: 13A: Boyanova L. Comparative evaluation of two methods for testing metronidazole susceptibility of *Helicobacter pylori* in routine practice. Diagn Microbiol Infect Dis. 1999; **35** (1): 33 - 36. **Цитирана от:**

2364) Ontsira Ngoyi EN. Resistance de *Helicobacter pylori* aux antibiotiques et d'autres substances antimicrobiennes. Aspects moleculaires des mecanismes de detection. L'Université de Bordeaux, France. 2016.
2365) Yetgin M. Mide duedenum hastaliklarinda izole edilen *Helicobacter* suşlarinda amoksisilin, klaritromisin, tetrasiklin, metranidazol ve rifampisin direncinin agar dilüsyon yöntemiyle araştirilmasi. Çukurova üniversitesi. Adana 2006.
2366) Сварваль АВл. Характеристика популяции возбудителя и изучение цитокинового звена иммунитета у лиц, инфицированных *Helicobacter pylori.* Дисертация кмн; Санкт - Петербург – 2012.

ЦИТИРАНА: 14A: Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in *Helicobacter pylori* in Sofia, Bulgaria. J. Med. Microbiol. 2000; **49**: 415–418. **Цитирана от:**

2367) Breurec S. *Helicobacter pylori*: migrations humaines et cancer gastrique. PhD diss., Université Paris Sud-Paris XI, 2011.
2368) Del Carmen Vergara MM. Expresión de HP0605 y HP0971 de bombas de eflujo en cepas de *Helicobacter pylori* resistentes a claritromicina aisladas de pacientes con patología gástrica. Chilpancingo, Guerrero, Enero de 2020.

2369) Gerrits MM. Molecular mechanisms of antibiotic resistance in *Helicobacter pylori.* Doctoral Thesis, Erasmus University Rotterdam, The Netherlands. 2004; 160 pages.
2370) Nkomo LP. In vitro bioactivity of crude extracts of *Lippia javanica* on clinical isolates of *Helicobacter pylori*: Preliminary phytochemical screening. A dissertation for Master Of Science. Department of Biochemistry and Microbiology, University of Fort Hare, 2010.
2371) Березняк ЕА. Особенности штаммов *Helicobacter pylori*, циркулирующих в Ростовской области, и конструирование антигенного полимерного хеликобактерного диагностикума. кандидат биологических наук. Ростов-на-Дону, 2010
2372) Глотова ОМ. Особенности хеликобактерных гастродуоденитов у школьников Забайкальского края. Диссертация, кандидат медицинских наук. Москва, Россия. 2009.
2373) Данилов, Александр Николаевич. Хеликобактериоз у детей с хроническим гастродуоденитом (возможности диагностики и лечения). кандидат медицинских наук. Барнаул, 2004.
2374) Джагаева ЗК. Оптимизация антихеликобактерной терапии хронической гастродуоденальной патологии у детей. кандидат медицинских наук. Ростов-на Дону, 2007.
2375) Дзебисова ФС. Лечение детей с хронической гастродуоденальной патологией, ассоциированной с *Helicobacter pylori* на этапах стационар - поликлиника – санаторий. кандидат медицинских наук. Владикавказ, 2006.
2376) Краснова ЕЕ. Заболевания желудка и двенадцатиперстной кишки у детей (патогенетические механизмы, диагностика, прогноз, лечебно-реабилитационные мероприятия). доктор медицинских наук. Иваново, 2005.
2377) Макина ОВ. Патология гастродуоденальной зоны и окислительный стресс при сахарном диабете 1-го типа у детейл кандидат медицинских наук. Ярославль, 2006
2378) Мельникова ИЮ. Течение и исходы хронических заболеваний гастродуоденальной зоны у детей и подростков. доктор медицинских наук. Санкт-Петербург, 2005.
2379) Подусенко ВВ. Распространенность и особенности течения хеликобактериоза у школьников приморского края. Диссертация. Москва, Россия. 2006 г.
2380) Прокофьева АА. Особенности диагностики и лечения синдрома диспепсии у детей при инфицировании CagA-позитивными штаммами *Helicodacter pylori*. кандидат медицинских наук. Самара, 2011.
2381) Созаева ЗЮ. Хронопатофизиологические механизмы гастродуоденальной патологии у детей. Хронотерапия патологического процесса. кандидат медицинских наук. Владикавказ, 2008.
2382) Филиппова ЮА. Клинико-лабораторное обоснование комбинированной терапии хронической гастродуоденальной патологии у детей. кандидат медицинских наук. Владикавказ, 2009.
2383) Царьков МВл. Прогноз развития и профилактика хронического гастродуоденита у детей, перенесших распространенные формы гнойного перитонита. кандидат медицинских наук. Иваново, 2006.

ЦИТИРАНА: 15A: Boyanova L, Petrov D, Osmanliev D, Mitov I, Usunova I, Minchev Tz, Goranov E, Plochev M, Dimitrov J. Anaerobic bacteriology in 75 cases of thoracic empyema in Sofia, Bulgaria. Anaerobe, 2000; **6**: 81-85. **Цитирана от:**

2384) Conteras GR. Flora bacteriana oral y su perfil de sensibilidad a antibioticos en monos de Costa Rica (especies *Alouatta palliata* y *Ateles geoffrogyi*). Universidad de Costa Rica, 2002.

ЦИТИРАНА: 16A: Boyanova L, Osmanliev D, Petrov D, Mitov I, I. Usunova, Petrov S, Minchev Tz. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study. Clin. Microbiol. Infect. 2000; **6**: 622-624. **Цитирана от:**

2385) El Moize Z. Traumatismes oculaires par projectiles de guerre au troisième millénaire." PhD diss., 2015. Universite Mohhamed V Rabat. file:///C:/Users/07012017/Downloads/M%20%20189%202015.pdf
2386) Jacinto RDC. Relação da sintomatologia com a presença de microrganismos e endotoxinas em canais radiculares com necrose e suscetibilidade antimicrobiana de bactérias anaeróbias estritas. Thesis Faculdade De Odontologia De Piracicaba, Piracicaba, Brazil, 2007.

ЦИТИРАНА: 17A: Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarcheken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M. The status of antimicrobial resistance of *Helicobacter pylori* in eastern Europe. Clin. Microbiol. Infect. 2002; **8** (7): 388-396**. Цитирана от:**

2387) Fernini F Moussa A. Gastrite a *Helicobacter pylori* chez l'enfant (Doctoral dissertation). Algerie, 2019.
2388) Gerrits MM. Molecular mechanisms of antibiotic resistance in *Helicobacter pylori.* Doctoral Thesis. Erasmus University Rotterdam, The Netherlands. 2004.
2389) Janssen MJR. Dyspepsia et al. Thesis Redbound University, Nijmegen, The Netherlands. 2007.
2390) Koivisto T. *Helicobacter pylori*: resistance and treatment results in Finland. Academic Dissertation. University of Helsinki, Finland. June 6th, 2008: 81 pages.
2391) Lindgren Å. the function of natural killer cells in *Helicobacter pylori* infection and gastric cancer. Thesis. The Sahlgrenska Academy, University of Gothenburg Göteborg, Sweden 2010.
2392) Nyström J. Experimental studies of *Helicobacter pylori* immunization; identification of protective immune responses and vaccine candidate antigens. Sahlgrenska Akademin vid Göteborgs. Göteborg 2006. file:///C:/Users/07012017/Downloads/gupea_2077_16822_3%20(3).pdf
2393) Oona M. *Helicobacter pylori* infection in children: epidemiological and therapeutic aspects. dissertation for the commencement of the degree of Doctor of Medical Sciences. Council of the Faculty of Medicine, University of Tartu, Estonia, 2004; 114 pages.
2394) Prechtl, J. Die *Helicobacter pylori*-infektion bei kindern und jugendlichen. Graz, am 26.5.2010 zur Erlangung des akademischen Grades Doktor Der Gesamten Heilkunde Dr. Med. Univ. Medizinischen Universität Graz. file:///C:/Users/07012017/Downloads/Diplomarbeit%20Prechtl%20Johannes%20(1).pdf
2395) Precious NL. In vitro bioactivity of crude extracts of *Lippia javanica* on clinical isolates of *Helicobacter pylori*: Preliminary phytochemical screening. A dissertation for Master Of Science. Department of Biochemistry and Microbiology, University of Fort Hare, 2010.

2396) Ramirez BPA. Prevalencia y mecanismos de resistencia de *Helicobacter pylori* a tetraciclina: revision sistematica de la literatura. Pontificia Universidad Javeriana. Bogotá. 2011:
2397) Абдуллоев ХС. Распространенность хеликобактериоза среди сельского населения и оценка эффективности эрадикационной терапии в амбулаторных условиях. кандидат медицинских наук. Душанбе, 2012.
2398) Бабінець ОМ. Біологічні властивості пробіотиків після іммобілізації на ентеросорбентах і низькотемпературного зберігання. Інститут проблем кріобіології і кріомедицини. Національна Академія Наук України. Дисертація. Харків 2016.
2399) Дехнич, Наталья Николаевна. Оптимизация ведения пациентов с язвенной болезнью желудка и двенадцатиперстной кишки в амбулаторной практике по данным фармакоэпидемиологического анализа. Диссертация для кандидата медицинский наук. Смолянск. 2005.
2400) Иванова, Татьяна Николаевна. Микробиологические особенности дисбиоза кишечника у жителей Крайнего Севера. кандидат медицинских наук. Санкт-Петербург, 2008.
2401) Консолар М. Новые подходы к диагностике и элиминации *Helicobacter pylori* при язвенной патологии желудочно-кишечного тракта. кандидат биологических наук. Казань, 2007.
2402) Коровина ТИ. Клинико-инструментальная оценка эффективности последовательной эрадикационной терапии у больных эрозивно-язвенными поражениями желудка и двенадцатиперстной кишки, ассоциированными с *Helicobacter pylori*. Диссертация на соискание ученой степени кандидата наук. Москва. 2014.

ЦИТИРАНА: 18A: Boyanova L, Koumanova R, Gergova G, Popova M, Mitov I, Kovacheva Y, Derejian S, Katsarov N, Nikolov R, Krastev Z. Prevalence of resistant *Helicobacter pylori* isolates in Bulgarian children. J. Med. Microbiol. 2002; **51**:786-790.
Цитирана от:

2403) Fernini F, Moussa A. Gastrite a *Helicobacter pylori* chez l'enfant (Doctoral dissertation). 2019.
2404) Mourad-Baars PEC. Antibiotic resistance of *Helicobacter pylori* in the Netherlands. *Helicobacter pylori* in childhood : aspects of prevalence, diagnosis and treatment. Leiden University dissertation. 2012.
2405) Жданова ИА. Распространенность болезней органов пищеварения и эффективность эрадикационной терапии при хеликобактерной инфекции у детей (на примере Краснодарского края). кандидат медицинских наук. 2006, Москва, Россия.
2406) Жуков АГ. Морфологические особенности слизистой оболочки желудка у больных с портальной гипертензией. кандидат медицинских наук. Москва, 2010
2407) Игнатов ВН. Оптимизация лечения больных с язвенной болезнью желудка и двенадцатиперстной кишки в условиях поликлиники. кандидат медицинских наук. Ростов-на Дону, 2008.
2408) Оприщенко ИВ. Течение и терапия язвенной болезни двенадцатиперстной кишки, ассоциированной с *Helicobacter pylori* у больных с аутоиммунным тиреоидитом. кандидат медицинских наук. Москва, Россия. 2006.
2409) Салимгареев АА. Применение эндоскопического метода в комплексном лечении язвенной болезни двенадцатиперстной кишки у детей. кандидат медицинских наук. Уфа, 2009.

ЦИТИРАНА: 19A: Boyanova L, Derejian S, Koumanova R, Katsarov N, Gergova G, Mitov I, Nikolov R, Krastev Z. Inhibition of *Helicobacter pylori* growth in vitro by Bulgarian propolis: preliminary report. J. Med. Microbiol. 2003; **52**: 417-419. **Цитирана от:**

2410) El Housseini. Intérêts et applications cliniques de la propolis en médicine bucco-dentaire. Thèse, Universite de Nantes, 2013.
2411) Fadipe LA. Phytochemical and antibacterial investigations of the fruits of *Nauclea latifolia Smith* (family: *Rubiaceae*). Faculty Of Pharmaceutical Sciences, Ahmadu Bello University, Zaria Nigeria. 2016.
2412) Illahi, M. F. In Silico Study of Propolis as a Potential Healing Agent for Gastric Ulcer (Doctoral dissertation, CAPITAL UNIVERSITY). 2020.
2413) Ketkar SS. Design and development of value added apiceutical products. PhD Thesis. Bharati Vidyapeeth University. 2015.
2414) Márquez Morales, F. A. *Helicobacter pylori*: La historia de una bacteria muy peculiar. Universidad de Sevilla. 2019. idus.us.es
2415) Miralimova SM. Antimicrobial properties of propolis, preparing of antihelicobacterial drugs" PhD Thesis. Тошкент, Узбекистан, 2009.
2416) Rosendale DI. Antimicrobial activity of functional food ingredients on Manuka honey action against *Escherichia coli*. PhD Dissertation.Massey University, Auckland. 2009.
2417) Suleman T. The antimicrobial and chemical properties of South African propolis. PhD diss., 2016.
2418) Tarimda Yenilikçi Yaklaşimlar; Sürdürülebilir Tarim Ve Biyoçeşitlilik. Kağan Kökten (ed) Ankara, 2020.

ЦИТИРАНА: 20A: Boyanova L, Koumanova R, Lazarova E, Jelev C. *Helicobacter pylori* and *Helicobacter heilmannii* in children. A Bulgarian study. Diagn Microbiol Infect Dis. 2003; **46**: 249-252. **Цитирана от:**

2419) Amorim IF. Canine gastric pathology. *Helicobacter* spp. infection in dogs - an epidemiological and molecular study. Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto (ICBAS-UP). 2014.
2420) Cooman LD. Serological diagnosis of infections with *Helicobacter suis*, a zoonotic agent present in pork. Ghent University, Faculty of Veterinary Medicine. 2015.
2421) De Bock M. In vivo studies on the pathogenic effect of canina and feline *Helicobacter* species. Thesis for the degree of doctor. Faculty of Veterinary medicine. Ghent University, Ghent, Belgium, 2006.
2422) Hoosein N. Phenotypic and molecular analysis of *Helicobacter* spp. and related micro organisms identified in clinical & environmental specimens. Thesis for Master of Science. University ofCape Town. 2006. file:///C:/Users/07012017/Downloads/thesis_hsf_2006_hoosain_n.pdf
2423) Flahou B. Experimental studies on *Helicobacter suis* virulence and control. PhD dissertation. Faculty of Veterinary Medicine, Ghent University, 2011.
2424) Vermoote M. An exploratory study of *Helicobacter suis* control strategies. PhD Dissertation. Ghent University, Faculty of Veterinary Medicine. 2013.

2425) Roberts SE, Samuel DG, Williams JG, Thorne K, Morrison-Rees S, John A, Akbari A, Williams JC. Survey of digestive health across Europe. Part one: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe. Report for United European Gastroenterology. 2014.: 275 pages.
2426) Валеева Ю Вл. Обнаружение *Helicobacter pylori* при хронических заболеваниях желчевыводящих путей. кандидат медицинских наук. Уфа, 2011.
2427) Волкова ГА. Клинико-биохимическая характеристика заболеваний желчевыводящих путей у детей. кандидат медицинских наук. Красноярск, 2007.
2428) Поливанова ТВ. Распространенность и клинико-морфологическая характеристика гастродуоденальной патологии у школьников различных регионов Восточной Сибири. доктор медицинских наук. Красноярск, 2007.
2429) Сокольских ТВ. Клинико-морфологическая характеристика заболеваний гастродуоденальной зоны с применением семейного подхода у детей, проживающих в бассейне среднего течения р. Енисей.. Красноярск, 2006.

ЦИТИРАНА: 21A: Boyanova L. Influence of transport conditions and media on *Helicobacter pylori* isolation. J. Med. Microbiol. 2003; **52**(Pt 12): 1129-1130. **Цитирана от:**

2430) Bayas Morejón IF. Aportaciones a la epidemiología de *Arcobacter* y *Helicobacter spp.:* Aplicación de métodos moleculares a su detección e identificación en alimentos (Doctoral dissertation). Universidad Politécnica de Valencia. 2016.
2431) Narkhede JR. One year crosssectional study of perforative peritonitis, to assess the association of gastroduodenal perforation and *H. pylori*. DMSc Dissertation. University of Health Sciences, Karnataka, Banglore.2006.

ЦИТИРАНА: 23A: Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev Z. *Campylobacter* infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease and other chronic intestinal diseases. Diagn Microbiol Infect Dis. 2004; **49** (1): 71-74. **Цитирана от:**

2432) Al Kandari S. Characterization and comparison of *Campylobacter* bacteriophages. PhD thesis. School of Biosciences. Loughborough, Leicestershire, UK. 2013.
2433) Alrubaye, Bilal Ali, "Microbiota Metabolic Product Deoxycholic Acid Prevents *Campylobacter* jejuni chicken colonization through modulating ceca anaerobes". Theses and Dissertations. 2018.
2434) Brunner, K. Early immunity to the *Campylobacter* genus-Insights into host and bacterial factors involved in health and disease (Doctoral dissertation, UCL-University College London). 2016.
2435) Flint A. The oxidative stress defenses of *Campylobacter jejuni*. Thesis, for the PhD degree in Biochemistry. Department of Biochemistry, Microbiology and Immunology Faculty of Medicine University of Ottawa, Canada, 2015. Flint_Annika_2015_thesis.pdf
2436) Ladely SR. Development of macrolide resistant *Campylobacter* in broilers administered tylosin and the genetic characterization of the associated mutations. PhD Dissetration. Athens, Georgia, USA, 2007.
2437) Narváez Román NA. Análisis de polimorfismos del gen *flaA* en cepas de *Campylobacter jejuni* y *Campylobacter coli* mediante la técnica RFLP (Bachelor's thesis). 2018. Loca, Ecuador.
2438) Nguyen H. *Acanthamoeba-Campylobacter* interactions. Doctoral Thesis, Faculty of Medicine, University of Ottawa, Ottawa, Canada. 2011.
2439) Pryjma MC. *Campylobacter jejuni* metabolism in survival and host cell interactions. A thesis for the degree of Doctor of Philosophy. The University of British Columbia. Vancouver.2014.
2440) Sethi, S. Long-term gastrointestinal complications of Clostridium difficile associated diarrhea (CDAD) (Doctoral dissertation, The University of Texas School of Public Health). 2008.
2441) Trokhymchuk A. Bacterial Levels In Saskatchewan Retail Ground Beef. Thesis for Master of Science. University of Saskatchewan, Saskatoon. 2013.
2442) Wine E. Host factors and cytoskeletal responses to bacterial-induced intestinal inflammation. Institute of Medical Science, University of Toronto. 2008.
2443) Ручкина, Ирина Николаевна. Роль острых кишечных инфекций и нарушений микробиоценоза в этиологии и патогенезе и лечении синдрома раздраженного кишечника. доктор медицинских наук. Москва, 2005.

ЦИТИРАНА: 24A: Boyanova L, Gergova G, Koumanova R, Jelev C, Lazarova E, Mitov I, Kovacheva Y. Risk factors for primary *Helicobacter pylori* resistance in Bulgarian children. J. Med. Microbiol.; 2004; **53** (Pt 9): 911-914. **Цитирана от:**

2444) Stais P. Verfügbarkeit von geschlechterbezogenen daten zu arzneimittelwirkungen in informationsquellen der ärztlichen praxis. dissertation. Institut für Toxikologie der Heinrich-Heine-Universität Düsseldorf, Germany. 2007.
2445) Nguyen TVH. Diagnosis and treatment of *Helicobacter pylori* infection in Vietnamese children. Thesis. Karolinska Institutet, Stockholm, Sweden, 2009.
2446) Салимгареев, Адик Адисович. Применение эндоскопического метода в комплексном лечении язвенной болезни двенадцатиперстной кишки у детей. кандидат медицинских наук. Уфа, 2009.
2447) Nkomo LP. In vitro bioactivity of crude extracts of *Lippia javanica* on clinical isolates of *Helicobacter pylori*: Preliminary phytochemical screening. A dissertation for Master Of Science. Department of Biochemistry and Microbiology, University of Fort Hare, 2010.
2448) Prechtl, J. Die *Helicobacter pylori*-infektion bei kindern und jugendlichen. Graz. 2010. zur Erlangung des akademischen Grades Doktor Der Gesamten Heilkunde Dr. Med. Univ. Medizinischen Universität Graz. 2010.

ЦИТИРАНА: 25A: Boyanova L, Djambazov V, Gergova G, Iotov D, Petrov D, Osmanliev D, Minchev Z, Mitov I. Anaerobic microbiology in 198 cases of pleural empyema. A Bulgarian study. Anaerobe. 2004; **10**(5): 261-267. **Цитирана от:**

2449) Doğan, M. Çeşitli klinik örneklerden izole edilen anaerop bakterilerin tanımlanması ve antibiyotik duyarlılıklarının belirlenmesi. Doctoral dissertation, Selçuk Üniversitesi Tıp Fakültesi. 2008.

ЦИТИРАНА: 26A: Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains in vitro by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; **54** (Pt 5):481-483. **Цитирана от:**

2450) Cesar Cunha Nunes L. Própolis vermelha do litoral de Pernambuco: Caracterização, atividade biológica e proposta de gel vaginal. PhD dissertation. Recife-Pe, 2008.
2451) Claimer CS. Isolation, screening, purification and characterization of lectin from Adhatoda vasica L.Ph.D. thesis.Bharathidasan University. 2013.
2452) De Luca MP. Verniz à base de quitosana contendo própolis verde brasileira: avaliação da atividade antimicrobiana, citotoxicidade e perfil de liberação. Belo Horizonte faculdade de odontologia universidade federal de Minas Gerais. 2011.
2453) Gonçalves GF. Efeito da própolis marrom e verde e de irrigantes endodônticos na resistência adesiva de pinos de fibra de vidro à dentina radicular. Dissertação. Cuiabá, 2017.
2454) Ketkar SS. Design and development of value added apiceutical products. PhD Thesis. Bharati Vidyapeeth University. 2015.
2455) Kikić A. The influence of propolis on fungal growth of *Sclerotinia sclerotiorum* and *Botrytis cinerea*. Master's thesis. Josip Juraj Strossmayer University of Osijek Faculty of agriculture. Osijek, Croatia. 2016.
2456) Edelamen LA. Efecto de la microencapsulación en. Facultad tecnológica. Diss. Universidad DE Santiago DE Chile, 2018.
2457) Maia SIC. Avaliação da atividade antioxidante de extratos de própolis e determinação de componentes com relevância fisiológica. Doctoral Dissertation. 2014.
2458) Makabe MLF. Higienização bucal com digluconato de clorexidina e extrato etanólico de própolis em pacientes de Unidade de Terapia Intensiva (UTI) de um Hospital Público na cidade de São Paulo-Brasil. São Paulo, Brasil 2015.
2459) Márquez Morales, Felipe Andrés. "*Helicobacter pylori*: La historia de una bacteria muy peculiar." Master's Thesis Universidad de Sevilla. Departamento de Microbiología y Parasitología (2019).
2460) Mekonnen S. Ethanolic extracts of *Warburgia ugandensis* against some test microorganisms. Thesis. School Of Graduate Studies Science Faculty, Addis Ababa University, Addis Ababa, Ethiopia. 2010.
2461) Miralimova SM. Antimicrobial properties of propolis, preparing of antihelicobacterial drugs" PhD Thesis. Тошкент, Узбекистан, 2009.
2462) Moretti, FRRC. Identification of candidate resistance metabolites to *Leifsonia xyli* subsp. *xyli* in sugarcane through metabolomic profiling. Escola Superior de Agricultura Luiz de Queiroz. Piracicaba, 2017.
2463) Njume C. Phytochemical analysis and bioactivity of selected South African medicinal plants on clinical isolates of *Helicobacter pylori*. thesis. Department of Biochemistry and Microbiology, Faculty of Science and Agriculture, University of Fort Hare. 2012.
2464) Odimári Pricila Pires do Prado. Própolis e monensina sódica em dietas volumosas sobre a digestibilidade e características ruminais de bovídeos. Ph D Thesis. Estado do Paraná, Brazil, 2008.
2465) Orizondo RA. Antibacterial Perfluorocarbon Ventilation: A Novel Treatment Method for Bacterial Respiratory Infections. PhD dissertation. University of Michigan, 2015.
2466) Palameta M. Influence of propolis on growth of fungi *Alternaria brassicae* and *Fusarium oxysporum*. Master's Thesis. National and University Library in Zagreb. 2015.
2467) Patrícia Cerqueira de Macêdo D. Etiologia da candidíase esofágica e avaliação do efeito antifúngico do extrato de própolis in vitro e in vivo. Recife, 2011.
2468) Pereira EMR. Evidências preliminares da eficácia de um enxaguante bucal contendo 5% de própolis para o controle de placa e gengivite. Faculdade de Odontologia – UFMG. Belo Horizonte. 2010.
2469) Pimenta HC. Potencial antimicrobiano de medicações intracanais a base de própolis marrom sobre *Enterococcus faecalis.* Universidade de Cuiabá – UNIC, Cuiabá, 2013.
2470) Qiu S. Evaluating the antimicrobial and antibiofilm activity of a lipid extract from the giant kelp *Macrocystis pyrifera*. Doctoral dissertation, University of Otago. 2020.
2471) Romero Rivera MH. Interacciones entre compuestos mayoritarios anti-*Helicobacter pylori* presentes en propóleos de la Región del BioBío (Doctoral dissertation, Universidad de Concepción. Facultad de Ciencias Biológicas. Departamento de Microbiología). 2017.
2472) Santos DC. Estudo químico do extrato hexânico e avaliação da atividade biológica dos extratos orgânicos da própolis marrom clara e escura da Bahia. DSc dissertation. Salvador, 2010.
2473) Silva EC. Estudo da composição química e atividade biológica da geoprópolis de *Melipona interrupta* e *Melipona seminigra*. Universidade Federal do Amazonas. Manaus, 2012.
2474) Soltani EK. Caractérisation et activités biologiques de substances naturelles, cas de la propolis (Doctoral dissertation). 2018.
2475) Valarezo Valdez BE. Innovative processes for the production of new nanocomposite materials by electrospinning technique. 2013.
2476) Viera VB. Obtenção do extrato de própolis assistida por micro-ondas, aplicação em linguica toscana e avaliação da sua capacidade antioxidante. Master Dissertation. Graduate Program in Food Science and Technology. Universidade federal de Santa Maria, Brasil, 2012.

ЦИТИРАНА: 27А: **Boyanova L**, Nikolov R, Lazarova E, Gergova G, Katsarov N, Kamburov V, Spassova Z, Derejian S, Jelev C, Mitov I, Krastev Z. Antibacterial resistance in *Helicobacter pylori* strains isolated from Bulgarian children and adult patients over 9 years. J. Med. Microbiol. 2006; **55**: 65-68. **Цитирана от:**

2477) Agudo Pena, S. Estudio molecular de los factores de virulencia y de la resistencia a claritromicina en la infección por" *Helicobacter pylori*". Tesis doctoral, Madrid, 2010.
2478) Becerra Becerra NZ. Prevalencia y mecanismos de resistencia de *Helicobacter pylori* a fluoroquinolonas y las mutaciones relacionadas. Revisión sistemática de la literatura. 2011.
2479) Cisneros Moreno, SJ. Mecanismos de resistencia de *Helicobacter pylori* a los antibióticos amoxicilina, claritromicina, levofloxacina y metronidazol. Bachelor's thesis, Bogotá, 2009.
2480) Correa Ruiz AM. Estudio de la actividad "in vitro" de compuestos fenólicos presentes en el vino y de seis antimicrobianos en aislados clínicos de "*Helicobacter pylori*". Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina. 2015:

2481) Matta AJ. Colonización múltiple de *helicobacter pylori* en mucosa gástrica de pacientes con gastritis crónica de Túquerres y Tumaco (Nariño)[recurso electrónico] (Doctoral dissertation). Nariño, Colombia. 2015. bibliotecadigital.univalle.edu.co
2482) Montoya Palacios, JS. Prevalencia de la resistencia de *Helicobacter pylori* a amoxicilina: revisión de la literatura. Bachelor's thesis, 2011.
2483) Mourad-Baars PEC. Antibiotic resistance of *Helicobacter pylori* in the Netherlands. *Helicobacter pylori* in childhood : aspects of prevalence, diagnosis and treatment. Leiden University dissertation. 2012.
2484) Pena SA. Estudio molecular de los factores de virulencia y de la resistencia a claritromicina en la infección por *Helicobacter pylori*. Doctoral thesis. Universidad Complutense de Madrid, Medical Faculty, Madrid, Spain, 2010.
2485) Ruiz, A. M. C. Estudio de la actividad" in vitro" de compuestos fenólicos presentes en el vino y de seis antimicrobianos en aislados clínicos de" *Helicobacter pylori*". Universidad Complutense de Madrid. 2014.
2486) Solís AS. Factores de virulencia, aspectos Inmunológicos y patrones de sensibilidad en aislamientos clínicos de *Helicobacter pylori*. Tesis Doctoral. Madrid, 2012.
2487) Sujatha R. Comparative study of *Helicobacter pylori* infection with invasive (culture, histopathology, rapid urease test) and non-invasive (serology) techniques. Rajiv Gandhi University of health sciences. Karnataka, Bangalore. 2007.
2488) Панисяк НА. Оптимизация антихеликобактерной терапии больных с язвенной болезнью двенадцатиперстной кишки (клинико-экономический анализ). кандидат медицинских наук. Смоленск, 2009.
2489) Салимгареев АА. Применение эндоскопического метода в комплексном лечении язвенной болезни двенадцатиперстной кишки у детей. кандидат медицинских наук. Уфа, 2009.
2490) Торгало ВВ. Клинико-иммуногенетические особенности течения язвенной болезни и хронических гастродуоденитов у детей города Новосибирска. кандидат медицинских наук. Томск, 2008.

ЦИТИРАНА: 28А: **Boyanova L**, Kolarov R, Gergova G, Deliverska E, Madjarov J, Marinov M, Mitov I. Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillo-Facial Surgery, Sofia, Bulgaria. J. Med. Microbiol. 2006, **55** (Pt 9): 1285-1289. Erratum in: J Med Microbiol. 2006; **55** (Pt 12): 1759-1760. **Цитирана от:**

2491) Al-Nawas B, Karbach J. Odontogene Infektionen (S3). file:///C:/Users/07012017/Downloads/007-006l_S3_Odontogene_Infektionen_2017-11.pdf
2492) Barnard N. Prevalence of gram-negative infections in cervico-facial sepsis. University of the Western Cape. etd.uwc.ac.za 2019.
2493) Dias ACS. Infecções odontogênicas graves: etiologia microbiana, perfil de citocinas e de suscetibilidade a drogas antimicrobianas. 2016.
2494) Doğan, M. Çeşitli klinik örneklerden izole edilen anaerop bakterilerin tanımlanması ve antibiyotik duyarlılıklarının belirlenmesi (Doctoral dissertation, Selçuk Üniversitesi Tıp Fakültesi). 2008.
2495) Gachinmath, Supriya B. Study of antibiotic sensitivity pattern of obligate and facultative anaerobic bacteria from cellulitis, wound infections and abscesses. Dissertation. Rajiv Gandhi University of health sciences. Karnataka, Bangalore. 2011.
2496) Gaetti Jardim EC. Fatores associados à presença de microrganismos superinfectantes ou oportunistas na cavidade bucal: relações com próteses totais, condições periodontais e susceptibilidade a antimicrobianos. Dissertation. Faculdade de Odontologia, Campus de Araçatuba, Universidade Estadual Paulista "Júlio de Mesquita Filho", Araçatuba, 2009.
2497) Geraldes AM. Ocorrência de *Porphyromonas gingivalis* na microbiota bucal de pacientes submetidos à radioterapia para tratamento de lesões malignas de cabeça e pescoço. Araçatuba 2010: 61-f.
2498) Karthikeyan RA. Clinical study on Deep Neck Space Infections (Doctoral dissertation, Thanjavur Medical College, Thanjavur). 2020.
2499) Melo ME. Ocorrência de *Prevotella intermedia* em pacientes com diferentes condições de saúde bucal e submetidos à radioterapia para tratamento de lesões malignas de cabeça e pescoço. Araçatuba – SP. 2010: 62.
2500) Naidoo S. Antimicrobial susceptibility of anaerobic organisms isolated from clinical specimens at Charlotte Maxeke Johannesburg academic hospital. Dissertation for Master of Science in Medicine. Johannesburg, South Africa, 2009.
2501) Novialdi PM. Pola kuman abses leher dalam. Bagian THT-KL Fakultas Kedokteran Universitas Andalas. 2010.
2502) Sarvan I. Orofacial sepsis and hiv at maxillo-facial surgery units in the Western Cape A prospesctive study. Dissertation for the degree Magister Chirugiae Dentium. University of the Western Cape. 2009.
2503) Sömmer C. Retrospektive analyse tiefer hals-infektionen: diagnostik, therapie, verläufe. inaugural – dissertation. Georg August Universität zu Göttingen. 2014.
2504) Гумилевский, Б. Ю. Эффективность комплексного лечения одонтогенных флегмон челюстно-лицевой области у больных пожилого возраста с применением полиоксидония. PhD Thesis. Волгоградский государственный медицинский университет. 2014.
2505) Станиславович СА. Эффективность комплексного лечения одонтогенных флегмон челюстно-лицевой области у больных пожилого возраста с применением полиоксидония. Diss. Волгоградский Государственный Медицинский Университет, 2014.

ЦИТИРАНА: 29А: **Boyanova L,** Kolarov R, Gergova G, Mitov I. *In vitro* activity of Bulgarian propolis against 94 clinical isolates of anaerobic bacteria. Anaerobe 2006; **12** (4):173-177. **Цитирана от:**

2506) Bastos ACT. Viagem e identidade em Mazanga e O último vôo do flamingo (Doctoral dissertation, Universidade Federal de Minas Gerais). 2006.
2507) Bodini RB. Deselvolvimento de materiais polimericos bioativos a base de gelatina e propolis. Dissertation. Pirassununga, Brazil, 2011.
2508) Borges JG. Desenvolvimento de filmes de desintegracao oral para liberacao de compostos bioactivos. Dissertation. Pirassununga, 2013.
2509) De Luca MP. Verniz à base de quitosana contendo própolis verde brasileira: avaliação da atividade antimicrobiana, citotoxicidade e perfil de liberação. Belo Horizonte faculdade de odontologia universidade federal de Minas Gerais. 2011.

2510) de Souza Noronha, V. R. A. Gel de própolis mucoadesivo versus solução de cloridrato de benzidamina na prevenção da mucosite oral em pacientes irradiados em região de cabeça e pescoço.: ensaio clinico, cego, randomizado-fase II. Belo Horizonte – Minas Gerais 2015.
2511) Gonzales Carrillo GC. Eficacia antibacteriana in vitro del extracto etanólico de propóleo frente a la Porphyromonas Gingivalis Atcc 33277. Facultad de Odontología, Universidad Nacional, Lima - Perú. 2018.
2512) Kamble UK. Use of liquid chromatography for assay of flavonoids as key constituents and antibiotics as trace elements in propolis. Investigation into the application of a range of liquid chromatography techniques for the analysis of flavonoids and antibiotics in propolis; and extraction studies of flavonoids in propolis (Doctoral dissertation, University of Bradford). 2016.
2513) Kanaga Priyaa V. Comparative Evaluation of Antibacterial Efficacy of Manuka Honey, Indian Honey and Sodium Hypochlorite against Enterococcus Faecalis Biofilm: An Invitro study (Doctoral dissertation, Adhiparasakthi Dental College and Hospital, Melmaruvathur). 2020.
2514) Mahdjouba L, Fatima Zohra B. L 'effet des polyphénols de la propolis de Tigzirt sur l'hépatotoxicité induite par l'épirubicine chez les rats Wistar. Master en biologie, Université Abdelhamid Ibn Badis-Mostaganem, 2016.
2515) Martinez CR. Cytotoxicity of propolis of *Apis mellifera* on human buccal mucosa fibroblasts: study in vitro. Campo Grande; 2010. Dissertation – Federal University of Mato Grosso do Sul, Brazil.
2516) Nedji N. Effets des acaricides sur l'abeille domestique *Apis mellifera intermissa* et analyse de l'activité antimicrobienne de la propolis et du miel. These de doctorat. Annee universitaire 2014 / 2015. Republique Algerienne.
2517) Pereira EMR. Evidências preliminares da eficácia de um enxaguante bucal contendo 5% de própolis para o controle de placa e gengivite. Faculdade de Odontologia – UFMG. Belo Horizonte. 2010.
2518) Potier F. La propolis, propriétés et intérêt thérapeutique (Doctoral dissertation, Université de Lorraine). 2014.
2519) Rodrigues AA. Evidências preliminares da eficácia de um gel contendo 5% de própolis para o controle da alteração gengival observada em pacientes portadores de aparelho ortodôntico fixo. Belo Horizonte, 2013.
2520) Tormos Esteve Ana. Estudio de la capacidad antimicrobiana de extractos de propóleos de diferentes orígenes. Valencia, 2019.
2521) Wu Q.Antimicrobial effect of Manuka honey and Kanuka honey alone and in combination with the bioactives against the growth of *Propionibacterium acnes* ATCC 6919. Thesis for Master of Food Technology. Massey University Albany, New Zealand.2011.

ЦИТИРАНА: 31A: **Boyanova L**, Lazarova E, Jelev C, Gergova G, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in untreated Bulgarian children over a period of 10 years. J Med Microbiol. 2007; **56**(Pt 8):1081-1085. **Цитирана от:**

2522) Ferrand J. *Helicobacter pylori* dans un modèle de carcinogenèse gastrique impliquant les cellules souches mésenchymateusesThèse pour le doctorat de l'université Bordeaux 2. Bordeaux, France, 2009.
2523) Joosten, M. The zoonotic pathogen Helicobacter heilmannii from feline origin: aspects of virulence and gastric colonization (Doctoral dissertation, Ghent University). 2017.
2524) Галова ЕА. Клинико-иммунологические особенности и коррекция терапии хронического гастродуоденита у детей дошкольного возраста. кандидат медицинских наук. Нижний Новгород, 2008.
2525) Галиакберова АР. Факторы риска, клинические особенности и пути профилактики заболеваний органов пищеварения у лиц призывного возраста. кандидат медицинских наук. Челябинск, 2009.
2526) Ивановская МА. Особенности клинического течения язвенной болезни двенадцатиперстной кишки у детей, лечение и профилактика обострений в условиях поликлиники. кандидат медицинских наук. Владивосток, 2011.
2527) Печкина КГ. Клинико-морфологические особенности и внежелудочные проявления хронического гастрита, ассоциированного с Cagа-позитивными штаммами *Helicobacter pylori* у детей школьного возраста: дисс. канд. мед. наук. Барнаул.–2014.

ЦИТИРАНА: 32A: **Boyanova L**, Kolarov R, Mitov I. Antimicrobial resistance and the management of anaerobic infections. Expert Rev. Anti Infect. Ther. 2007; **5**(4):685-701. **Цитирана от:**

2528) Chakor B. Abcès pulmonaire: Bactériologie et prise en charge. Dissertation. Universite Mohammed V De Rabat. 2020
2529) Nastase N, Malo Fumanal S. Presencia de bacterias resistentes a los antibióticos en los alimentos. Faculdad de veterinaria, Universidad de Zaragoza. 2015.
2530) Pecarski D. Antibacterial activity of Lamiaceae and Apiaceae essential oils on bacterias and fungi. Докторска дисертација. Универзитет у Крагујевцу, Факултет медицинских наука. Крагујевац, 2014.

ЦИТИРАНА: 33A: **Boyanova L.** Detection of *Helicobacter pylori* infection in symptomatic Bulgarian adults. Clin. Microbiol. Infect. 2007; **13** (9): 908-914. **Цитирана от:**

2531) Borejsza-Wysocki Maciej, Karpiński Tomasz M. Badania kliniczne i odpowiedzi cytokinowej w raku żołądka związanym z *Helicobacter pylori* [Clinical and cytokine response studies in gastric cancer associated with *Helicobacter pylori*]. rozprawa doktorska. Biblioteka Uniwersytetu Medycznego w Poznaniu. 2009.

ЦИТИРАНА: 34A: Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of *Helicobacter pylori* resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008; **60 (4)**: 409-415. **Цитирана от:**

2532) Črnič A. The release of amoxicillin from bilayer floating tablets based on xanthan gum. Diplomska naloga. Univerza v Ljubljani, Fakulteta za Farmacijo. Ljubljana, 2008.
2533) Daza FFF. Análisis de mutaciones en los genes 23S rRNA y *pbp1A* de aislados de *Helicobacter pylori* resistentes a Claritromicina y Amoxicilina, provenientes de Tumaco y Túquerres.-Pimenta (Anexo B) Universidad del Valle, Santiago de Cali, 2013.
2534) Koivisto T. *Helicobacter pylori*: resistance and treatment results in Finland. Academic Dissertation. University of Helsinki, Finland. 2008:
2535) Mourad-Baars PEC. Antibiotic resistance of *Helicobacter pylori* in the Netherlands. *Helicobacter pylori* in childhood : aspects of prevalence, diagnosis and treatment. Leiden University dissertation. 2012.

2536) Prechtl J. Die *Helicobacter pylori*-infektion bei kindern und jugendlichen. Graz, am 26.5.2010 zur Erlangung des akademischen Grades Doktor Der Gesamten Heilkunde Dr. Med. Univ. Medizinischen Universität Graz. file:///C:/Users/07012017/Downloads/Diplomarbeit%20Prechtl%20Johannes%20(1).pdf
2537) Precious NL. In vitro bioactivity of crude extracts of *Lippia javanica* on clinical isolates of *Helicobacter pylori*: Preliminary phytochemical screening. A dissertation for Master Of Science. Department of Biochemistry and Microbiology, University of Fort Hare, 2010
2538) Ramirez BPA. Prevalencia y mecanismos de resistencia de *Helicobacter pylori* a tetraciclina: revision sistematica de la literatura. Pontificia Universidad Javeriana. Bogotá. 2011.
2539) Zhou Y. An antimicrobial agent from celery seed active against *Helicobacter pylori*.(PhD thesis) Sheffield Hallam University. 2008.
2540) Абдуллоев ХС. Распространенность хеликобактериоза среди сельского населения и оценка эффективности эрадикационной терапии в амбулаторных условиях. кандидат медицинских наук. Душанбе, 2012.
2541) Бессонов АГ. Клиническое обоснование и эффективность комплексной антихеликобактерной терапии больных хроническим гастритом с эрозиями. Дисертация**.** Ижевск 2015.
2542) Варванина СЭ. Оптимизация диагностики и лечения пациентов с заболеваниями слизистой оболочки полости рта, ассоциированными с *Helicobacter pylori*, до и после эрадикации. Диссертация Стоматология,Нижний Новгород. 2016.
2543) Жигунова ТП. Обоснование укороченных сроков курортного лечения больных с эрозивно-язвенными поражениями эзофагогастродуоденальной системы. 2013.
2544) Смолькина АВ. Оптимизация комплексного лечения ранних постгастрорезекционных осложнений у больных язвенной болезнью желудка и двенадцатиперстной кишки. доктор медицинских наук. Ульяновск, 2010.
2545) Чуева МА. Оптимизация терапии заболеваний верхних отделов желудочно-кишечного тракта у детей с атопическим дерматитом и хронической крапивницей. PhD dissertation. Волгоград 2015:

ЦИТИРАНА: 35A: Boyanova L, Ilieva J, Gergova G, Spassova Z, Nikolov R, Davidkov L, Evstatiev I, Kamburov V, Katsarov N, Mitov I. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58**(1):94-100. **Цитирана от:**

2546) Becerra Becerra NZ. Prevalencia y mecanismos de resistencia de *Helicobacter pylori* a fluoroquinolonas y las mutaciones relacionadas. Revisión sistemática de la literatura. Tesis doctoral. Facultad De Ciencias. Pontificia Universidad Javeriana. 2011.
2547) Solís AS. Factores de virulencia, aspectos Inmunológicos y patrones de sensibilidad en aislamientos clínicos de *Helicobacter pylori*. Tesis Doctoral. Madrid, 2012.
2548) Suwalak, S. Mechanisms of bioactive products from Quercus infectoria against enterohaemorrhagic escherichia coli (EHEC) O157: H7 (Doctoral dissertation, Prince of Songkla University). 2009.

ЦИТИРАНА: 36A: Boyanova L, Stephanova-Kondratenko M, Mitov I. Anti-*Helicobacter pylori* activity of *Lactobacillus delbrueckii* subsp. *bulgaricus* strains: preliminary report. Lett Appl Microbiol. 2009; **48** (5): 579-584. **Цитирана от:**

2549) Portello F. Caractérisation du dialogue entre *Streptococcus thermophilus* et le tractus gastro-intestinal de son hôte. 78350 Jouy-en-Josas. Master Biologie Appliquée aux Productions et à la Santé Animale 2012.

ЦИТИРАНА: 37A: **Boyanova L.** Prevalence of multidrug-resistant *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58** (Pt 7): 930-935.**Цитирана от:**

2550) Correa Ruiz AM. Estudio de la actividad "in vitro" de compuestos fenólicos presentes en el vino y de seis antimicrobianos en aislados clínicos de "*Helicobacter pylori*".Tesis doctoral. Universidad Complutense De Madrid. Madrid, 2014.
2551) Mourad-Baars PEC. Antibiotic resistance of *Helicobacter pylori* in the Netherlands. *Helicobacter pylori* in childhood : aspects of prevalence, diagnosis and treatment. Leiden University dissertation. 2012.
2552) Pena SA. Estudio molecular de los factores de virulencia y de la resistencia a claritromicina en la infección por *Helicobacter pylori*. Doctoral thesis. Universidad Complutense de Madrid, Medical Faculty, Madrid, Spain, 2010.
2553) Prechtl, J. Die *Helicobacter pylori*-infektion bei kindern und jugendlichen. Graz, am 26.5.2010 zur Erlangung des akademischen Grades Doktor Der Gesamten Heilkunde Dr. Med. Univ. Medizinischen Universität Graz. 2010.
2554) Precious NL. In vitro bioactivity of crude extracts of *Lippia javanica* on clinical isolates of *Helicobacter pylori*: Preliminary phytochemical screening. A dissertation for Master Of Science. Department of Biochemistry and Microbiology, University of Fort Hare, 2010.
2555) Ramirez BPA. Prevalencia y mecanismos de resistencia de *Helicobacter pylori* a tetraciclina: revision sistematica de la literatura. Pontificia Universidad Javeriana. Bogotá. 2011.
2556) Varda Brkić D. Detekcija gena virulencije otoka patogenosti *cag* i gena *dupA* izolata *Helicobacter pylori* nakon višestruke neuspjele eradikacijske terapije (Doctoral dissertation, Sveučilište u Zagrebu). 2016.
2557) Березняк, Елена Александровна. Особенности штаммов *Helicobacter pylori*, циркулирующих в Ростовской области, и конструирование антигенного полимерного хеликобактерного диагностикума. кандидат биологических наук. Ростов-на-Дону, 2010.
2558) Бессонов АГ. Клиническое обоснование и эффективность комплексной антихеликобактерной терапии больных хроническим гастритом с эрозиями. Дисертация**.** Ижевск 2015.
2559) Калюжная ОА. Комплексная медицинская реабилитация больных с гастродуоденальной патологией с применением физических факторов (Doctoral dissertation, международная высшая школа). 2018.
2560) Приходько, М. Н. Стабильная стенокардия напряжения с сочетанием хронического *Helicobacter pylori*– ассоциированного гастрита: клинико-функциональные особенности, оптимизация терапии. Киров. 2020.
2561) Редакция. Динамика резистентности *Helicobacter pylori* к компонентам схем эрадикационной терапии. Медицинская практика. 2011.

ЦИТИРАНА: 7M: Boyanova L, Setchanova L, Gergova G, Kostianev T, Yordanov D, Popova C, Kotsilkov K, Mitov I. Microbiological diagnosis of the severe chronic periodontitis. Journal of IMAB- Annual Proceeding (Scientific Papers) 2009; 15, Book 2 (Part Dentistry (Oral and Dental Medicine): 89-94. http://www.journal-imab-bg.org/en/vol-15_book-2.htm **Цитирана от:**

2562) Azaria CS. Efektivitas ekstrak teh hijau dalam menghambat pertumbuhan staphylococcus aereus untuk mencegah risiko meningitis pasca ekstraksi (Laporan Penelitian). SKRIPSI-2015. Universitas Trisakti, Jakarta, 2015.
2563) Azzawi SMHY., Abdul-Rahman GY. The prevalence of anaerobic bacteria in periodontitis in relation to pocket depth.Thesis. University of Mosul. 2010.
2564) Pasaribu F. Test of the effectiveness of liny orange leather extract (*Citrus aurantifolia* (Chrism.) Swingle) against some bacterial pathogen periodontal in vitro/ Uji efektivitas ekstrak kulit jeruk nipis (*Citrus aurantifolia* (Chrism.) Swingle) terhadap beberapa bakteri patogen periodontal secara in vitro. Universitas Sumatera Utara. Medan. 2017.
2565) Pattar VS. To assess and compare the role of dental plaque as a reservoir for respiratory pathogens in causing ventilator associated pneumonia- a case –control study. Dissertation. KLE unversity, Bekgaum, Karnataka. 2012.

ЦИТИРАНА: 39A: **Boyanova L,** Mitov I. Geographic map and evolution of primary *Helicobacter pylori* resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010; **8**(1):59-70. **Цитирана от:**

2566) Alvarado Huertas LV, Bustos Fuentes SM. Identificación de *Helicobacter pylori* en aguas residuales del rio Arzobispo (Bachelor's thesis). Pontificia universidad Javeriana Facultad de ciencias carrera de microbiología industrial. Bogota, 2013.
2567) Arce Gómez, Angy Vanessa. Infección por *Helicobacter pylori* y la relación con el perfil lipídico. Bachelor's thesis, Universidad Técnica de Ambato-Facultad de Ciencias de la Salud-Carrera Laboratorio Clínico, 2016.
2568) Becerra Becerra NZ. Prevalencia y mecanismos de resistencia de *Helicobacter pylori* a fluoroquinolonas y las mutaciones relacionadas. Revisión sistemática de la literatura. (tesis) 2011.
2569) Guevara Guevara PA. Resistencia de *Helicobacter pylori* a furazolidona mediada por le Gen porD. Pontificia Universidad Javeriana. Facultad de Ciencias. Trabajos de Grado Ciencias. 2014.
2570) Mathias F. Synthèse et évaluation biologique de nouveaux nitroimidazoles: challenges et recherche de nouvelles relations structure-activité (Doctoral dissertation, Aix-Marseille). 2017.
2571) Miendje Deyi V-Y. Contribution au management de l'infection à *Helicobacter pylori* en Belgique Doctorat en Sciences biomédicales et pharmaceutiques. Universite libre de Bruxelles. Faculte de pharmacie. Bruxelles, Belgique. 2011.
2572) Nikić S. Utjecaj antibiotske rezistencije *Helicobacter pylori* na postojeće eradikacijske metode. Impact of antibiotic resistance on existing *Helicobacter pylori* eradication methods.Diplomski Rad. Zagreb, Farmaceutsko-biokemijski fakultet.2015.
2573) Njume C. Phytochemical analysis and bioactivity of selected South African medicinal plants on clinical isolates of *Helicobacter pylori*. thesis. Department of Biochemistry and Microbiology, Faculty of Science and Agriculture, University of Fort Hare. 2012.
2574) Ontsira Ngoyi EN. Resistance de *Helicobacter pylori* aux antibiotiques et d'autres substances antimicrobiennes. Aspects moleculaires des mecanismes de detection. L'Université de Bordeaux, France. 2016.
2575) Ponce C, Luis J, Gómez A, Vanessa A. Infección por *Helicobacter pylori* y la relación con el perfil lipídico. Repositorio Universidad Técnica de Ambato. Ambato – Ecuador. 2016:
2576) Williams KF. Investigating the effect of antibiotic exposure on the prevalence of antibiotic-resistant *H. pylori* infection and the incidence of anti-*H. pylori* treatment failure in Northern Canadian communities. PhD diss., University of Alberta, 2016.
2577) Μήταρη, Ερμιόνη Ι. [Internal *Helicobacter pylori* transmission study in Epirus (Doctoral thesis)]Μελέτη ενδοοικογενειακής μετάδοσης ελικοβακτηριδίου του πυλωρού στην Ήπειρο (Doctoral thesis). ΙΩΑΝΝΙΝΑ 2016.

ЦИТИРАНА: 40A: **Boyanova L,** Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, Panteleeva E, Spasova Z, Mitov I. Two-decade trends in primary *H. pylori* resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010; **67**: 319-326. **Цитирана от:**

2578) Miendje Deyi V-Y. Contribution au management de l'infection à *Helicobacter pylori* en Belgique Doctorat en Sciences biomédicales et pharmaceutiques. Universite libre de Bruxelles. Faculte de pharmacie. Bruxelles, Belgique. 2011.
2579) Mourad-Baars PEC. Antibiotic resistance of *Helicobacter pylori* in the Netherlands. *Helicobacter pylori* in childhood : aspects of prevalence, diagnosis and treatment. Leiden University dissertation. 2012.
2580) Williams KF. Investigating the effect of antibiotic exposure on the prevalence of antibiotic-resistant *H. pylori* infection and the incidence of anti-*H. pylori* treatment failure in Northern Canadian communities. PhD diss., University of Alberta, 2016.
2581) Μήταρη, Ερμιόνη Ι. [Internal *Helicobacter pylori* transmission study in Epirus (Doctoral thesis)]Μελέτη ενδοοικογενειακής μετάδοσης ελικοβακτηριδίου του πυλωρού στην Ήπειρο (Doctoral thesis). ΙΩΑΝΝΙΝΑ 2016

ЦИТИРАНА: 41A: **Boyanova L,** Yordanov D, Gergova G, Markovska R, Mitov I. Association of *iceA* and *babA* genotypes in *Helicobacter pylori* strains with patient and strain characteristics. Antonie Van Leeuwenhoek. 2010; **98** (3):343-350. **Цитирана от:**

2582) Delgado Arcentales, F. R. Comparación de genes de virulencia entre *helicobacter pylori* y otras especies de Helicobacter en pacientes ecuatorianos (Master's thesis, Quito). 2018.
2583) Вшивков, В. А. Распространенность, клиническое течение синдрома диспепсии и характеристика ассоциированной с ним гастродуоденальной патологии у школьников Тывы (Doctoral dissertation, ГОУВПО" Красноярская государственная медицинская академия"). 2013.
2584) Нехаєнко, М. І. Клініко-патогенетичне обґрунтування диференційованої терапії хронічних гастродуоденітів у підлітків. Kiiv, 2018.

ЦИТИРАНА: 42A: Boyanova L, Kolarov R, Gergova G, Dimitrova L, Mitov I. Trends in antibiotic resistance in *Prevotella* species from patients of the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in 2003-2009. Anaerobe. 2010; **16**(5): 489-492. **Цитирана от:**

2585) Binta, B. N. The prevalence of B-lactamase-producing anaerobic oral bacteria and the genes responsible for this enzyme production in patients with chronic periodontitis (Doctoral dissertation). 2014.
2586) Diaztagle Cadena, B. V., & Muñoz Gamboa, L. M. Prevalencia de los genes de resistencia antibiótica cfxA, cfxA2, blaTEM, tetM, tetQ y ermF en aislamientos orales de Prevotella melaninogenica. Bogotá DC.2019

2587) Carey DE. The role of household antimicrobials in the proliferation of antibiotic resistance during anaerobic digestion. 2016. Dissertations (2009). Paper 639. Marquette University, Milwaukee, Wisconsin.
2588) Lloreda Rey LP. Efecto antibacteriano de una nanoemulsión de ftalocianina de aluminio clorada sobre periodontopatógenos relevantes en el paciente diabético tipo 2: Estudio in vitro. (Trabajo de grado - Maestría) Universidad de Santander, 2019.
2589) Regnault, L. Comparaison de la sensibilité aux antibiotiques des bactéries anaérobies isolées d'hémocultures au CHU de Nancy en 2010 et en 2014 (Doctoral dissertation, Université de Lorraine). 2015.
2590) Wikstén EJ. Peritonsillar Abscess-Aetiology, Diagnostics and Treatment. University of Helsinki, Faculty of medicine, Institute of Clinical Medicine, Doctoral dissertation. 2016.

ЦИТИРАНА: 43A: Medeiros JA, Gonçalves TM, **Boyanova L**, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM. Evaluation of *Helicobacter pylori* eradication by triple therapy plus *Lactobacillus acidophilus* compared to triple therapy alone. Eur J Clin Microbiol Infect Dis. 2011; **30** (4):555-559. **Цитирана от:**

2591) Zhao Q. An immobilised cell system for the delivery of functional *Lactobacillus reuteri* DPC16 cells to their target site in a simulated gastrointestinal tract : PhD thesis. Massey University, Albany, New Zealand. 2012.

ЦИТИРАНА: 44A: Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I. Benefits of *Helicobacter pylori cagE* genotyping in addition to *cagA* genotyping. A Bulgarian study. Antonie Van Leeuwenhoek. 2011; **100**(4):529-35. **Цитирана от:**

2592) Borjabad, A. C. Trabajo Fin de Máster. Galleria mellonella como modelo animal de la infección por *Helicobacter pylori* y para estudios de eficacia preclínica de nuevos antimicrobianos frente a este patógeno. Universidad Zaragoza. 2020
2593) Da Silva Costa Maia KC. Marcadores de virulência do *Helicobacter pylori* em crianças e adolescentes residentes em uma comunidade de Fortaleza.. Dissertation. Universidade Federal do Ceará. Fortaleza, 2015.

ЦИТИРАНА: 45A: Boyanova L. Role of *Helicobacter pylori* virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiol. 2011; **6**(8): 843-846. **Цитирана от:**

2594) Radovanović Spurnić AP. Ispitivanje epidemioloških, kliničkih i patohistoloških specifičnosti infekcije izazvane bakterijom *Helicobacter pylori* kod osoba inficiranim virusom humane imunodeficijencije (Doctoral dissertation, Univerzitet u Beogradu-Medicinski fakultet). Beograd, 2017.
2595) Нехаєнко, М. І. Клініко-патогенетичне обґрунтування диференційованої терапії хронічних гастродуоденітів у підлітків. Kiiv, 2018.

ЦИТИРАНА: 46A: Markovska R, **Boyanova L**, Yordanov D, Gergova G, Mitov I. *Helicobacter pylori oipA* genetic diversity and its associations with both disease and *cagA*, *vacA* s, m and i alleles among Bulgarian patients. Diagn Microbiol Infect Dis. 2011; **71**(4):335-340. **Цитирана от:**

2596) Leslie, K. A. (2013). Investigation of Prophage in Clinical Isolates of H pylori. Thesis.The College of William and Mary. 2013.
2597) Skoog E. *Helicobacter* spp. interactions with mucins: adhesion and mucin regulation of pathogen proliferation and gene expression. University of Gothenburg. Sahlgrenska Academy. Doctoral thesis. 2014.

ЦИТИРАНА: 47A: Boyanova L, Mitov I. Coadministration of probiotics with antibiotics: why, when and for how long? Expert Rev Anti Infect Ther. 2012; **10**(4):407-409. **Цитирана от:**

2598) Martz SL. Modulating the gut microbiota with a synthetic stool "MET-1": protective effects in animal models of antibiotic associated colitis (Doctoral dissertation). 2013.

ЦИТИРАНА: 48A: Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for *Helicobacter pylori* antibiotic resistance revealed by extended anamnesis. A Bulgarian study. J Med Microbiol. 2012; **61**(Pt 1):85-93. **Цитирана от:**

2599) Morilla Morilla A. Epidemiología, diagnóstico molecular y estudio de resistencias de *Helicobacter pylori*. Universidad de Oviedo. 2018.
2600) Rodríguez-Batllori Aran L. Detección y cuantificación de patógenos periodontales en pacientes con gingivitis mediante el uso de técnicas moleculares. Máster de Ciencias Odontológicas Universidad Complutense de Madrid. 2016.
2601) Solís AS. Factores de virulencia, aspectos Inmunológicos y patrones de sensibilidad en aislamientos clínicos de *Helicobacter pylori*. Tesis Doctoral. Universidad Complutense de Madrid, 217p. Madrid, 2012.
2602) Williams KF. Investigating the effect of antibiotic exposure on the prevalence of antibiotic-resistant *H. pylori* infection and the incidence of anti-*H. pylori* treatment failure in Northern Canadian communities. PhD diss., University of Alberta, 2016.

ЦИТИРАНА: 50A: Yordanov D, Boyanova L, Markovska R, Gergova G, Mitov I. Significance of *Helicobacter pylori vacA* intermediate region genotyping—a Bulgarian study, Diagn Microbiol Infect Dis 2012; **74**(3):253-257. **Цитирана от:**

2603) Chong A. Examining whether *Helicobacter pylori* has a causal effect on cardiovascular disease and cancer. (thesis).University of Bristol. 2019.
2604) González-Rivera C. Structure and function of the *Helicobacter pylori vacA* P33 domain. Dissertation for PhD. Nashville, Tennessee. 2013.
2605) Stepanian Rozo, J. Análisis de genómica comparativa en aislamientos colombianos de *Helicobacter pylori*: enfoque asociado a virulencia, resistencia antibiótica y estructura poblacional. Bogotá Noviembre, 2020.

ЦИТИРАНА: 51A: Boyanova L, Mitov I. Antibiotic resistance rates in causative agents of infections in diabetic patients. Rising concerns. Expert Rev. Anti Infect. Ther. 2013; **11** (4): 411-420. **Цитирана от:**

2606) Mendes JJ. Topical bacteriophage therapy of the infected diabetic foot. Doutoramento em Medicina. Faculdade de Medicina da Universidade de Lisboa. 2014.
2607) Mottola C. Virulence characterization and antimicrobial resistance of major bacterial genera from diabetic foot infections. Universidade de Lisboa. 2017.
2608) Tebarek Lega. Bacterial uropathogens and their drug resistance pattern in diabetic patients attending Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia. Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University. Degree of Master of Sciences. 2015:

2609) Yilma S. Assessment of knowledge, attitude and intention to use long acting and permanenet contraceptive methods among women in hiv chronic care,Addis Abeba, Ethiopia. College of Health Sciences School of Public Health. Diss. Addis Ababa University, 2016.

ЦИТИРАНА: 53A:Boyanova L, Panov V, Yordanov D, Gergova G, Mitov I. Characterization of oral *Helicobacter pylori* strain by 4 methods. Diagn Microbiol Infect Dis 2013; **77** (4): 287-288. **Цитирана от:**

2610) Dawson EM. The characterisation of dynamin-like proteins in the gastric pathogen *Helicobacter pylori* (Doctoral dissertation). University of Technology Sydney, Australia. 2018**.**

2611) Veiga NJ. Epidemiology of Dental Caries. From prevention to the relationship with *Helicobacter pylori* infection. PhD thesis. Universidade Da Beira Interior, Covilhã, julho 2015.

ЦИТИРАНА: 55A: Boyanova L. Comparative evaluation of the activity of plant infusions against *Helicobacter pylori* strains by three methods. World J Microbiol Biotechnol. 2014; **30** (5):1633-1637. **Цитирана от:**

2612) Andrews HE, Carvajal ZY, Márquez EG. Avances en la seguridad y actividad biológica de sustancias bioactivas y probióticos. 2017.

2613) Dube P. The antimicrobial and associated antioxidant activity of rooibos (*Aspalathus linearis*) and honeybush (*Cyclopia intermedia*) herbal teas. Dissertation for the degree Master of Technology. Cape Peninsula University of Technology.Bellville. 2015.

ЦИТИРАНА: 56A:Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I. *Helicobacter pylori* susceptibility to fosfomycin, rifampin and five usual antibiotics for *H. pylori* eradication. Diagn Microbiol Infect Dis 2014; **79**:358–361 **Цитирана от:**

2614) Kuffour EO. The unending war between HIV and the intrinsic innate and adaptive immune system: dissecting the role of USP18 (UBP43) and *H. pylori* coinfection. Heinrich Heine University Düsseldorf, Düsseldorf. 2019.

2615) Samson M. Analysis of antibacterial activity of *Terminalia sericea* and *Combretum imberbe* two combretaceae species from Namibia. TheE University of Namibia. 2019.

2616) Williams KF. Investigating the effect of antibiotic exposure on the prevalence of antibiotic-resistant *H. pylori* infection and the incidence of anti-*H. pylori* treatment failure in Northern Canadian communities. PhD diss., University of Alberta, 2016.

ЦИТИРАНА: 58A: Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015, **31**: 4-10. **Цитирана от:**

2617) Cherkaoui, A. Imipenem Heteroresistance in Nontypeable *Haemophilus influenzae* (Doctoral dissertation, University of Geneva). 2019.

2618) Foth F. Grundlegende Untersuchungen zum Implant Directed-Magnetic-Drug-Targeting und zu seinem möglichen, zukünftigen Einsatz bei der Behandlung von Implantat-assoziierten-Infektionen in der orthopädischen Chirurgie. Inaugural – Dissertation. Dr. med. vet. Hannover 2014.

2619) Guet-Revillet H. Métagénomique bactérienne de l'hidrosadénite suppurée (Doctoral dissertation, Paris 5). file:///C:/Users/07012017/Downloads/vd_guet-revillet_helene%20(2).pdf

2620) Litterio BM. Detección del determinante genético (*cfiA*) de la resistencia a carbapenems y su entorno molecular en aislamientos clínicos de bacilos gram negativos anaerobios 2016. (Doctoral dissertation, Universidad de Buenos Aires).

2621) Plach M. Evolution of substrate specificity and protein-protein interactions in three enzyme superfamilies. fakultät für biologie und vorklinische medizin der Universität Regensburg. 2017.

2622) Regnault L. Comparaison de la sensibilité aux antibiotiques des bactéries anaérobies isolées d'hémocultures au CHU de Nancy en 2010 et en 2014. (Doctoral dissertation, Université de Lorraine). 2015.

2623) Urbán E. Klinikailag fontos humán patogén anaerob baktériumok diagnosztikája és antibiotikum rezisztencia vizsgálata (Doctoral dissertation, SZTE ÁOK). 2020.

2624) Wirsing T. Untersuchung des in-vitro Resistenzverhaltens parodontalpathogener Keime gegenüber Amoxicillin, Metronidazol und Clindamycin (Doctoral dissertation). 2019.

ЦИТИРАНА: 59A: Boyanova L. Susceptibility of anaerobes to fusidic acid and fosfomycin. Int J Antimicrob Agents. 2015; 45(5):560-561. **Цитирана от:**

2625) Popović J. Fosfomicin u liječenju infekcija uzrokovanih višestruko otpornim bakterijama (Doctoral dissertation, University of Zagreb. School of Medicine. Chair of Infectious Diseases). 2018.

ЦИТИРАНА: 60A: Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. Diagn Microbiol Infect Dis 2015; **82**(1):85-86. **Цитирана от:**

2626) Popović, Josipa. Fosfomicin u liječenju infekcija uzrokovanih višestruko otpornim bakterijama. Diss. University of Zagreb. School of Medicine. Chair of Infectious Diseases., 2018.

ЦИТИРАНА: 62A: Kotsilkov K ,Popova C , **Boyanova L** , Setchanova L , Mitov I. Comparison of culture method and real-time PCR for detection of putative periodontopathogenic bacteria in deep periodontal pockets. Biotechnol. Biotechnol. Equip. 2015; doi**:** 10.1080/13102818.2015.1058188 http://www.tandfonline.com/doi/abs/10.1080/13102818.2015.1058188#.Vco9c_ntmko **Цитирана от:**

2627) Ambrosio Elejalde, N. Bacteriemias de origen periodontal: validación de técnicas microbiológicas. Madrid, 2020

2628) Fernandes LS. Climate change impact on agricultural practices: reuse of municipal reclaimed water and treated greywaterand respective implications for crop irrigation and human health. Thesis for Master of Science Degree. Biological Engineering, Universidade de Lisboa.. 2019.

2629) Herrera González, D. Efecto de unas membranas nanoestructuradas, cargadas o no con doxicilina, para la liberación controlada de fármacos, en un modelo de biofilm oral in vitro. Universidad Complutense De Madrid. 2018.

2630) Kannosh IY. Prisustvo oralnih patogenih mikroorganizama u ateromu i trombu pacijenata sa aterosklerozom i infarktom miokarda (Doctoral dissertation, Univerzitet u Beogradu-Biološki fakultet).2020.

2631) Rodríguez-Batllori Aran, L. Detección y cuantificación de patógenos periodontales en pacientes con gingivitis mediante el uso de técnicas moleculares. Universidad Complutense de Madrid. 2016.
2632) Olmeda VO. Efecto de unas membranas nanoestructuradas, cargadas o no con doxiciclina, para la liberación controlada de fármacos, en un modelo de biofilm oral in vitro. Olmeda VO. Efecto de unas membranas nanoestructuradas, cargadas o no con doxiciclina, para la liberación controlada de fármacos, en un modelo de biofilm oral in vitro. Máster en ciencias odontológicas, Universidad Complutense De Madrid, Madrid. 2018.
2633) Ragha Malika, S. Microbial Analysis of red complex organisms of the whole saliva in patients with gingivitis and gingival recession using next generation sequencing (Doctoral dissertation, Ragas Dental College and Hospital, Chennai). 2020.
2634) Rodríguez-Batllori Aran, L. Detección y cuantificación de patógenos periodontales en pacientes con gingivitis mediante el uso de técnicas moleculares. Universidad Complutense de Madrid. 2016.

ЦИТИРАНА: 63A: Markovska R, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015;**123**(10):887-94. **Цитирана от:**

2635) Dias DJ. Assessing antibiotic resistance in Gram negative bacteria from animals and the wider environment. Dissertação para obtenção do Grau de Doutor em Biologia, Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa, 2016.
2636) García MH. Colonización por enterobacterias productoras de carbapenamasas durante el proyecto europeo R-GNOSIS: epidemiología, estructura poblacional y caracterización molecular (Doctoral dissertation, Universidad Complutense de Madrid). 2018.
2637) Mouftah Ali SFM. The role of plasmids and clones in the emergence of carbapenem resistant enterobacteriaceae in the United Arab Emirates. Dissertations. 90. 2019.

ЦИТИРАНА 64A. Markovska R, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015; 123(10):887-894. **Цитирана от**:

2638) Yousfi H. Developpment de nouvelles strategies therapeutiques pour pallier l'emergence de la resistance aux antibiotiques. These de dotorat (Maladies infectieuses). AIX-Marseille Universite. 2019.

ЦИТИРАНА: 65A: Boyanova L, Evstatiev I**, Gergova G, Yaneva P**, Mitov I. Linezolid susceptibility *in Helicobacter pylori*, including strains with multidrug resistance. Int J Antimicrob Agents. 2015;**46**(6):703-706. **Цитирана от:**

2639) Popović J. Fosfomicin u liječenju infekcija uzrokovanih višestruko otpornim bakterijama. Master's thesis Zagreb, 2018.

ЦИТИРАНА: 67A: Boyanova L, Markovska R, Yordanov D, Gergova G, Mitov I. Clarithromycin resistance mutations in *Helicobacter pylori* in association with virulence factors and antibiotic susceptibility of the strains. Microb Drug Resist. 2016;**22**(3):227-232. **Цитирана от:**

2640) Tiago Gomes da Silva Benigno. Resistência genotípica primária Do *H. pylori* à claritromicina e associação com genótipos de virulência do *H. pylori* no nordeste do Brasil. Universidade Federal Do Ceará, Fortaleza, 2020.
2641) Савилова ИВ. Возможности персонификации антихеликобактерной терапии. (доктор наук) 2021.

ЦИТИРАНА: 68A:Boyanova L, Ilieva J, Gergova G, Mitov I. Levofloxacin susceptibility testing against *Helicobacter pylori*: evaluation of a modified disk diffusion method compared to E test. Diagn Microbiol Infect Dis. 2016; **84**(1):55-56.**Цитирана от:**

2642) Arévalo Granda JV. Genotipificación de *Klebsiella pneumoniae* mediante el análisis de secuencias de Locus Múltiples (MLST) en una colección de aislados clínicos provenientes de infecciones sistémicas de dos hospitales de referencia del Ecuador. Bachelor's thesis, Universidad de las Fuerzas Armada ESPE. Carrera de Ingeniería en Biotecnología., 2018.
2643) Otero LL. Características del microbioma gástrico e intestinal en relación al estado de *Helicobacter pylori* en una población pediátrica (Doctoral dissertation, Universidad Complutense de Madrid). Madrid, 2017.
2644) Wilkinson, D. J. High throughput genomic analysis of *Helicobacter pylori* within-host diversity (Doctoral dissertation, Nottingham Trent University). 2019.
2645) Савилова ИВ. Возможности персонификации антихеликобактерной терапии. (доктор наук) 2021.

ЦИТИРАНА: 71B: Marteva-Proevska Y, Velinov T, Markovska R, DobrikovaD, Pavlov I, **Boyanova L**, Mitov I. Antibiotic combinations with colistin against carbapenem-resistant *Klebsiella pneumoniae* - in vitro assessment. J of IMAB. 2018;**24**(4):2258-2266. DOI: 10.5272/jimab.2018244.2258. **Цитирана от:**

2646) De Souza RC. Caracterização fenotípica e molecular dos mecanismos de resistência aos beta-lactâmicos em linhagens clínicas de *Klebsiella pneumoniae* isoladas do Amazonas. São Carlos – SP. 2018.

ЦИТИРАНА 72A: Markovska R, Stoeva T, **Boyanova L**, Stankova P, Pencheva D, Kaneva R, Mitev V, Mitov I. Isolation of *Escherichia coli* ST131 producing KPC-2 in Bulgaria. Infect Dis (Lond). 2017; **49**(5): 429-431. **Цитирана от:**

2647) Duprilot M. Étude comparative du clade émergent de Escherichia coli ST131 O25b H4 de son clade progéniteur: fitness in vitro et in vivo et formation de biofilm (Doctoral dissertation, Université de Paris). 2019.

ЦИТИРАНА 73A: Boyanova L. Stress hormone epinephrine (adrenaline) and norepinephrine (noradrenaline) effects on the anaerobic bacteria. Anaerobe. 2017; **44**:13-19. **Цитирана от:**

2648) Azad A. The role of catecholamines in human chronic wounds. 2018.
2649) Gannesen A. "Structure et composition de biofilms mono-et multispécies de bactéries cutanées et environnementales: effets des cosmétiques et de certains autres composés biologiquement actifs." PhD diss., Normandie, 2018.
2650) Kuntzel L. Troubled love: The downside of love and possible ways to fix it (Doctoral dissertation). 2019.
2651) Otero LL. Características del microbioma gástrico e intestinal en relación al estado de *Helicobacter pylori* en una población pediátrica. Tesis doctoral. Universidad Complutense de Madrid; 2017.
2652) Volgers C. Beyond communication: membrane vesicle release during macrophage infection by common respiratory pathogens. Maastricht University. 2017:

ЦИТИРАНА: 75A. Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. Diagn Microbiol Infect Dis. 2017; 88(3): 264-267.

2653) Buitrago Gómez, M. A., Díaz Ramírez, L., & Mejía Romero, M. Comparación de la concordancia entre métodos para la detección de la resistencia en aislamientos de Helicabacter pylori (Doctoral dissertation, Universidad Libre Seccional Pereira). 2018.

2654) Meincheim, I. Taxa de erradicação do *Helicobacter pylori* e fatores associados em indivíduos de uma clínica do município de Florianópolis. Medicina-Pedra Branca. Universidade do Sul de Santa Catarina. 2018.

ЦИТИРАНА: 76A. Markovska R, Stoeva T, **Boyanova L**, Stankova P, Pencheva D, Keuleyan E, Murjeva M, Sredkova M, Ivanova D, Lazarova G, Nedelcheva G, Kaneva R, Mitov I. Dissemination of successful international clone ST15 and clonal complex 17 among Bulgarian CTX-M-15 producing K. pneumoniae isolates. Diagn Microbiol Infect Dis. 2017; 89(4):310-313.

2655) Davies YM. Virulência e resistência aos antimicrobianos de *Klebsiella* spp isoladas de psitacídeos com doença respiratória (Doctoral dissertation, Universidade de São Paulo). 2018.

2656) Mouftah Ali SFM. The role of plasmids and clones in the emergence of carbapenem resistant *Enterobacteriaceae* in the United Arab Emirates. Dissertations. 90. 2019.

ЦИТИРАНА:77A: Boyanova L, Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. Lett Appl Microbiol. 2017;**65**(6):469-474.doi: 10.1111/lam.12807

2657) Oyeniran, Ayowole Caleb. A Modified RCM medium for the growth of *Lactobacillus bulgaricus*. PhD Thesis. North Carolina Agricultural and Technical State University.2019.

ЦИТИРАНА:78A: Boyanova L. Direct Gram staining and its various benefits in the diagnosis of bacterial infections. Postgrad Med. 2018;**130**(1):105-110. doi: 10.1080/00325481.2018.1398049.

2658) Guzmán Hernández, X. Características de la microbiota cultivable de la piel de *Ambystoma ordinarium* en cautiverio. Universidad Michoacana de San Nicolas de Hidalgo. 2020.

ЦИТИРАНА: 79A: Markovska R, **Boyanova L**, Yordanov D, Stankova P, Gergova G, Mitov I. Status of *Helicobacter pylori cag* pathogenicity island (*cag*PAI) integrity and significance of its individual genes. Infect Genet Evol. 2018;**59**: 167-171..

2659) Wilkinson DJ. High throughput genomic analysis of *Helicobacter pylori* within-host diversity (Doctoral dissertation, Nottingham Trent University). 2019.

ЦИТИРАНА:80A: Nagy E, **Boyanova L**, Justesen US; ESCMID Study Group of Anaerobic Infections. How to isolate, identify and determine antimicrobial susceptibility of anaerobic bacteria in routine laboratories? Clin Microbiol Infect. 2018;**24**(11):1139-1148. doi: 10.1016/j.cmi.2018.02.008.

2660) Collij V. The gut microbiota and inflammatory bowel disease: From exploration to clinical translation. Thesis. University of Groningen. 2021. https://doi.org/10.33612/diss.150928851

2661) Никольский, В. И. Современные тенденции в диагностике и лечении больных острыми гнойно-воспалительными заболеваниями параректальной клетчатки. 2020.

ЦИТИРАНА 86A: Markovska R, Stoeva T, Boyanova L, Stankova P, Schneider I, Keuleyan E, Mihova K, Murdjeva M, Sredkova M, Lesseva M, Nedelcheva G, Petrova A, Ivanova D, Lazarova G, Kaneva R, Mitov I. Multicentre investigation of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing *K. pneumoniae*. Infect Genet Evol. 2019; 69:61-67. **Цитирана от:**

2662) Mahon, B. The role of the aquatic environment in the spread of antimicrobial resistance of public health significance (Doctoral dissertation, NUI Galway). 2020.

ЦИТИРАНА 92A: Boyanova L, Markovska R, Mitov I. Multidrug resistance in anaerobes. FutureMicrobiol. 2019; 14(12):1055–1064.. **Цитирана от:**

2663) George S. Evaluation of the prevalence and transmission of asymptomatic *Clostridioides difficile* Carriage in the Hamilton In-patient setting using multi-level modelling. PhD Thesis. 2020.

ЦИТИРАНА: 16M: Boyanova L. *H. pylori* resistance to antibiotics. In *Helicobacter pylori*. Boyanova L. (ed.) Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011: 201-235.

2664) Adebisi AO. Design of gastro-retentive systems for the eradication of *Helicobacter pylori* infections in the treatment of peptic ulcer. Doctoral thesis, University of Huddersfield. 2014.

ЦИТИРАНА 11-17M: Boyanova, L., Mitov, I. & Vladimirov, B., 2011. Boyanova L. (ed.) *Helicobacter pylori*. Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011. **Цитирана от:**

2665) Awad LG. Detection of *Helicobacter* species in chronic liver diseases and chronic inflammatory bowel diseases in human and calves. Thesis for the degree of Master of Veterinary Medical Science. Zagazig University. 2011.

2666) Bhimani DR. Design and development of stomach site specific drug system against *Helicobacter pylori* infections.PhD dissertation. Ganpat University, Ganpat Vidyanagar, India. 2013.

2667) Breckan RK. *Helicobacter pylori* infection in the 21st century Epidemiology, transmission and clinical aspects. A dissertation for the degree of PhD. The ArcticUniversity of Norway. 2016.

2668) Chávez MJX. Prevalencia de la infección activa por *Helicobacter pylori* en los expendedores callejeros de alimentos de Champerico y El Asintal, Retalhuleu. Química Bióloga. Universidad de San Carlos de Guatemala, Guatemala, 2018.

2669) Henriksson S. *Helicobacter pylori* – multitalented adaptation of binding properties. Thesis. Department of Medical Biochemistry and Biophysics, Umeå, Sweden 2012.

2670) Hsu C-W. Effect of Lactic Acid Bacteria-fermented Sake Lees on Activating CYP2E1 Activity and Scavenging ROS in HepG2 Cell. E-Thesis dissertation system. TaTung University Library. 2011.

2671) Huamaní Cárdenas CA, Sánchez Paredes JL. Seroprevalencia de *Helicobacter pylori* y factores asociados en escolares de la Institución Educativa N.o 0026 Ate (Lima) en diciembre de 2011. Universidad Wiener, Lima-Perú, 2013.

2672) Javed S. Effect of *Helicobacter* gamma-glutamyl transpeptidase on epithelial cells. PhD dissertation.Medical faculty, München, 2012.
2673) Na Galipedia, a Wikipedia en galego.
2674) Raza Y. *Helicobacter pylori* infection and host genetic factors in human gastric carcinoma. PhD thesis, University of Karachi, Karachi. 2015.
2675) Soares ARP. Codeteção de *Helicobacter pullorum* e *Campylobacter* spp. em materiais de origem avícola. Universidade De Lisboa, Faculdade de Medicina Veterinária, Lisboa, 2015.
2676) Solomon S. Prevalence of cytotoxin-associated gene A (*cagA*) positive *Helicobacter pylori* among seropositive asymptomatic children attending Kenyatta National Hospital, Nairobi, Kenya. The University of Nairobi. 2014.
2677) Vermoote M. An exploratory study of *Helicobacter suis* control strategies. Ghent University, Faculty of Veterinary Medicine, 2013.
2678) Wasimuddin. Genetic variation of selected pathogens in the house mouse hybrid zone. Masaryk University, Thesis, Academy of Sciences of the Czech Republic, Brno, 2014.
2679) Yasir R. *Helicobacter pylori* infection and host genetic factors in human gastric carcinoma (Doctoral dissertation, University Of Karachi, Karachi). 2012.
2680) Баасансүрэн Д. Gastric muscle disorders, *Helicobacter pylori* bacteria *baba2* gene relationship research results/ салстын эмгэг өөрчлөлт, *Helicobacter pylori* нянгийн *baba2* генийн хамаарлыг судалсан дүн. Улаанбаатар хот. 2012

ЦИТИРАНА 49B: McNicholl AG, Tepes B, Gasbarrini A, **Boyanova L**, Leja M, Lerang F, Rokkas T, Kupcinskas L, Przytulski K, Katicic M, Machado JC. **Su1173** Pan-European Registry on *H. pylori* Management: Interim Analysis. Gastroenterology. 2014;**146**(5):S-395. **Цитирана от:**

2681) Налетов, А. В. Хроническая гастродуоденальная патология, ассоциированная с *Helicobacter pylori* у детей: особенности патогенеза, диагностика, лечение (Doctoral dissertation. Донецкий национальный медицинский университет им. М. Горького, Донецк). 2017.

ЦИТИРАНА 51B. McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskas L, Perez-Aisa A, Axon T, Buzas GM, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, **Boyanova L,** Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Huerta A, Perez-Lasala J, Caldas M, Ramas M, Megraud F, O'Morain CA, Gisbert JP. Pan-European Registry on *H. pylori* Management (HP-EuReg): **Bacterial Resistance**. XXVIIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Nicosia, Cyprus, September 24–26, 2015. Gastroenterology, 2015; **148**(4): S-417.. **Цитирана от:**

2682) Márquez Morales FA. *Helicobacter pylori*: La historia de una bacteria muy peculiar. Trabajo Fin de Máster. Universidad de Sevilla. 2019.

<u>В БЪЛГАРСКИ СПИСАНИЯ:</u>

ЦИТИРАНА: Боянова Л. *Helicobacter pylori* в гастродуоденалната патология- микробиологични проучвания и връзка с терапевтичния подход. Дисертация за получаване н. ст. "доктор". СНС по микробиология, вирусология и имунология при ВАК. 1996 г., 233 стр. **Цитирана от:**

2683) Иванова К, Й Чурчев, Б Владимиров, М Марина, И Терзиев. Изолиране на *Helicobacter pylori* и изследване на чувствителността му към различни антимикробни средства. Информационен журнал на НЦЗПБ. 1999; (2):4-7.

ЦИТИРАНА: 4A: Boyanova L, Andreev N, Bouchard S, Megraud F. *Helicobacter pylori* seroprevalence in Bulgaria. Med. Microbiol. Lett. 1994; 3: 107-113**. Цитирана от:**

2684) Ivanova L, Stoeva T. *Helicobacter pylori* colonization status in outpatients with gadtroduodenal diseases. Scripta Scientifica medica. 2005; **37**:19-21.

ЦИТИРАНА: 10A: Boyanova L, Neshev G. Inhibitory effect of rose oil products on *Helicobacter pylori* growth in vitro: preliminary report. J. Med. Microbiol. 1999; **48**: 705-706. **Цитирана от:**

2685) Chobanova S, Penchev IG, Atanasoff A, Ribarski S, Karkelanov N. Chemical composition, technological and organoleptic characteristics of meat from chicken broilers, fed with supplement of rose petal meal. Bulgarian Journal of Agricultural Science. 2019; 25(Suppl. 3), 81-84.

ЦИТИРАНА: 14A: Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in *Helicobacter pylori* in Sofia, Bulgaria. J. Med. Microbiol. 2000; 49: 415–418. **Цитирана от:**

2686) Georgieva-Shakola M., Tzaneva V., Popowa M. Modern therapy of *Helicobacter pylori* infection in childhood. Pediatriya 2000; **40**(4): 34-37.

ЦИТИРАНА: 24A: Boyanova L, Gergova G, Koumanova R, Jelev C, Lazarova E, Mitov I, Kovacheva Y. Risk factors for primary *Helicobacter pylori* resistance in Bulgarian children. J. Med. Microbiol.; 2004; **53** (Pt 9): 911-914. **Цитирана от:**

2687) Стамболийска М. Антибиотична резистентност – нов поглед върху съвременната анти-*Helicobacter pylori* терапия. GP News. 2013; 10: http://gpnews.bg/антибиотична-резистентност-нов-погл/

ЦИТИРАНА: 26A: Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains in vitro by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; **54** (Pt 5):481-483. **Цитирана от:**

2688) Gardjeva PA, Dimitrova SZ, Kostadinov ID, Murdjeva MA, Peyche LP, Lukanov LK, Stanimirova IV, Alexandrov AS. A study of chemical composition and antimicrobial activity of Bulgarian propolis. Folia Med (Plovdiv). 2007; **49**(3-4): 63-69.
2689) Драганова-Филипова М.Н., Ангелова С., Пейчев Л., Сарафян В. Прополисът в медицинската и дентална практики – биологични ефекти. Юбилеен сборник със статии по случай 65 години чуждоезиково обучение, 30 години специализирано обучение за чуждестранни студенти, 10 години департамент за езиково и специализиранообучение в Медицинскияуниверситет –Пловдив. Медицински университет- Пловдив, 2011; стр. 235-243.

ЦИТИРАНА: 27А: **Boyanova L**, Nikolov R, Lazarova E, Gergova G, Katsarov N, Kamburov V, Spassova Z, Derejian S, Jelev C, Mitov I, Krastev Z. Antibacterial resistance in *Helicobacter pylori* strains isolated from Bulgarian children and adult patients over 9 years. J Med Microbiol. 2006; **55**: 65-68. **Цитирана от:**

2690) Стамболийска М. Антибиотична резистентност – нов поглед върху съвременната анти-*Helicobacter pylori* терапия. GP News. 2013; 10: http://gpnews.bg/антибиотична-резистентност-нов-погл/

ЦИТИРАНА: 31А: **Boyanova L**, Lazarova E, Jelev C, Gergova G, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in untreated Bulgarian children over a period of 10 years. J Med Microbiol. 2007; **56**(Pt 8):1081-1085. **Цитирана от:**

2691) Панов В. *Helicobacter pylori* и устната кухина. Дентамедика. 2017; №9: 10-11.

ЦИТИРАНА: 34А: **Boyanova L,** Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of *Helicobacter pylori* resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008; **60(4)**: 409-415. **Цитирана от:**

2692) Панов В, Механджийски Н. Проучване относно наличието на *Helicobacter pylori* при овце. Ветеринарна сбирка 2012 /1; 46-49. http://fliphtml5.com/tivz/fsmh/basic

2693) Стамболийска М. Антибиотична резистентност – нов поглед върху съвременната анти-*Helicobacter pylori* терапия. GP News. 2013; 10: http://gpnews.bg/антибиотична-резистентност-нов-погл/

ЦИТИРАНА: 35А: Boyanova L, Ilieva J, Gergova G, Spassova Z, Nikolov R, Davidkov L, Evstatiev I, Kamburov V, Katsarov N, Mitov I. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58**(1):94-100. **Цитирана от:**

2694) Стамболийска М. Антибиотична резистентност – нов поглед върху съвременната анти-*Helicobacter pylori* терапия. GP News. 2013; 10: http://gpnews.bg/антибиотична-резистентност-нов-погл/

ЦИТИРАНА: 37А: **Boyanova L.** Prevalence of multidrug-resistant *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58** (Pt 7): 930-935.**Цитирана от:**

2695) Стамболийска М. Антибиотична резистентност – нов поглед върху съвременната анти-*Helicobacter pylori* терапия. GP News. 2013; 10: http://gpnews.bg/антибиотична-резистентност-нов-погл/

ЦИТИРАНА: 40А: **Boyanova L,** Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, Panteleeva E, Spasova Z, Mitov I. Two-decade trends in primary *H. pylori* resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010; **67**: 319-326. **Цитирана от:**

2696) Стамболийска М. Антибиотична резистентност – нов поглед върху съвременната анти-*Helicobacter pylori* терапия. GP News. 2013; 10: http://gpnews.bg/антибиотична-резистентност-нов-погл/

ЦИТИРАНА: 47А: Boyanova L, Mitov I. Coadministration of probiotics with antibiotics: why, when and for how long? Expert Rev Anti Infect Ther. 2012; **10**(4):407-409. **Цитирана от:**

2697) Mladenova-Hristova I. The inhibitory effect of genus *Lactobacillus* on *Helicobacter pylori* infection. Trakia Journal of Sciences. 2013;11(4):299-303. http://www.uni-sz.bg/tsj/N4,%20Vol.11,2013/I.Mladenova.pdf

ЦИТИРАНА: 48А: Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for *Helicobacter pylori* antibiotic resistance revealed by extended anamnesis. A Bulgarian study. J Med Microbiol. 2012; **61**(Pt 1):85-93. **Цитирана от:**

2698) Stamboliyska M, Kaludova V, Mirchev M, Kotzev I, Madjov R, Metodiev K. Role and importance of microbiology testing in the diagnosis and treatment of *Helicobacter pylori* infection. J of IMAB 2015; **21**(4):969-973. http://www.journal-imab-bg.org/issues-2015/issue4/vol21issue4p969-973.html

ЦИТИРАНА: 53А: Boyanova L, Panov V, Yordanov D, Gergova G, Mitov I. Characterization of oral *Helicobacter pylori* strain by 4 methods. Diagn Microbiol Infect Dis 2013; **77** (4): 287-288 **Цитирана от:**

2699) Stamboliyska M, Dokova K, Angelova S, Koleva A, Bazitova M. The oral cavity-reservoir of infection with *Helicobacter pylori.* Scripta Scientifica Medicinae Dentalis. 2015; **1**(2): 30-35. http://press.mu-varna.bg/ojs/index.php/ssmd/article/view/1310

2700) Panov V. Oral malodor and *Helicobacter pylori*. InВарненски медицински форум (Varna Medical Forum). 2017; 6(2):131-134.

ЦИТИРАНА: 54А: Markovska R, Schneider I, Stoeva T, Bojkova K, **Boyanova L,** Bauernfeind A, Mitov I. First identification of KPC-2 and VIM-1 producing *Klebsiella pneumoniae* in Bulgaria. Diagn Microbiol Infect Dis. 2013;**77**(3):252-253. **Цитирана от:**

2701) Ivanova K. Carbapenemases-types and detection. Probl Inf Parasit Dis. 2014;**42**(2):9-13.

ЦИТИРАНА: 56А: Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I. *Helicobacter pylori* susceptibility to fosfomycin, rifampin and five usual antibiotics for *H. pylori* eradication. Diagn Microbiol Infect Dis 2014; **79**:358–361. **Цитирана от:**

2702) Българска Академия на Науките. Институт по микробиология "Стефан Ангелов". Отчет за работата на Института по микробиология "Стефан Ангелов" – БАН. 2014, pp. 169Report-IMCB_2014_full.pdf

ЦИТИРАНА: 63А: Markovska R, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015;**123**(10):887-94. **Цитирана от:**

2703) Veselin Dobrinov. Multilocus sequence typing of multi-drug resistant bacteria in the era of whole genome sequencing. Probl. Inf. Parasit. Dis. 2017; 45 (2):11-24.

ЦИТИРАНА: 66А: Boyanova L, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, Markovska R, Mitov I. *Helicobacter pylori* resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infect Dis (Lond). 2016;**48**(1):56-62. **Цитирана от:**

2704) Angelov, I.T., Churchev, S., Valkov, H., (...), Golemanov, B., Vladimirov, B. Advanced diagnosis and treatment of the *Helicobacter pylori* infection. General Medicine. 2020; 22(1): 51-56.

2705) Димитров Д, Гоцева А. Ерадикация на *Helicobacter pylori*. Индикации и терапевтични режими. MedInfo. 2018; 9.

2706) Петров П, Петров Б. Съвременен подход при диагноза и лечение на Хеликобактер пилори инфекцията. Med Post. 2017; III(21): 46-51.

ЦИТИРАНА: 75А. Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. Diagn Microbiol Infect Dis. 2017; 88(3): 264-267. .

2707) Angelov, I.T., Churchev, S., Valkov, H., (...), Golemanov, B., Vladimirov, B. Advanced diagnosis and treatment of the *Helicobacter pylori* infection. General Medicine 2020; 22(1):51-56.

ЦИТИРАНА: 6Б: Боянова Л, Н Андреев, С Бушар, Ф Мегро. Разпространение на инфекцията от *Helicobacter pylori* в София, България. Бълг. мед., 1993, **1** (5/6): 13-16. **Цитирана от:**

2708) Младенова И. Епидемиология на *Helicobacter pylori*-инфекцията. Бълг. мед., 1994; **II**(3/4): 3-6.
2709) Младенова И, И Дукова. Епидемиологични проучвания върху *Helicobacter pylori* в Старозагорски регион. Инфектология. 1995; **XXXII**(2): 15 -17.
2710) Геогиева-Шакола М, М Стамболийска, М Атанасова, Г Върбанов, Е Дянков, И Русева, И Красналиев. Детската възраст начало на инфекцията с *Helicobacter pylori*. Съвр. мед., 1996, **XLVII**(5 -6): 36-39.
2711) Младенова И. Епидемиология на *Helicobacter pylori* в Стара Загора - проучване на възможните рискове за заразяване и начини за предаване на инфекцията. Бълг. мед. 1998, **VI**, (3-4): 30-33.
2712) Петров П. Хеликобактер пилори. Инфектология, 2000; **XXXVII**(1): 3-7.
2713) Спасова З, В Дончев, М Милева, Л Матева. Ултраструктурни промени в лигавицата на стомаха при болни с чернодробна цироза и портална хипертензивна гастропатия. Бълг. Хепато-гастроентерол. 2002; **4**(1): 27-32.
2714) Попов И, Чакърски И, Дженева Х. Инфекция с *Helicobacter pylori* при пациенти с ХБН на хемодиализа. Нефрол., хемодиал. и транспл. 2003; **9**(1): 48-51.

ЦИТИРАНА: 8Б: Куманова Р, **Л. Боянова**. *Helicobacter pylori* причина за заболявания на горните отдели на храносмилателната система в детската възраст. Педиатрия. 1995, (3): 10-13. **Цитирана от:**

2715) Георгиева-Шакола М. Диагностика и лечение на *Helicobacter pylori* инфекция, свързана с гастродуоденални заболявания у деца и юноши. Педиатрия. 1996; (2): 17-21.
2716) Печилкова М, Генов Е, Вълканова З, Тинчева Л, Христозова Е, Хайдушка И, Хубавенска И, Запрянов З. Честотата на *Helicobacter pylori* инфекцията при деца със заболявания на гастродуоденалния сегмент. Педиатрия 1999; (1): 36-38.
2717) Маневска Б, Ив Красналиев, М Георгиева-Шакола. Морфологична диагностика на *Helicobacter pylori* асоциирания гастрит у деца и юноши. Бълг. Мед. 1996 (5/6): 53-55.

ЦИТИРАНА 12Б: Keuleyan E, R. Avramova, S. Barzashka, L. Boyanova, R. Gergova, I. Mitov. Analysis of antibiotic susceptibility in orthopedics and traumatology hospital. Probl. Inf. Parasit. Dis. 1998; 26 (1): 24-27. **Цитирана от:**

2718) Bozhkova, K. Methicillin resistant staphylococci-distribution in clinical specimens and in vitro susceptibility to some antibacterial drugs. Scripta Scientifica Medica, 1999; 31, 115-120.

ЦИТИРАНА: 21Б: Кръстев З, Р Николов, С Дереджян, **Л Боянова**. Азитромицин за ерадикация на *Helicobacter pylori*-пилотно проучване. Българска хепатогастроентерология. 2002; (3): 16-21. **Цитирана от:**

2719) Бързашка Ев, Хр Христов. Ерадикация на *Helicobacter pylori* при деца с язвена болест. Мед. и фармац. 2003; **3**(7-8): 13-14.

ЦИТИРАНА: 30Б: Боянова Л. Ролята на лактобацилите като пробиотици за профилактика, или терапия на *Helicobacter pylori* инфекцията: анализ на резултати от литературата и собствени предварителни проучвания. Съвр мед. 2004; **LV** (No 5): 27-33. **Цитирана от:**

2720) Stamboliyska M, Dokova K, Angelova S, Koleva A, Bazitova M. The oral cavity-reservoir of infection with *Helicobacter pylori.* Scripta Scientifica Medicinae Dentalis. 2015; **1**(2): 30-35. http://press.mu-varna.bg/ojs/index.php/ssmd/article/view/1310
2721) Сираков И, Милашка М, Таков Д, Кацаров Кр. Диагностично- лечебен алгоритъм при *H.pylori*-пози тивни пациенти с пептична язвена болест и/или ГЕРБ. MD. 2013; **X**(2):14-18.

ЦИТИРАНА: 37Б: Боянова, Л., Г. Железова, В. Камбуров, Р. Николов, Е. Лазарова, Г. Гергова, З. Спасова, Н. Кацаров, Хр. Желев, С. Дереджян, И. Митов, З. Кръстев. Проучване на *Helicobacter pylori* инфекцията чрез класически микробиологични методи и фекален антигенен тест. Бълг. Хепато-гастроентерол. 2006; **VIII** (кн. 2):14-19. **Цитирана от:**

2722) Сираков И, Милашка М, Таков Д, Кацаров Кр. Диагностично- лечебен алгоритъм при *H.pylori*-пози тивни пациенти с пептична язвена болест и/или ГЕРБ. MD. 2013; X(2):14-18.

ЦИТИРАНА: 50Б: Боянова Л., Марина М., Кантарджиев Т., Митов И. Диагноза и терпия на *Clostridium difficile* - асоцииранатa болест. Съвр. мед. 2008; 59 (3): 71-80. **Цитирана от:**

2723) Вачева Р. *Clostridium difficile* асоциирана болест-клиничен спектър, съвременни проблеми и мерки за ограничаването й. Мединфо. 2011, XI, 10: 1-6.

ЦИТИРАНА: 51Б: Боянова Л., Марина М., Кантарджиев Т., Митов И. *Clostridium difficile* – асоцииранатa болест – нарастваща тревога след появата на хипервирулентния щам. Съвр. мед. 2008; 59 (4): 70-78. **Цитирана от:**

2724) Вачева Р. *Clostridium difficile* асоциирана болест-клиничен спектър, съвременни проблеми и мерки за ограничаването й. Мединфо. 2011, XI, 10:1-6.

ЦИТИРАНА: 7В: Boyanova, L, Mitova R, Pehlivanov N, Petrov S. Bacteriological study of *Helicobacter pylori* and the effect of *Lactobacillus bulgaricus* on *Helicobacter pylori* growth. Preliminary report. Cs. Gastroenterol. Vyz., 1993, **47**(2): 10 (poster). Workshop *Helicobacter pylori* and the new concepts in gastroduodenal diseases. October 30-31, 1992, Prague, Czechoslovakia. **Цитирана от:**

2725) Младенова И. Млечнокиселите бактерии и инфекцията с *H. pylori*. Бълг. Мед., 2002 (6): 18-19.
2726) Младенова- Христова И. Сравнение между две географски зони с различна консумация на кисело мляко с оглед на разпространението на гастродуоденалните заболявания, свързани с *H. pylori*. Сборник доклади от Научната конференция с международно участие на СУБ "Стара Загора 2002", 6-7.06. 2002, **3**:206-208.

2727) Mladenova I. Is there a preventive effect of *Lactobacillus bulgaricus* in yoghurt to the clinical outcome of *H.pylori* infection? Probl Inf and Paras Dis. 2004,**1,** 21-22.

ЦИТИРАНА: 54Б: Боянова Л. Диагностични методи за *Helicobacter pylori* инфекцията. Съвр. мед. 2009; **60** (1-2): 5-14. **Цитирана от:**

2728) Stamboliyska M, Kaludova V, Mirchev M, Kotzev I, Madjov R, Metodiev K. Role and importance of microbiology testing in the diagnosis and treatment of *Helicobacter pylori* infection. J of IMAB 2015;**21**(4):969-973. http://www.journal-imab-bg.org/issues-2015/issue4/vol21issue4p969-973.html

ЦИТИРАНА: 7М: Boyanova L, Setchanova L, Gergova G, Kostianev T, Yordanov D, Popova C, Kotsilkov K, Mitov I. Microbiological diagnosis of the severe chronic periodontitis. Journal of IMAB- Annual Proceeding (Scientific Papers) 2009; 15, Book 2 (Part Dentistry (Oral and Dental Medicine): 89-94. http://www.journal-imab-bg.org/en/vol-15_book-2.htm **Цитирана от:**

2729) Dosseva-Panova VT, Popova CL, Panov VE. Subgingival microbial profile and production of proinflammatory cytokines in chronic periodontitis. Folia medica. 2014;**56(**3):152-160.

2730) Kazi MM, Bharadwaj R. Microbiota of chronic periodontitis and their association with severity of the disease. Int J Cur Res Rev. 2017; 2017; 9(7):28.

ЦИТИРАНА:60Б: Боянова Л, Гергова Г, Митов И. Чувствителност на клинични щамове *Helicobacter pylori* към metronidazole, tinidazole, clarithromycin и azithromycin. Български медицински журнал. 2011: **5**(3):35-39. **Цитирана от:**

2731) Stamboliyska M, Kaludova V, Mirchev M, Kotzev I, Madjov R, Metodiev K. Role and importance of microbiology testing in the diagnosis and treatment of *Helicobacter pylori* infection. J of IMAB 2015;**21**(4):969-973. http://www.journal-imab-bg.org/issues-2015/issue4/vol21issue4p969-973.html

<u>В БЪЛГАРСКИ ДИСЕРТАЦИИ:</u>

ЦИТИРАНА: Боянова Л. *Helicobacter pylori* в гастродуоденалната патология- микробиологични проучвания и връзка с терапевтичния подход. Дисертация за получаване н. ст. "доктор". СНС по микробиология, вирусология и имунология при ВАК. 1996 г., 233 стр. **Цитирана от:**

2732) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

2733) Петров П. *Helicobacter pylori*-микробиологична характеристика, генетични и имунологични аспекти в диагностиката. Дисертация за получаване на образователна и научна степен “Доктор”. Н. ръководител: ст.н.с. II ст. д-р Т. Кантарджиев,д.м. НЦЗПБ. София, 2000; 119 стр. 310 библиогр.справки.

ЦИТИРАНА: 3А: Boyanova L, Pehlivanov N, Mitova R. Recherche *d'Helicobacter pylori* au niveau des muqueuses gastrique et oesophagienne. L'experience bulgare. Med Mal Infect. 1992, **22**, (11): 954-956. **Цитирана от:**

2734) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 6А: Boyanova L, Stancheva I, Todorov D, Kumanova R, Petrov S, Vladimirov B, Pehlivanov N, Mitova R, Chakarski I, Churchev I. Comparison of three urease tests for detection of *Helicobacter pylori* in gastric biopsy specimens. Eur J Gastroenterol Hepatol. 1996; **8**(9): 911-914. **Цитирана от:**

2735) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 12А: Boyanova L, Spassova Z, Krastev Z, Petrov S, Stancheva I, Docheva J, Mitov I, Koumanova R. Characteristics and trends in macrolide resistance among *Helicobacter pylori* strains isolated in Bulgaria over four years. Diagn Microbiol Infect Dis. 1999; **34**(4): 309 -313. **Цитирана от:**

2736) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 13А: Boyanova L. Comparative evaluation of two methods for testing metronidazole susceptibility of *Helicobacter pylori* in routine practice. Diagn Microbiol Infect Dis. 1999; **35**(1): 33 - 36. **Цитирана от:**

2737) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА:77А: Boyanova L, Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. Lett Appl Microbiol. 2017;**65(**6):469-474.doi: 10.1111/lam.12807

2738) Пенка Младенова Петрова ПМ. Молекулярно-биологични изследвания на нови бактериални гликозид-хидролази с промишлено приложение. Дисертация за дн. БАН, Институт по микробиология „Стефан Ангелов“, София 2019.

ЦИТИРАНА: 1Б: Боянова Л, М Марина, Т Цаловска, Ю Стефанова. Изолиране на *Campylobacter jejuni* от болни с ентероколитен синдром. Епидемиолог. Микробиолог, Инфекц бол. 1988; **XXV**(4):16-19. **Цитирана от:**

2739) Иванова К. "Изолиране и микробиологична характеристика на щамове *Campylobacter jejuni* и *Campylobacter coli*". Дисертация за получаване н. ст. “к.м.н.”. Н. ръководител: ст. н.с. I ст. А. Томов, кмн. София, 1991. Столична хигиенно-епидемиологична инспекция (директор д-р Любомир Куманов), Военно-медицинска академия (началник проф. Григор Мечков). 143 стр.; 242 библиогр. справки.

ЦИТИРАНА: 6Б: Боянова Л, Н Андреев, С Бушар, Ф Мегро. Разпространение на инфекцията от *Helicobacter pylori* в София, България. Бълг. мед., 1993, **1** (5/6): 13-16. **Цитирана от:**

2740) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 9Б: Боянова Л, И Станчева, Др Тодоров, Р Куманова, С Петров, Б Владимиров, Н Пехливанов, Р Митова, И Чакърски, И Чурчев, Д Николовска. Сравнение на три уреазни теста за откриване на *Helicobacter pylori* в стомашни биопсични проби. Инфектология, 1996; **XXXIII**, (1): 22-24. **Цитирана от:**

2741) Петров П. *Helicobacter pylori* - микробиологична характеристика, генетични и имунологични аспекти в диагностиката. Дисертация за получаване на образователна и научна степен "Доктор". Н. ръководител: ст.н.с. II ст. д-р Т. Кантарджиев, д.м. Национален център по заразни и паразитни болести. София, 2000; 119 стр., 310 библиогр.справки.

ЦИТИРАНА: 10Б: Боянова Л. Хомоложна трансформация на маркери за резистентност към макролиди и нитроимидазоли при *Helicobacter pylori.* Инфектология 1996, **XXXIII**, (2): 17-20. **Цитирана от:**

2742) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 11Б: Boyanova L, Koumanova R, Jelev Chr, Petrov S. *Helicobacter pylori* and *Helicobacter heilmanii* in paediatric patients. Probl. Inf. Parasit. Dis. 1997; **XXIV**(2): 21-22. **Цитирана от:**

2743) Младенова-Христова, И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 13Б: Boyanova L, Koumanova R, Dotcheva J, Mitov I, Jelev Chr, Kovatcheva J, Petrov S. Resistance of *Helicobacter pylori* to metronidazole in paediatric patients. Probl. Inf Parasit. Dis. 1998; **26**(2):7-8. **Цитирана от:**

2744) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 14Б: Boyanova L, Katzarov N, Petrov S, Krastev Z, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in gastric ulcer patients. Probl. Inf. Parasit. Dis. 1999; **27**(2): 22-24. **Цитирана от:**

2745) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 30Б: Боянова, Л. Ролята на лактобацилите като пробиотици за профилактика, или терапия на *Helicobacter pylori* инфекцията: анализ на резултати от литературата и собствени предварителни проучвания. Съвр. мед. 2004; LV (No 5): 27-33. **Цитирана от:**

2746) Stamboliyska M,. Dokova K, Angelova S, Koleva A, Bazitova M. The oral cavity- reservoir of infection with *Helicobacter pylori*. Scripta Scientifica Medicinae Dentalis, 2015; **1**(2): 30-35.

ЦИТИРАНА: 36Б: Боянова Л, М Стефанова-Кондратенко, Г Гергова, И Митов. Определяне на инхибиращото действие на *Lactobacillus delbrueckii* subsp. *bulgaricus* върху растежа на *Helicobacter pylori in vitro*. Съвр мед. 2006; **LVII** (No 3): 3-13. **Цитирана от:**

2747) Чолаков Р. Селекциониране на щамове *Lactobacillus delbrueckii* subsp. *bulgaricus* с пробиотични свойства, изолирани от различни източници. Дипломна работа. Университет по хранителни технологии Пловдив, 2012: 57 стр.

ЦИТИРАНА: 50Б: Боянова Л., Марина М., Кантарджиев Т., Митов И. Диагноза и терпия на *Clostridium difficile* - асоциираната болест. Съвр. мед. 2008; 59 (3): 71-80. **Цитирана от:**

2748) Добрева ЕГ. Молекулярно-биологични проучвания за характеризиране на клинични изолати *Clostridium difficile.* Дисертация за придобиване на образователна и научна степен доктор, 2013 г., 102 стр.

ЦИТИРАНА: 51Б: Боянова Л., Марина М., Кантарджиев Т., Митов И. *Clostridium difficile* – асоциираната болест – нарастваща тревога след появата на хипервирулентния щам. Съвр. мед. 2008; 59 (4): 70-78. **Цитирана от:**

2749) Добрева ЕГ. Молекулярно-биологични проучвания за характеризиране на клинични изолати *Clostridium difficile.* Дисертация за придобиване на образователна и научна степен доктор, 2013 г., 102 стр.

ЦИТИРАНА: 53А:Boyanova L, Panov V, Yordanov D, Gergova G, Mitov I. Characterization of oral *Helicobacter pylori* strain by 4 methods. Diagn Microbiol Infect Dis 2013; **77** (4): 287-288. **Цитирана от:**

2750) Панов В. Промени в оралната среда и общи заболявания (Дисертация за „доктор" Медицински университет Варна. 2016.

ЦИТИРАНА: 60А: Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. Diagn Microbiol Infect Dis 2015; **82**(1):85-86. **Цитирана от:**

2751) Йорданов ДВ. *Helicobacter pylori*–фактори на вирулентност, резистентност и серопревалиране. Дисертация за „доктор". МУ-София, 2017.

ЦИТИРАНА: 63А: Markovska R, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015;**123**(10):887-94. **Цитирана от:**

2752) Kuyumdzhieva, G. N. Epidemiological Typing and Mechanisms of Antibiotic Resistance in Clinically Relevant *Klebsiella pneumoniae* Isolated at St. Marina University Hospital–Varna (Doctoral dissertation, Medical University of Varna (Bulgaria). 2019.

2753) Неделчева, Г. Епидемиологично типизиране и механизми на антибиотична резистентност в клинично значими *Klebsiella pneumoniae*, изолирани в УМБАЛ „Света Марина ", Варна (Doctoral dissertation). 2019.

ЦИТИРАНА 86А: Markovska R, Stoeva T, Boyanova L, Stankova P, Schneider I, Keuleyan E, Mihova K, Murdjeva M, Sredkova M, Lesseva M, Nedelcheva G, Petrova A, Ivanova D, Lazarova G, Kaneva R, Mitov I. Multicentre investigation of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing *K. pneumoniae*. Infect Genet Evol. 2019; 69:61-67. **Цитирана от:**

2754) Kuyumdzhieva, GN. Epidemiological Typing and Mechanisms of Antibiotic Resistance in Clinically Relevant *Klebsiella pneumoniae* Isolated at St. Marina University Hospital–Varna (Doctoral dissertation, Medical University of Varna (Bulgaria). 2019.

ЦИТИРАНА: 7В: Boyanova, L, Mitova R, Pehlivanov N, Petrov S. Bacteriological study of *Helicobacter pylori* and the effect of *Lactobacillus bulgaricus* on *Helicobacter pylori* growth. Preliminary report. Cs. Gastroenterol. Vyz., 1993, **47**(2): 10 (poster). Workshop *Helicobacter pylori* and the new concepts in gastroduodenal diseases. October 30-31, 1992, Prague, Czechoslovakia. **Цитирана от:**

2755) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 12В: Boyanova L, Andreev N, Bouchard S, Megraud F. *Helicobacter pylori* seroprevalence in Sofia, Bulgaria. Acta Gastroenterol. Belg. 1993; **56**: 69. **Цитирана от:**

2756) Петров П.: "*Helicobacter pylori*- микробиологична характеристика, генетични и имунологични аспекти в диагностиката". Дисертация за получаване на образователна и научна степен Доктор. Н. ръководител: ст.н.с. II ст. д-р Т. Кантарджиев, д.м. Национален център по заразни и паразитни болести. София, 2000; 119 стр., 310 библиогр.справки.

ЦИТИРАНА: 14В: Megraud F, Bouchard S, Brugmann D, **Boyanova L**, Coman G, Fixa B, Matysiak-Budnik T, Prifti S, Tamassy K. Seroprevalence of *Helicobacter pylori* in six countries of Eastern Europe using a common methodology. VIIIth International Workshop on Gastroduodenal Pathology and *Helicobacter pylori*, 7-9th July 1995, Edinburgh, Scotland. **Цитирана от:**

2757) Младенова-Христова И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

ЦИТИРАНА: 78В: Куманова Р, Хр Желев, **Л Боянова**, М Хубавешка, А Радивенска, Е Лазарова, П Янева, Е Панталеева, К Кънчев. Ендоскопска и морфологична характеристика на промените в стомаха и дванадесетопръстника при деца с коремни болки. VII Нац. конгрес по гастроентерология, 25-28 XI 1998, София. **Цитирана от:**

2758) Младенова-Христова, И. Епидемиологични проучвания върху инфекцията с *H. pylori.* Дисертация. Ст. Загора, Тракийски университет. 2000, 176 стр.

<u>В БЪЛГАРСКИ КНИГИ:</u>

ЦИТИРАНА: Боянова Л. *Helicobacter pylori* инфекцията у нас – разпространение, диагностика и насоки за терапия. Дисертационен труд за присъждане на научната степен „**Доктор на медицинските науки**" Научна специалност 01.06.12 Микробиология. Рецензенти: Ст.н.с. I ст. д-р Пламен Ненков, дмн, Ст.н.с. I ст. д-р Тодор Кантарджиев, дмн, Ст.н.с. I ст. Игнат Абрашев, дбн. Защитата се състоя на 25.05.2009 г.

2759) Ламбев Ив. Лекарства, повлияващи храносмилателната система. В кн. Фармакотерапевтичен справочник – VII изд. Под ред. на Ив. Ламбев. Мед. изд. „Арсо", С., 2010, стр. 335 и 925:

ЦИТИРАНА: 26А: Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains *in vitro* by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; **54 (Pt 5):**481-483. **Цитирана от:**

2760) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов" Варна. 2016. 200 стр. ISBN: 9786197137835.

ЦИТИРАНА: 27А: Boyanova L, Nikolov R, Lazarova E, Gergova G, Katsarov N, Kamburov V, Spassova Z, Derejian S, Jelev C, Mitov I, Krastev Z. Antibacterial resistance in *Helicobacter pylori* strains isolated from Bulgarian children and adult patients over 9 years. J Med Microbiol. 2006; **55**: 65-68. **Цитирана от:**

2761) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов" Варна. 2016. 200 стр. ISBN**:** 9786197137835.

ЦИТИРАНА: 33А: **Boyanova L.** Detection of *Helicobacter pylori* infection in symptomatic Bulgarian adults. Clin. Microbiol. Infect. 2007; **13** (9): 908-914. **Цитирана от:**

2762) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов" Варна. 2016. 200 стр. ISBN**:** 9786197137835.

ЦИТИРАНА: 34А: Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of *Helicobacter pylori* resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008; **60**(4): 409-415. **Цитирана от:**

2763) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов" Варна. 2016. 200 стр. ISBN**:** 9786197137835.

ЦИТИРАНА: 38А: **Boyanova L,** Markovska R, Yordanov D, Marina M, Ivanova K, Panayotov S, Gergova G, Mitov I. High prevalence of virulent *Helicobacter pylori* strains in symptomatic Bulgarian patients. Diagn Microbiol Infect Dis. 2009; **64**(4): 374-380. **Цитирана от:**

2764) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов" Варна. 2016. 200 стр. ISBN**:** 9786197137835.

ЦИТИРАНА: 6Б: Боянова, Л, Н Андреев, С Бушар, Ф Мегро. Разпространение на инфекцията от *Helicobacter pylori* в София, България. Бълг. мед., 1993, **1** (5/6): 13-16. **Цитирана от:**

2765) Георгиева-Шакола М, М Стамболийска. "*Helicobacter pylori* - предизвикателство на XX век в гастроентерологията". Color Print, Варна, 1997 (Медицински университет - Варна), 71 стр.

2766) Младенова И. Епидемиология на незаразните болести с инфекциозен ключов механизъм на проявление: Язвена болест и *Helicobacter pylori.* Теоретичен анализ на съвременната епидемиология 2006 г., Издателство "Медицина и физкултура"; 60-72.

ЦИТИРАНА: 8Б: Куманова Р, **Л Боянова**. *Helicobacter pylori* причина за заболявания на горните отдели на храносмилателната система в детската възраст. Педиатрия. 1995, (3): 10-13. **Цитирана от:**

2767) Георгиева-Шакола М, Стамболийска М. *Helicobacter pylori*-предизвикателство XX век в гастроентерологията. Color Print, Варна, 1997 (Медицински институт-Варна),71 стр.